

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number  
**WO 02/096927 A2**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04,**  
**C12Q 1/68, C12N 5/00**

(21) International Application Number: **PCT/US02/17674**

(22) International Filing Date: **29 May 2002 (29.05.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
09/870,161 29 May 2001 (29.05.2001) US  
60/334,461 30 November 2001 (30.11.2001) US  
10/138,674 3 May 2002 (03.05.2002) US

(71) Applicants (for all designated States except US):  
**RIBOZYME PHARMACEUTICALS, INCORPORATED** [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US). **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ESCOBEDO, Jaime** [US/US]; 1470 Livorna Road, Alamo, CA 94507

(US). **MCSWIGGEN, James** [US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US). **PAVCO, Pamela** [US/US]; 705 Barberry Circle, Lafayette, CO 80026 (US). **STINCHCOMB, Dan** [US/US]; 8409 South Country Road 3, Ft. Collins, CO 80528 (US). **SANDBERG, Jennifer** [US/US]; 620 Bluegrass Drive, Longmont, CO 80503 (US). **GORDON, Gilad** [US/US]; 3605 Silver Plume Lane, Boulder, CO 80303 (US).

(74) Agent: **TERPSTRA, Anita, J.**; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **NUCLEIC ACID BASED MODULATION OF FEMALE REPRODUCTIVE DISEASES AND CONDITIONS**

**RPI.4731 Reduces Hypoxia-Induced Retinal Neovascularization in Neonatal Mice**



SEQ ID NO: 5978  
Results: ~40% decrease in retinal neovascularization following two intraocular injections of RPI.4731

(57) Abstract: The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNazymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFR) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

WO 02/096927 A2

BEST AVAILABLE COPY



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

NUCLEIC ACID BASED MODULATION OF FEMALE REPRODUCTIVE DISEASES  
AND CONDITIONS

This patent application claims priority from Sandberg *et al.*, USSN 60/334,461, filed  
5 November 30, 2001, entitled "Method and Reagent for the Modulation of Female  
Reproductive Diseases and Conditions" and Pavco *et al.*, USSN 10/138,674, filed May 3,  
2002, which is a continuation in part of Pavco *et al.*, USSN 09/870,161, which is a  
continuation-in-part of Pavco *et al.*, USSN 09/708,690, filed November 7, 2000, which is  
a continuation-in-part of Pavco *et al.*, USSN 09/371,722, filed August 10, 1999, which is a  
10 continuation-in-part of Pavco *et al.*, USSN 08/584,040, filed January 11, 1996, which  
claims the benefit of Pavco *et al.*, USSN 60/005,974, filed on October 26, 1995; these  
earlier applications are entitled "Method and Reagent for Treatment of Diseases or  
Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor". Each of  
these applications is hereby incorporated by reference herein in it's entirety including the  
15 drawings and tables.

Technical Field Of The Invention

This invention relates to methods and reagents for the treatment of diseases or  
conditions relating to the levels of expression of vascular endothelial growth factor (VEGF)  
and vascular endothelial growth factor receptor(s). Specifically, the instant invention features  
20 nucleic-acid based molecules and methods that modulate the expression of vascular  
endothelial growth factor and/or vascular endothelial growth factor receptors, such as  
VEGFR1 and/or VEGFR2, that are useful in preventing, treating, controlling and/or  
diagnosing disorders and conditions related to angiogenesis, including but not limited to  
cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related  
25 macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis,  
rheumatoid arthritis, psoriasis, wound healing, endometriosis, endometrial carcinoma,  
gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome  
(PMS), and menopausal dysfunction.

Background Of The Invention

30 The following is a discussion of relevant art, none of which is admitted to be prior art to  
the present invention.

VEGF, also referred to as vascular permeability factor (VPF) and vasculotropin, is a potent and highly specific mitogen of vascular endothelial cells (for a review see Ferrara, 1993 *Trends Cardiovas. Med.* 3, 244; Neufeld *et al.*, 1994, *Prog. Growth Factor Res.* 5, 89). VEGF-induced neovascularization is implicated in various pathological conditions such as tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing and others.

VEGF, an endothelial cell-specific mitogen, is a 34-45 kDa glycoprotein with a wide range of activities that include promotion of angiogenesis, enhancement of vascular-permeability and others. VEGF belongs to the platelet-derived growth factor (PDGF) family of growth factors with approximately 18% homology with the A and B chain of PDGF at the amino acid level. Additionally, VEGF contains the eight conserved cysteine residues common to all growth factors belonging to the PDGF family (Neufeld *et al.*, *supra*). VEGF protein is believed to exist predominantly as disulfide-linked homodimers; monomers of VEGF have been shown to be inactive (Plouet *et al.*, 1989 *EMBO J.* 8, 3801).

VEGF exerts its influence on vascular endothelial cells by binding to specific high-affinity cell surface receptors. Covalent cross-linking experiments with <sup>125</sup>I-labeled VEGF protein have led to the identification of three high molecular weight complexes of 225, 195 and 175 kDa presumed to be VEGF and VEGF receptor complexes (Vaisman *et al.*, 1990 *J. Biol. Chem.* 265, 19461). Based on these studies VEGF-specific receptors of 180, 150 and 130 kDa molecular mass were predicted. In endothelial cells, receptors of 150 and 130 kDa have been identified. The VEGF receptors belong to the superfamily of receptor tyrosine kinases (RTKs) characterized by a conserved cytoplasmic catalytic kinase domain and a hydrophilic kinase sequence. The extracellular domains of the VEGF receptors consist of seven immunoglobulin-like domains that are thought to be involved in VEGF binding functions.

The two most abundant and high-affinity receptors of VEGF are flt-1 (VEGFR1) (*fms*-like tyrosine kinase) cloned by Shibuya *et al.*, 1990 *Oncogene* 5, 519 and KDR (VEGFR2) (kinase-insert-domain-containing receptor) cloned by Terman *et al.*, 1991 *Oncogene* 6, 1677. The murine homolog of KDR, cloned by Mathews *et al.*, 1991, *Proc. Natl. Acad. Sci., USA*, 88, 9026, shares 85% amino acid homology with KDR and is termed as flk-1 (fetal liver kinase-1). The high-affinity binding of VEGF to its receptors is modulated by cell surface-associated heparin and heparin-like molecules (Gitay-Goren *et al.*, 1992 *J. Biol. Chem.* 267, 6093).



VEGF expression has been associated with several pathological states such as tumor angiogenesis, several forms of blindness, rheumatoid arthritis, psoriasis and others. In addition, a number of studies have demonstrated that VEGF is both necessary and sufficient for neovascularization. Takashita *et al.*, 1995 *J. Clin. Invest.* 93, 662, demonstrated that a  
5 single injection of VEGF augmented collateral vessel development in a rabbit model of ischemia. VEGF also can induce neovascularization when injected into the cornea. Expression of the VEGF gene in CHO cells is sufficient to confer tumorigenic potential to the cells. Kim *et al.*, *supra* and Millauer *et al.*, *supra* used monoclonal antibodies against VEGF or a dominant negative form of VEGFR2 receptor to inhibit tumor-induced  
10 neovascularization.

During development, VEGF and its receptors are associated with regions of new vascular growth (Millauer *et al.*, 1993 *Cell* 72, 835; Shalaby *et al.*, 1993 *J. Clin. Invest.* 91, 2235). Furthermore, transgenic mice lacking either of the VEGF receptors are defective in blood vessel formation and these mice do not survive; VEGFR2 appears to be required for  
15 differentiation of endothelial cells, while VEGFR1 appears to be required at later stages of vessel formation (Shalaby *et al.*, 1995 *Nature* 376, 62; Fung *et al.*, 1995 *Nature* 376, 66). Thus, these receptors apparently need to be present to properly signal endothelial cells or their precursors to respond to vascularization-promoting stimuli.

Increasing evidence suggests that the VEGF family may also be involved with both the  
20 etiology and maintenance of peritoneal endometriosis. Peritoneal endometriosis is a significant debilitating gynecological problem of widespread prevalence. It is now generally accepted that the pathogenesis of peritoneal endometriosis involves the implantation of exfoliated endometrium. Maintenance of exfoliated endometrial tissue is dependent upon the generation and maintenance of an extensive blood supply both within and surrounding the  
25 ectopic tissue.

Endometriosis is a disease affecting an estimated 77 million women and teenagers worldwide. Endometriosis is a leading cause of infertility, chronic pelvic pain and hysterectomy. Endometriosis can be characterized when endometrial tissue (the tissue inside the uterus which builds up and is shed each month during menses) is found outside the uterus,  
30 in other areas of the body. The endometrial tissue can respond to hormonal commands each month and break down and bleed. However, unlike the endometrium, these tissue deposits have no way of leaving the body. The result is internal bleeding, degeneration of blood and tissue shed from the growths, inflammation of the surrounding areas, expression of irritating enzymes and formation of scar tissue. In addition, depending on the location of the growths,

interference with the bowel, bladder, intestines and other areas of the pelvic cavity can occur. Endometrial tissue has even been found lodged in the skin and at other extrapelvic locations like the arm, leg and even brain.

Currently, the presence of Endometriosis can only be confirmed through surgery such as laparoscopy, but can be suspected based on symptoms, physical findings and diagnostic tests. Endometriosis can be treated in many different ways, both surgically and medically. Most commonly, surgery will be performed during which the disease will be excised, ablated, fulgurated, cauterized or otherwise removed, and adhesions will also be freed. Surgeries include but are not limited to laparoscopy; laparotomy; presacral and uterosacral and various levels of hysterectomies, where some or all of the reproductive organs are removed. Often, this method will only relieve the symptoms associated with growths on the reproductive organs, not the bowels or kidneys and related areas where Endometriosis can be present.

There are several drugs used to treat Endometriosis that are utilized either alone or in combination with surgery. These include contraceptives, GnRH agonists, and/or synthetic hormones. GnRH agonists are commonly used on women in all stages of the disease and may sometimes have serious side affects. GnRH (gonadotropin releasing hormone) analogues are classified into 2 groups: agonists and antagonists. Agonists are commonly used in the treatment of Endometriosis by suppressing the manufacture of follicle stimulating hormone (FSH) and luteinizing hormone (LH), common hormones required in ovulation. When they are not secreted, the body will go into "pseudo-menopause," stalling the growth of more implants. However, these are again only stop-gap measures that can be utilized only for short term intervals. Once the body returns to it's normal state, the Endometriosis will again begin to implant itself.

Angiogenesis is likely to be involved in the pathogenesis of endometriosis. According to the transplantation theory, when the exfoliated endometrium is attached to the peritoneal layer, the establishment of a new blood supply is essential for the survival of the endometrial implant and development of endometriosis (Donnez *et al.*, 1998, *Hum. Reprod.*, 13, 1686-1690). Endometrial growth and repair after menstruation are associated with profound angiogenesis. Abnormalities in these processes result in excessive or unpredictable bleeding patterns and are common in many women. It is therefore important to understand which factors regulate normal endometrial angiogenesis. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen that plays an important role in normal and pathological angiogenesis (Fasciani *et al.*, 2000, *Mol. Hum. Reprod.*, 6, 50-54; Sharkey *et al.*, 2000, *J. Clin. Endocrinol. Metab.*, 85, 402-409). Sources of this factor include the eutopic

endometrium, ectopic endometriotic tissue and peritoneal fluid macrophages. Important to its etiology is the correct peritoneal environment in which the exfoliated endometrium is seeded and implants. Established ectopic tissue is then dependent on the peritoneal environment for its survival, an environment that supports angiogenesis. The increasing knowledge of the involvement of the VEGF family in endometriotic angiogenesis raises the possibility of novel approaches to its medical management, with particular focus on the anti-angiogenic control of the action of VEGF (McLaren, 2001, *Hum. Reprod. Update*, 6, 45-55).

Pavco *et al.*, International PCT Publication No. WO 97/15662, describes methods and reagents for treating diseases or conditions related to levels of vascular endothelial growth factor receptor.

Robinson, International PCT Publication No. WO 95/04142, describes the use of certain antisense oligonucleotides targeted against VEGF RNA to inhibit VEGF expression.

Jellinek *et al.*, 1994 *Biochemistry* 33, 10450 describe the use of specific VEGF-specific high-affinity RNA aptamers to inhibit the binding of VEGF to its receptors.

Rockwell and Goldstein, International PCT Publication No. WO 95/21868, describe the use of certain anti-VEGF receptor monoclonal antibodies to neutralize the effect of VEGF on endothelial cells.

Pappa, International PCT Publication No. WO 01/32920, describes inhibitors, including certain ribozyme and antisense nucleic acid molecules, of specific genes, including cathepsin D, AEBP-1, stromelysin-3, cystatin B, protease inhibitor 1, sFRP4, gelsolin, IGFBP-3, dual specificity phosphatase 1, PAEP, Ig gamma chain, ferritin, complement component 3, pro-alpha-1 type III collagen, proline 4-hydroxylase, alpha-2 type I collagen, claudin-4, melanoma adhesion protein, procollagen C-endopeptidase enhancer, nascent-polypeptide-associated complex alpha polypeptide, elongation factor 1 alpha (EF-1-alpha), vitamin D3 hydroxylase, CSRP-1, steroidogenic acute regulatory protein, apolipoprotein E, transcobalamin II, prosaposin, early growth response 1 (EGR1), ribosomal protein S6, adenosine deaminase RNA-specific protein, RAD21, guanine nucleotide binding protein beta polypeptide 2-like 1 (RACK1) and podocalyxin genes which are all differentially expressed in tissues within individual patients with endometriosis.

Labarbera *et al.*, International PCT Publication No. WO 00/73416, describes specific antisense nucleic acid molecules targeting follicle-stimulating hormone receptor.

Storella *et al.*, International PCT Publication No. WO 99/63116, describes modulators of Prothymosin gene products for treating endometriosis, including certain ribozymes and antisense nucleic acid molecules.

Summary Of The Invention

5

This invention features nucleic acid-based molecules, for example, enzymatic nucleic acid molecules, allozymes, antisense nucleic acids, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNA, dsRNA, siRNA, aptamers, and antisense nucleic acids containing nucleic acid cleaving chemical groups, and methods to modulate vascular  
10 endothelial growth factor (VEGF) and/or vascular endothelial growth factor receptor (VEGFR) gene expression. Non-limiting examples of genes that encode vascular endothelial growth factor receptors of the invention include VEGFR1, VEGFR2 or combinations thereof. In particular, the instant invention features nucleic acid-based molecules and methods that modulate the expression of vascular endothelial growth factor and/or vascular endothelial  
15 growth factor receptors, such as VEGFR1 and/or VEGFR2, that are useful in preventing, treating, controlling, and/or diagnosing angiogenesis related diseases and conditions, including but not limited to tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and female reproductive disorders  
20 and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

In one embodiment, the invention features one or more nucleic acid-based molecules and methods that independently or in combination modulate the expression of gene(s)  
25 encoding vascular endothelial growth factor receptors. Specifically, the present invention features nucleic acid molecules that modulate the expression of VEGF (for example Genbank Accession No. NM\_003376), VEGFR1 receptor (for example Genbank Accession No. NM\_002019), and VEGFR2 receptor (for example Genbank Accession No. NM\_002253) that are useful in preventing, treating, controlling, and/or diagnosing tumor angiogenesis,  
30 cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and female reproductive disorders and conditions, including but not limited to

endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

In one embodiment, the present invention features a compound having Formula I: (SEQ ID NO: 5977)

5                   5' g<sub>s</sub>a<sub>s</sub>g<sub>s</sub>u<sub>s</sub>ugcUGAuGagg ccgaaa ggccGaaAgucngB 3'

wherein each a is 2'-O-methyl adenosine nucleotide, each g is a 2'-O-methyl guanosine nucleotide, each c is a 2'-O-methyl cytidine nucleotide, each u is a 2'-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2'-deoxy-2'-C-allyl uridine, and B is an  
10 inverted deoxyabasic moiety. This compound is also referred to as ANGIOZYME™ ribozyme.

In another embodiment, the present invention features a compound having Formula II: (SEQ ID NO: 5978).

15                   5'-u<sub>s</sub>a<sub>s</sub>c, a<sub>s</sub>au ucU GAu Gag gcg aaa gcc Gaa Aag aca aB-3'

wherein each a is 2'-O-methyl adenosine nucleotide, each g is a 2'-O-methyl guanosine nucleotide, each c is a 2'-O-methyl cytidine nucleotide, each u is a 2'-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2'-deoxy-2'-C-allyl uridine, and B is an  
20 inverted deoxyabasic moiety.

In one embodiment, the invention features a composition comprising a nucleic acid molecule of the invention in a pharmaceutically acceptable carrier. In another embodiment, the invention features a composition comprising a compound of Formula I and/or Formula II in a pharmaceutically acceptable carrier or diluent.

25                   In one embodiment, the invention features a method of administering to a cell, for example a mammalian cell, including a human cell, a nucleic acid molecule of the invention comprising contacting the cell with the nucleic acid molecule under conditions suitable for administration, for example in the presence of a delivery reagent such as a lipid, cationic lipid, phospholipid, or liposome. In another embodiment, the invention features a method of  
30 administering to a cell, for example a mammalian cell, including a human cell, a compound of Formula I and/or Formula II comprising contacting the cell with the compound under

conditions suitable for administration, for example in the presence of a delivery reagent such as a lipid, cationic lipid, phospholipid, or liposome.

In one embodiment, the present invention features a mammalian cell comprising a nucleic acid molecule of the invention, wherein the mammalian cell is, for example, a human cell. In another embodiment, the present invention also features a mammalian cell comprising the compound of Formula I and/or Formula II, wherein the mammalian cell is, for example, a human cell.

In one embodiment, the invention features a method of inhibiting angiogenesis, for example tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, or endometrial neovascularization, in a subject comprising contacting the subject with a nucleic acid molecule of the invention, under conditions suitable for the inhibition. In another embodiment, the invention features a method of inhibiting angiogenesis, for example tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, or endometrial neovascularization, in a subject, comprising contacting the subject with a compound of Formula I and/or Formula II, under conditions suitable for the inhibition.

In another embodiment, the invention features a method of treatment of a subject having an ocular condition associated with the increased level of a VEGF receptor, for example diabetic retinopathy, or age related macular degeneration, comprising contacting cells of the subject with a nucleic acid molecule, such as an enzymatic nucleic acid molecule targeted against a VEGF receptor RNA, e.g., molecule according to Formula I and/or II, under conditions suitable for the treatment.

In another embodiment, the invention features a method of treatment of a subject having a condition associated with an increased level of VEGFR and/or a VEGF receptor, for example tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, ocular diseases or ocular indications such as diabetic retinopathy, or age related macular degeneration, rheumatoid arthritis, psoriasis endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), or menopausal dysfunction, comprising contacting cells of the subject with a nucleic acid molecule of the invention, such as a compound of Formula I and/or Formula II, under conditions suitable for the treatment.

In yet another embodiment, the inventive method of treatment further comprises the use of one or more drug therapies under conditions suitable for the treatment. Non-limiting

examples of other drug therapies that can be used in combination with nucleic acid molecules of the invention include 5-fluoro uridine, Leucovorin, Irinotecan (CAMPTOSAR® or CPT-11 or Camptothecin-11 or Campto), Paclitaxel, or Carboplatin, GnRH (gonadotropin releasing hormone) agonists, Lupron Depot (Leuprolide Acetate), Synarel (nafaralin acetate),  
5 Zolodex (goserelin acetate), Suprefact (buserelin acetate), Danazol, or oral contraceptives including but not limited to Depo-Provera or Provera (medroxyprogesterone acetate), or any other estrogen/progesterone contraceptive.

In one embodiment, the invention features a method of administering to a mammal, for example a human, a nucleic acid molecule of the invention comprising contacting the  
10 mammal with the nucleic acid molecule under conditions suitable for the administration, for example, in the presence of a delivery reagent such as a lipid, cationic lipid, phospholipid, or liposome. In another embodiment, the invention features a method of administering to a mammal, for example a human, a compound of Formula I and/or Formula II comprising  
15 contacting the mammal with the compound under conditions suitable for the administration, for example, in the presence of a delivery reagent such as a lipid, cationic lipid, phospholipid, or liposome.

In one embodiment, the invention features a nucleic acid molecule which down regulates expression of a vascular endothelial growth factor (VEGF) and/or vascular  
20 endothelial growth factor receptor (VEGFR) gene, for example, wherein the VEGFR gene comprises VEGFR1 or VEGFR2 and any combination thereof.

In one embodiment, a nucleic acid molecule of the invention, such as an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid  
25 containing nucleic acid cleaving chemical groups, is adapted to treat, control and/or diagnose tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, ocular diseases or ocular indications, such as diabetic retinopathy, or age related macular degeneration, rheumatoid arthritis, psoriasis endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), or menopausal dysfunction.

30 Such nucleic acid molecules are also useful for the prevention of the diseases and conditions including diabetic retinopathy, macular degeneration, neovascular glaucoma, myopic degeneration, verruca vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kippel-Trenaumay-Weber syndrome, Osler-Weber-Rendu syndrome

and other diseases or conditions that are related to the levels of VEGFR1 or VEGFR2 in a cell or tissue.

In another embodiment, the invention features a composition in a pharmaceutically acceptable carrier or diluent, comprising the nucleic acid molecule of the instant invention.

5 In another embodiment, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention is adapted for birth control.

10 In one embodiment, an enzymatic nucleic acid molecule of the invention is in a hammerhead, Inozyme, Zinzyme, DNAzyme, Amberzyme, or G-cleaver configuration.

In one embodiment, an enzymatic nucleic acid molecule of the invention comprises between 8 and 100 bases complementary to RNA of VEGFR1 and/or VEGFR2 gene. In another embodiment, an enzymatic nucleic acid molecule of the invention comprises between 14 and 24 bases complementary to RNA of VEGFR1 and/or VEGFR2 gene.

15 In one embodiment, a siRNA molecule of the invention comprises a double stranded RNA wherein one strand of the RNA is complementary to RNA of a VEGFR1 and/or VEGFR2 gene. In another embodiment, a siRNA molecule of the invention comprises a double stranded RNA wherein one strand of the RNA comprises a portion of a sequence of RNA having a VEGFR1 and/or VEGFR2 sequence. In yet another embodiment, a siRNA  
20 molecule of the invention comprises a double stranded RNA wherein both strands of RNA are connected by a non-nucleotide linker. Alternately, a siRNA molecule of the invention comprises a double stranded RNA wherein both strands of RNA are connected by a nucleotide linker, such as a loop or stem loop structure.

25 In one embodiment, a single strand component of a siRNA molecule of the invention is from about 14 to about 50 nucleotides in length. In another embodiment, a single strand component of a siRNA molecule of the invention is about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides in length. In yet another embodiment, a single strand component of a siRNA molecule of the invention is about 23 nucleotides in length. In one embodiment, a siRNA molecule of the invention is from about 28 to about 56 nucleotides in  
30 length. In another embodiment, a siRNA molecule of the invention is about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 nucleotides in length. In yet another embodiment, a siRNA molecule of the invention is about 46 nucleotides in length.



In one embodiment, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention is chemically synthesized.

- 5 In another embodiment, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention comprises at least one 2'-sugar modification.

- 10 In another embodiment, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acids containing nucleic acid cleaving chemical groups of the invention comprises at least one nucleic acid base modification.

- 15 In another embodiment, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention comprises at least one phosphate backbone modification.

In one embodiment, the invention features a mammalian cell, for example a human cell, comprising a nucleic acid molecule of the invention.

- 20 In another embodiment, the invention features a method of reducing VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 expression or activity in a cell comprising contacting the cell with a nucleic acid molecule of the invention that modulates the expression and/or activity of VEGF and/or VEGFr, under conditions suitable for the reduction.

- 25 In another embodiment, a method of treatment of a subject having a condition associated with the level of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 is featured, wherein the method further comprises the use of one or more drug therapies under conditions suitable for the treatment.

- 30 In one embodiment, the invention features a method for treatment of a subject having tumor angiogenesis, tumor angiogenesis, cancers including but not limited to tumor and cancer types shown under Diagnosis in Table III, ocular diseases or ocular indications such as diabetic retinopathy, or age related macular degeneration, rheumatoid arthritis, psoriasis and/or endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular

menstrual cycles, ovulation, premenstrual syndrome (PMS), or menopausal dysfunction, comprising administering to the subject a nucleic acid molecule of the invention that modulates the expression and/or activity of VEGF and/or VEGFr under conditions suitable for the treatment.

- 5           In another embodiment, the invention features a method for birth control in a subject comprising administering to the subject a nucleic acid molecule of the invention that modulates the expression and/or activity of VEGF and/or VEGFr under conditions suitable for the treatment.

- 10           In another embodiment, the invention features a method of cleaving RNA encoded by a VEGF, VEGFR1 and/or VEGFR2 gene comprising contacting an enzymatic nucleic acid molecule of the invention having endonuclease activity with RNA encoded by a VEGFR1 and/or VEGFR2 gene under conditions suitable for the cleavage, for example, wherein the cleavage is carried out in the presence of a divalent cation, such as  $Mg^{2+}$ .

- 15           In one embodiment, a nucleic acid molecule of the invention comprises a cap structure, for example a 3',3'-linked or 5',5'-linked deoxyabasic ribose derivative, wherein the cap structure is at the 5'-end, or 3'-end, or both the 5'-end and the 3'-end of the enzymatic nucleic acid molecule.

- 20           In another embodiment, a nucleic acid molecule of the invention comprises a cap structure, for example a 3',3'-linked or 5',5'-linked deoxyabasic ribose derivative, wherein the cap structure is at the 5'-end, or 3'-end, or both the 5'-end and the 3'-end of the antisense nucleic acid molecule.

          In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one nucleic acid molecule of the invention such that the vector allows expression of the nucleic acid molecule.

- 25           In another embodiment, the invention features a mammalian cell, for example, a human cell comprising an expression vector of the invention.

          In yet another embodiment, an expression vector of the invention further comprises a sequence for a nucleic acid molecule complementary to RNA encoded by a VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 gene.

In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more nucleic acid molecules of the invention, which can be the same or different.

In another embodiment, the invention features a method for treatment or control of tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and/or endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), or menopausal dysfunction, comprising administering to a subject a nucleic acid molecule of the invention that modulates the expression and/or activity of VEGF and/or VEGFr, such as an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention, under conditions suitable for the treatment, including administering to the subject one or more other therapies, for example, 5-fluoro uridine, Leucovorin, Irinotecan (CAMPTOSAR® or CPT-11 or Camptothecin-11 or Campto), Paclitaxel, or Carboplatin. GnRH (gonadotropin releasing hormone) agonists, Lupron Depot (Leuprolide Acetate), Synarel (naferalin acetate), Zolodex (goserelin acetate), Suprefact (buserelin acetate), Danazol, or oral contraceptives including but not limited to Depo-Provera or Provera (medroxyprogesterone acetate), or any other estrogen/progesterone contraceptive.

In one embodiment, the method of treatment features a nucleic acid molecule of the invention, such as an enzymatic nucleic acid or antisense nucleic acid molecule, that comprises at least five ribose residues, at least ten 2'-O-methyl modifications, and a 3'- end modification, such as a 3'-3' inverted abasic moiety. In another embodiment, a nucleic acid molecule of the invention further comprises phosphorothioate linkages on at least three of the 5' terminal nucleotides.

In another embodiment, the invention features a method of administering to a mammal, for example a human, an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention, comprising contacting the mammal with the nucleic acid molecule under conditions suitable for the administration, for example, in the presence of a delivery reagent such as a lipid, cationic lipid, phospholipid, or liposome.

In yet another embodiment, the invention features a method of administering to a mammal an enzymatic nucleic acid molecule, antisense nucleic acid molecule, 2-5A antisense chimera, triplex forming oligonucleotide, decoy RNA, dsRNA, siRNA, aptamer, or antisense nucleic acid containing nucleic acid cleaving chemical groups of the invention in conjunction  
5 with other therapies, comprising contacting the mammal, for example a human, with the nucleic acid molecule and the other therapy under conditions suitable for the administration.

In another embodiment, other therapies contemplated by the instant invention that can be used in conjunction with the nucleic acid molecules of the instant invention include, but are not limited to, 5-fluoro uridine, Leucovorin, Irinotecan (CAMPTOSAR® or CPT-11 or  
10 Camptothecin-11 or Campto), Paclitaxel, or Carboplatin, GnRH (gonadotropin releasing hormone) agonists, Lupron Depot (Leuprolide Acetate), Synarel (naferalin acetate), Zolodex (goserelin acetate), Suprefact (buserelin acetate), Danazol, or oral contraceptives including but not limited to Depo-Provera or Provera (medroxyprogesterone acetate), or other estrogen/progesterone contraceptive.

15 In one embodiment, the invention features the use of an enzymatic nucleic acid molecule, to down-regulate the expression of VEGFR1 and/or VEGFR2 genes in the treatment or control of tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and/or endometriosis, endometrial  
20 carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), or menopausal dysfunction. Such enzymatic nucleic acid molecule can be in the hammerhead, NCH, G-cleaver, Amberzyme, Zinzyme, and/or DNAzyme motif.

In another embodiment, the invention features the use of an enzymatic nucleic acid  
25 molecule to down-regulate the expression of VEGF and/or VEGFR, such as VEGFR1 and/or VEGFR2 genes, as a method of birth control. Such enzymatic nucleic acid molecule can be in the hammerhead, NCH, G-cleaver, Amberzyme, Zinzyme, and/or DNAzyme motif. In one embodiment, the nucleic acid molecules of the invention have complementarity to the substrate sequences in Tables V and VI. Examples of enzymatic nucleic acid molecules of  
30 the invention are shown in Tables V and VI. Examples of such enzymatic nucleic acid molecules consist essentially of sequences defined in these Tables.

By "inhibit", "down-regulate", or "reduce", it is meant that the expression of the gene, or level of nucleic acids or equivalent nucleic acids encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, such as VEGFR1, VEGFR2

and/or flk-1, is reduced below that observed in the absence of the nucleic acid molecules of the invention. In one embodiment, inhibition, down-regulation or reduction with enzymatic nucleic acid molecule preferably is below that level observed in the presence of an enzymatically inactive or attenuated molecule that is able to bind to the same site on the target  
5 nucleic acid, but is unable to cleave that nucleic acid. In another embodiment, inhibition, down-regulation, or reduction with antisense oligonucleotides is preferably below that level observed in the presence of, for example, an oligonucleotide with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 with the nucleic acid molecule of the  
10 instant invention is greater in the presence of the nucleic acid molecule than in its absence.

By "up-regulate" is meant that the expression of a gene, or level of nucleic acids or equivalent nucleic acids encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, such as VEGFR1 and/or VEGFR2, is greater than that observed in the absence of the nucleic acid molecules of the invention. For example, the  
15 expression of a gene, such as VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 gene, can be increased in order to treat, prevent, ameliorate, or modulate a pathological condition caused or exacerbated by an absence or low level of gene expression.

By "modulate" is meant that the expression of a gene, or level of nucleic acids or equivalent nucleic acids encoding one or more proteins or protein subunits, or activity of one  
20 or more proteins protein subunit(s) is up-regulated or down-regulated, such that the expression, level, or activity is greater than or less than that observed in the absence of the nucleic acid molecules of the invention.

By "enzymatic nucleic acid molecule" it is meant a nucleic acid molecule which has complementarity in a substrate binding region to a specified gene target, and also has an  
25 enzymatic activity which is active to specifically cleave a target nucleic acid. That is, the enzymatic nucleic acid molecule is able to intermolecularly cleave a nucleic acid and thereby inactivate a target nucleic acid molecule. These complementary regions allow sufficient hybridization of the enzymatic nucleic acid molecule to the target nucleic acid and thus permit cleavage. One hundred percent complementarity is preferred, but complementarity as  
30 low as 50-75% can also be useful in this invention (see for example Werner and Uhlenbeck, 1995, *Nucleic Acids Research*, 23, 2092-2096; Hammann *et al.*, 1999, *Antisense and Nucleic Acid Drug Dev.*, 9, 25-31). The nucleic acids can be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such

as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme or aptamer-binding ribozyme, regulatable ribozyme, catalytic oligonucleotides, nucleozyme, DNzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving and/or ligation activity to the molecule (Cech *et al.*, U.S. Patent No. 4,987,071; Cech *et al.*, 1988, 260 *JAMA* 3030).

Several varieties of naturally-occurring enzymatic nucleic acids are known presently. Each can catalyze the hydrolysis of nucleic acid phosphodiester bonds in *trans* (and thus can cleave other nucleic acid molecules) under physiological conditions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target nucleic acid. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target nucleic acid. Thus, the enzymatic nucleic acid first recognizes and then binds a target nucleic acid through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target nucleic acid. Strategic cleavage of such a target nucleic acid will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its nucleic acid target, it is released from that nucleic acid to search for another target and can repeatedly bind and cleave new targets. Thus, a single ribozyme molecule is able to cleave many molecules of target nucleic acid. In addition, the ribozyme is a highly specific inhibitor of gene expression, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target nucleic acid, but also on the mechanism of target nucleic acid cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme.

In one embodiment of the inventions described herein, an enzymatic nucleic acid molecule of the invention is formed in a hammerhead or hairpin motif, but can also be formed in the motif of a hepatitis delta virus, group I intron, group II intron or RNase P RNA (in association with an RNA guide sequence), *Neurospora* VS RNA, DNzymes, NCH cleaving motifs, or G-cleavers. Examples of such hammerhead motifs are described by Dreyfus, *supra*, Rossi *et al.*, 1992, *AIDS Research and Human Retroviruses* 8, 183; of hairpin motifs

by Hampel *et al.*, EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, Feldstein *et al.*, 1989, *Gene* 82, 53, Haseloff and Gerlach, 1989, *Gene*, 82, 43, and Hampel *et al.*, 1990 *Nucleic Acids Res.* 18, 299; Chowrira & McSwiggen, US. Patent No. 5,631,359; an examples of a hepatitis delta virus motif is described by Perrotta and Been, 1992 *Biochemistry* 31, 16;

5 examples of RNase P motifs are described by Guerrier-Takada *et al.*, 1983 *Cell* 35, 849; Forster and Altman, 1990, *Science* 249, 783; Li and Altman, 1996, *Nucleic Acids Res.* 24, 835; examples of *Neurospora* VS RNA ribozyme motifs are described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Collins and Olive, 1993 *Biochemistry* 32, 2795-2799; Guo and Collins, 1995,

10 *EMBO. J.* 14, 363); examples of Group II introns are described by Griffin *et al.*, 1995, *Chem. Biol.* 2, 761; Michels and Pyle, 1995, *Biochemistry* 34, 2965; Pyle *et al.*, International PCT Publication No. WO 96/22689; an example of a Group I intron is described by Cech *et al.*, U.S. Patent 4,987,071; and examples of DNazymes are described by Usman *et al.*, International PCT Publication No. WO 95/11304; Chartrand *et al.*, 1995, *NAR* 23, 4092;

15 Breaker *et al.*, 1995, *Chem. Bio.* 2, 655; Santoro *et al.*, 1997, *PNAS* 94, 4262, and Beigelman *et al.*, International PCT publication No. WO 99/55857. NCH cleaving motifs are described in Ludwig & Sproat, International PCT Publication No. WO 98/58058; and G-cleavers are described in Kore *et al.*, 1998, *Nucleic Acids Research* 26, 4116-4120 and Eckstein *et al.*, International PCT Publication No. WO 99/16871. Additional motifs such as the Aptazyme

20 (Breaker *et al.*, WO 98/43993), Amberzyme (Beigelman *et al.*, U.S. Serial No. 09/301,511) and Zinzyme (Figure 7) (Beigelman *et al.*, U.S. Serial No. 09/918,728), all included by reference herein including drawings, can also be used in the present invention. These specific motifs or configurations are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is

25 that it have a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a RNA cleaving activity to the molecule (Cech *et al.*, U.S. Patent No. 4,987,071).

By "nucleic acid molecule" as used herein is meant a molecule having nucleotides. The

30 nucleic acid can be single, double, or multiple stranded and can comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.

By "enzymatic portion" or "catalytic domain" is meant that portion/region of a enzymatic nucleic acid molecule essential for cleavage of a nucleic acid substrate (for example see Figure 6).

By "substrate binding arm" or "substrate binding domain" is meant that portion/region of an enzymatic nucleic acid which is able to interact, for example via complementarity (*i.e.*, able to base-pair with), with a portion of its substrate. Preferably, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 can be base-paired (see for example Werner and Uhlenbeck, 1995, *Nucleic Acids Research*, 23, 2092-2096; Hammann *et al.*, 1999, *Antisense and Nucleic Acid Drug Dev.*, 9, 25-31). Examples of such arms are shown generally in Figures 6-8. That is, these arms contain sequences within an enzymatic nucleic acid which are intended to bring enzymatic nucleic acid and target nucleic acid together through complementary base-pairing interactions. An enzymatic nucleic acid of the invention can have binding arms that are contiguous or non-contiguous and can be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides and of sufficient length to stably interact with the target nucleic acid; preferably 12-100 nucleotides; more preferably 14-24 nucleotides long (see for example Werner and Uhlenbeck, *supra*; Hamman *et al.*, *supra*; Hampel *et al.*, EP0360257; Berzal-Herranz *et al.*, 1993, *EMBO J.*, 12, 2567-73) or between 8 and 14 nucleotides long. If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (*i.e.*, each of the binding arms is of the same length; *e.g.*, four and four, five and five nucleotides, or six and six nucleotides, or seven and seven nucleotides long) or asymmetrical (*i.e.*, the binding arms are of different length; *e.g.*, three and five, six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like).

By "Inozyme" or "NCH" motif or configuration is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as NCH Rz in Figure 6 and in Ludwig *et al.*, International PCT Publication No. WO 98/58058 and US Patent Application Serial No. 08/878,640. Inozymes possess endonuclease activity to cleave nucleic acid substrates having a cleavage triplet NCH/, where N is a nucleotide, C is cytidine and H is adenosine, uridine or cytidine, and "/" represents the cleavage site. H is used interchangeably with X. Inozymes can also possess endonuclease activity to cleave nucleic acid substrates having a cleavage triplet NCN/, where N is a nucleotide, C is cytidine, and "/" represents the cleavage site. "T" in Figure 6 represents an Inosine nucleotide, preferably a ribo-Inosine or xylo-Inosine nucleoside.

By "G-cleaver" motif or configuration is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described as G-cleaver Rz in Figure 6 and in Eckstein *et al.*, US 6,127,173. G-cleavers possess endonuclease activity to cleave nucleic acid substrates having a cleavage triplet NYN/, where N is a nucleotide, Y is uridine or cytidine and "/"



represents the cleavage site. G-cleavers can be chemically modified as is generally shown in Figure 6.

By "amberzyme" motif or configuration is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Beigelman *et al.*, International PCT publication No. WO 99/55857 and US Patent Application Serial No. 09/476,387. Amberzymes possess endonuclease activity to cleave nucleic acid substrates having a cleavage triplet NG/N, where N is a nucleotide, G is guanosine, and "/" represents the cleavage site. Amberzymes can be chemically modified to increase nuclease stability through substitutions using modified nucleotides. In addition, differing nucleoside and/or non-nucleoside linkers can be used to substitute the 5'-gaaa-3' loops shown in the figure. Amberzymes represent a non-limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2'-OH) group within its own nucleic acid sequence for activity.

By "zinzyme" motif or configuration is meant, an enzymatic nucleic acid molecule comprising a motif as is generally described in Figure 7 and in Beigelman *et al.*, International PCT publication No. WO 99/55857 and US Patent Application Serial No. 09/918,728. Zinzymes possess endonuclease activity to cleave nucleic acid substrates having a cleavage triplet including but not limited to YG/Y, where Y is uridine or cytidine, and G is guanosine and "/" represents the cleavage site. Zinzymes can be chemically modified to increase nuclease stability through substitutions as are generally shown in Figure 7, including substituting 2'-O-methyl guanosine nucleotides for guanosine nucleotides. In addition, differing nucleotide and/or non-nucleotide linkers can be used to substitute the 5'-gaaa-2' loop shown in the figure. Zinzymes represent a non-limiting example of an enzymatic nucleic acid molecule that does not require a ribonucleotide (2'-OH) group within its own nucleic acid sequence for activity.

By 'DNAzyme' is meant, an enzymatic nucleic acid molecule that does not require the presence of a 2'-OH group within its own nucleic acid sequence for activity. In particular embodiments the enzymatic nucleic acid molecule can have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. DNAzymes can be synthesized chemically or expressed endogenously *in vivo*, by means of a single stranded DNA vector or equivalent thereof. An example of a DNAzyme is shown in Figure 8 and is generally reviewed in Usman *et al.*, US patent No., 6,159,714; Chartrand *et al.*, 1995, *NAR* 23, 4092; Breaker *et al.*, 1995, *Chem. Bio.* 2, 655; Santoro *et al.*, 1997, *PNAS* 94, 4262; Breaker, 1999, *Nature Biotechnology*, 17, 422-423; and

Santoro *et al.*, 2000, *J. Am. Chem. Soc.*, 122, 2433-39. The "10-23" DNAzyme motif is one particular type of DNAzyme that was evolved using *in vitro* selection, see Santoro *et al.*, *supra* and as generally described in Joyce *et al.*, US 5,807,718. Additional DNAzyme motifs can be selected for using techniques similar to those described in these references, and hence,  
5 are within the scope of the present invention.

By "sufficient length" is meant a nucleic acid molecule of the invention is long enough to provide the intended function under the expected condition. For example, a nucleic acid molecule of the invention needs to be of "sufficient length" to provide stable interaction with a target nucleic acid molecule under the expected binding conditions and environment. In  
10 another non-limiting example, for the binding arms of an enzymatic nucleic acid, "sufficient length" means that the binding arm sequence is long enough to provide stable binding to a target site under the expected reaction conditions and environment. The binding arms are not so long as to prevent useful turnover of the nucleic acid molecule.

By "stably interact" is meant interaction of an oligonucleotides with target nucleic acid  
15 (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions) that is sufficient to the intended purpose (e.g., cleavage of target nucleic acid by an enzyme).

By "equivalent" RNA to VEGF, VEGFR1 and/or VEGFR2 is meant to include nucleic acid molecules having homology (partial or complete) to a nucleic acid encoding VEGF,  
20 VEGFR1 and/or VEGFR2 proteins or encoding proteins with similar function as VEGF, VEGFR1 and/or VEGFR2 proteins in various organisms, including human, rodent, primate, rabbit, pig, protozoans, fungi, plants, and other microorganisms and parasites. The equivalent nucleic acid sequence also includes, in addition to the coding region, regions such as 5'-untranslated region, 3'-untranslated region, introns, intron-exon junction and the like.

25 By "homology" is meant the nucleotide sequence of two or more nucleic acid molecules is partially or completely identical.

By "antisense nucleic acid", it is meant a non-enzymatic nucleic acid molecule that binds to target nucleic acid by means of RNA-RNA or RNA-DNA or RNA-PNA (protein  
30 nucleic acid; Egholm *et al.*, 1993 *Nature* 365, 566) interactions and alters the activity of the target nucleic acid (for a review, see Stein and Cheng, 1993 *Science* 261, 1004 and Woolf *et al.*, US patent No. 5,849,902). Typically, antisense molecules are complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule can bind to substrate such that the substrate molecule

forms a loop, and/or an antisense molecule can bind such that the antisense molecule forms a loop. Thus, an antisense molecule can be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule can be complementary to a target sequence or both. For a review of current antisense strategies, see Schmajuk *et al.*, 1999, *J. Biol. Chem.*, 274, 21783-21789, 5 Delihás *et al.*, 1997, *Nature*, 15, 751-753, Stein *et al.*, 1997, *Antisense N. A. Drug Dev.*, 7, 151, Crooke, 2000, *Methods Enzymol.*, 313, 3-45; Crooke, 1998, *Biotech. Genet. Eng. Rev.*, 15, 121-157, Crooke, 1997, *Ad. Pharmacol.*, 40, 1-49. In addition, antisense DNA can be used to target nucleic acid by means of DNA-RNA interactions, thereby activating RNase H, 10 which digests the target nucleic acid in the duplex. The antisense oligonucleotides can comprise one or more RNase H activating region, which is capable of activating RNase H cleavage of a target nucleic acid. Antisense DNA can be synthesized chemically or expressed via the use of a single stranded DNA expression vector or equivalent thereof.

By "RNase H activating region" is meant a region (generally greater than or equal to 4- 15 25 nucleotides in length, preferably from 5-11 nucleotides in length) of a nucleic acid molecule capable of binding to a target nucleic acid to form a non-covalent complex that is recognized by cellular RNase H enzyme (see for example Arrow *et al.*, US 5,849,902; Arrow *et al.*, US 5,989,912). The RNase H enzyme binds to a nucleic acid molecule-target nucleic acid complex and cleaves the target nucleic acid sequence. The RNase H activating region 20 comprises, for example, phosphodiester, phosphorothioate (preferably at least four of the nucleotides are phosphorothioate substitutions; more specifically, 4-11 of the nucleotides are phosphorothioate substitutions); phosphorodithioate, 5'-thiophosphate, or methylphosphonate backbone chemistry or a combination thereof. In addition to one or more backbone chemistries described above, the RNase H activating region can also comprise a variety of 25 sugar chemistries. For example, the RNase H activating region can comprise deoxyribose, arabino, fluoroarabino or a combination thereof, nucleotide sugar chemistry. Those skilled in the art will recognize that the foregoing are non-limiting examples and that any combination of phosphate, sugar and base chemistry of a nucleic acid that supports the activity of RNase H enzyme is within the scope of the definition of the RNase H activating region and the instant 30 invention.

By "2-5A antisense chimera" is meant an antisense oligonucleotide containing a 5'-phosphorylated 2'-5'-linked adenylate residue. These chimeras bind to target nucleic acid in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target nucleic acid (Torrence *et al.*, 1993 *Proc. Natl. Acad. Sci. USA* 90, 1300;

Silverman *et al.*, 2000, *Methods Enzymol.*, 313, 522-533; Player and Torrence, 1998, *Pharmacol. Ther.*, 78, 55-113).

By "triplex forming oligonucleotides" is meant an oligonucleotide that can bind to a double-stranded polynucleotide, such as DNA, in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 504; Fox, 2000, *Curr. Med. Chem.*, 7, 17-37; Praseuth *et al.*, 2000, *Biochim. Biophys. Acta*, 1489, 181-206).

By "gene" it is meant a nucleic acid that encodes an RNA, for example, nucleic acid sequences including but not limited to structural genes encoding a polypeptide.

The term "complementarity" as used herein refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., enzymatic nucleic acid cleavage, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner *et al.*, 1987, *CSH Symp. Quant. Biol.* LII pp.123-133; Frier *et al.*, 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner *et al.*, 1987, *J. Am. Chem. Soc.* 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" or "2'-OH" is meant a nucleotide with a hydroxyl group at the 2' position of a  $\beta$ -D-ribo-furanose moiety.

By "nucleic acid decoy molecule", or "decoy" as used herein is meant a nucleic acid molecule that mimics the natural binding domain for a ligand. The decoy therefore competes with the natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation response (TAR) RNA can act as a

"decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIV RNA (Sullenger et al., 1990, *Cell*, 63, 601-608).

By "aptamer" or "nucleic acid aptamer" as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that is distinct from sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. Similarly, the nucleic acid molecules of the instant invention can bind to VEGFR1 or VEGFR2 receptors to block activity of the receptor. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art, see for example Gold *et al.*, US 5,475,096 and 5,270,163; Gold *et al.*, 1995, *Annu. Rev. Biochem.*, 64, 763; Brody and Gold, 2000, *J. Biotechnol.*, 74, 5; Sun, 2000, *Curr. Opin. Mol. Ther.*, 2, 100; Kusser, 2000, *J. Biotechnol.*, 74, 27; Hermann and Patel, 2000, *Science*, 287, 820; and Jayasena, 1999, *Clinical Chemistry*, 45, 1628.

The term "double stranded RNA" or "dsRNA" as used herein refers to a double stranded RNA molecule capable of RNA interference "RNAi", including short interfering RNA "siRNA" see for example Bass, 2001, *Nature*, 411, 428-429; Elbashir et al., 2001, *Nature*, 411, 494-498; and Kreutzer *et al.*, International PCT Publication No. WO 00/44895; Zernicka-Goetz *et al.*, International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck *et al.*, International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li *et al.*, International PCT Publication No. WO 00/44914.

By "nucleic acid sensor molecule" or "allozyme" as used herein is meant a nucleic acid molecule comprising an enzymatic domain and a sensor domain, where the enzymatic nucleic acid domain's ability to catalyze a chemical reaction is dependent on the interaction with a target signaling molecule, such as a nucleic acid, polynucleotide, oligonucleotide, peptide, polypeptide, or protein, for example VEGF, VEGFR1 and/or VEGFR2. The introduction of chemical modifications, additional functional groups, and/or linkers, to the nucleic acid sensor molecule can provide enhanced catalytic activity of the nucleic acid sensor molecule, increased binding affinity of the sensor domain to a target nucleic acid, and/or improved nuclease/chemical stability of the nucleic acid sensor molecule, and are

hence within the scope of the present invention (see for example Usman *et al.*, US Patent Application No. 09/877,526, George *et al.*, US Patent Nos. 5,834,186 and 5,741,679, Shih *et al.*, US Patent No. 5,589,332, Nathan *et al.*, US Patent No 5,871,914, Nathan and Ellington, International PCT publication No. WO 00/24931, Breaker *et al.*, International PCT Publication Nos. WO 00/26226 and 98/27104, and Sullenger *et al.*, US Patent Application Serial No. 09/205,520).

By "sensor component" or "sensor domain" of the nucleic acid sensor molecule as used herein is meant, a nucleic acid sequence (e.g., RNA or DNA or analogs thereof) which interacts with a target signaling molecule, for example a nucleic acid sequence in one or more regions of a target nucleic acid molecule or more than one target nucleic acid molecule, and which interaction causes the enzymatic nucleic acid component of the nucleic acid sensor molecule to either catalyze a reaction or stop catalyzing a reaction. In the presence of target signaling molecule of the invention, such as VEGF, VEGFR1 and/or VEGFR2, the ability of the sensor component, for example, to modulate the catalytic activity of the nucleic acid sensor molecule, is inhibited or diminished. The sensor component can comprise recognition properties relating to chemical or physical signals capable of modulating the nucleic acid sensor molecule via chemical or physical changes to the structure of the nucleic acid sensor molecule. The sensor component can be derived from a naturally occurring nucleic acid binding sequence, for example, RNAs that bind to other nucleic acid sequences *in vivo*. Alternately, the sensor component can be derived from a nucleic acid molecule (aptamer) which is evolved to bind to a nucleic acid sequence within a target nucleic acid molecule (see for example Gold *et al.*, US 5,475,096 and 5,270,163). The sensor component can be covalently linked to the nucleic acid sensor molecule, or can be non-covalently associated. A person skilled in the art will recognize that all that is required is that the sensor component is able to selectively inhibit the activity of the nucleic acid sensor molecule to catalyze a reaction.

By "target molecule" or "target signaling molecule" is meant a molecule capable of interacting with a nucleic acid sensor molecule, specifically a sensor domain of a nucleic acid sensor molecule, in a manner that causes the nucleic acid sensor molecule to be active or inactive. The interaction of the signaling agent with a nucleic acid sensor molecule can result in modification of the enzymatic nucleic acid component of the nucleic acid sensor molecule via chemical, physical, topological, or conformational changes to the structure of the molecule, such that the activity of the enzymatic nucleic acid component of the nucleic acid sensor molecule is modulated, for example is activated or deactivated. Signaling agents can comprise target signaling molecules such as macromolecules, ligands, small molecules,

metals and ions, nucleic acid molecules including but not limited to RNA and DNA or analogs thereof, proteins, peptides, antibodies, polysaccharides, lipids, sugars, microbial or cellular metabolites, pharmaceuticals, and organic and inorganic molecules in a purified or unpurified form, for example VEGF, VEGFR1 and/or VEGFR2.

- 5           The term "triplex forming oligonucleotides" as used herein refers to an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such a triple helix structure has been shown to inhibit transcription of a targeted gene (Duval-Valentin *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 504; Fox, 2000, *Curr. Med. Chem.*, 7, 17-37; Praseuth *et al.*, 2000, *Biochim. Biophys. Acta*, 1489, 181-206).
- 10           The nucleic acid molecules that modulate the expression of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 specific nucleic acids, represent a novel therapeutic approach to treat or control a variety of angiogenesis related disorders and conditions, including but not limited to tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic
- 15   retinopathy, or age related macular degeneration, and/or endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and/or menopausal dysfunction. The nucleic acid molecules that modulate the expression of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 specific nucleic acids also represent a novel approach to control ovulation or embryonic
- 20   implantation and therefore provide a novel means of birth control.

- In one embodiment of the present invention, a nucleic acid molecule of the instant invention can be between 12 and 100 nucleotides in length. An exemplary enzymatic nucleic acid molecule of the invention is shown as Formula I and/or Formula II. For example, enzymatic nucleic acid molecules of the invention are preferably between 15 and 50
- 25   nucleotides in length, more preferably between 25 and 40 nucleotides in length, *e.g.*, 34, 36, or 38 nucleotides in length (for example see Jarvis *et al.*, 1996, *J. Biol. Chem.*, 271, 29107-29112). Exemplary DNAzymes of the invention are preferably between 15 and 40 nucleotides in length, more preferably between 25 and 35 nucleotides in length, *e.g.*, 29, 30, 31, or 32 nucleotides in length (see for example Santoro *et al.*, 1998, *Biochemistry*, 37, 13330-13342; Chartrand *et al.*, 1995, *Nucleic Acids Research*, 23, 4092-4096). Exemplary antisense
- 30   molecules of the invention are preferably between 15 and 75 nucleotides in length, more preferably between 20 and 35 nucleotides in length, *e.g.*, 25, 26, 27, or 28 nucleotides in length (see for example Woolf *et al.*, 1992, *PNAS*, 89, 7305-7309; Milner *et al.*, 1997, *Nature Biotechnology*, 15, 537-541). Exemplary triplex forming oligonucleotide molecules
- 35   of the invention are preferably between 10 and 40 nucleotides in length, more preferably

between 12 and 25 nucleotides in length, *e.g.*, 18, 19, 20, or 21 nucleotides in length (see for example Maher *et al.*, 1990, *Biochemistry*, 29, 8820-8826; Strobel and Dervan, 1990, *Science*, 249, 73-75). Those skilled in the art will recognize that all that is required is that the nucleic acid molecule be of length and conformation sufficient and suitable for the nucleic acid molecule to catalyze a reaction contemplated herein. The length of the nucleic acid molecules of the instant invention are not limiting within the general limits stated.

In a preferred embodiment, a nucleic acid molecule that modulates, for example, down-regulates, VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 replication or expression comprises between 8 and 100 bases complementary to a nucleic acid molecule of VEGFR1 and/or VEGFR2. More preferably, a nucleic acid molecule that modulates VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 replication or expression comprises between 14 and 24 bases complementary to a nucleic acid molecule of VEGFR1 and/or VEGFR2.

The invention provides a method for producing a class of nucleic acid-based gene modulating agents which exhibit a high degree of specificity for the nucleic acid of a desired target. For example, a nucleic acid molecule of the invention is preferably targeted to a highly conserved sequence region of target nucleic acids encoding VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 (specifically VEGF, VEGFR1 and/or VEGFR2 genes) such that specific treatment of a disease or condition can be provided with either one or several nucleic acid molecules of the invention. Such nucleic acid molecules can be delivered exogenously to specific tissue or cellular targets as required. Alternatively, the nucleic acid molecules can be expressed from DNA and/or RNA vectors that are delivered to specific cells.

As used in herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism. The cell can, for example, be *in vitro*, *e.g.*, in cell culture, or present in a multicellular organism, including, *e.g.*, birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell may be prokaryotic (*e.g.*, bacterial cell) or eukaryotic (*e.g.*, mammalian or plant cell).

By "VEGFR1 and/or VEGFR2 proteins" is meant, protein receptor or a mutant protein derivative thereof, having vascular endothelial growth factor receptor activity, for example, having the ability to bind vascular endothelial growth factor and/or having tyrosine kinase activity.



By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other.

5 "Angiogenesis" refers to formation of new blood vessels which is an essential process in reproduction, development and wound repair. "Tumor angiogenesis" refers to the induction of the growth of blood vessels from surrounding tissue into a solid tumor. Tumor growth and tumor metastasis are dependent on angiogenesis (for a review see Folkman, 1985 *supra*; Folkman 1990 *J. Natl. Cancer Inst.*, 82, 4; Folkman and Shing, 1992 *J. Biol. Chem.* 267, 10931).

10 Angiogenesis plays an important role in other diseases such as arthritis wherein new blood vessels have been shown to invade the joints and degrade cartilage (Folkman and Shing, *supra*).

"Retinopathy" refers to inflammation of the retina and/or degenerative condition of the retina which may lead to occlusion of the retina and eventual blindness. In "diabetic  
15 retinopathy" angiogenesis causes the capillaries in the retina to invade the vitreous resulting in bleeding and blindness which is also seen in neonatal retinopathy (for a review see Folkman, 1985 *supra*; Folkman 1990 *supra*; Folkman and Shing, 1992 *supra*).

Nucleic acid-based inhibitors of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2, expression are useful for the prevention, treatment, and/or control of angiogenesis  
20 related disorders and conditions, including but not limited to, tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and/or endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), menopausal  
25 dysfunction, and other diseases or conditions that are related to or will respond to the levels of VEGF, VEGFR1 and/or VEGFR2 in a cell or tissue, alone or in combination with other therapies. The reduction of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 expression (specifically VEGF, VEGFR1 and/or VEGFR2 gene RNA levels) and thus reduction in the level of the respective protein relieves, to some degree, the symptoms of the  
30 disease or condition. Nucleic acid-based inhibitors of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 expression are also useful as birth control agents, for example by inhibition of ovulation or embryonic uterine implantation.

The nucleic acid molecules of the invention can be added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid complexes can be locally administered to relevant tissues *ex vivo*, or in *vivo* through injection or infusion pump, with or without their incorporation in biopolymers. In preferred embodiments, the nucleic acid inhibitors comprise sequences, which are complementary to polynucleotides, for example DNA and RNA, having VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 sequence.

Triplex molecules of the invention can be provided targeted to DNA target regions, and containing the DNA equivalent of a target sequence or a sequence complementary to the specified target (substrate) sequence. Antisense molecules typically are complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule can bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule can bind such that the antisense molecule forms a loop. Thus, the antisense molecule can be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule can be complementary to a target sequence or both.

By "consists essentially of" is meant that the active nucleic acid molecule of the invention, for example, an enzymatic nucleic acid molecule, contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind nucleic acid such that cleavage at the target site occurs. Other sequences can be present which do not interfere with such cleavage. Thus, a core region can, for example, include one or more loop, stem-loop structure, or linker which does not prevent enzymatic activity. Thus, a particular region of a nucleic acid molecule of the invention can be such a loop, stem-loop, nucleotide linker, and/or non-nucleotide linker and can be represented generally as sequence "X". Thus, a core region may, for example, include one or more loop or stem-loop structures which do not prevent enzymatic activity. For example, a core sequence for a hammerhead enzymatic nucleic acid can comprise a conserved sequence, such as 5'-CUGAUGAG-3' and 5'-CGAA-3' connected by "X", where X is 5'-GCCGUUAGGC-3' (SEQ ID NO 5979), or any other Stem II region known in the art, or a nucleotide and/or non-nucleotide linker. Similarly, for other nucleic acid molecules of the instant invention, such as Inozyme, G-cleaver, amberzyme, zinzyme, DNAzyme, antisense, 2-5A antisense, triplex forming nucleic acid, aptamers, decoy nucleic acids, dsRNA or siRNA, other sequences or non-nucleotide linkers can be present that do not interfere with the function of the nucleic acid molecule.

Sequence X can be a linker of  $\geq 2$  nucleotides in length, preferably 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 26, 30, where the nucleotides can preferably be internally base-paired to form a stem of preferably  $\geq 2$  base pairs. Alternatively or in addition, sequence X can be a non-nucleotide linker. In yet another embodiment, the nucleotide linker X can be a nucleic acid aptamer, such as an ATP aptamer, HIV Rev aptamer (RRE), HIV Tat aptamer (TAR) and others (for a review see Gold *et al.*, 1995, *Annu. Rev. Biochem.*, 64, 763; and Szostak & Ellington, 1993, in *The RNA World*, ed. Gesteland and Atkins, pp. 511, CSH Laboratory Press). A nucleic acid aptamer includes a nucleic acid sequence capable of interacting with a ligand. The ligand can be any natural or a synthetic molecule, including but not limited to a resin, metabolites, nucleosides, nucleotides, drugs, toxins, transition state analogs, peptides, lipids, proteins, amino acids, nucleic acid molecules, hormones, carbohydrates, receptors, cells, viruses, bacteria and others.

In yet another embodiment, the non-nucleotide linker X is as defined herein. The term "non-nucleotide" as used herein include either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, or polyhydrocarbon compounds. Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma *et al.*, *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand *et al.*, *Nucleic Acids Res.* 1990, 18:6353; McCurdy *et al.*, *Nucleosides & Nucleotides* 1991, 10:287; Ischke *et al.*, *Tetrahedron Lett.* 1993, 34:301; Ono *et al.*, *Biochemistry* 1991, 30:9914; Arnold *et al.*, International Publication No. WO 89/02439; Usman *et al.*, International Publication No. WO 95/06731; Dudycz *et al.*, International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein.

A "non-nucleotide" further means any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine. Thus, in one embodiment, the invention features an enzymatic nucleic acid molecule having one or more non-nucleotide moieties, and having enzymatic activity to cleave an RNA or DNA molecule.

In another aspect of the invention, nucleic acid molecules that interact with target nucleic acid molecules and down-regulate VEGF and/or VEGFr, such as VEGFR1 and/or

VEGFR2 (specifically VEGF, VEGFR1 and/or VEGFR2 gene) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Enzymatic nucleic acid molecule or antisense expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the enzymatic nucleic acid molecules or antisense are delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of enzymatic nucleic acid molecules or antisense. Such vectors can be repeatedly administered as necessary. Once expressed, the enzymatic nucleic acid molecules or antisense bind to the target nucleic acid and down-regulate its function or expression. Delivery of enzymatic nucleic acid molecule or antisense expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells explanted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector.

By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

By "subject" or "patient" is meant an organism, which is a donor or recipient of explanted cells, or the cells themselves. "Subject" or "Patient" also refers to an organism to which the nucleic acid molecules of the invention can be administered. Preferably, a subject or patient is a mammal or mammalian cells. More preferably, a subject or patient is a human or human cells.

By "enhanced enzymatic activity" is meant to include activity measured in cells and/or in vivo where the activity is a reflection of both the catalytic activity and the stability of the nucleic acid molecules of the invention. In this invention, the product of these properties can be increased *in vivo* compared to an all RNA enzymatic nucleic acid or all DNA enzyme. In some cases, the activity or stability of the nucleic acid molecule can be decreased (i.e., less than ten-fold), but the overall activity of the nucleic acid molecule is enhanced, *in vivo*.

The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with the levels of VEGFR1 and/or VEGFR2, the patient can be treated, or other appropriate cells can be treated, as is evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

In a further embodiment, the described molecules of the invention can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules can be used in combination with one or more known therapeutic agents to treat angiogenesis related disorders and conditions, including but not limited to tumor angiogenesis, cancers such as breast cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, or melanoma, or ocular indications such as diabetic retinopathy, or age related macular degeneration, and/or endometriosis, birth control, endometrial tumors, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), menopausal dysfunction, endometrial carcinoma, and/or other diseases or conditions which respond to the modulation of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 expression.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

15

#### Brief Description of the Drawings

Figure 1 shows a secondary structure model of ANGIOZYME™ ribozyme bound to its RNA target.

Figure 2 shows a time course of inhibition of primary tumor growth following systemic administration of ANGIOZYME™ in the LLC mouse model.

20

Figure 3 shows inhibition of primary tumor growth following systemic administration of ANGIOZYME™ according to a certain dosing regimen in the LLC mouse model.

Figure 4 shows a dose-dependent inhibition of tumor metastases following systemic administration of ANGIOZYME™ in a mouse colorectal model.

Figure 5 is a graph showing the plasma concentration profile of ANGIOZYME™ after a single subcutaneous (SC) dose of 10, 30, 100 or 300 mg/m<sup>2</sup>.

25

Figure 6 shows examples of chemically stabilized ribozyme motifs. HH Rz, represents hammerhead ribozyme motif (Usman *et al.*, 1996, *Curr. Op. Struct. Bio.*, 1, 527); NCH Rz represents the NCH ribozyme motif (Ludwig *et al.*, International PCT Publication No. WO 98/58058 and US Patent Application Serial No. 08/878,640); G-Cleaver, represents G-cleaver ribozyme motif (Kore *et al.*, 1998, *Nucleic Acids Research* 26, 4116-4120, Eckstein *et*

30

al., US 6,127,173). N or n, represent independently a nucleotide which can be same or different and have complementarity to each other; rI, represents ribo-Inosine nucleotide; arrow indicates the site of cleavage within the target. Position 4 of the HH Rz and the NCH Rz is shown as having 2'-C-allyl modification, but those skilled in the art will recognize that this position can be modified with other modifications well known in the art, so long as such modifications do not significantly inhibit the activity of the ribozyme.

Figure 7 shows an example of a Zinzyme A ribozyme motif that is chemically stabilized (see for example Beigelman *et al.*, International PCT publication No. WO 99/55857 and US Patent Application Serial No. 09/918,728).

Figure 8 shows an example of a DNAzyme motif described by Santoro *et al.*, 1997, *PNAS*, 94, 4262 and Joyce *et al.*, US 5,807,718 .

Figure 9 shows data demonstrating the inhibition of soluble VEGFR1 in a clinical study using ANGIOZYME (SEQ ID NO: 5977) .

Figure 10 shows an generalized outline for the mouse model of proliferative retinopathy showing the points of ribozyme administration.

Figure 11 shows a graph demonstrating the efficacy of a VEGF-receptor-targeted enzymatic nucleic acid molecule in a mouse model of proliferative retinopathy.

#### Detailed Description of the Invention

##### Nucleic Acid Molecules and Mechanism of Action

**Enzymatic Nucleic Acid:** Several varieties of naturally-occurring enzymatic nucleic acids are presently known. In addition, several *in vitro* selection (evolution) strategies (Orgel, 1979, *Proc. R. Soc. London*, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989, *Gene*, 82, 83-87; Beaudry *et al.*, 1992, *Science* 257, 635-641; Joyce, 1992, *Scientific American* 267, 90-97; Breaker *et al.*, 1994, *TIBTECH* 12, 268; Bartel *et al.*, 1993, *Science* 261:1411-1418; Szostak, 1993, *TIBS* 17, 89-93; Kumar *et al.*, 1995, *FASEB J.*, 9, 1183; Breaker, 1996, *Curr. Op. Biotech.*, 7, 442; Santoro *et al.*, 1997, *Proc. Natl. Acad. Sci.*, 94, 4262; Tang *et al.*, 1997, *RNA* 3, 914; Nakamaye & Eckstein, 1994, *supra*; Long & Uhlenbeck, 1994, *supra*; Ishizaka *et al.*, 1995, *supra*; Vaish *et al.*, 1997, *Biochemistry* 36, 6495; all of these are incorporated by reference herein). Each can catalyze a series of reactions including the hydrolysis of

phosphodiester bonds in *trans* (and thus can cleave other nucleic acid molecules) under physiological conditions.

The enzymatic nature of an enzymatic nucleic acid molecule has significant advantages, one advantage being that the concentration of enzymatic nucleic acid molecule necessary to affect a therapeutic treatment is lower. This advantage reflects the ability of the enzymatic nucleic acid molecule to act enzymatically. Thus, a single enzymatic nucleic acid molecule is able to cleave many molecules of target nucleic acid. In addition, the enzymatic nucleic acid molecule is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target nucleic acid, but also on the mechanism of target nucleic acid cleavage. Single mismatches, or base-substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of a enzymatic nucleic acid molecule.

Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. With the proper design, such enzymatic nucleic acid molecules can be targeted to RNA transcripts, and achieve efficient cleavage *in vitro* (Zaug *et al.*, 324, *Nature* 429 1986; Uhlenbeck, 1987 *Nature* 328, 596; Kim *et al.*, 84 *Proc. Natl. Acad. Sci. USA* 8788, 1987; Dreyfus, 1988, *Einstein Quart. J. Bio. Med.*, 6, 92; Haseloff and Gerlach, 334 *Nature* 585, 1988; Cech, 260 *JAMA* 3030, 1988; and Jefferies *et al.*, 17 *Nucleic Acids Research* 1371, 1989; Santoro *et al.*, 1997 *supra*).

Because of their sequence specificity, *trans*-cleaving enzymatic nucleic acid molecules can be used as therapeutic agents for human disease (Usman & McSwiggen, 1995 *Ann. Rep. Med. Chem.* 30, 285-294; Christoffersen and Marr, 1995 *J. Med. Chem.* 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific nucleic acid targets within the background of cellular nucleic acid. Such a cleavage event renders the nucleic acid non-functional and abrogates protein expression from that nucleic acid. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited (Warashina *et al.*, 1999, *Chemistry and Biology*, 6, 237-250).

Enzymatic nucleic acid molecules of the invention that are allosterically regulated ("allozymes") can be used to down-regulate VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2, expression. These allosteric enzymatic nucleic acids or allozymes (see for example Usman *et al.*, US Patent Application No. 09/877,526, George *et al.*, US Patent Nos. 5,834,186 and 5,741,679, Shih *et al.*, US Patent No. 5,589,332, Nathan *et al.*, US Patent No 5,871,914, Nathan and Ellington, International PCT publication No. WO 00/24931, Breaker

*et al.*, International PCT Publication Nos. WO 00/26226 and 98/27104, and Sullenger *et al.*, US Patent Application Serial No. 09/205,520) are designed to respond to a signaling agent, for example, mutant VEGFR1 and/or VEGFR2 protein, wild-type VEGFR1 and/or VEGFR2 protein, mutant VEGFR1 and/or VEGFR2 RNA, wild-type VEGFR1 and/or VEGFR2 RNA, other proteins and/or RNAs involved in VEGF signal transduction, compounds, metals, polymers, molecules and/or drugs that are targeted to VEGFR1 and/or VEGFR2 expression, which in turn modulates the activity of the enzymatic nucleic acid molecule. In response to interaction with a predetermined signaling agent, the activity of the allosteric enzymatic nucleic acid is activated or inhibited such that the expression of a particular target is selectively down-regulated. The target can comprise wild-type VEGFR1 and/or VEGFR2, mutant VEGFR1 and/or VEGFR2, and/or a predetermined component of the VEGF signal transduction pathway. In a specific example, allosteric enzymatic nucleic acid molecules that are activated by interaction with a RNA encoding VEGF protein are used as therapeutic agents *in vivo*. The presence of RNA encoding the VEGF protein activates the allosteric enzymatic nucleic acid molecule that subsequently cleaves the RNA encoding a VEGFR1 and/or VEGFR2 protein resulting in the inhibition of VEGFR1 and/or VEGFR2 protein expression.

In another non-limiting example, an allozyme can be activated by a VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 protein, peptide, or mutant polypeptide that causes the allozyme to inhibit the expression of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 genes, by, for example, cleaving RNA encoded by VEGF, VEGFR1 and/or VEGFR2 gene. In this non-limiting example, the allozyme acts as a decoy to inhibit the function of VEGF, VEGFR1 and/or VEGFR2 and also inhibit the expression of VEGF, VEGFR1 and/or VEGFR2 once activated by the VEGF, VEGFR1 and/or VEGFR2 protein.

Antisense: Antisense molecules can be modified or unmodified RNA, DNA, or mixed polymer oligonucleotides and primarily function by specifically binding to matching sequences resulting in inhibition of peptide synthesis (Wu-Pong, Nov 1994, *BioPharm*, 20-33). The antisense oligonucleotide binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules can also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay & Roth, 1996, *Crit. Rev. in Oncogenesis* 7, 151-190).

In addition, binding of single stranded DNA to RNA can result in nuclease degradation of the heteroduplex (Wu-Pong, *supra*; Crooke, *supra*). To date, the only backbone modified



DNA chemistry which act as substrates for RNase H are phosphorothioates, phosphorodithioates, and borontrifluoridates. Recently it has been reported that 2'-arabino and 2'-fluoro arabino- containing oligos can also activate RNase H activity.

5 A number of antisense molecules have been described that utilize novel configurations of chemically modified nucleotides, secondary structure, and/or RNase H substrate domains (Woolf *et al.*, International PCT Publication No. WO 98/13526; Thompson *et al.*, International PCT Publication No. WO 99/54459; Hartmann *et al.*, USSN 60/101,174 which was filed on September 21, 1998) all of these are incorporated by reference herein in their entirety.

10 In addition, antisense deoxyoligoribonucleotides can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector or equivalents and variations thereof.

15 Triplex Forming Oligonucleotides (TFO): Single stranded DNA can be designed to bind to genomic DNA in a sequence specific manner. TFOs are comprised of pyrimidine-rich oligonucleotides which bind DNA helices through Hoogsteen Base-pairing (Wu-Pong, *supra*). The resulting triple helix composed of the DNA sense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase. The TFO mechanism can result in gene expression or cell death since binding can be irreversible (Mukhopadhyay & Roth, *supra*).

20 2-5A Antisense Chimera: The 2-5A system is an interferon mediated mechanism for RNA degradation found in higher vertebrates (Mitra *et al.*, 1996, *Proc Nat Acad Sci USA* 93, 6780-6785). Two types of enzymes, 2-5A synthetase and RNase L, are required for RNA cleavage. The 2-5A synthetases require double stranded RNA to form 2'-5' oligoadenylates (2-5A). 2-5A then acts as an allosteric effector for utilizing RNase L which has the ability to  
25 cleave single stranded RNA. The ability to form 2-5A structures with double stranded RNA makes this system particularly useful for inhibition of viral replication.

(2'-5') oligoadenylate structures can be covalently linked to antisense molecules to form chimeric oligonucleotides capable of RNA cleavage (Torrence, *supra*). These molecules putatively bind and activate a 2-5A dependent RNase, the oligonucleotide/enzyme  
30 complex then binds to a target RNA molecule which can then be cleaved by the RNase enzyme.

RNAi: Double-stranded RNAs can suppress expression of homologous genes through an evolutionarily conserved process named RNA interference (RNAi) or post-transcriptional gene silencing (PTGS). One mechanism underlying silencing is the degradation of target mRNAs by an RNP complex, which contains short interfering RNAs (siRNAs) as guides to substrate selection. Short interfering RNAs are typically 21 to 23 nucleotides in length. A bidentate nuclease called Dicer has been implicated as the protein responsible for siRNA production. For example, a double-stranded RNA (dsRNA) matching a gene sequence is synthesized *in vitro* and introduced into a cell. The dsRNA feeds into a biological pathway and is broken into short pieces of short interfering (si) RNAs. With the help of cellular enzymes such as Dicer, the siRNA triggers the degradation of the messenger RNA that matches its sequence (see for example Tuschl *et al.*, International PCT Publication No. WO 01/75164; Bass, 2001, *Nature*, 411, 428-429; Elbashir *et al.*, 2001, *Nature*, 411, 494-498; and Kreutzer *et al.*, International PCT Publication No. WO 00/44895).

#### Target sites

Targets for useful nucleic acid molecules of the invention, such as enzymatic nucleic acid molecules, dsRNA, and antisense nucleic acids can be determined as disclosed in Draper *et al.*, WO 93/23569; Sullivan *et al.*, WO 93/23057; Thompson *et al.*, WO 94/02595; Draper *et al.*, WO 95/04818; McSwiggen *et al.*, US Patent No. 5,525,468, and hereby incorporated by reference herein in totality. Other examples include the following PCT applications, which concern inactivation of expression of disease-related genes: WO 95/23225, WO 95/13380, WO 94/02595, incorporated by reference herein. Rather than repeat the guidance provided in those documents here, below are provided specific examples of such methods, not limiting to those in the art. Enzymatic nucleic acid molecules and antisense to such targets are designed as described in those applications and synthesized to be tested *in vitro* and *in vivo*, as also described. The sequences of human VEGF, VEGFR1 and/or VEGFR2 RNAs are screened for optimal nucleic acid target sites using a computer-folding algorithm. Potential nucleic acid binding/cleavage sites are identified. While human sequences can be screened and nucleic acid molecules thereafter designed, as discussed in Stinchcomb *et al.*, WO 95/23225, mouse targeted enzymatic nucleic acid molecules can be useful to test efficacy of action of the nucleic acid molecule prior to testing in humans.

Nucleic acid molecule binding/cleavage sites are identified, for example enzymatic nucleic acid, antisense, and dsRNA mediated binding sites are chosen. For enzymatic nucleic acid molecules of the invention, the nucleic acid molecules are individually analyzed by computer folding (Jaeger *et al.*, 1989 *Proc. Natl. Acad. Sci. USA*, 86, 7706) to assess whether

the sequences fold into the appropriate secondary structure. Those nucleic acid molecules with unfavorable intramolecular interactions such as between the binding arms and the catalytic core can be eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity.

5 Nucleic acids, such as antisense, RNAi, and/or enzymatic nucleic acid molecule binding/cleavage sites are identified and are designed to anneal to various sites in the nucleic acid target. The binding arms of enzymatic nucleic acid molecules of the invention are complementary to the target site sequences described above. Antisense and RNAi sequences are designed to have partial or complete complementarity to the nucleic acid target. The  
10 nucleic acid molecules can be chemically synthesized. The method of synthesis used follows the procedure for normal DNA/RNA synthesis as described below and in Usman *et al.*, 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990 *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684; Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19.

#### 15 Synthesis of Nucleic acid Molecules

Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small refers to nucleic acid motifs less than about 100 nucleotides in length, preferably less than about 80 nucleotides in length, and more preferably  
20 less than about 50 nucleotides in length; *e.g.*, antisense oligonucleotides, enzymatic nucleic acids, aptamers, allozymes, decoys, siRNA etc.) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.

25 DNA Oligonucleotides are synthesized using protocols known in the art as described in Caruthers *et al.*, 1992, *Methods in Enzymology* 211, 3-19, Thompson *et al.*, International PCT Publication No. WO 99/54459, Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677-2684, Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, Brennan *et al.*, 1998, *Biotechnol Bioeng.*, 61, 33-45, and Brennan, US patent No. 6,001,311. All of these references are incorporated herein  
30 by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2  $\mu$ mol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 sec coupling step for 2'-deoxy nucleotides. Table II

outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2  $\mu\text{mol}$  scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60  $\mu\text{L}$  of 0.11 M = 6.6  $\mu\text{mol}$ ) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60  $\mu\text{L}$  of 0.25 M = 15  $\mu\text{mol}$ ) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40  $\mu\text{L}$  of 0.11 M = 4.4  $\mu\text{mol}$ ) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40  $\mu\text{L}$  of 0.25 M = 10  $\mu\text{mol}$ ) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include; detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM  $\text{I}_2$ , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

Deprotection of the DNA polynucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

The method of synthesis used for RNA oligonucleotides including certain nucleic acid molecules of the invention follows the procedure as described in Usman *et al.*, 1987, *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990, *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677-2684 Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2  $\mu\text{mol}$  scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O-methylated nucleotides. Table II outlines the amounts and the

contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2  $\mu\text{mol}$  scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60  $\mu\text{L}$  of 0.11 M = 6.6  $\mu\text{mol}$ ) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60  $\mu\text{L}$  of 0.25 M = 15  $\mu\text{mol}$ ) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120  $\mu\text{L}$  of 0.11 M = 13.2  $\mu\text{mol}$ ) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120  $\mu\text{L}$  of 0.25 M = 30  $\mu\text{mol}$ ) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include; detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM  $\text{I}_2$ , 49 mM pyridine, 9% water in THF (PERSEPTIVE<sup>TM</sup>). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300  $\mu\text{L}$  of a solution of 1.5 mL *N*-methylpyrrolidinone, 750  $\mu\text{L}$  TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65 °C. After 1.5 h, the oligomer is quenched with 1.5 M  $\text{NH}_4\text{HCO}_3$ .

Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65 °C for 15 min. The vial is brought to r.t. TEA•3HF (0.1 mL) is added and the vial is heated at 65 °C for 15 min. The sample is cooled at -20 °C and then quenched with 1.5 M  $\text{NH}_4\text{HCO}_3$ .

For purification of the trityl-on oligomers, the quenched  $\text{NH}_4\text{HCO}_3$  solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

Inactive hammerhead ribozymes or binding attenuated control (BAC) oligonucleotides are synthesized by substituting a U for G5 and a U for A14 (numbering from Hertel, K. J., *et al.*, 1992, *Nucleic Acids Res.*, 20, 3252). Similarly, one or more nucleotide substitutions can be introduced in other enzymatic nucleic acid molecules to inactivate the molecule and such molecules can serve as a negative control.

The average stepwise coupling yields are typically >98% (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96 well format, all that is important is the ratio of chemicals used in the reaction.

Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example by ligation (Moore *et al.*, 1992, *Science* 256, 9923; Draper *et al.*, International PCT publication No. WO 93/23569; Shabarova *et al.*, 1991, *Nucleic Acids Research* 19, 4247; Bellon *et al.*, 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon *et al.*, 1997, *Bioconjugate Chem.* 8, 204).

Preferably, the nucleic acid molecules of the present invention are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163). Ribozymes are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Wincott *et al.*, *Supra*, the totality of which is hereby incorporated herein by reference) and are re-suspended in water.

#### Optimizing Activity of the nucleic acid molecule of the invention.

Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases can increase their potency (see *e.g.*, Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991, *Science* 253, 314; Usman and Cedergren, 1992, *Trends*

in *Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; Gold *et al.*, US 6,300,074; and Burgin *et al.*, *supra*; all of which are incorporated by reference herein). Modifications which enhance their efficacy in cells, and removal of bases from  
5 nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired. (All these publications are hereby incorporated by reference herein).

There are several examples in the art describing sugar, base and phosphate  
10 modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H,  
nucleotide base modifications (for a review see Usman and Cedergren, 1992, *TIBS*, 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996, *Biochemistry*, 35,  
15 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein *et al.*, International Publication PCT No. WO 92/07065; Perrault *et al.* *Nature*, 1990, 344, 565-568; Pieken *et al.* *Science*, 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.*, 1992, 17, 334-339; Usman *et al.* International  
Publication PCT No. WO 93/15187; Sproat, US Patent No. 5,334,711 and Beigelman *et al.*,  
20 1995, *J. Biol. Chem.*, 270, 25702; Beigelman *et al.*, International PCT publication No. WO 97/26270; Beigelman *et al.*, US Patent No. 5,716,824; Usman *et al.*, US patent No. 5,627,053; Woolf *et al.*, International PCT Publication No. WO 98/13526; Thompson *et al.*,  
USSN 60/082,404 which was filed on April 20, 1998; Karpeisky *et al.*, 1998, *Tetrahedron Lett.*, 39, 1131; Earnshaw and Gait, 1998, *Biopolymers (Nucleic acid Sciences)*, 48, 39-55;  
25 Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134; and Burlina *et al.*, 1997, *Bioorg. Med. Chem.*, 5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into ribozymes without inhibiting catalysis, and are incorporated by reference herein. In  
30 view of such teachings, similar modifications can be used as described herein to modify the nucleic acid molecules of the instant invention.

While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5'-methylphosphonate linkages improves stability, too many of these modifications can cause some toxicity. Therefore when designing  
35 nucleic acid molecules the amount of these internucleotide linkages should be minimized.

The reduction in the concentration of these linkages should lower toxicity resulting in increased efficacy and higher specificity of these molecules.

Nucleic acid molecules having chemical modifications that maintain or enhance activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or *in vivo* the activity may not be significantly lowered. Therapeutic nucleic acid molecules delivered exogenously are optimally stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA and DNA (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677; Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19 (incorporated by reference herein) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

In one embodiment, nucleic acid molecules of the invention include one or more G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets. In another embodiment, nucleic acid molecules of the invention include one or more LNA "locked nucleic acid" nucleotides such as a 2', 4'-C myethylene bicyclo nucleotide (see for example Wengel *et al.*, International PCT Publication No. WO 00/66604 and WO 99/14226).

In another embodiment, the invention features conjugates and/or complexes of nucleic acid molecules targeting VEGF receptors such as VEGFR1 and/or VEGFR2. Such conjugates and/or complexes can be used to facilitate delivery of molecules into a biological system, such as cells. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including but not limited to small



molecules, lipids, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-  
5 component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, US 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as  
10 biodegradable nucleic acid linker molecules.

The term "biodegradable nucleic acid linker molecule" as used herein, refers to a nucleic acid molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule. The stability of the biodegradable nucleic acid linker molecule can be modulated by using various combinations  
15 of ribonucleotides, deoxyribonucleotides, and chemically modified nucleotides, for example, 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can  
20 comprise a single nucleotide with a phosphorus based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

The term "biodegradable" as used herein, refers to degradation in a biological system,  
25 for example enzymatic degradation or chemical degradation.

The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, hormones, antivirals, peptides,  
30 proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siRNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active

molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus  
5 containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acid molecules and antisense nucleic acid molecules) delivered exogenously are optimally stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the  
10 undesirable protein. This period of time varies between hours to days depending upon the disease state. These nucleic acid molecules should be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance  
15 their nuclease stability as described above.

In another embodiment, nucleic acid catalysts having chemical modifications that maintain or enhance enzymatic activity are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or *in vivo* the  
20 activity of the nucleic acid may not be significantly lowered. As exemplified herein such enzymatic nucleic acids are useful in a cell and/or *in vivo* even if activity over all is reduced 10 fold (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Such enzymatic nucleic acids herein are said to "maintain" the enzymatic activity of an all RNA ribozyme or all DNA DNAzyme.

In another aspect the nucleic acid molecules comprise a 5' and/or a 3'-cap structure.

By "cap structure" is meant chemical modifications, which have been incorporated at  
25 either terminus of the oligonucleotide (see for example Wincott *et al.*, WO 97/26270, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or can be present on both terminus. In non-limiting examples, the 5'-cap includes inverted abasic  
30 residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-

dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details see Wincott *et al.*, International PCT publication No. WO 97/26270, incorporated by reference herein).

In another embodiment the 3'-cap includes, for example 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-aminoalkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminoethyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925; incorporated by reference herein).

By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine.

An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term also includes alkenyl groups which are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term "alkyl" also includes alkynyl groups which have an unsaturated hydrocarbon group containing at least

one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, 5 alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino or SH.

Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group which has at least one ring having a conjugated p electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which can be optionally substituted. The preferred substituent(s) of 10 aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 15 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, 20 alkylaryl or hydrogen.

By "nucleotide" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a phosphorylated sugar. Nucleotides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a 25 phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; Uhlman & 30 Peyman, *supra* all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach *et al.*, 1994, Nucleic Acids Res. 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, for example, 35 inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g.,

5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5'-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, beta-D-galactosylqueosine, 1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine, 3-methylcytidine, 2-methyladenosine, 2-methylguanosine, N6-methyladenosine, 7-methylguanosine, 5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylcarbonylmethyluridine, 5-methoxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine, beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases can be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule.

By "nucleoside" is meant a heterocyclic nitrogenous base in N-glycosidic linkage with a sugar. Nucleosides are recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleoside sugar moiety. Nucleosides generally comprise a base and sugar group. The nucleosides can be unmodified or modified at the sugar, and/or base moiety, (also referred to interchangeably as nucleoside analogs, modified nucleosides, non-natural nucleosides, non-standard nucleosides and other; see for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; Uhlman & Peyman, *supra* all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of chemically modified and other natural nucleic acid bases that can be introduced into nucleic acids include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 5'-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, beta-D-galactosylqueosine, 1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine, 3-methylcytidine, 2-methyladenosine, 2-methylguanosine, N6-methyladenosine, 7-methylguanosine, 5-

methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylcarbonylmethyluridine, 5-methyloxyuridine, 5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine, beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine, threonine derivatives and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleoside bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases can be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule.

In one embodiment, the invention features modified enzymatic nucleic acid molecules with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications see Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties*, in *Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker *et al.*, 1994, *Novel Backbone Replacements for Oligonucleotides*, in *Carbohydrate Modifications in Antisense Research*, ACS, 24-39. These references are hereby incorporated by reference herein.

By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, for example a 3',3'-linked or 5',5'-linked deoxyabasic ribose derivative (for more details see Wincott *et al.*, International PCT publication No. WO 97/26270).

By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1' carbon of  $\beta$ -D-ribo-furanose.

By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.

In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH<sub>2</sub> or 2'-O-NH<sub>2</sub>, which can be modified or unmodified. Such modified groups are described, for example, in Eckstein *et al.*, U.S. Patent 5,672,695 and Matulic-Adamic *et al.*, WO 98/28317, respectively, which are both incorporated by reference in their entireties.

Various modifications to nucleic acid (*e.g.*, antisense and ribozyme) structure can be made to enhance the utility of these molecules. For example, such modifications can enhance

shelf-life, half-life *in vitro*, stability, and ease of introduction of such oligonucleotides to the target site, including, *e.g.*, enhancing penetration of cellular membranes and conferring the ability to recognize and bind to targeted cells.

5 Use of the nucleic acid-based molecules of the invention can lead to better treatment of the disease progression by affording the possibility of combination therapies (*e.g.*, multiple enzymatic nucleic acid molecules targeted to different genes, enzymatic nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acid molecules (including different enzymatic nucleic acid molecule motifs) and/or other chemical or biological molecules). The treatment of patients  
10 with nucleic acid molecules can also include combinations of different types of nucleic acid molecules. Therapies can be devised which include a mixture of enzymatic nucleic acid molecules (including different enzymatic nucleic acid molecule motifs), allozymes, antisense, dsRNA, aptamers, and/or 2-5A chimera molecules to one or more targets to alleviate symptoms of a disease.

#### 15 Administration of Nucleic Acid Molecules

Methods for the delivery of nucleic acid molecules are described in Akhtar *et al.*, 1992, *Trends Cell Bio.*, 2, 139; and *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995 which are both incorporated herein by reference. Sullivan *et al.*, PCT WO 94/02595, further describes the general methods for delivery of enzymatic RNA molecules.  
20 These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. Alternatively, the nucleic  
25 acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Other routes of delivery include, but are not limited to oral (tablet or pill form) and/or intrathecal delivery (Gold, 1997, *Neuroscience*, 76, 1153-1158). Other approaches include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. For a comprehensive review on drug delivery strategies including  
30 CNS delivery, see Ho *et al.*, 1999, *Curr. Opin. Mol. Ther.*, 1, 336-343 and Jain, *Drug Delivery Systems: Technologies and Commercial Opportunities*, Decision Resources, 1998 and Groothuis *et al.*, 1997, *J. NeuroVirol.*, 3, 387-400. More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan *et al.*, *supra*, Draper *et al.*, PCT

WO93/23569, Beigelman *et al.*, PCT WO99/05094, and Klimuk *et al.*, PCT WO99/04819 all of which have been incorporated by reference herein.

5 The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient.

10 The polynucleotides of the invention can be administered (*e.g.*, RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and the other compositions known in the art.

15 The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, *e.g.*, acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.

20 A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, *e.g.*, systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (*i.e.*, a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.

25 By "systemic administration" is meant *in vivo* systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes expose the desired negatively charged polymers, *e.g.*, nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can



potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking  
5 advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cells implicated in endometriosis, birth control, endometrial tumors, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), menopausal dysfunction, and endometrial carcinoma.

By pharmaceutically acceptable formulation is meant, a composition or formulation that  
10 allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: PEG conjugated nucleic acids, phospholipid conjugated nucleic acids, nucleic acids containing lipophilic moieties, phosphorothioates, P-glycoprotein inhibitors (such as Pluronic  
15 P85) which can enhance entry of drugs into various tissues, for example the CNS (Jolliet-Riant and Tillement, 1999, *Fundam. Clin. Pharmacol.*, 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after implantation (Emerich, DF *et al.*, 1999, *Cell Transplant*, 8, 47-58) Alkermes, Inc. Cambridge, MA; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can  
20 deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (*Prog Neuropsychopharmacol Biol Psychiatry*, 23, 941-949, 1999). Other non-limiting examples of delivery strategies, including CNS delivery of the nucleic acid molecules of the instant invention include material described in Boado *et al.*, 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler *et al.*, 1999, *FEBS Lett.*, 421, 280-284; Pardridge *et al.*, 1995, *PNAS USA*, 92, 5592-  
25 5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada *et al.*, 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler *et al.*, 1999, *PNAS USA*, 96, 7053-7058. All these references are hereby incorporated herein by reference.

The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating  
30 liposomes or stealth liposomes). Nucleic acid molecules of the invention can also comprise covalently attached PEG molecules of various molecular weights. These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the  
35 encapsulated drug (Lasic *et al. Chem. Rev.* 1995, 95, 2601-2627; Ishiwata *et al., Chem.*

*Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic *et al.*, *Science* 1995, 267, 1275-1276; Oku *et al.*, 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu *et al.*, *J. Biol. Chem.* 1995, 270, 24864-24870; Choi *et al.*, International PCT Publication No. WO 96/10391; Ansell *et al.*, International PCT Publication No. WO 96/10390; Holland *et al.*, International PCT Publication No. WO 96/10392; all of which are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. All of these references are incorporated by reference herein.

The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of *p*-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.

A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

The nucleic acid molecules of the invention and formulations thereof can be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or

infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic acid molecules of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or  
5    adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use can be prepared according to any method known to  
10   the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be for  
15   example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by  
20   known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.

Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium  
25   phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose,  
30   sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters

derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-  
5 hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax,  
10 hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents  
15 or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.

Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these.  
20 Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening  
25 and flavoring agents.

Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension.  
30 This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and

isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

- 5       The nucleic acid molecules of the invention can also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
- 10       Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

- 15       Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.

- 20       It is understood that the specific dose level for any particular patient depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

- 25       For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

- 30       The nucleic acid molecules of the present invention can also be administered to a patient in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.

Alternatively, certain of the nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, *Science*, 229, 345; McGarry and Lindquist, 1986, *Proc. Natl. Acad. Sci.*, USA 83, 399; Scanlon *et al.*, 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Dropulic *et al.*, 1992, *J. Virol.*, 66, 1432-41; Weerasinghe *et al.*, 1991, *J. Virol.*, 65, 5531-4; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Sarver *et al.*, 1990 *Science*, 247, 1222-1225; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Good *et al.*, 1997, *Gene Therapy*, 4, 45; all of these references are hereby incorporated in their totalities by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper *et al.*, PCT WO 93/23569, and Sullivan *et al.*, PCT WO 94/02595; Ohkawa *et al.*, 1992, *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira *et al.*, 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura *et al.*, 1993, *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994, *J. Biol. Chem.*, 269, 25856; all of these references are hereby incorporated in their totalities by reference herein). Gene therapy approaches specific to the CNS are described by Blesch *et al.*, 2000, *Drug News Perspect.*, 13, 269-280; Peterson *et al.*, 2000, *Cent. Nerv. Syst. Dis.*, 485-508; Peel and Klein, 2000, *J. Neurosci. Methods*, 98, 95-104; Hagihara *et al.*, 2000, *Gene Ther.*, 7, 759-763; and Herrlinger *et al.*, 2000, *Methods Mol. Med.*, 35, 287-312. AAV-mediated delivery of nucleic acid to cells of the nervous system is further described by Kaplitt *et al.*, US 6,180,613.

In another aspect of the invention, RNA molecules of the present invention are preferably expressed from transcription units (see for example Couture *et al.*, 1996, *TIG.*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the nucleic acid molecules are delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the nucleic acid molecule binds to the target mRNA. Delivery of nucleic acid molecule expressing vectors can be systemic, such as by intravenous or intra-muscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review see Couture *et al.*, 1996, *TIG.*, 12, 510).

In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules of the instant invention. The nucleic acid sequence encoding the nucleic acid molecule of the instant invention is operably linked in a manner which allows expression of that nucleic acid molecule.

5 In another aspect the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a nucleic acid sequence encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said sequence is operably linked to said initiation region and said  
10 termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).

Transcription of the nucleic acid molecule sequences are driven from a promoter for  
15 eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme  
20 is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, *Proc. Natl. Acad. Sci. U S A*, 87, 6743-7; Gao and Huang 1993, *Nucleic Acids Res.*, 21, 2867-72; Lieber *et al.*, 1993, *Methods Enzymol.*, 217, 47-66; Zhou *et al.*, 1990, *Mol. Cell. Biol.*, 10, 4529-37). All of these references are incorporated by reference herein. Several investigators have demonstrated that nucleic acid molecules, such as ribozymes expressed from such promoters  
25 can function in mammalian cells (e.g. Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. U S A*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Yu *et al.*, 1993, *Proc. Natl. Acad. Sci. U S A*, 90, 6340-4; L'Huillier *et al.*, 1992, *EMBO J.*, 11, 4411-8; Lisiewicz *et al.*, 1993, *Proc. Natl. Acad. Sci. U. S. A.*, 90, 8000-4; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived  
30 from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as ribozymes in cells (Thompson *et al.*, *supra*; Couture and Stinchcomb, 1996, *supra*; Noonberg *et al.*, 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg *et al.*, US Patent No. 5,624,803; Good *et al.*, 1997, *Gene Ther.*, 4, 45; Beigelman *et al.*, International PCT Publication No. WO

96/18736; all of these publications are incorporated by reference herein. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, *supra*).

In another aspect the invention features an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecules of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

Flt-1 (VEGFR1), KDR (VEGFR2) and/or flk-1 are attractive nucleic acid-based therapeutic targets by several criteria. The interaction between VEGF and VEGF-R is well-established. Efficacy can be tested in well-defined and predictive animal models. Finally, the disease conditions are serious and current therapies are inadequate. Whereas protein-based



therapies are designed to affect VEGF activity, nucleic acid-based therapy based on the molecules and methods described herein provides a direct and elegant approach to directly modulate flt-1, KDR and/or flk-1 expression.

Because VEGFR1 and VEGFR2 mRNAs are highly homologous in certain regions, some nucleic acid target sites are also homologous. In this case, a single nucleic acid molecule of the invention can target both VEGFR1 and VEGFR2 mRNAs. At partially homologous sites, a single nucleic acid molecule can sometimes be designed to accommodate a site on both mRNAs by including G/U base pairing. For example, if there is a G present in a enzymatic nucleic acid target site in VEGFR1 mRNA at the same position there is an A in the VEGFR2 enzymatic nucleic acid target site, the enzymatic nucleic acid can be synthesized with a U at the complementary position and it will bind both to sites. The advantage of one enzymatic nucleic acid that targets both VEGFR1 and VEGFR2 mRNAs is clear, especially in cases where both VEGF receptors may contribute to the progression of angiogenesis in the disease state.

15

#### Examples

The following are non-limiting examples showing the selection, isolation, synthesis and activity of exemplary nucleic acids of the instant invention.

The following examples demonstrate the selection and design of antisense, aptamer, dsRNA, allozyme, hammerhead, DNAzyme, NCH, Amberzyme, Zinzyme, or G-Cleaver ribozyme molecules and binding/cleavage sites within VEGF, VEGFR1 and/or VEGFR2 RNA.

20

#### Example 1: Enzymatic nucleic acid-mediated inhibition of angiogenesis *in vivo*

The study described below was performed to assess the anti-angiogenic activity of hammerhead ribozymes targeted against flt-1 4229 site (SED ID NO: 5977) in the rat cornea model of VEGF induced angiogenesis (see above). These ribozymes have either active or inactive catalytic core and either bind and cleave or just bind to VEGF-R mRNA of the flt-1 subtype. The active ribozymes, that are able to bind and cleave the target RNA, have been shown to inhibit (<sup>125</sup>I-labeled) VEGF binding in cultured endothelial cells and produce a dose-dependent decrease in VEGF induced endothelial cell proliferation in these cells. The catalytically inactive forms of these ribozymes, which can only bind to the RNA but cannot catalyze RNA cleavage, failed to inhibit VEGF binding and failed to decrease VEGF induced endothelial cell proliferation. The ribozymes and VEGF were co-delivered using the filter

25

30

disk method: Nitrocellulose filter disks (Millipore®) of 0.057 diameter were immersed in appropriate solutions and were surgically implanted in rat cornea as described by Pandey *et al., supra*. This delivery method has been shown to deliver rhodamine-labeled free ribozyme to scleral cells and, in all likelihood cells of the pericorneal vascular plexus. Since the active  
5 ribozymes show cell culture efficacy and can be delivered to the target site using the disk method, it is essential that these ribozymes be assessed for *in vivo* anti-angiogenic activity.

The stimulus for angiogenesis in this study was the treatment of the filter disk with 30  $\mu$ M VEGF which is implanted within the cornea's stroma. This dose yields reproducible neovascularization stemming from the pericorneal vascular plexus growing toward the disk in  
10 a dose-response study 5 days following implant. Filter disks treated only with the vehicle for VEGF show no angiogenic response. The ribozymes were co-administered with VEGF on a disk in two different ribozyme concentrations. One concern with the simultaneous administration is that the ribozymes will not be able to inhibit angiogenesis since VEGF receptors can be stimulated. However, we have observed that in low VEGF doses, the  
15 neovascular response reverts to normal suggesting that the VEGF stimulus is essential for maintaining the angiogenic response. Blocking the production of VEGF receptors using simultaneous administration of anti-VEGF-R mRNA ribozymes could attenuate the normal neovascularization induced by the filter disk treated with VEGF.

#### Materials and Methods:

##### 20 1. Stock hammerhead ribozyme solutions:

- a. flt-1 4229 (786  $\mu$ M)– Active
- b. flt-1 4229 (736  $\mu$ M)– Inactive

##### 2. Experimental solutions/groups:

- |            |            |   |
|------------|------------|---|
| Group 1    | Solution 1 | Control VEGF solution: 30 $\mu$ M in 82mM Tris base                 |
| 25 Group 2 | Solution 2 | flt-1 4229 (1 $\mu$ g/ $\mu$ L) in 30 $\mu$ M VEGF/82 mM Tris base  |
| Group 3    | Solution 3 | flt-1 4229 (10 $\mu$ g/ $\mu$ L) in 30 $\mu$ M VEGF/82 mM Tris base |
| Group 4    | Solution 4 | No VEGF, flt-1 4229 (10 $\mu$ g/ $\mu$ L) in 82 mM Tris base        |
| Group 5    | Solution 5 | No VEGF, No ribozyme in 82 mM Tris base                             |

10 eyes per group, 5 animals (Since they have similar molecular weights, the molar concentrations should be essentially similar).

Each solution (VEGF and RIBOZYMES) were prepared as a 2X solution for 1:1 mixing for final concentrations above, with the exception of solution 1 in which VEGF was 2X and  
5 diluted with ribozyme diluent (sterile water).

### 3. VEGF Solutions

The 2X VEGF solution (60  $\mu$ M) was prepared from a stock of 0.82  $\mu$ g/ $\mu$ L in 50 mM Tris base. 200  $\mu$ L of VEGF stock was concentrated by speed vac to a final volume of 60.8  $\mu$ L, for a final concentration of 2.7  $\mu$ g/ $\mu$ L or 60  $\mu$ M. Six 10  $\mu$ L aliquots was prepared for daily  
10 mixing. 2X solutions for VEGF and Ribozyme was stored at 4°C until the day of the surgery. Solutions were mixed for each day of surgery. Original 2X solutions was prepared on the day before the first day of the surgery.

### 4. Surgical Solutions:

#### Anesthesia:

15 stock ketamine hydrochloride 100 mg/mL

stock xylazine hydrochloride 20 mg/mL

stock acepromazine 10 mg/mL

Final anesthesia solution: 50 mg/mL ketamine, 10 mg/mL xylazine, and 0.5 mg/mL  
acepromazine

20 5% povidone iodine for ophthalmic surgical wash

2% lidocaine (sterile) for ophthalmic administration (2 drops per eye)

sterile 0.9% NaCl for ophthalmic irrigation

### 5. Surgical Methods:

Standard surgical procedure as described in Pandey *et al.*, *supra*. Filter disks were  
25 incubated in 1  $\mu$ L of each solution for approximately 30 minutes prior to implantation.

### 6. Experimental Protocol:

The animal cornea were treated with the treatment groups as described above. Animals were allowed to recover for 5 days after treatment with daily observation (scoring 0 - 3). On the fifth day animals were euthanized and digital images of each eye was obtained for quantitation using Image Pro Plus. Quantitated neovascular surface area were analyzed by ANOVA followed by two post-hoc tests including Dunnett's and Tukey-Kramer tests for significance at the 95% confidence level. Dunnett's provide information on the significance between the differences within the means of treatments vs. controls while Tukey-Kramer provide information on the significance of differences within the means of each group.

The *flt-1* 4229 (SEQ ID NO: 5977) active hammerhead ribozyme at both concentrations was effective at inhibiting angiogenesis while the inactive ribozyme did not show any significant reduction in angiogenesis. A statistically significant reduction in neovascular surface area was observed only with active ribozymes. This result clearly shows that the ribozymes are capable of significantly inhibiting angiogenesis *in vivo*. Specifically, given ribozyme mechanism of action, the observed inhibition is by the binding and cleavage of target RNA by ribozymes.

Example 2: Bioactivity of anti-angiogenesis ribozymes targeting *flt-1* and *kdr* RNA

## MATERIALS AND METHODS

**Ribozymes :** Hammerhead ribozymes and controls designed to have attenuated activity (attenuated controls) were synthesized and purified as previously described above. The attenuated ribozyme controls maintain the binding arm sequence of the parent ribozyme and thus are still capable of binding to the mRNA target. However, they have two nucleotide changes in the core sequence that substantially reduce their ability to carry out the cleavage reaction. Ribozymes were designed to target *Flt-1* or *KDR* mRNA sites conserved in human, mouse, and rat. In general, ribozymes with binding arms of seven nucleotides were designed and tested. If, however, only six nucleotides surrounding the cleavage site were conserved in all three species, six nucleotide binding arms were used. Data are presented herein for 2'-NH<sub>2</sub> uridine modified ribozymes in cell proliferation studies and for 2'-C-allyl uridine modified ribozymes in RNase protection, *in vitro* cleavage and corneal studies.

***In vitro* ribozyme cleavage assays:** *In vitro* RNA cleavage rates on a 15 nucleotide synthetic RNA substrate were measured as previously described above.

**Cell culture:** Human dermal microvascular endothelial cells (HMVEC-d, Clonetics Corp.) were maintained at 37°C in flasks or plates coated with 1.5% porcine skin gelatin (300

bloom, Sigma) in Growth medium (Clonetics Corp.) supplemented with 10-20% fetal bovine serum (FBS, Hyclone). Cells were grown to confluency and used up to the seventh passage. Stimulation medium consisted of 50% Sigma 99 media and 50% RPMI 1640 with L-glutamine and additional supplementation with 10 µg/mL Insulin-Transferrin-Selenium (Gibco BRL) and 10% FBS. Cell growth was stimulated by incubation in Stimulation medium supplemented with 20 ng/mL of either VEGF<sub>165</sub> or bFGF. VEGF<sub>165</sub> (165 amino acids) was selected for cell culture and animal studies because it is the predominant form of the four native forms of VEGF generated by alternative mRNA splicing. Cell culture assays were carried out in triplicate.

10 **Ribozyme and ribozyme/LIPOFECTAMINE™ formulations:**

*Cell culture:* Ribozymes or attenuated controls (50-200 nM) were formulated for cell culture studies and used immediately. Formulations were carried out with LIPOFECTAMINE™ (Gibco BRL) at a 3:1 lipid to phosphate charge ratio in serum-free medium (OPTI-MEM™, Gibco BRL) by mixing for 20 minutes at room temperature. For example, a 3:1 lipid to phosphate charge ratio was established by complexing 200 nM ribozyme with 10.8 µg/µL LIPOFECTAMINE™ (13.5 µM DOSPA).

*In vivo:* For corneal studies, lyophilized ribozyme or attenuated controls were resuspended in sterile water at a final stock concentration of 170 µg/µL (highest dose). Lower doses (1.7-50 µg/µL) were prepared by serial dilution in sterile water.

20 **Proliferation assay:** HMVEC-d were seeded ( $5 \times 10^3$  cells/well) in 48-well plates (Costar) and incubated 24-30 hours in Growth medium at 37°C. After removal of the Growth medium, cells were treated with 50-200 nM LIPOFECTAMINE™ complexes of ribozyme or attenuated controls for 2 hours in OPTI-MEM™. The ribozyme/control-containing medium was removed and the cells were washed extensively in 1X PBS. The medium was then replaced with Stimulation medium or Stimulation medium supplemented with 20 ng/mL VEGF<sub>165</sub> or bFGF. After 48 hours, the cell number was determined using a Coulter™ cell counter. Data are presented as cell number per well following 48 hours of VEGF stimulation.

25 **RNAse protection assay:** HMVEC-d were seeded ( $2 \times 10^5$  cells/well) in 6-well plates (Costar) and allowed to grow 32-36 hours in Growth medium at 37°C. Cells were treated with LIPOFECTAMINE™ complexes containing 200 nM ribozyme or attenuated control for 2 h as described under "Proliferation Assay" and then incubated in Growth medium containing 20 ng/mL VEGF<sub>165</sub> for 24 hours. Cells were harvested and an RNAse protection assay was carried out using the Ambion Direct Protect kit and protocol with the exception that 50 mM

EDTA was added to the lysis buffer to eliminate the possibility of ribozyme cleavage during sample preparation. Antisense RNA probes targeting portions of *Flt-1* and *KDR* were prepared by transcription in the presence of [<sup>32</sup>P]-UTP. Samples were analyzed on polyacrylamide gels and the level of protected RNA fragments was quantified using a  
5 Molecular Dynamics PhosphorImager. The levels of *Flt-1* and *KDR* were normalized to the level of cyclophilin (human cyclophilin probe template, Ambion) in each sample. The coefficient of variation for cyclophilin levels was 11% [265940 cpm ± 29386 (SD)] for all conditions tested here (*i.e.* in the presence of either active ribozymes or attenuated controls). Thus, cyclophilin is useful as an internal standard in these studies.

10 **Rat corneal pocket assay of VEGF-induced angiogenesis:**

*Animal guidelines and anesthesia.* Animal housing and experimentation adhered to standards outlined in the 1996 Guide for the Care and Use of Laboratory Animals (National Research Council). Male Sprague Dawley rats (250-300 g) were anesthetized with ketamine (50 mg/kg), xylazine (10 mg/kg), and acepromazine (0.5 mg/kg) administered intramuscularly  
15 (im). The level of anesthesia was monitored every 2-3 min by applying hind limb paw pressure and examining for limb withdrawal. Atropine (0.4 mg/kg, im) was also administered to prevent potential corneal reflex-induced bradycardia.

*Preparation of VEGF soaked disk.* For corneal implantation, 0.57 mm diameter nitrocellulose disks, prepared from 0.45 µm pore diameter nitrocellulose filter membranes (Millipore Corporation), were soaked for 30 min in 1 µL of 30 µM VEGF<sub>165</sub> in 82 mM  
20 Tris HCl (pH 6.9) in covered petri dishes on ice.

*Corneal surgery.* The rat corneal model used in this study was a modified from Koch *et al. Supra* and Pandey *et al., supra*. Briefly, corneas were irrigated with 0.5% povidone iodine solution followed by normal saline and two drops of 2% lidocaine. Under a dissecting  
25 microscope (Leica MZ-6), a stromal pocket was created and a presoaked filter disk (see above) was inserted into the pocket such that its edge was 1 mm from the corneal limbus.

*Intraconjunctival injection of test solutions.* Immediately after disk insertion, the tip of a 40-50 µm OD injector (constructed in our laboratory) was inserted within the conjunctival tissue 1 mm away from the edge of the corneal limbus that was directly adjacent to the  
30 VEGF-soaked filter disk. Six hundred nanoliters of test solution (ribozyme, attenuated control or sterile water vehicle) were dispensed at a rate of 1.2 µL/min using a syringe pump (Kd Scientific). The injector was then removed, serially rinsed in 70% ethanol and sterile water and immersed in sterile water between each injection. Once the test solution was injected,

closure of the eyelid was maintained using microaneurism clips until the animal began to recover gross motor activity. Following treatment, animals were warmed on a heating pad at 37°C.

*Animal treatment groups/experimental protocol.* Ribozymes targeting *Flt-1* site 4229 (SEQ ID NO: 5977) and *KDR* mRNA site 726 (SEQ ID NO: 5978) were tested in the corneal model along with their attenuated controls. Five treatment groups were assigned to examine the effects of five doses of each test substance over a dose range of 1-100 µg on VEGF-stimulated angiogenesis. Negative (30 µM VEGF soaked filter disk and intraconjunctival injection of 600 nL sterile water) and no stimulus (Tris-soaked filter disk and intraconjunctival injection of sterile water) control groups were also included. Each group consisted of five animals (10 eyes) receiving the same treatment.

*Quantitation of angiogenic response.* Five days after disk implantation, animals were euthanized following im administration of 0.4 mg/kg atropine and corneas were digitally imaged. The neovascular surface area (NSA, expressed in pixels) was measured *postmortem* from blood-filled corneal vessels using computerized morphometry (Image Pro Plus, Media Cybernetics, v2.0). The individual mean NSA was determined in triplicate from three regions of identical size in the area of maximal neovascularization between the filter disk and the limbus. The number of pixels corresponding to the blood-filled corneal vessels in these regions was summated to produce an index of NSA. A group mean NSA was then calculated. Data from each treatment group were normalized to VEGF/ribozyme vehicle-treated control NSA and finally expressed as percent inhibition of VEGF-induced angiogenesis.

*Statistics.* After determining the normality of treatment group means, group mean percent inhibition of VEGF-induced angiogenesis was subjected to a one-way analysis of variance. This was followed by two post-hoc tests for significance including Dunnett's (comparison to VEGF control) and Tukey-Kramer (all other group mean comparisons) at alpha = 0.05. Statistical analyses were performed using JMP v.3.1.6 (SAS Institute).

## RESULTS

**Ribozyme-mediated reduction of VEGF-induced cell proliferation:** Ribozyme cleavage of *Flt-1* or *KDR* mRNA should result in a decrease in the density of cell surface VEGF receptors. This decrease should limit VEGF binding and consequently interfere with the mitogenic signaling induced by VEGF. To determine if cell proliferation was impacted by anti-*Flt-1* and/or anti-*KDR* ribozyme treatment, proliferation assays using cultured human microvascular cells were carried out. Ribozymes included in the proliferation assays were

initially chosen by their ability to decrease the level of VEGF binding to treated cells. In these initial studies, ribozymes targeting 20 sites in the coding region of each mRNA were screened. The most effective ribozymes against two sites in each target, *Flt-1* sites 1358 and 4229 and *KDR* sites 726 and 3950, were included in the proliferation assays reported here. In addition, attenuated analogs of each ribozyme were used as controls. These attenuated controls are still capable of binding to the mRNA target since the binding arm sequence is maintained. However, these controls have two nucleotide changes in the core sequence that substantially reduce their ability to carry out the cleavage reaction.

The active ribozymes tested decreased the relative proliferation of HMVEC-d after VEGF stimulation, an effect that increased with ribozyme concentration. This concentration dependency was not observed following treatment with the attenuated controls designed for these sites. In fact, little or no change in cell growth was noted following treatment with the attenuated controls, even though these controls can still bind to the specific target sequences. At 200 nM, there was a distinct "window" between the anti-proliferative effects of each ribozyme and its attenuated control; a trend also observed at lower doses. This window of inhibition of proliferation (56-77% based on total cells/well) reflects the contribution of ribozyme-mediated activity. In comparison, no effect of anti-*Flt-1* or anti-*KDR* ribozymes was noted on bFGF-stimulated cell proliferation. Moreover, an irrelevant, but active, ribozyme whose binding sequence is not found in either *Flt-1* or *KDR* mRNA had no effect in this assay. These data are consistent with the basic ribozyme mechanism in which binding and cleavage are necessary components. Although the relative surface distribution of *Flt-1* and *KDR* receptors in this cell type is not known, the antiproliferative effects of these ribozymes indicate that, at least in cell culture, both receptors are functionally coupled to proliferation.

**Specific reduction of *Flt-1* or *KDR* mRNA by ribozyme treatment:** To confirm that anti-*Flt-1* and anti-*KDR* ribozymes reduce their respective mRNA targets, cellular levels of *Flt-1* or *KDR* were quantified using an RNase protection assay with specific *Flt-1* or *KDR* probes. For each target, one ribozyme/attenuated control pair was chosen for continued study. Exposure of HMVEC-d to active ribozyme targeting *Flt-1* site 4229 decreased *Flt-1* mRNA, but not *KDR* mRNA. Likewise, treatment with the active ribozyme targeting *KDR* site 726 decreased *KDR*, but not *Flt-1* mRNA. Both ribozymes decreased the level of their respective target RNA by greater than 50%. The degree of reduction associated with the corresponding attenuated controls was not greater than 13%.

*In vitro* activity of anti-*Flt* and anti-*KDR* ribozymes.



To confirm further the necessity of an active ribozyme core, *in vitro* cleavage activities were determined for the *Flt-1* site 4229 ribozyme and the KDR site 726 ribozyme as well as their paired attenuated controls. The first order rate constants calculated from the time-course of short substrate cleavage for the anti-*Flt-1* ribozyme and its attenuated control were  $0.081 \pm 0.0007 \text{ min}^{-1}$  and  $0.001 \pm 6 \times 10^{-5} \text{ min}^{-1}$ , respectively. For the anti-KDR ribozyme and its paired control, the first order rate constants were  $0.434 \pm 0.024 \text{ min}^{-1}$  and  $0.002 \pm 1 \times 10^{-4} \text{ min}^{-1}$ , respectively. Although the attenuated controls retain a very slight level of cleavage activity under these optimized conditions, the decrease in *in vitro* cleavage activity between each active ribozyme and its paired attenuated control is about two orders of magnitude. Thus, an active core is essential for cleavage activity *in vitro* and is also necessary for ribozyme activity in cell culture.

**Ribozyme-mediated reduction of VEGF-induced angiogenesis *in vivo*.** To assess whether ribozymes targeting VEGF receptor mRNA could impact the complex process of angiogenesis, prototypic anti-*Flt-1* and *KDR* ribozymes that were identified in cell culture studies were screened in a rat corneal pocket assay of VEGF-induced angiogenesis. In this assay, corneas implanted with VEGF-containing filter disks exhibited a robust neovascular response in the corneal region between the disk and the corneal limbus (from which the new vessels emerge). Disks containing a vehicle solution elicited no angiogenic response. In separate studies, intraconjunctival injections of sterile water vehicle did not affect the magnitude of the VEGF-induced angiogenic response. In addition, ribozyme injections alone did not induce angiogenesis.

The dose-related effects of anti-*Flt-1* or *KDR* ribozymes on the VEGF-induced angiogenic response were then examined. The antiangiogenic effect of the anti-*Flt-1* (site 4229) and *KDR* (site 726) ribozymes and their attenuated controls over a dose range from 1 to 100  $\mu\text{g}$ , respectively was determined. For both ribozymes, the maximal antiangiogenic response (48 and 36% for anti-*Flt-1* and *KDR* ribozymes, respectively) was observed at a dose of 10  $\mu\text{g}$ .

The anti-*Flt-1* ribozyme produced a significantly greater antiangiogenic response than its attenuated control at 3 and 10  $\mu\text{g}$  ( $p < 0.05$ ). Its attenuated control exhibited a small but significant antiangiogenic response at doses above 10  $\mu\text{g}$  compared to vehicle treated VEGF controls ( $p < 0.05$ ). At its maximum, this response was not significantly greater than that observed with the lowest dose of active anti-*Flt-1* ribozyme. The anti-KDR ribozyme significantly inhibited angiogenesis from 3 to 30  $\mu\text{g}$  ( $p < 0.05$ ). The anti-KDR attenuated control had no significant effect at any dose tested.

Example 3. *In vivo* inhibition of tumor growth and metastases by VEGF-R ribozymes.

**A. Lewis Lung Carcinoma Mouse Model:** Ribozymes were chemically synthesized as described above. The sequence of ANGIOZYME™ bound to its target RNA is shown in Figure 1.

5        The tumors in this study were derived from a cell line (LLC-HM) which gives rise to reproducible numbers of spontaneous lung metastases when propagated *in vivo*. The LLC-HM line was obtained from Dr. Michael O'Reilly, Harvard University. Tumor neovascularization in Lewis lung carcinoma has been shown to be VEGF-dependent. Tumors from mice bearing LLC-HM (selected for the highly metastatic phenotype by serial  
10        propagation) were harvested 20 days post-inoculation. A tumor brei suspension was prepared from these tumors according to standard protocols. On day 0 of the study,  $0.5 \times 10^6$  viable LLC-HM tumor cells were injected subcutaneously (sc) into the dorsum or flank of previously untreated mice (100  $\mu$ L injectate). Tumors were allowed to grow for a period of 3 days prior to initiating continuous intravenous administration of saline or 30 mg/kg/d  
15        ANGIOZYME™ *via* Alzet mini-pumps. One set of animals was dosed from days 3 to 17, inclusive. Tumor length and width measurements and volumes were calculated according to the formula:  $\text{Volume} = 0.5(\text{length})(\text{width})^2$ . At post-inoculation day 25, animals were euthanized and lungs harvested. The number of lung macrometastatic nodules was counted. It should be noted that metastatic foci were quantified 8 days after the cessation of dosing.  
20        Ribozyme solutions were prepared to deliver to another set of animals 100, 10, 3, or 1 mg/kg/day of ANGIOZYME™ *via* Alzet mini-pumps. A total of 10 animals per dose or saline control group were surgically implanted on the left flank with osmotic mini-pumps pre-filled with the respective test solution three days following tumor inoculation. Pumps were attached to indwelling jugular vein catheters.

25        Figure 2 shows the antitumor effects of ANGIOZYME™. There is a statistically significant inhibition ( $p < 0.05$ ) of primary LLC-HM tumor growth in tumors grown in the flank regions compared to saline control. ANGIOZYME™ significantly reduced ( $p < 0.05$ ) the number of lung metastatic foci in animals inoculated either in the flank regions. Figure 3 illustrates the dose-dependent anti-metastatic effect of ANGIOZYME™ compared to saline  
30        control.

**B. Mouse Colorectal Cancer Model.** KM12L4a-16 is a human colorectal cancer cell line. On day 0 of the study,  $0.5 \times 10^6$  KM12L4a-16 cells were implanted into the spleen of nude mice. Three days after tumor inoculation, Alzet minipumps were implanted and continuous subcutaneous delivery of either saline or 12, 36 or 100 mg/kg/ day of

ANGIOZYME™ was initiated. On day 5, the spleens containing the primary tumors were removed. On day 18, the Alzet minipumps were replaced with fresh pumps so that delivery of saline or ANGIOZYME™ was continuous over a 28 day period from day 3 to day 32. Animals were euthanized on day 41 and the liver tumor burden was evaluated.

- 5        Following treatment with 100 mg/kg/day of ANGIOZYME™, there was a significant reduction in the incidence and median number of liver metastasis (Figure 4). In saline-treated animals, the median number of metastases was 101. However, at the high dose of ANGIOZYME™ (100 mg/kg/day), the median number of metastases was zero.

10        Example 4: Effect of ANGIOZYME™ alone or in combination with chemotherapeutic agents in the mouse Lewis Lung Carcinoma Model.

**Methods**

**Tumor inoculations.** Male C57/BL6 mice, age 6 to 8 weeks, were inoculated subcutaneously in the flank with  $5 \times 10^5$  LLC-HM cells from brei preparations made from tumors grown in mice.

- 15        **Ribozymes and controls.** RPL4610, also known as ANGIOZYME™ (SEQ ID NO: 5977), is an anti-*Flt-1* ribozyme that targets site 4229 in the human *Flt-1* receptor mRNA (EMBL accession no. X51602). The controls tested include RPL13141, an attenuated version of RPL4610 in which four nucleotides in the catalytic core are changed so that the cleavage activity is dramatically decreased. RPL13141, however, maintains the base composition and  
20        binding arms of RPL4610 and so is still capable of binding to the target site. The second control (RPL13030) also has changes to the catalytic core (three) to inhibit cleavage activity, but in addition the sequence of the binding arms has been scrambled so that it can no longer bind to the target sequence. One nucleotide in the arm of RPL13030 is also changed to maintain the same base composition as RPL4610.

- 25        **Ribozyme administrations.** Ribozymes and controls were resuspended in normal saline. Administration was initiated seven days following tumor inoculation. Animals either received a daily subcutaneous injection (30 mg/kg test substance) from day 7 to day 20 or were instrumented with an Alzet osmotic minipump (12  $\mu$ L/day flow rate) containing a solution of ribozyme or control. Subcutaneous infusion pumps delivered the test substances  
30        (30 mg/kg/day) from day 7 to 20 (14-day pumps, 420 mg/kg total test substance) or days 7-34 (28-day pumps, 840 mg/kg total test substance). Where indicated, chemotherapeutic agents were given in combination with ribozyme treatment. Cyclophosphamide was given by intraperitoneal administration on days 7, 9 and 11 (125 mg/kg). Gemcitabine was given by

intraperitoneal administration on days 8, 11 and 14 (125 mg/kg). Untreated, uninstrumented animals were used as comparison. Five animals were included in each group.

## Results

- 5        The antiangiogenic ribozyme, ANGIOZYME™, was tested in a model of Lewis lung carcinoma alone and in combination with two chemotherapeutic agents. Previously (see above), 30 mg/kg/day ANGIOZYME™ alone was determined to inhibit both primary tumor growth and lung metastases in a highly metastatic variant of Lewis lung (continuous 14-day iv delivery via Alzet minipump, manuscript in preparation).
- 10        In this study, 30 mg/kg/day ANGIOZYME™ delivered either as a daily subcutaneous bolus injection or as a continuous infusion from an Alzet minipump resulted in a delay in tumor growth. On average, tumor growth to 500 mm<sup>3</sup> was delayed by ~7 days in animals being treated with ANGIOZYME™ compared to an untreated group. Growth of tumors in animals being treated with either of two attenuated controls was delayed by only ~2 days.
- 15        ANGIOZYME™ delivered by subcutaneous bolus was also tested in combination with either Gemcytabine or cyclophosphamide. Tumor growth delay increased by about 3 days in the presence of combination therapy with ANGIOZYME™ and Gemcytabine over the effects of either treatment alone. The combination of ANGIOZYME™ and cyclophosphamide did not
- 20        increase tumor growth delay over that of cyclophosphamide alone, however, suboptimal doses of cyclophosphamide were not included in this study. Neither of the attenuated controls increased the effect of the chemotherapeutic agents.
- 25        The effect of ANGIOZYME™ on metastases to the lung was also determined in the presence and absence of additional chemotherapeutic treatment. Macrometastases to the lungs were counted in two animals in each treatment group on day 20. In the presence of ANGIOZYME™, with or without a chemotherapeutic agent, the lung metastases were reduced to zero. Treatment with either Gemcytabine or cyclophosphamide alone (mean number of metastases 4.5 and 4, respectively) were not as effective as ANGIOZYME™ alone
- 30        or when used in combination with ANGIOZYME™. Neither of the attenuated controls increased the effect of the chemotherapeutic agents.

- 35        The effect on metastases to the lung was also determined following continuous treatment with ANGIOZYME™. At day 20, an average of ~8 macrometastases were noted in the treatment groups which had been instrumented with Alzet minipumps (either 14- or 28-day pumps). This is a decrease in metastases of ~50% from the untreated group. Since

ANGIOZYME™ delivered by a daily subcutaneous bolus resulted in zero metastases (Fig.4) in the two animals counted, it is possible that the additional burden of being instrumented with the minipump contributes to a slightly decreased response to ANGIOZYME™.

Example 5: Identification of Potential Target Sites in Human VEGFR1 and/or VEGFR2 RNA

5        The sequence of human VEGFR1 and/or VEGFR2 genes are screened for accessible sites using a computer-folding algorithm. Regions of the RNA that do not form secondary folding structures and contain potential enzymatic nucleic acid molecule and/or antisense binding/cleavage sites are identified. An exemplary sequence of an enzymatic nucleic acid molecule of the invention is shown in Formula I and/or Formula II (SEQ ID Nos: 5977 and  
10    5978, respectively). Other nucleic acid molecules and targets contemplated by the invention are described in Pavco *et al.*, US Patent Application No. 09/870,161, incorporated by reference herein in its entirety. Similarly, other nucleic acid molecules of the invention, including antisense, aptamers, dsRNA, siRNA, and/or 2,5-A chimeras, can be designed to modulate the expression of the nucleic acid targets described in Pavco *et al.*, US Patent  
15    Application No. 09/870,161.

Example 6: Selection of Enzymatic Nucleic Acid Cleavage Sites in Human VEGFR1 and/or VEGFR2 RNA

Enzymatic nucleic acid molecule target sites are chosen by analyzing sequences of human VEGFR1 receptor (for example Genbank Accession No. NM\_002019), and VEGFR2  
20    receptor (for example Genbank Accession No. NM\_002253) genes and prioritizing the sites on the basis of folding. Enzymatic nucleic acid molecules are designed that can bind each target and are individually analyzed by computer folding (Christoffersen *et al.*, 1994 *J. Mol. Struc. Theochem*, 311, 273; Jaeger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA*, 86, 7706) to assess whether the enzymatic nucleic acid molecule sequences fold into the appropriate  
25    secondary structure. Those enzymatic nucleic acid molecules with unfavorable intramolecular interactions between the binding arms and the catalytic core can be eliminated from consideration. As discussed herein, varying binding arm lengths can be chosen to optimize activity. Generally, at least 4 bases on each arm are able to bind to, or otherwise interact with, the target RNA.

30    Example 7: Chemical Synthesis and Purification of Ribozymes and Antisense for Efficient Cleavage and/or blocking of VEGFR1 and/or VEGFR2 RNA

Enzymatic nucleic acid molecules and antisense constructs are designed to anneal to various sites in the RNA message. The binding arms of the enzymatic nucleic acid molecules are complementary to the target site sequences described above, while the antisense constructs are fully complementary to the target site sequences described above. RNAi molecules (dsRNA) likewise have one strand of RNA or a portion of RNA complementarity to the target site sequence or a portion of the target site sequence. For example, complementarity within the double-strand RNAi structure is formed from two separate individual RNA strands or from self-complementary areas of a topologically closed, individual RNA strand which can be optionally circular. The nucleic acid molecules were chemically synthesized. The method of synthesis used followed the procedure for normal RNA synthesis as described above and in Usman *et al.*, (1987 J. Am. Chem. Soc., 109, 7845), Scaringe *et al.*, (1990 Nucleic Acids Res., 18, 5433) and Wincott *et al.*, *supra*, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. The average stepwise coupling yields were typically >98%.

Nucleic acid molecules are also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol. 180, 51). Nucleic acid molecules of the invention are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Wincott *et al.*, *supra*; the totality of which is hereby incorporated herein by reference) and are resuspended in water. Examples of sequences of chemically synthesized enzymatic nucleic acid molecules are shown in Formula I (SEQ ID NO: 5977), Formula II (SEQ ID NO: 5978) and in Pavco *et al.*, US Patent Application No. 09/870,161.

**Example 8: Enzymatic Nucleic Acid Molecule Cleavage of VEGFR1 and/or VEGFR2 RNA Target *in vitro***

Enzymatic nucleic acid molecules targeted to the human VEGFR1 and/or VEGFR2 RNA are designed and synthesized as described above. These enzymatic nucleic acid molecules can be tested for cleavage activity *in vitro*, for example, using the following procedure. The target sequences and the nucleotide location within the VEGFR1 and/or VEGFR2 RNA are described in Pavco *et al.*, US Patent Application No. 09/870,161.

***Cleavage Reactions:*** Full-length or partially full-length, internally-labeled target RNA for enzymatic nucleic acid molecule cleavage assay is prepared by *in vitro* transcription in the presence of [ $\alpha$ - $^{32}$ P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5'- $^{32}$ P-end

labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming a 2X concentration of purified enzymatic nucleic acid molecule in enzymatic nucleic acid molecule cleavage buffer (50 mM Tris-HCl, pH 7.5 at 37°C, 10 mM MgCl<sub>2</sub>) and the cleavage reaction was initiated by adding the 2X enzymatic nucleic acid molecule mix to an equal volume of  
5 substrate RNA (maximum of 1-5 nM) that was also pre-warmed in cleavage buffer. As an initial screen, assays are carried out for 1 hour at 37°C using a final concentration of either 40 nM or 1 mM enzymatic nucleic acid molecule, *i.e.*, enzymatic nucleic acid molecule excess. The reaction is quenched by the addition of an equal volume of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated  
10 to 95°C for 2 minutes, quick chilled and loaded onto a denaturing polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by enzymatic nucleic acid molecule cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor Imager<sup>®</sup> quantitation of bands representing the intact substrate and the cleavage products.

15 Example 9: Phase I/II Study of Repetitive Dosing of ANGIOZYME<sup>™</sup> Targeting the VEGFR1 (FLT-1) Receptor of VEGF

A ribozyme therapeutic agent ANGIOZYME<sup>™</sup> (SEQ ID NO: 5977), was assessed by daily subcutaneous administration in a phase I/II trial for 31 patients with refractory solid tumors. Demographic information relating to patients enrolled in the study are shown in Table III.  
20 The primary study endpoint was to determine the safety and maximum tolerated dose of ANGIOZYME<sup>™</sup>. Secondary endpoints assessed ANGIOZYME<sup>™</sup> pharmacokinetics and clinical response. Patients were treated at the following doses: 3 patients received doses of 10 mg/m<sup>2</sup>/day, 4 patients received 30 mg/m<sup>2</sup>/day, 20 patients received 100 mg/m<sup>2</sup>/day, and 4 patients received 300 mg/m<sup>2</sup>/day. All but one patient were dosed for a minimum of 29  
25 consecutive days with 24-hour pharmacokinetic analyses on Day 1 and 29. Clinical response was assessed monthly. Results The data from 20 patients indicated that ANGIOZYME<sup>™</sup> was well tolerated, with no systemic adverse events. Figure 5 shows the plasma concentration profile of ANGIOZYME<sup>™</sup> after a single subcutaneous dose of 10, 30, 100, or 300 mg/m<sup>2</sup>. The pharmacokinetic parameters of ANGIOZYME<sup>™</sup> after subcutaneous  
30 bolus administration are outlined in Table IV. An MTD (maximum tolerated dose) could not be established. One patient in the 300 mg/m<sup>2</sup>/d group experienced a grade 3 injection site reaction. Patients in the other groups experienced intermittent grade 1 and grade 2 injection site reactions with erythema and induration. No systemic or laboratory toxicities were observed. Pharmacokinetic analyses demonstrated dose-dependent plasma concentrations  
35 with good bioavailability (70-90%), t<sub>1/2</sub> = 209-384 min, and no accumulation after repeated

5 doses. To date, 17/28 (61%) of evaluable patients have had stable disease for periods of one to six months and two patients (nasopharyngeal squamous cell carcinoma and melanoma) had minor clinical responses. The patient with nasopharyngeal carcinoma demonstrated central tumor necrosis as indicated by MRI. The longest period of treatment thus far has been 8 months for two patients at 100 mg/m<sup>2</sup>/d (breast, peritoneal mesothelioma).

Example 10: Down-regulation of VEGFR1 gene expression to treat gynecologic neovascularization dependent conditions

10 One patient in the Phase I/II trial described in Example 19 was menstruating prior to enrollment in the ANGIOZYME™ monotherapy trial. After 1-2 months on trial, the patient's menstrual cycles ceased. The patient remained on trial for approximately 11 months and did not menstruate. The patient then went off the trial for about 4 months and the menstrual cycles resumed. Re-enrollment in the ANGIOZYME™ trial resulted in the patient's menstrual cycle stopping again. This clinical observation suggests that ANGIOZYME™ is interfering with the patient's menstrual cycle, perhaps by inhibiting neovascularization of  
15 uterine tissue. This data also suggests that ANGIOZYME™ has a direct effect on the endometrial tissue or an effect on LH/FSH stimulation. These results suggest the treatment or control, using ANGIOZYME™ (SEQ ID NO: 5977) and/or other nucleic acid molecules of the instant invention, of various clinical targets and/or processes associated with female reproduction and gynecologic neovascularization, such as endometriosis, birth control,  
20 gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), menopausal dysfunction, endometrial carcinoma or other condition associated with the expression of VEGFR1 and/or VEGFR2 VEGF receptors.

Example 11: Down-regulation of VEGFR1 in clinical setting

25 Twenty-seven of the patients enrolled in the Phase I/II trial described in Example 19 had day 1 (baseline) and day 43 (six-week) serum samples assayed for VEGFR1 biomarker. VEGFR1 levels were statistically different after six weeks of ANGIOZYME treatment (Figure 9). Although statistical testing involving all 27 patients showed statistical support for effects, not all patients presented with elevated levels of VEGF-R1. Since the effects of ANGIOZYME on VEGF-R1 may only be demonstrated when sufficient levels are present at  
30 baseline, a cutoff of 100 pg/mL was chosen and changes in this VEGF-R1 were re-analyzed. Ten of the 27 patients presented with baseline VEGF-R1 levels in excess of 100 pg/mL. For this subgroup VEGF-R1 levels were lower by 3-fold, p<.001. After six weeks of treatment the average (geometric mean) of VEGF-R1 decreased for this subgroup from 419 pg/ml to



132pg/ml,  $p < .001$ . These results show that treatment with ANGIOZYME results in a statistically significant reduction in VEGFR1 expression.

**Example 22: *In vivo* inhibition of neovascularization in an ocular animal model by VEGF-R ribozymes.**

5       **Summary of the Mouse Model:** A mouse model of proliferative retinopathy (Aiello et al., 1995, *Proc. Natl. Acad. Sci. USA* 92: 10457-10461; Robinson et al., 1996, *Proc. Natl. Acad. Sci. USA* 93: 4851-4856; Pierce et al., 1996, *Archives of Ophthalmology* 114: 1219-1228) in which neovascularization of the mouse retina is induced by exposure of 7-day old mice to 75% oxygen followed by a return to normal room air. The initial period in high  
10 oxygen causes an obliteration of developing blood vessels in the retina. Exposure to room air five days later is perceived as hypoxia by the now underperfused retina. The result is an immediate upregulation of VEGF mRNA and VEGF protein (between 6-12 hours) followed by an extensive retinal neovascularization that peaks in ~5 days. Although this model is more representative of retinopathy of prematurity than diabetic retinopathy, it is an accepted small  
15 animal model in which to study neovascular pathophysiology of the retina. In fact, intravitreal injection of certain antisense DNA constructs targeting VEGF mRNA have been found to be antiangiogenic in this model, as were soluble VEGF receptor chimeric proteins designed to bind VEGF in the vitreous humor (Aiello et al., 1995, *Proc. Natl. Acad. Sci. USA* 92: 10457-10461; Robinson et al., 1996, *Proc. Natl. Acad. Sci. USA* 93: 4851-4856; Pierce et al., 1996, *Archives of Ophthalmology* 114: 1219-1228).  
20

**Summary of experiment:** The effect of an anti-*KDR/Flk-1* ribozyme on the peak level of neovascularization was tested in the mouse model described above. As shown in Figure 10, P7 mice were removed from the hyperoxic chamber and the mice received two intraocular injections (P12 and P13) in the right eye of 10 µg RPL4731, the anti- *KDR/Flk-1* ribozyme.  
25 The left eye of each mouse was treated as a control and received intraocular injections of saline. Five days after being exposed to room air, neovascular nuclei in the retina of both eyes were counted. Data are presented in Figure 11. There was a significant decrease in retinal neovascularization (~40%) compared to the control, saline-injected eyes.

30       RPL4731 sequence and chemical composition:  
5'-u<sub>3</sub>a<sub>3</sub>c<sub>3</sub> a<sub>3</sub>au ucU GAU Gag gcg aaa gcc Gaa Aag aca aB-3' (SEQ ID NO: 5978)

where:

35       uppercase G, A = ribonucleotides  
lowercase = 2'-OMe  
U = 2'-C-allyl uridine

B = inverted abasic nucleotide

S = phosphorothioate internucleotide linkage

### Indications

5        1) Tumor angiogenesis: Angiogenesis has been shown to be necessary for tumors to grow into pathological size (Folkman, 1971, *PNAS* 76, 5217-5221; Wellstein & Czubayko, 1996, *Breast Cancer Res and Treatment* 38, 109-119). In addition, it allows tumor cells to travel through the circulatory system during metastasis. Increased levels of gene expression of a number of angiogenic factors such as vascular endothelial growth factor (VEGF) have  
10       been reported in vascularized and edema-associated brain tumors (Berkman *et al.*, 1993 *J. Clin. Invest.* 91, 153). A more direct demonstration of the role of VEGF in tumor angiogenesis was demonstrated by Jim Kim *et al.*, 1993 *Nature* 362,841 wherein, monoclonal antibodies against VEGF were successfully used to inhibit the growth of rhabdomyosarcoma, glioblastoma multiforme cells in nude mice. Similarly, expression of a dominant negative  
15       mutated form of the flt-1 VEGF receptor inhibits vascularization induced by human glioblastoma cells in nude mice (Millauer *et al.*, 1994, *Nature* 367, 576). Specific tumor/cancer types that can be targeted using the nucleic acid molecules of the invention include but are not limited to the tumor/cancer types described under Diagnosis in Table III.

20       2) Ocular diseases: Neovascularization has been shown to cause or exacerbate ocular diseases including but not limited to, macular degeneration, neovascular glaucoma, diabetic retinopathy, myopic degeneration, and trachoma (Norrby, 1997, *APMIS* 105, 417-437). Aiello *et al.*, 1994 *New Engl. J. Med.* 331, 1480, showed that the ocular fluid, of a majority of patients suffering from diabetic retinopathy and other retinal disorders, contains a high concentration of VEGF. Miller *et al.*, 1994 *Am. J. Pathol.* 145, 574, reported elevated levels  
25       of VEGF mRNA in patients suffering from retinal ischemia. These observations support a direct role for VEGF in ocular diseases. Other factors including those that stimulate VEGF synthesis may also contribute to these indications.

30       3) Dermatological Disorders: Many indications have been identified which may by angiogenesis dependent including but not limited to psoriasis, verruca vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kippel-Trenaunay-Weber syndrome, and Osler-Weber-Rendu syndrome (Norrby, *supra*). Intradermal injection of the angiogenic factor b-FGF demonstrated angiogenesis in nude mice (Weckbecker *et al.*, 1992, *Angiogenesis: Key principles-Science-Technology-Medicine*, ed R. Steiner) Detmar *et al.*, 1994 *J. Exp. Med.* 180, 1141 reported that VEGF and its receptors were over-expressed in

psoriatic skin and psoriatic dermal microvessels, suggesting that VEGF plays a significant role in psoriasis.

4) Rheumatoid arthritis: Immunohistochemistry and *in situ* hybridization studies on tissues from the joints of patients suffering from rheumatoid arthritis show an increased level of VEGF and its receptors (Fava *et al.*, 1994 *J. Exp. Med.* 180, 341). Additionally, Koch *et al.*, 1994 *J. Immunol.* 152, 4149, found that VEGF-specific antibodies were able to significantly reduce the mitogenic activity of synovial tissues from patients suffering from rheumatoid arthritis. These observations support a direct role for VEGF in rheumatoid arthritis. Other angiogenic factors including those of the present invention may also be involved in arthritis.

5) Endometriosis: Various studies indicate that VEGF is directly implicated in endometriosis. In one study, VEGF concentrations measured by ELISA in peritoneal fluid were found to be significantly higher in women with endometriosis than in women without endometriosis ( $24.1 \pm 15$  ng/ml vs  $13.3 \pm 7.2$  ng/ml in normals). In patients with endometriosis, higher concentrations of VEGF were detected in the proliferative phase of the menstrual cycle ( $33 \pm 13$  ng/ml) compared to the secretory phase ( $10.7 \pm 5$  ng/ml). The cyclic variation was not noted in fluid from normal patients (McLaren *et al.*, 1996, *Human Reprod.* 11, 220-223). In another study, women with moderate to severe endometriosis had significantly higher concentrations of peritoneal fluid VEGF than women without endometriosis. There was a positive correlation between the severity of endometriosis and the concentration of VEGF in peritoneal fluid. In human endometrial biopsies, VEGF expression increased relative to the early proliferative phase approximately 1.6-, 2-, and 3.6-fold in midproliferative, late proliferative, and secretory endometrium (Shifren *et al.*, 1996, *J. Clin. Endocrinol. Metab.* 81, 3112-3118).

In a third study, VEGF-positive staining of human ectopic endometrium was shown to be localized to macrophages (double immunofluorescent staining with CD14 marker). Peritoneal fluid macrophages demonstrated VEGF staining in women with and without endometriosis. However, increased activation of macrophages (acid phosphatase activity) was demonstrated in fluid from women with endometriosis compared with controls. Peritoneal fluid macrophage conditioned media from patients with endometriosis resulted in significantly increased cell proliferation ( $[^3\text{H}]$  thymidine incorporation) in HUVEC cells compared to controls. The percentage of peritoneal fluid macrophages with VEGFR2 mRNA was higher during the secretory phase, and significantly higher in fluid from women with endometriosis ( $80 \pm 15\%$ ) compared with controls ( $32 \pm 20\%$ ). Flt-mRNA was detected in

peritoneal fluid macrophages from women with and without endometriosis, but there was no difference between the groups or any evidence of cyclic dependence (McLaren *et al.*, 1996, *J. Clin. Invest.* 98, 482-489).

5 In the early proliferative phase of the menstrual cycle, VEGF has been found to be expressed in secretory columnar epithelium (estrogen-responsive) lining both the oviducts and the uterus in female mice. During the secretory phase, VEGF expression was shown to have shifted to the underlying stroma composing the functional endometrium. In addition to examining the endometrium, neovascularization of ovarian follicles and the corpus luteum, as well as angiogenesis in embryonic implantation sites have been analyzed. For these processes,  
10 VEGF was expressed in spatial and temporal proximity to forming vasculature (Shweiki *et al.*, 1993, *J. Clin. Invest.* 91, 2235-2243).

The present body of knowledge in VEGFR1 and/or VEGFR2 research indicates the need for methods to assay VEGFR1 and/or VEGFR2 activity and for compounds that can regulate VEGFR1 and/or VEGFR2 expression for research, diagnostic, and therapeutic use.  
15 As described herein, the nucleic acid molecules of the present invention can be used in assays to diagnose disease state related of VEGF, VEGFR1 and/or VEGFR2 levels. In addition, the nucleic acid molecules can be used to treat disease state related to VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2 levels.

Particular processes, diseases, or conditions that can be associated with VEGFR1  
20 and/or VEGFR2 levels include, but are not limited to, gynecologic neovascularization, such as endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), menopausal dysfunction, other diseases and conditions discussed herein, and other diseases or conditions that are related to or respond to the levels of VEGF and/or VEGFr, such as VEGFR1 and/or VEGFR2, in a cell or tissue,  
25 alone or in combination with other therapies

The use of GnRH (gonadotropin releasing hormone) agonists, Lupron Depot (Leuprolide Acetate), Synarel (nafarelin acetate), Zolodex (goserelin acetate), Suprefact (buserelin acetate), Danazol, or oral contraceptives including, but not limited to, Depo-Provera or Provera (medroxyprogesterone acetate), or any other estrogen/progesterone contraceptive, are  
30 all non-limiting examples of compounds and methods that can be combined with or used in conjunction with the nucleic acid molecules of the instant invention. Various chemotherapies can be readily combined with nucleic acid molecules of the invention for the treatment of endometrial carcinoma. Common chemotherapies that can be combined with nucleic acid molecules of the instant invention include various combinations of cytotoxic drugs to kill the

cancer cells. These drugs include but are not limited to paclitaxel (Taxol), docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate, gemcitabine, vinorelbine *etc.* Those skilled in the art will recognize that other drug compounds and therapies can be readily combined with the nucleic acid molecules of the instant invention and are hence within the scope of the instant invention.

#### Animal Models

There are several animal models in which the anti-angiogenesis effect of nucleic acids of the present invention, such as ribozymes, directed against VEGF-R mRNAs can be tested. Typically, a corneal model has been used to study angiogenesis in rat and rabbit since recruitment of vessels can easily be followed in this normally avascular tissue (Pandey *et al.*, 1995 *Science* 268: 567-569). In these models, a small Teflon or Hydron disk pretreated with an angiogenesis factor (e.g. bFGF or VEGF) is inserted into a pocket surgically created in the cornea. Angiogenesis is monitored 3 to 5 days later. Ribozymes directed against VEGF-R mRNAs would be delivered in the disk as well, or dropwise to the eye over the time course of the experiment. In another eye model, hypoxia has been shown to cause both increased expression of VEGF and neovascularization in the retina (Pierce *et al.*, 1995 *Proc. Natl. Acad. Sci. USA*. 92: 905-909; Shweiki *et al.*, 1992 *J. Clin. Invest.* 91: 2235-2243).

In human glioblastomas, it has been shown that VEGF is at least partially responsible for tumor angiogenesis (Plate *et al.*, 1992 *Nature* 359, 845). Animal models have been developed in which glioblastoma cells are implanted subcutaneously into nude mice and the progress of tumor growth and angiogenesis is studied (Kim *et al.*, 1993 *supra*; Millauer *et al.*, 1994 *supra*).

Another animal model that addresses neovascularization involves Matrigel, an extract of basement membrane that becomes a solid gel when injected subcutaneously (Passaniti *et al.*, 1992 *Lab. Invest.* 67: 519-528). When the Matrigel is supplemented with angiogenesis factors such as VEGF, vessels grow into the Matrigel over a period of 3 to 5 days and angiogenesis can be assessed. Ribozymes directed against VEGF-R mRNAs can be delivered in the Matrigel to assess anti-angiogenesis effect.

Several animal models exist for screening of anti-angiogenic agents. These include corneal vessel formation following corneal injury (Burger *et al.*, 1985 *Cornea* 4: 35-41; Lepri, *et al.*, 1994 *J. Ocular Pharmacol.* 10: 273-280; Ormerod *et al.*, 1990 *Am. J. Pathol.* 137: 1243-1252) or intracorneal growth factor implant (Grant *et al.*, 1993 *Diabetologia* 36: 282-291; Pandey *et al.* 1995 *supra*; Ziehe *et al.*, 1992 *Lab. Invest.* 67: 711-715), vessel

growth into Matrigel matrix containing growth factors (Passaniti *et al.*, 1992 *supra*), female reproductive organ neovascularization following hormonal manipulation (Shweiki *et al.*, 1993 *Clin. Invest.* 91: 2235-2243), several models involving inhibition of tumor growth in highly vascularized solid tumors (O'Reilly *et al.*, 1994 *Cell* 79: 315-328; Senger *et al.*, 1993 *Cancer and Metas. Rev.* 12: 303-324; Takahasi *et al.*, 1994 *Cancer Res.* 54: 4233-4237; Kim *et al.*, 1993 *supra*), and transient hypoxia-induced neovascularization in the mouse retina (Pierce *et al.*, 1995 *Proc. Natl. Acad. Sci. USA.* 92: 905-909).

The cornea model, described in Pandey *et al. supra*, is the most common and well characterized anti-angiogenic agent efficacy screening model. This model involves an avascular tissue into which vessels are recruited by a stimulating agent (growth factor, thermal or alkali burn, endotoxin). The corneal model utilizes the intrastromal corneal implantation of a Teflon pellet soaked in a VEGF-Hydron solution to recruit blood vessels toward the pellet which can be quantitated using standard microscopic and image analysis techniques. To evaluate their anti-angiogenic efficacy, ribozymes are applied topically to the eye or bound within Hydron on the Teflon pellet itself. This avascular cornea as well as the Matrigel (see below) provide for low background assays. While the corneal model has been performed extensively in the rabbit, studies in the rat have also been conducted.

The mouse model (Passaniti *et al. supra*) is a non-tissue model which utilizes Matrigel, an extract of basement membrane (Kleinman *et al.*, 1986) or Millipore® filter disk, which can be impregnated with growth factors and anti-angiogenic agents in a liquid form prior to injection. Upon subcutaneous administration at body temperature, the Matrigel or Millipore® filter disk forms a solid implant. VEGF embedded in the Matrigel or Millipore® filter disk would be used to recruit vessels within the matrix of the Matrigel or Millipore® filter disk which can be processed histologically for endothelial cell specific vWF (factor VIII antigen) immunohistochemistry, Trichrome-Masson stain, or hemoglobin content. Like the cornea, the Matrigel or Millipore® filter disk are avascular; however, it is not tissue. In the Matrigel or Millipore® filter disk model, ribozymes are administered within the matrix of the Matrigel or Millipore® filter disk to test their anti-angiogenic efficacy. Thus, delivery issues in this model, as with delivery of ribozymes by Hydron- coated Teflon pellets in the rat cornea model, are minimized due to the homogeneous presence of the ribozyme within the respective matrix.

These models offer a distinct advantage over several other angiogenic models listed previously. The ability to use VEGF as a pro-angiogenic stimulus in both models is highly desirable since ribozymes target only VEGF mRNA. In other words, the involvement of

other non-specific types of stimuli in the cornea and Matrigel models is not advantageous from the standpoint of understanding the pharmacologic mechanism by which the anti-VEGFr mRNA ribozymes produce their effects. In addition, the models allow for testing the specificity of the anti-VEGFr mRNA ribozymes by using either aFGF or bFGF as a pro-angiogenic factor. Vessel recruitment using FGF should not be affected in either model by anti-VEGFr mRNA ribozymes. Other models of angiogenesis, including vessel formation in the female reproductive system using hormonal manipulation (Shweiki *et al.*, 1993 *supra*); a variety of vascular solid tumor models which involve indirect correlations with angiogenesis (O'Reilly *et al.*, 1994 *supra*; Senger *et al.*, 1993 *supra*; Takahasi *et al.*, 1994 *supra*; Kim *et al.*, 1993 *supra*); and retinal neovascularization following transient hypoxia (Pierce *et al.*, 1995 *supra*), were not selected for efficacy screening due to their non-specific nature, although they can be useful models due to a demonstrated correlation between VEGF and angiogenesis.

Other model systems to study tumor angiogenesis is reviewed by Folkman, 1985 *Adv. Cancer. Res.* 43, 175.

#### *Use of murine models*

For a typical systemic study involving 10 mice (20 g each) per dose group, 5 doses (1, 3, 10, 30 and 100 mg/kg daily over 14 days continuous administration), approximately 400 mg of ribozyme, formulated in saline would be used. A similar study in young adult rats (200 g) would require over 4 g. Parallel pharmacokinetic studies involve the use of similar quantities of ribozymes further justifying the use of murine models.

#### *Ribozymes and Lewis lung carcinoma and B-16 melanoma murine models*

Identifying a common animal model for systemic efficacy testing of ribozymes is an efficient way of screening ribozymes for systemic efficacy.

The Lewis lung carcinoma and B-16 murine melanoma models are well accepted models of primary and metastatic cancer and are used for initial screening of anti-cancer agents. These murine models are not dependent upon the use of immunodeficient mice, are relatively inexpensive, and minimize housing concerns. Both the Lewis lung and B-16 melanoma models involve subcutaneous implantation of approximately  $10^6$  tumor cells from metastatically aggressive tumor cell lines (Lewis lung lines 3LL or D122, LLC-LN7; B-16-BL6 melanoma) in C57BL/6J mice. Alternatively, the Lewis lung model can be produced by the surgical implantation of tumor spheres (approximately 0.8 mm in diameter). Metastasis

also can be modeled by injecting the tumor cells directly intravenously. In the Lewis lung model, microscopic metastases can be observed approximately 14 days following implantation with quantifiable macroscopic metastatic tumors developing within 21-25 days. The B-16 melanoma exhibits a similar time course with tumor neovascularization beginning 4  
5 days following implantation. Since both primary and metastatic tumors exist in these models after 21-25 days in the same animal, multiple measurements can be taken as indices of efficacy. Primary tumor volume and growth latency as well as the number of micro- and macroscopic metastatic lung foci or number of animals exhibiting metastases can be quantitated. The percent increase in lifespan can also be measured. Thus, these models  
10 provide suitable primary efficacy assays for screening systemically administered ribozymes/ribozyme formulations.

In the Lewis lung and B-16 melanoma models, systemic pharmacotherapy with a wide variety of agents usually begins 1-7 days following tumor implantation/inoculation with either continuous or multiple administration regimens. Concurrent pharmacokinetic studies can be  
15 performed to determine whether sufficient tissue levels of ribozymes can be achieved for pharmacodynamic effect to be expected. Furthermore, primary tumors and secondary lung metastases can be removed and subjected to a variety of *in vitro* studies (i.e. target RNA reduction).

Flt-1, KDR and/or flk-1 protein levels can be measured clinically or experimentally by  
20 FACS analysis. Flt-1, KDR and/or flk-1 encoded mRNA levels can be assessed by Northern analysis, RNase-protection, primer extension analysis and/or quantitative RT-PCR. Ribozymes that block flt-1, KDR and/or flk-1 protein encoding mRNAs and therefore result in decreased levels of flt-1, KDR and/or flk-1 activity by more than 20% *in vitro* can be identified.

25 Ribozymes and/or genes encoding them are delivered by either free delivery, liposome delivery, cationic lipid delivery, adeno-associated virus vector delivery, adenovirus vector delivery, retrovirus vector delivery or plasmid vector delivery in these animal model experiments (see above).

Subjects can be treated by locally administering nucleic acids targeted against VEGF-R  
30 by direct injection. Routes of administration include, but are not limited to, intravascular, intramuscular, subcutaneous, intraarticular, aerosol inhalation, oral (tablet, capsule or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery.



Surgically induced models of endometriosis have been developed in rats, mice, and rabbits. Non-human primates demonstrate spontaneous endometriosis, but surgical induction can also be used. In addition to the surgical technique, cycle monitoring can be performed by daily vaginal cytology in primates. For all of the surgically induced models of endometriosis, the following general procedure is used. An initial laparotomy is performed to implant tissue from a donor animal. A portion of one uterine horn (or one complete horn in the case of mice) is removed. The endometrium of this piece of uterus is separated from the myometrium and cut into small segments (4-10 mm<sup>2</sup>). Segments (approximately 3) are sutured to various locations within the abdominal cavity (peritoneum, intestinal mesentery vessels, uterus, broad ligament). Cummings and Metcalf (1996) attached whole segments of mouse uterus without separating the endometrium from the myometrium. Implants are allowed to grow for 3-6 weeks. A second laparotomy is sometimes performed to verify development of endometriosis-like foci (vascularization and cysts filled with clear fluid). This second laparotomy was done in the studies by Quereda *et al.*, (1996) and Stoeckemann *et al.*, (1995). After 3-6 weeks post-surgery and/or following visualization of endometriosis, drug treatment is initiated and continued for a prescribed period of time. At the termination of these studies, animals are euthanized. Endpoints include, but are not limited to, changes in the surface area of the implants and tissue mass of the ectopic endometrial implants (see for example Brogniez *et al.*, 1995, *Human Reprod.* 10, 927-931; Cummings *et al.*, 1996, *Tox. Appl. Pharm.* 138, 131-139; Cummings and Metcalf, 1996, *Proc. Soc. Exp. Biol. Med.* 212, 332-337; D'Hooghe *et al.*, 1996, *Fertility and Sterility.* 66, 809-813; Quereda *et al.*, 1996, *Eur. J. Obstet. Gynecol. Rep. Biol.* 67, 35-40; and Stoeckemann *et al.*, 1995, *Human Reprod.* 10, 3264-3271).

#### *Combination therapies*

Gemcytabine and cyclophosphamide are non-limiting examples of chemotherapeutic agents that can be combined with or used in conjunction with the nucleic acid molecules (*e.g.* ribozymes and antisense molecules) of the instant invention. Those skilled in the art will recognize that other anti-angiogenic and/or anti-cancer compounds and therapies can be similarly be readily combined with the nucleic acid molecules of the instant invention (*e.g.* ribozymes and antisense molecules) and are hence within the scope of the instant invention. Such compounds and therapies are well known in the art (see for example Cancer: Principles

and Practice of Oncology, Volumes 1 and 2, eds Devita, V.T., Hellman, S., and Rosenberg, S.A., J.B. Lippincott Company, Philadelphia, USA; incorporated herein by reference) and include, without limitations, folates, antifolates, pyrimidine analogs, fluoropyrimidines, purine analogs, adenosine analogs, topoisomerase I inhibitors, anthracyclins, retinoids, antibiotics, anthacyclins, platinum analogs, alkylating agents, nitrosoureas, plant derived compounds such as vinca alkaloids, epipodophyllotoxins, tyrosine kinase inhibitors, taxols, radiation therapy, surgery, nutritional supplements, gene therapy, radiotherapy, for example 3D-CRT, immunotoxin therapy, for example ricin, and monoclonal antibodies. Specific examples of chemotherapeutic compounds that can be combined with or used in conjunction with the nucleic acid molecules of the invention include but are not limited to Paclitaxel; Docetaxel; Methotrexate; Doxorubin; Edatrexate; Vinorelbine; Tomaxifen; Leucovorin; 5-fluoro uridine (5-FU); Irinotecan (CAMPTOSAR® or CPT-11 or Camptothecin-11 or Campto); Cisplatin; Carboplatin; Amsacrine; Cytarabine; Bleomycin; Mitomycin C; Dactinomycin; Mithramycin; Hexamethylmelamine; Dacarbazine; L-asparaginase; Nitrogen mustard; Melphalan, Chlorambucil; Busulfan; Ifosfamide; 4-hydroperoxycyclophosphamide, Thiotepa; Tamoxifen, Herceptin; IMC C225; ABX-EGF; and combinations thereof.

#### Diagnostic uses

The nucleic acid molecules of this invention (*e.g.*, enzymatic nucleic acid molecules) can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of VEGF and/or VEGFR, such as VEGFR1 and/or VEGFR2 RNA in a cell. The close relationship between enzymatic nucleic acid molecule activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple enzymatic nucleic acid molecules described in this invention, one can map nucleotide changes which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with enzymatic nucleic acid molecules can be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments can lead to better treatment of the disease progression by affording the possibility of combinational therapies (*e.g.*, multiple enzymatic nucleic acid molecules targeted to different genes, enzymatic nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acid molecules and/or other chemical or biological molecules). Other *in*

*vitro* uses of enzymatic nucleic acid molecules of this invention are well known in the art, and include detection of the presence of mRNAs associated with VEGF, VEGFR1 and/or VEGFR2-related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with an enzymatic nucleic acid molecule using standard methodology.

5 In a specific example, enzymatic nucleic acid molecules which cleave only wild-type or mutant forms of the target RNA are used for the assay. The first enzymatic nucleic acid molecule is used to identify wild-type RNA present in the sample and the second enzymatic nucleic acid molecule is used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both enzymatic nucleic acid molecules to demonstrate the relative enzymatic nucleic acid molecule efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis requires two enzymatic nucleic acid molecules, two substrates and one unknown sample which is combined into six reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (*i.e.*, VEGFR1 and/or VEGFR2) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively. The use of enzymatic nucleic acid molecules in diagnostic applications contemplated by the instant invention is described, for example, in Usman *et al.*, US Patent Application No. 09/877,526, George *et al.*, US Patent Nos. 5,834,186 and 5,741,679, Shih *et al.*, US Patent No. 5,589,332, Nathan *et al.*, US Patent No 5,871,914, Nathan and Ellington, International PCT publication No. WO 00/24931, Breaker *et al.*, International PCT Publication Nos. WO 00/26226 and 98/27104, and Sullenger *et al.*, US Patent Application Serial No. 09/205,520.

#### Additional Uses

Uses of sequence-specific enzymatic nucleic acid molecules of the instant invention can have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans *et al.*, 1975 *Ann. Rev. Biochem.* 44:273). For example,

the pattern of restriction fragments can be used to establish sequence relationships between two related RNAs, and large RNAs can be specifically cleaved to fragments of a size more useful for study. The ability to engineer sequence specificity of the enzymatic nucleic acid molecule is ideal for cleavage of RNAs of unknown sequence. Applicant has described the use of nucleic acid molecules to down-regulate gene expression of target genes in bacterial, microbial, fungal, viral, and eukaryotic systems including plant, or mammalian cells.

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

5        Other embodiments are within the following claims.

**TABLE I****Characteristics of Ribozymes****Group I Introns**

Size: ~200 to >1000 nucleotides.

Requires a U in the target sequence immediately 5' of the cleavage site.

Binds 4-6 nucleotides at 5' side of cleavage site.

Over 75 known members of this class. Found in *Tetrahymena thermophila* rRNA, fungal mitochondria, chloroplasts, phage T4, blue-green algae, and others.

**RNAseP RNA (M1 RNA)**

Size: ~290 to 400 nucleotides.

RNA portion of a ribonucleoprotein enzyme. Cleaves tRNA precursors to form mature tRNA.

Roughly 10 known members of this group all are bacterial in origin.

**Hammerhead Ribozyme**

Size: ~13 to 40 nucleotides.

Requires the target sequence UH immediately 5' of the cleavage site.

Binds a variable number of nucleotides on both sides of the cleavage site.

14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent (Figure 1 and 2)

**Hairpin Ribozyme**

Size: ~50 nucleotides.

Requires the target sequence GUC immediately 3' of the cleavage site.

Binds 4-6 nucleotides at 5' side of the cleavage site and a variable number to the 3' side of the cleavage site.

Only 3 known member of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent (Figure 3).

**Hepatitis Delta Virus (HDV) Ribozyme**

Size: 50 - 60 nucleotides (at present).

Sequence requirements not fully determined.

Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required.

Only 1 known member of this class. Found in human HDV (Figure 4).

***Neurospora* VS RNA Ribozyme**

Size: ~144 nucleotides (at present)

Cleavage of target RNAs recently demonstrated.

Sequence requirements not fully determined.

Binding sites and structural requirements not fully determined. Only  
1 known member of this class. Found in *Neurospora* VS RNA  
(Figure 5).

Table II:

A. 2.5 $\mu$ mol Synthesis Cycle ABI 394 Instrument						
Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time* RNA	
Phosphoramidites	6.5	163 $\mu$ L	45 sec	2.5 min	7.5 min	
S-Ethyl Tetrazole	23.8	238 $\mu$ L	45 sec	2.5 min	7.5 min	
Acetic Anhydride	100	233 $\mu$ L	5 sec	5 sec	5 sec	
N-Methyl Imidazole	186	233 $\mu$ L	5 sec	5 sec	5 sec	
TCA	176	2.3 mL	21 sec	21 sec	21 sec	
Iodine	11.2	1.7 mL	45 sec	45 sec	45 sec	
Beaucage	12.9	645 $\mu$ L	100 sec	300 sec	300 sec	
Acetonitrile	NA	6.67 mL	NA	NA	NA	
B. 0.2 $\mu$ mol Synthesis Cycle ABI 394 Instrument						
Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time* RNA	
Phosphoramidites	15	31 $\mu$ L	45 sec	233 sec	465 sec	
S-Ethyl Tetrazole	38.7	31 $\mu$ L	45 sec	233 min	465 sec	
Acetic Anhydride	655	124 $\mu$ L	5 sec	5 sec	5 sec	
N-Methyl Imidazole	1245	124 $\mu$ L	5 sec	5 sec	5 sec	
TCA	700	732 $\mu$ L	10 sec	10 sec	10 sec	
Iodine	20.6	244 $\mu$ L	15 sec	15 sec	15 sec	



Beaucage	7.7	232 $\mu$ L	100 sec	300 sec
Acetonitrile	NA	2.64 mL	NA	NA

C. 0.2  $\mu$ mol Synthesis Cycle 96 well Instrument

Reagent	Equivalents DNA/2'-O-methyl//Ribo	Amount DNA/2'-O-methyl//Ribo	Wait Time* DNA	Wait Time* 2'-O- methyl	Wait Time* Ribo
Phosphoramidites	22/33/66	40/60/120 $\mu$ L	60 sec	180 sec	360sec
S-Ethyl Tetrazole	70/105/210	40/60/120 $\mu$ L	60 sec	180 min	360 sec
Acetic Anhydride	265/265/265	50/50/50 $\mu$ L	10 sec	10 sec	10 sec
N-Methyl Imidazole	502/502/502	50/50/50 $\mu$ L	10 sec	10 sec	10 sec
TCA	238/475/475	250/500/500 $\mu$ L	15 sec	15 sec	15 sec
Iodine	6.8/6.8/6.8	80/80/80 $\mu$ L	30 sec	30 sec	30 sec
Beaucage	34/51/51	80/120/120	100 sec	200 sec	200 sec
Acetonitrile	NA	1150/1150/1150 $\mu$ L	NA	NA	NA

\* Wait time does not include contact time during delivery.

**Table III: Patient Demographics**

Dose cohort (mg/m <sup>2</sup> )	Pt#	Age	Sex	Diagnosis	Doses
10	1001	49	F	NSC Lung	29
10	1002	65	F	liposarcoma	120
10	1003	49	M	nasopharyngeal CA	109
30	1004	35	M	non-small cell lung	1
30	1005	45	F	melanoma (ocular)	113
30	1006	57	M	colon	199
30	1007	39	F	epitheliod hemangioendothelioma	198
100	1008	52	M	adrenal CA	57
100	1009	44	F	breast	35
100	1010	62	F	renal	134
300	1011	24	F	melanoma	31
300	1012	57	M	renal cell	178
300	1013	53	M	nasopharyngeal SCCA	29
300	1014	64	F	peritoneal mesothelioma	324
100	1015	65	M	melanoma	140
100	1016	77	F	breast	265
100	1017		F	melanoma	35
100	1018	26	F	melanoma	7
100	1019	69	F	endometrial sarcoma	500
100	1020	65	M	carcinoid	124
100	1021	59	M	gallbladder adeno carcinoma	34
100	1022	43	M	colorectal	8
100	1023	78	F	breast	50
100	1024	40	F	parotid adenocarcinoma	285
100	1025	52	F	breast	71
100	1026	39	F	breast	34
100	1027	55	F	breast	36
100	1028	52	M	melanoma	29
100	1029	38	M	pancreatic	36
100	1030	83	M	melanoma	41
100	1031	50	M	medullary thyroid	108

One patient taken off study due to progressive disease. Allowed to resume ANGIOZYME on a compassionate basis.

As of September 1, 2001, all patients were off study. (Although one patient resumed treatment per above note)

Table V: Human FLT DNzyme and Substrate Sequence

Pos	Substrate	Seq ID No	DNzyme	Seq ID No
17	UCCUCUCG G CUCCUCC	1	GGGAGGAG GGCTAGCTACAACGA CGAGAGGA	1703
28	CCUCCCCG G CAGCGGCG	2	CGCCGCTG GGCTAGCTACAACGA CGGGGAGG	1704
31	CCCCGGCA G CGGCGGCG	3	CGCCGCTG GGCTAGCTACAACGA TGCCGGGG	1705
34	CGGCAGCG G CGGCGGCU	4	AGCCGCTG GGCTAGCTACAACGA CGCTGCCG	1706
37	CAGCGGCG G CGGCUCGG	5	CCGAGCCG GGCTAGCTACAACGA CGCCGCTG	1707
40	CGGCGGCG G CUCGGAGC	6	GCTCCGAG GGCTAGCTACAACGA CGCCGCTG	1708
47	GGCUCGGA G CGGGCUCC	7	GGAGCCCG GGCTAGCTACAACGA TCCGAGCC	1709
51	CGGAGCGG G CUCCGGGG	8	CCCCGGAG GGCTAGCTACAACGA CCGCTCCG	1710
59	GCUCGGGG G CUCGGGUG	9	CACCCGAG GGCTAGCTACAACGA CCGGAGGC	1711
65	GGGUCGGG G UGCAGCGG	10	CCGCTGCA GGCTAGCTACAACGA CCGAGCCC	1712
67	GCUCGGGU G CAGCGGCC	11	GGCCGCTG GGCTAGCTACAACGA ACCCGAGC	1713
70	CGGGUGCA G CGGCCAGC	12	GCTGGCCG GGCTAGCTACAACGA TGCACCCG	1714
73	GUGCAGCG G CCAGCGGG	13	CCCGCTGG GGCTAGCTACAACGA CGCTGCAC	1715
77	AGCGGCCA G CGGGCCUG	14	CAGGCCCG GGCTAGCTACAACGA TGGCCGCT	1716
81	GCCAGCGG G CCUGGCGG	15	CCGCCAGG GGCTAGCTACAACGA CCGCTGGC	1717
86	CGGGCCUG G CGGCGAGG	16	CCTCGCCG GGCTAGCTACAACGA CAGGCCCG	1718
89	GCCUGGCG G CGAGGAUU	17	AATCCTCG GGCTAGCTACAACGA CGCCAGGC	1719
95	CGGCGAGG A UUACCCGG	18	CCGGGTAA GGCTAGCTACAACGA CCTCGCCG	1720
98	CGAGGAUU A CCGGGGA	19	TCCCGGGG GGCTAGCTACAACGA AATCCTCG	1721
108	CCGGGGAA G UGGUUGUC	20	GACAACCA GGCTAGCTACAACGA TTCCCCGG	1722
111	GGGAAGUG G UUGUCUCC	21	GGAGACAA GGCTAGCTACAACGA CACTTCCC	1723
114	AAGUGGUU G UCUCUGG	22	CCAGGAGA GGCTAGCTACAACGA AACCCTTT	1724
122	GUCUCCUG G CUGGAGCC	23	GGCTCCAG GGCTAGCTACAACGA CAGGAGAC	1725
128	UGGUGGA G CCGCGAGA	24	TCTCGCCG GGCTAGCTACAACGA TCCAGCCA	1726
131	CUGGAGCC G CGAGACGG	25	CCGTCTCG GGCTAGCTACAACGA GGCTCCAG	1727
136	GCCGCGAG A CGGGCGCU	26	AGCGCCCG GGCTAGCTACAACGA CTCGCGGC	1728
140	CGAGACGG G CGCUCAGG	27	CCTGAGCG GGCTAGCTACAACGA CCGTCTCG	1729
142	AGACGGGC G CUCAGGGC	28	GCCCTGAG GGCTAGCTACAACGA GCCCGTCT	1730
149	CGCUCAGG G CGCGGGGC	29	GCCCCGCG GGCTAGCTACAACGA CCTGAGCG	1731
151	CUCAGGGC G CGGGGCCG	30	CGGCCCGG GGCTAGCTACAACGA GCCCTGAG	1732
156	GGCGCGGG G CCGCGGCG	31	GCCGCGCG GGCTAGCTACAACGA CCGCGGCC	1733
160	CGGGGCCG G CGGCGGCG	32	CGCGCGCG GGCTAGCTACAACGA CGGCCCGG	1734
163	GGCGGGCG G CGGCGAAC	33	GTTGCGCG GGCTAGCTACAACGA CGGCCCGG	1735
166	CGGCGGCG G CGAACGAG	34	CTCGTTCG GGCTAGCTACAACGA CGCGCGCG	1736
170	GGCGGCGA A CGAGAGGA	35	TCCTCTCG GGCTAGCTACAACGA TCGCGGCC	1737
178	ACGAGAGG A CGGACUCU	36	AGAGTCCG GGCTAGCTACAACGA CCTCTCGT	1738
182	GAGGACGG A CUCUGGCG	37	CGCCAGAG GGCTAGCTACAACGA CCGTCTCT	1739
188	GGACUCUG G CGGCGGGG	38	CCCGGCCG GGCTAGCTACAACGA CAGAGTCC	1740
191	CUCUGGCG G CCGGGUCG	39	CGACCCCG GGCTAGCTACAACGA CGCCAGAG	1741
196	GCGGCCGG G UCGUUGGC	40	GCCAACGA GGCTAGCTACAACGA CCGGCCGC	1742
199	GCCGGGUC G UUGGCCGG	41	CCGGCCAA GGCTAGCTACAACGA GACCCGCG	1743
203	GGUCGUUG G CCGGGGGA	42	TCCCCCGG GGCTAGCTACAACGA CAACGACC	1744
212	CCGGGGGA G CGCGGGCA	43	TGCCCCCG GGCTAGCTACAACGA TCCCCCGG	1745
214	GGGGGAGC G CGGGCAC	44	GGTGCCCG GGCTAGCTACAACGA GCTCCCCC	1746
218	GAGCGCGG G CACCGGGC	45	GCCCCGTC GGCTAGCTACAACGA CCGCGCTC	1747
220	GCGCGGGC A CCGGGCGA	46	TGCCCCCG GGCTAGCTACAACGA GCCCGGCG	1748
225	GGCACCAG G CGAGCAGG	47	CCTGCTCG GGCTAGCTACAACGA CCGGTGCC	1749
229	CCGGGGCA G CAGGCCG	48	GCGGCCCT GGCTAGCTACAACGA TCGCCCCG	1750

Table IV Pharmacokinetic parameters of ANGIOZYME after bolus subcutaneous administration.

	10 mg/m <sup>2</sup>		30 mg/m <sup>2</sup>		100 mg/m <sup>2</sup>		300 mg/m <sup>2</sup>	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
<b>Day 1</b>								
C <sub>max</sub> (ug/mL)	0.43	0.07	0.62	0.28	3.17	0.69	8.91	2.93
AUC <sub>t</sub> (ug*hr/mL)	2.60	1.43	6.04	2.70	34.14	2.28	89.87	21.68
AUC <sub>inf</sub> (ug*hr/mL)	4.40	0.06	7.99	1.66	37.51	1.91	101.57	13.47
t(1/2) (hr)	3.62	0.79	7.32	6.94	4.58	0.02	9.26	6.20
CL/F (L/hr/m <sup>2</sup> )	2.24	0.08	3.73	0.92	2.96	0.61	2.99	0.43
<b>Day 29</b>								
C <sub>max</sub> (ug/mL)	0.35	0.19	1.17	0.53	3.23	0.35	8.93	6.71
AUC <sub>t</sub> (ug*hr/mL)	2.11	1.31	7.29	1.16	31.87	1.91	119.42	65.84
AUC <sub>inf</sub> (ug*hr/mL)	3.38	1.31	8.54	2.46	33.61	2.16	132.73	67.82
t(1/2) (hr)	4.49	1.60	3.26	1.01	4.66	0.35	7.24	0.70
CL/F (L/hr/m <sup>2</sup> )	2.49	1.48	3.69	0.94	3.21	0.56	2.72	1.40

233	GCGAGCAG G CCGCGUCG	49	CGACGCGG GGCTAGCTACAACGA CTGCTCGC	1751
236	AGCAGGCC G CGUCGCG	50	GCGCGACG GGCTAGCTACAACGA GGCCTGCT	1752
238	CAGGCCGC G UCGCGCUC	51	GAGCGCGA GGCTAGCTACAACGA GCGGCCTG	1753
241	GCCGCGUC G CGCUCACC	52	GGTGAGCG GGCTAGCTACAACGA GACGCGGC	1754
243	CGCGUCGC G CUCACCAU	53	ATGCTGAG GGCTAGCTACAACGA GCGACGCG	1755
247	UCGCGCUC A CCAUGGUC	54	GACCATGG GGCTAGCTACAACGA GAGCGCGA	1756
250	CGCUCACC A UGGUCAGC	55	GCTGACCA GGCTAGCTACAACGA GGTGAGCG	1757
253	UCACCAUG G UCAGCUAC	56	GTAGCTGA GGCTAGCTACAACGA CATGGTGA	1758
257	CAUGGUCA G CUACUGGG	57	CCCAGTAG GGCTAGCTACAACGA TGACCATG	1759
260	GGUCAGCU A CUGGGACA	58	TGTCCTAG GGCTAGCTACAACGA AGCTGACC	1760
266	CUACUGGG A CACCGGGG	59	CCCCGGTG GGCTAGCTACAACGA CCCAGTAG	1761
268	ACUGGGAC A CCGGGGUC	60	GACCCCGG GGCTAGCTACAACGA GTCCCGAGT	1762
274	ACACCGGG G UCCUGCUG	61	CAGCAGGA GGCTAGCTACAACGA CCCGGTGT	1763
279	GGGGUCCU G CUGUGCGC	62	GCGCACAG GGCTAGCTACAACGA AGGACCCC	1764
282	GUCCUGCU G UGCGCGCU	63	AGCGCGCA GGCTAGCTACAACGA AGCAGGAC	1765
284	CCUGCUGU G CGCGCUGC	64	GCAGCGCG GGCTAGCTACAACGA ACAGCAGG	1766
286	UGCUGUGC G CGCUCUC	65	GAGCAGCG GGCTAGCTACAACGA GCACAGCA	1767
288	CUGUGCGC G CUGCUCAG	66	CTGAGCAG GGCTAGCTACAACGA GCGCACAG	1768
291	UGCGCGCU G CUCAGCUG	67	CAGCTGAG GGCTAGCTACAACGA AGCGCGCA	1769
296	GCUGCUCA G CUGUCUGC	68	GCAGACAG GGCTAGCTACAACGA TGAGCAGC	1770
299	GCUCAGCU G UCUGCUUC	69	GAAGCAGA GGCTAGCTACAACGA AGCTGAGC	1771
303	AGCUGUCU G CUUCUCAC	70	GTGAGAAG GGCTAGCTACAACGA AGACAGCT	1772
310	UGCUCUC A CAGGAUCU	71	AGATCCTG GGCTAGCTACAACGA GAGAAGCA	1773
315	CUCACAGG A UCAGGUUC	72	GAAGTAGA GGCTAGCTACAACGA CCTGTGAG	1774
320	AGGAUCUA G UUCAGGUU	73	AACCTGAA GGCTAGCTACAACGA TAGATCCT	1775
326	UAGUUCAG G UUCAAAUA	74	ATTTTGAA GGCTAGCTACAACGA CTGAACCTA	1776
333	GGUUCAAA A UUAAGA	75	TCTTTTAA GGCTAGCTACAACGA TTTGAACC	1777
341	AUUAAGA A UCCUGAAC	76	GTTTCAGG GGCTAGCTACAACGA CTTTTAAT	1778
348	GAUCCUGA A CUGAGUUU	77	AAACTCAG GGCTAGCTACAACGA TCAGGATC	1779
353	UGAACUGA G UUAAGA	78	CTTTTAAA GGCTAGCTACAACGA TCAGTTCA	1780
362	UUAAGA G CACCCAGC	79	GCTGGGTG GGCTAGCTACAACGA CTTTTAAA	1781
364	UAAAAGGC A CCCAGCAC	80	GTGCTGGG GGCTAGCTACAACGA GCCTTTTA	1782
369	GGCACCCA G CACAUCAU	81	ATGATGTG GGCTAGCTACAACGA TGGGTGCC	1783
371	CACCCAGC A CAUCAUGC	82	GCATGATG GGCTAGCTACAACGA GCTGGGTG	1784
373	CCCAGCAC A UCAUGCAA	83	TTGCATGA GGCTAGCTACAACGA GTGCTGGG	1785
376	AGCAUUC A UGCAAGCA	84	TGCTTGCA GGCTAGCTACAACGA GATGTGCT	1786
378	CACAUCAU G CAAGCAGG	85	CCTGCTTG GGCTAGCTACAACGA ATGATGTG	1787
382	UCAUGCAA G CAGGCCAG	86	CTGGCCTG GGCTAGCTACAACGA TTGCATGA	1788
386	GCAAGCAG G CCAGACAC	87	GTGTCTGG GGCTAGCTACAACGA CTGCTTGC	1789
391	CAGGCCAG A CACUGCAU	88	ATGCAGTG GGCTAGCTACAACGA CTGGCCTG	1790
393	GGCCAGAC A CUGCAUCU	89	AGATGCAG GGCTAGCTACAACGA GTCTGGCC	1791
396	CAGACACU G CAUCUCCA	90	TGGAGATG GGCTAGCTACAACGA AGTGTCTG	1792
398	GACACUGC A UCUCAAU	91	ATTGGAGA GGCTAGCTACAACGA GCAGTGTC	1793
405	CAUCUCCA A UGCAGGGG	92	CCCCTGCA GGCTAGCTACAACGA TGGAGATG	1794
407	UCUCCAAU G CAGGGGGG	93	CCCCCTG GGCTAGCTACAACGA ATTGGAGA	1795
418	GGGGGGA A CAGCCCAU	94	ATGGGCTG GGCTAGCTACAACGA TTCCCCC	1796
421	GGGAAGCA G CCAUAAA	95	TTTATGGG GGCTAGCTACAACGA TGCTTCCC	1797
425	AGCAGCCC A UAAUGGU	96	ACCATTTA GGCTAGCTACAACGA GGGCTGCT	1798
429	GCCCAUAA A UGUUUUU	97	AAAGACCA GGCTAGCTACAACGA TTATGGGC	1799
432	CAUAAAUG G UCUCUGCC	98	GGCAAAGA GGCTAGCTACAACGA CATTTATG	1800
438	UGGUCUUU G CCUGAAAU	99	ATTTTAGG GGCTAGCTACAACGA AAAGACCA	1801
445	UGCCUGAA A UGUUGAGU	100	ACTCACCA GGCTAGCTACAACGA TTCAGGCA	1802

448	CUGAAAUG G UGAGUAAG	101	CTTACTCA GGCTAGCTACAACGA CATTTCAG	1803
452	AAUGGUGA G UAAGGAAA	102	TTTCCTTA GGCTAGCTACAACGA TCACCATT	1804
461	UAAGGAAA G CGAAAGGC	103	GCCTTTTCG GGCTAGCTACAACGA TTTCCTTA	1805
468	AGCGAAAG G CUGAGCAU	104	ATGCTCAG GGCTAGCTACAACGA CTTTCGCT	1806
473	AAGGUGA G CAUAACUA	105	TAGTTATG GGCTAGCTACAACGA TCAGCCTT	1807
475	GGCUGAGC A UAACUAAA	106	TTTAGTTA GGCTAGCTACAACGA GCTCAGCC	1808
478	UGAGCAUA A CUAAUUCU	107	AGATTTAG GGCTAGCTACAACGA TATGCTCA	1809
483	AUAACUAA A UCUGCCUG	108	CAGGCAGA GGCTAGCTACAACGA TTAGTTAT	1810
487	CUAAUUCU G CCUGUGGA	109	TCCACAGG GGCTAGCTACAACGA AGATTTAG	1811
491	AUCUGCCU G UGGAAGAA	110	TTCTTCCA GGCTAGCTACAACGA AGGCAGAT	1812
500	UGGAAGAA A UGGCAAAC	111	GTTTGCCA GGCTAGCTACAACGA TTCTTCCA	1813
503	AAGAAUG G CAAACAAU	112	ATTGTTTG GGCTAGCTACAACGA CATTTCCT	1814
507	AAUGGCAA A CAAUUCUG	113	CAGAAATG GGCTAGCTACAACGA TTGCCATT	1815
510	GGCAAACA A UUCUGCAG	114	CTGCAGAA GGCTAGCTACAACGA TGTTTGCC	1816
515	ACAAUUCU G CAGUACUU	115	AAGTACTG GGCTAGCTACAACGA AGAATTGT	1817
518	AUUCUGCA G UACUUUAA	116	TTAAAGTA GGCTAGCTACAACGA TGCAGAAT	1818
520	UCUGCAGU A CUUUAACC	117	GGTTAAAG GGCTAGCTACAACGA ACTGCAGA	1819
526	GUACUUUA A CCUUGAAC	118	GTTCAAGG GGCTAGCTACAACGA TAAAGTAC	1820
533	AACCUUGA A CACAGCUC	119	GAGCTGTG GGCTAGCTACAACGA TCAAGGTT	1821
535	CCUUGAAC A CAGCUCAA	120	TTGAGCTG GGCTAGCTACAACGA GTTCAAGG	1822
538	UGAACACA G CUCAAGCA	121	TGCTTGAG GGCTAGCTACAACGA TGTGTTCA	1823
544	CAGCUCAA G CAAACCAC	122	GTGGTTTG GGCTAGCTACAACGA TTGAGCTG	1824
548	UCAAGCAA A CCACACUG	123	CAGTGTGG GGCTAGCTACAACGA TTGCTTGA	1825
551	AGCAAACC A CACUGGCU	124	AGCCAGTG GGCTAGCTACAACGA GGTTCGCT	1826
553	CAACCAC A CUGGCUUC	125	GAAGCCAG GGCTAGCTACAACGA GTGGTTTG	1827
557	CCACACUG G CUUCUACA	126	TGTAGAAG GGCTAGCTACAACGA CAGTGTGG	1828
563	UGGCUUCU A CAGCUGCA	127	TGCAGCTG GGCTAGCTACAACGA AGAAGCCA	1829
566	CUUCUACA G CUGCAAU	128	ATTTGCAG GGCTAGCTACAACGA TGTAAG	1830
569	CUACAGCU G CAAUAUC	129	GATATTTG GGCTAGCTACAACGA AGCTGTAG	1831
573	AGCUGCAA A UAUCUAGC	130	GCTAGATA GGCTAGCTACAACGA TTGCAGCT	1832
575	CUGCAAU A UCUAGCUG	131	CAGCTAGA GGCTAGCTACAACGA ATTTGCAG	1833
580	AAUAUCUA G CUGUACCU	132	AGGTACAG GGCTAGCTACAACGA TAGATATT	1834
583	AUCUAGCU G UACCUACU	133	AGTAGTA GGCTAGCTACAACGA AGCTAGAT	1835
585	CUAGCUGU A CCUACUUC	134	GAAGTAGG GGCTAGCTACAACGA ACAGCTAG	1836
589	CUGUACCU A CUUCAAG	135	CTTTGAAG GGCTAGCTACAACGA AGGTACAG	1837
607	AGAAGGAA A CAGAAUCU	136	AGATTCTG GGCTAGCTACAACGA TTCCTTCT	1838
612	GAAACAGA A UCUGCAAU	137	ATTGCAGA GGCTAGCTACAACGA TCTGTTTC	1839
616	CAGAAUCU G CAAUCUUA	138	ATAGATTG GGCTAGCTACAACGA AGATTCTG	1840
619	AAUCUGCA A UCUAUAUA	139	TATATAGA GGCTAGCTACAACGA TGCAGATT	1841
623	UGCAAUCU A UAUAUUUA	140	TAAATATA GGCTAGCTACAACGA AGATTGCA	1842
625	CAUCUUAU A UAUUUAUU	141	AATAAATA GGCTAGCTACAACGA ATAGATTG	1843
627	AUCUAUAU A UUUUAUAG	142	CTAATAAA GGCTAGCTACAACGA ATATAGAT	1844
631	AUAUAUUU A UUAGUGAU	143	ATCACTAA GGCTAGCTACAACGA AAATATAT	1845
635	AUUUAUUA G UGAUACAG	144	CTGTATCA GGCTAGCTACAACGA TAATAAAT	1846
638	UAUUAUGU A UACAGGUA	145	TACCTGTA GGCTAGCTACAACGA CACTAATA	1847
640	UUAGUGAU A CAGGUAGA	146	TCTACCTG GGCTAGCTACAACGA ATCACTAA	1848
644	UGAUACAG G UAGACCUU	147	AAGGTCTA GGCTAGCTACAACGA CTGTATCA	1849
648	ACAGGUGA A CCUUUCGU	148	ACGAAAGG GGCTAGCTACAACGA CTACCTGT	1850
655	GACCUUUC G UAGAGAUG	149	CATCTCTA GGCTAGCTACAACGA GAAAGGTC	1851
661	UCGUAGAG A UGUACAGU	150	ACTGTACA GGCTAGCTACAACGA CTCTACGA	1852
663	GUAGAGAU G UACAGUGA	151	TCACTGTA GGCTAGCTACAACGA ATCTCTAC	1853
665	AGAGAUGU A CAGUGAAA	152	TTTCACTG GGCTAGCTACAACGA ACATCTCT	1854

668	GAUGUACA G UGAAAUCC	153	GGATTTC A GGCTAGCTACAACGA TGTACATC	1855
673	ACAGUGAA A UCCCCGAA	154	TTCGGGGA GGCTAGCTACAACGA TTCACTGT	1856
682	UCCCCGAA A UUAUACAC	155	GTGTATAA GGCTAGCTACAACGA TTCGGGGA	1857
685	CCGAAAUU A UACACAUG	156	CATGTGTA GGCTAGCTACAACGA AATTTCCG	1858
687	GAAAUUUA A CACAUGAC	157	GTCATGTG GGCTAGCTACAACGA ATAATTTT	1859
689	AAUUAUAC A CAUGACUG	158	CAGTCATG GGCTAGCTACAACGA GTATAATT	1860
691	UUAUACAC A UGACUGAA	159	TTCAGTCA GGCTAGCTACAACGA GTGTATAA	1861
694	UACACAUG A CUGAAGGA	160	TCCTTCAG GGCTAGCTACAACGA CATGTGTA	1862
708	GGAAGGGA G CUCGUCAU	161	ATGACGAG GGCTAGCTACAACGA TCCCTTCC	1863
712	GGGAGCUC G UCAUCCCO	162	GGGAATGA GGCTAGCTACAACGA GAGCTCCC	1864
715	AGCUCGUC A UUCCUGC	163	GCAGGGAA GGCTAGCTACAACGA GACGAGCT	1865
722	CAUUCUUU G CCGGUUA	164	TAACCCGG GGCTAGCTACAACGA AGGGAATG	1866
727	CCUGCCGG G UUACGUCA	165	TGACGTAA GGCTAGCTACAACGA CCGGCAGG	1867
730	GCCGGGUU A CGUCACCU	166	AGGTGACG GGCTAGCTACAACGA AACCCGGC	1868
732	CGGGUUAC G UCACCUAA	167	TTAGGTGA GGCTAGCTACAACGA GTAACCCG	1869
735	GUUACGUC A CCUAACAU	168	ATGTTAGG GGCTAGCTACAACGA GACGTAAC	1870
740	GUCACCUA A CAUCACUG	169	CAGTGATG GGCTAGCTACAACGA TAGGTGAC	1871
742	CACCUAAC A UCACUGUU	170	AACAGTGA GGCTAGCTACAACGA GTTAGGTG	1872
745	CUAACAU C CUGUUACU	171	AGTAACAG GGCTAGCTACAACGA GATGTTAG	1873
748	ACAUCACU G UUACUUUA	172	TAAAGTAA GGCTAGCTACAACGA AGTGATGT	1874
751	UCACUGUU A CUUAAAA	173	TTTTAAAG GGCTAGCTACAACGA AACAGTGA	1875
762	UUAAAAAA G UUCCACU	174	AGTGGAAG GGCTAGCTACAACGA TTTTTTAA	1876
768	AAGUUUCC A CUUGACAC	175	GTGTCAAG GGCTAGCTACAACGA GGAACACT	1877
773	UCCACUUG A CACUUUGA	176	TCAAAGTG GGCTAGCTACAACGA CAAGTGGA	1878
775	CACUUGAC A CUUUGAUC	177	GATCAAAG GGCTAGCTACAACGA GTCAGGTG	1879
781	ACACUUUG A UCCUGAU	178	ATCAGGGA GGCTAGCTACAACGA CAAAGTGT	1880
788	GAUCCUG A UGGAAGAC	179	GTTTTCCA GGCTAGCTACAACGA CAGGGATC	1881
795	GAUGGAAA A CGCAUAAU	180	ATTATGCG GGCTAGCTACAACGA TTTCCATC	1882
797	UGGAAAAC G CAUAAUCU	181	AGATTATG GGCTAGCTACAACGA GTTTTCCA	1883
799	GAAAACGC A UAAUCUGG	182	CCAGATTA GGCTAGCTACAACGA GCGTTTTC	1884
802	AACGCAU A UCUGGGAC	183	GTCCCAGA GGCTAGCTACAACGA TATGCGTT	1885
809	AAUCUGGG A CAGUAGAA	184	TTCTACTG GGCTAGCTACAACGA CCCAGATT	1886
812	UUGGGACA G UAGAAAGG	185	CCTTTCTA GGCTAGCTACAACGA TGTCCCAG	1887
821	UAGAAAGG G CUUCAUCA	186	TGATGAAG GGCTAGCTACAACGA CCTTTCTA	1888
826	AGGGCUUC A UCAUAUCA	187	TGATATGA GGCTAGCTACAACGA GAAGCCCT	1889
829	GCUUCAUC A UAUCAAU	188	ATTTGATA GGCTAGCTACAACGA GATGAAGC	1890
831	UUCAUCAU A UCAAAUGC	189	GCATTTGA GGCTAGCTACAACGA ATGATGAA	1891
836	CAUAUCAA A UGCAACGU	190	ACGTTGCA GGCTAGCTACAACGA TTGATATG	1892
838	UAUCAAU G CAACGUAC	191	GTACGTTG GGCTAGCTACAACGA ATTTGATA	1893
841	CAAAUGCA A CGUACAA	192	TTTGTACG GGCTAGCTACAACGA TGCATTG	1894
843	AAUGCAAC G UACAAAGA	193	TCTTTGTA GGCTAGCTACAACGA GTTGCAAT	1895
845	UGCAACGU A CAAAGAAA	194	TTTCTTTG GGCTAGCTACAACGA ACGTTGCA	1896
853	ACAAAGAA A UAGGGCUU	195	AAGCCCTA GGCTAGCTACAACGA TTCTTTGT	1897
858	GAAAUAGG G CUUCUGAC	196	GTCAGAAG GGCTAGCTACAACGA CCTATTTC	1898
865	GGCUUCUG A CCUGUGAA	197	TTACAGG GGCTAGCTACAACGA CAGAAGCC	1899
869	UCUGACCU G UGAAGCAA	198	TTGCTTCA GGCTAGCTACAACGA AGGTCAGA	1900
874	CCUGUGAA G CAACAGUC	199	GACTGTTG GGCTAGCTACAACGA TTCACAGG	1901
877	GUGAAGCA A CAGUCAU	200	ATTGACTG GGCTAGCTACAACGA TGCTTCAC	1902
880	AAGCAACA G UCAAUGG	201	CCCATTGA GGCTAGCTACAACGA TGTGCTT	1903
884	AACAGUCA A UGGGCAU	202	AATGCCCA GGCTAGCTACAACGA TGACTGTT	1904
888	GUCAAUGG G CAUUUGUA	203	TACAAATG GGCTAGCTACAACGA CCATTGAC	1905
890	CAAUGGCG A UUUGUAUA	204	TATACAAA GGCTAGCTACAACGA GCCCATTG	1906

894	GGGCAUUU G UAUAGAC	205	GTCTTATA GGCTAGCTACAACGA AAATGCCC	1907
896	GCAUUUGU A UAAGACAA	206	TTGTCCTTA GGCTAGCTACAACGA ACAATGTC	1908
901	UGUAUAAG A CAAACUUA	207	ATAGTTTG GGCTAGCTACAACGA CTTATACA	1909
905	UAAGACAA A CUUUCUA	208	TGAGATAG GGCTAGCTACAACGA TTGTCCTTA	1910
908	GACAAACU A UCUCACAC	209	GTGTGAGA GGCTAGCTACAACGA AGTTTGTC	1911
913	ACUAUCUC A CACAUCGA	210	TCGATGTG GGCTAGCTACAACGA GAGATAGT	1912
915	UAUCUCAC A CAUCGACA	211	TGTCGATG GGCTAGCTACAACGA GTGAGATA	1913
917	UCUCACAC A UCGACAAA	212	TTTGTGGA GGCTAGCTACAACGA GTGTGAGA	1914
921	ACACAUCG A CAAACCAA	213	TTGTTTGG GGCTAGCTACAACGA CGATGTGT	1915
925	AUCGACAA A CCAUACA	214	TGTATTGG GGCTAGCTACAACGA TTGTCGAT	1916
929	ACAAACCA A UACAUCA	215	TGATTGTA GGCTAGCTACAACGA TGGTTTGT	1917
931	AAACCAAU A CAUUAUA	216	TATGATTG GGCTAGCTACAACGA ATTGGTTT	1918
934	CCAUAACA A UCAUAGAU	217	ATCTATGA GGCTAGCTACAACGA TGTATTGG	1919
937	AUACAAUC A UAGAUGUC	218	GACATCTA GGCTAGCTACAACGA GATTGTAT	1920
941	AAUCAUAG A UGUCCAAA	219	TTTGGACA GGCTAGCTACAACGA CTATGATT	1921
943	UCAUAGAU G UCCAAUA	220	TATTTGGA GGCTAGCTACAACGA ATCTATGA	1922
949	AUGUCCAA A UAAGCACA	221	TGTGCTTA GGCTAGCTACAACGA TTGGACAT	1923
953	CCAAAUAA G CACACCAC	222	GTGGTGTG GGCTAGCTACAACGA TTATTGG	1924
955	AAUAAGC A CACCACGC	223	GCGTGGTG GGCTAGCTACAACGA GCTTATTT	1925
957	AUAAGCA A CCACGCCC	224	GGGCGTGG GGCTAGCTACAACGA GTGCTTAT	1926
960	AGCACACC A CGCCAGU	225	ACTGGGCG GGCTAGCTACAACGA GGTGTGCT	1927
962	CACACCAC G CCCAGUCA	226	TGACTGGG GGCTAGCTACAACGA GTGGTGTG	1928
967	CACGCCCA G UCAAAUA	227	TAATTTGA GGCTAGCTACAACGA TGGGCGTG	1929
972	CCAGUCAA A UUACUAG	228	CTAAGTAA GGCTAGCTACAACGA TTGACTGG	1930
975	GUCAAAUU A CUUAGAGG	229	CCTCTAAG GGCTAGCTACAACGA AATTTGAC	1931
983	ACUAGAG G CCAUACUC	230	GAGTATGG GGCTAGCTACAACGA CTCTAAGT	1932
986	UAGAGGCC A UACUCUUG	231	CAAGAGTA GGCTAGCTACAACGA GGCCTCTA	1933
988	GAGGCCAU A CUCUUGUC	232	GACAAGAG GGCTAGCTACAACGA ATGGCCTC	1934
994	AUACUCUU G UCCUCAU	233	ATTGAGGA GGCTAGCTACAACGA AAGAGTAT	1935
1001	UGUCCUCA A UUGUACUG	234	CAGTACAA GGCTAGCTACAACGA TGAGGACA	1936
1004	CCUCAAUU G UACUGCUA	235	TAGCAGTA GGCTAGCTACAACGA AATTGAGG	1937
1006	UCAAUUGU A CUGCUACC	236	GGTAGCAG GGCTAGCTACAACGA ACAATTGA	1938
1009	AUUGUACU G CUACCACU	237	AGTGGTAG GGCTAGCTACAACGA AGTACAAT	1939
1012	GUACUGCU A CCACUCCC	238	GGGAGTGG GGCTAGCTACAACGA AGCAGTAC	1940
1015	CUGCUACC A CUCCUUG	239	CAAGGGAG GGCTAGCTACAACGA GGTAGCAG	1941
1025	UCCUUGA A CACGAGAG	240	CTCTCGTG GGCTAGCTACAACGA TCAAGGGA	1942
1027	CCUUGAAC A CGAGAGUU	241	AACTCTCG GGCTAGCTACAACGA GTTCAAGG	1943
1033	ACACGAGA G UUCAAAUG	242	CATTTGAA GGCTAGCTACAACGA TCTCGTGT	1944
1039	GAGUUCAA A UGACCUGG	243	CCAGGTCA GGCTAGCTACAACGA TTGAAGTC	1945
1042	UUCAAAUG A CCUGGAGU	244	ACTCCAGG GGCTAGCTACAACGA CATTTGAA	1946
1049	GACCUGGA G UUAACCUUG	245	CAGGGTAA GGCTAGCTACAACGA TCCAGGTC	1947
1052	CUGGAGUU A CCCUGAUG	246	CATCAGGG GGCTAGCTACAACGA AACTCCAG	1948
1058	UUAACCUUG A UGAAAAA	247	TTTTTTCA GGCTAGCTACAACGA CAGGGTAA	1949
1067	UGAAAAA A UAAGAGAG	248	CTCTCTTA GGCTAGCTACAACGA TTTTTTCA	1950
1075	AUAAGAGA G CUUCCGUA	249	TACGGAAG GGCTAGCTACAACGA TCTCTTAT	1951
1081	GAGCUUCC G UAAGGCGA	250	TCGCCTTA GGCTAGCTACAACGA GGAAGCTC	1952
1086	UCCGUAAG G CGACGAU	251	ATTCTGTC GGCTAGCTACAACGA CTTACGGA	1953
1089	GUAGGCG A CGAAUUGA	252	TCAATTCT GGCTAGCTACAACGA CGCCTTAC	1954
1093	GGCGACGA A UUGACCAA	253	TTGGTCAA GGCTAGCTACAACGA TCGTCGCC	1955
1097	ACGAAUUG A CCAAGCA	254	TGCTTTGG GGCTAGCTACAACGA CAATTCTG	1956
1103	UGACCAAA G CAAUCCCC	255	GGGAATTG GGCTAGCTACAACGA TTTGGTCA	1957
1106	CAAAGCA A UUCCCAUG	256	CATGGGAA GGCTAGCTACAACGA TGCTTTGG	1958



1112	CAAUCC A UGCCAACA	257	TGTTGGCA GGCTAGCTACAACGA GGAATG	1959
1114	AUCCCAU G CCAACAU	258	TATGTTGG GGCTAGCTACAACGA ATGGGAAT	1960
1118	CAUGCCA A CADAUUCU	259	AGAATATG GGCTAGCTACAACGA TGGCATGG	1961
1120	AUGCCAAC A UAUUCUAC	260	GTAGAATA GGCTAGCTACAACGA GTTGGCAT	1962
1122	GCCAACAU A UUCUACAG	261	CTGTAGAA GGCTAGCTACAACGA ATGTTGGC	1963
1127	CADAUUCU A CAGUGUUC	262	GAACACTG GGCTAGCTACAACGA AGAATATG	1964
1130	AUUCUACA G UGUUCUUA	263	TAAGAACA GGCTAGCTACAACGA TGTAGAA	1965
1132	UCUACAGU G UUCUUACU	264	AGTAAGAA GGCTAGCTACAACGA ACTGTAGA	1966
1138	GUGUUCU A CUAUGAC	265	GTCAATAG GGCTAGCTACAACGA AAGAACAC	1967
1141	UUCUUACU A UUGACAAA	266	TTTGTCAA GGCTAGCTACAACGA AGTAAGAA	1968
1145	UACUAUUG A CAAAUGC	267	GCATTTTG GGCTAGCTACAACGA CAATAGTA	1969
1150	UUGACAAA A UGCAGAAC	268	GTCTGCA GGCTAGCTACAACGA TTTGTCAA	1970
1152	GACAAAU G CAGAACAA	269	TTGTTCTG GGCTAGCTACAACGA ATTTTGTC	1971
1157	AAUGCAGA A CAAAGACA	270	TGCTTTG GGCTAGCTACAACGA TCTGCATT	1972
1163	GAACAAAG A CAAAGGAC	271	GTCCTTTG GGCTAGCTACAACGA CTTGTGTC	1973
1170	GACAAAGG A CUUUAUAC	272	GTATAAAG GGCTAGCTACAACGA CCTTTGTC	1974
1175	AGGACUUU A UACUUGUC	273	GACAAAGTA GGCTAGCTACAACGA AAAGTCCT	1975
1177	GACUUUAU A CUUGUCGU	274	ACGACAAG GGCTAGCTACAACGA ATAAAGTC	1976
1181	UUAUACU G UCGUGUAA	275	TTACACGA GGCTAGCTACAACGA AAGTATAA	1977
1184	UACUUGUC G UGUAAAGGA	276	TCCTTACA GGCTAGCTACAACGA GACAGTA	1978
1186	CUUGUCGU G UAAGGAGU	277	ACTCCTTA GGCTAGCTACAACGA ACGACAAG	1979
1193	UGUAAGGA G UGGACCAU	278	ATGGTCCA GGCTAGCTACAACGA TCCTTACA	1980
1197	AGGAGUGG A CCAUCAU	279	AATGATGG GGCTAGCTACAACGA CCACTCCT	1981
1200	AGUGGACC A UCAUCAA	280	TGGAATGA GGCTAGCTACAACGA GGTCCACT	1982
1203	GGACCAUC A UUCAAAUC	281	GATTTGAA GGCTAGCTACAACGA GATGGTCC	1983
1209	UCAUCAA A UCUGUAA	282	TTAACAGA GGCTAGCTACAACGA TTGAATGA	1984
1213	UCAAAUCU G UUAACACC	283	GGTGTAA GGCTAGCTACAACGA AGATTTGA	1985
1217	AUCUGUUA A CACCUCAG	284	CTGAGGTG GGCTAGCTACAACGA TAACAGAT	1986
1219	CUGUUAAC A CCUCAGUG	285	CACTGAGG GGCTAGCTACAACGA GTTAACAG	1987
1225	ACACCUCA G UGCAUUA	286	TATATGCA GGCTAGCTACAACGA TGAGGTGT	1988
1227	ACCUCAGU G CAUAUUA	287	TATATATG GGCTAGCTACAACGA ACTGAGGT	1989
1229	CUCAGUGC A UUAUAUG	288	CATATATA GGCTAGCTACAACGA GCACTGAG	1990
1231	CAGUGCAU A UUAUGAU	289	ATCATATA GGCTAGCTACAACGA ATGCACGT	1991
1233	GUGCAUUA A UAUGAUAA	290	TTATCATA GGCTAGCTACAACGA ATATGCAC	1992
1235	GCAUUAU A UGAUAAAG	291	CTTATCA GGCTAGCTACAACGA ATATATGC	1993
1238	UAUAUUG A UAAAGCAU	292	ATGCTTTA GGCTAGCTACAACGA CATATATA	1994
1243	AUGAUAAA G CAUUCUUC	293	GATGAATG GGCTAGCTACAACGA TTTATCAT	1995
1245	GAUAAAGC A UCAUCAC	294	GTGATGAA GGCTAGCTACAACGA GCTTTATC	1996
1249	AAGCAUUC A UCACUGUG	295	CACAGTGA GGCTAGCTACAACGA GAATGCTT	1997
1252	CAUUCUUC A CUGUGAAA	296	TTTCACAG GGCTAGCTACAACGA GATGAATG	1998
1255	UCAUCACU G UGAAACAU	297	ATGTTTCA GGCTAGCTACAACGA AGTGATGA	1999
1260	ACUGUGAA A CAUCGAAA	298	TTTCGATG GGCTAGCTACAACGA TTCACAGT	2000
1262	UGUAAAC A UCGAAAC	299	GTTTTCGA GGCTAGCTACAACGA GTTTCACA	2001
1269	CAUCGAAA A CAGCAGGU	300	ACCTGCTG GGCTAGCTACAACGA TTTGATG	2002
1272	CGAAACA G CAGGUGCU	301	AGCACCTG GGCTAGCTACAACGA TGTTCG	2003
1276	AACAGCAG G UGCUUGAA	302	TTCAAGCA GGCTAGCTACAACGA CTGCTGTT	2004
1278	CAGCAGGU G CUUGAAAC	303	GTTTCAAG GGCTAGCTACAACGA ACCTGCTG	2005
1285	UGCUUGAA A CCGUAGCU	304	AGCTACGG GGCTAGCTACAACGA TTCAGCA	2006
1288	UUGAAACC G UAGCUGGC	305	GCCAGCTA GGCTAGCTACAACGA GGTTCAA	2007
1291	AAACCGUA G CUGGCAAG	306	CTTGCCAG GGCTAGCTACAACGA TACGTTT	2008
1295	CGUAGCUG G CAAGCGGU	307	ACCGCTTG GGCTAGCTACAACGA CAGCTACG	2009
1299	GCUGGCAA G CGGUCUUA	308	TAAGACCG GGCTAGCTACAACGA TTGCCAGC	2010

1302	GGCAAGCG G UCUUACCG	309	CGGTAAGA GGCTAGCTACAACGA CGCTTGCC	2011
1307	GCGGUCUU A CCGGCUCU	310	AGAGCCGG GGCTAGCTACAACGA AAGACCGC	2012
1311	UCUUACCG G CUCUCU	311	ATAGAGAG GGCTAGCTACAACGA CGGTAAGA	2013
1318	GGCUCUCU A UGAAAGUG	312	CACCTTCA GGCTAGCTACAACGA AGAGAGCC	2014
1324	CUAUGAAA G UGAAGGCA	313	TGCCTTCA GGCTAGCTACAACGA TTTCATAG	2015
1330	AAGUGAAG G CAUUUCCC	314	GGGAAATG GGCTAGCTACAACGA CTTCACCT	2016
1332	GUGAAGGC A UUUCCUC	315	GAGGGAAA GGCTAGCTACAACGA GCCTTCAC	2017
1341	UUUCCUC G CCGGAAGU	316	ACTTCCGG GGCTAGCTACAACGA GAGGGAAA	2018
1348	CGCCGGAA G UUGUAUGG	317	CCATACAA GGCTAGCTACAACGA TTCCGGCG	2019
1351	CGGAAGUU G UAUGGUUA	318	TAACCATA GGCTAGCTACAACGA AACTTCCG	2020
1353	GAAGUUGU A UGGUAAA	319	TTTAACCA GGCTAGCTACAACGA ACAACTTC	2021
1356	GUUGUAUG G UUAAGA	320	TCTTTAA GGCTAGCTACAACGA CATACAAC	2022
1364	GUUAAAAG A UGGGUUAC	321	GTAACCCA GGCTAGCTACAACGA CTTTTAA	2023
1368	AAAGAUGG G UUACCGC	322	GCAGGTAA GGCTAGCTACAACGA CCATCTTT	2024
1371	GAUGGGUU A CCUGCGAC	323	GTCGCAGG GGCTAGCTACAACGA AACCCATC	2025
1375	GGUUAACU G CGACUGAG	324	CTCAGTCG GGCTAGCTACAACGA AGGTAACC	2026
1378	UACCUGCG A CUGAGAAA	325	TTTCTCAG GGCTAGCTACAACGA CGCAGGTA	2027
1386	ACUGAGAA A UCUGCUCG	326	CGAGCAGA GGCTAGCTACAACGA TTCTCAGT	2028
1390	AGAAAUUC G CUCGCUAU	327	ATAGCGAG GGCTAGCTACAACGA AGATTCT	2029
1394	AUCUGCUC G CUUUUGA	328	TCAAATAG GGCTAGCTACAACGA GAGCAGAT	2030
1397	UGCUCGCU A UUUGACUC	329	GAGTCAAA GGCTAGCTACAACGA AGCGAGCA	2031
1402	GCUAUUUG A CUCGUGGC	330	GCCACGAG GGCTAGCTACAACGA CAAATAGC	2032
1406	UUUGACUC G UGGCUACU	331	AGTAGCCA GGCTAGCTACAACGA GAGTCAAA	2033
1409	GACUCGUG G CUACUCGU	332	ACGAGTAG GGCTAGCTACAACGA CACGAGTC	2034
1412	UCGUGGCU A CUCGUUAA	333	TTAACGAG GGCTAGCTACAACGA AGCCACGA	2035
1416	GGCUACUC G UUAUUUAU	334	ATAATTAA GGCTAGCTACAACGA GAGTAGCC	2036
1420	ACUCGUUA A UUAUCAAG	335	CTTGATAA GGCTAGCTACAACGA TAACGAGT	2037
1423	CGUUAUUU A UCAAGGAC	336	GTCCCTGA GGCTAGCTACAACGA AATTACG	2038
1430	UAUCAAGG A CGUAACUG	337	CAGTTACG GGCTAGCTACAACGA CCTTGATA	2039
1432	UCAAGGAC G UAACUGAA	338	TTCACTTA GGCTAGCTACAACGA GTCCTTGA	2040
1435	AGGACGUA A CUGAAGAG	339	CTCTTCAG GGCTAGCTACAACGA TACGTCCT	2041
1445	UGAAGAGG A UGCAGGGA	340	TCCCTGCA GGCTAGCTACAACGA CCTCTTCA	2042
1447	AAGAGGAU G CAGGGAU	341	ATTCCCTG GGCTAGCTACAACGA ATCCTCTT	2043
1454	UGCAGGGA A UUAUACAA	342	TTGTATAA GGCTAGCTACAACGA TCCCTGCA	2044
1457	AGGGAAUU A UACAAUCU	343	AGATTGTA GGCTAGCTACAACGA AATTCCCT	2045
1459	GGAAUUUA A CAUUCUUG	344	CAAGATTG GGCTAGCTACAACGA ATAATTCC	2046
1462	AUUUAUACA A UCUUGCUG	345	CAGCAAGA GGCTAGCTACAACGA TGTATAAT	2047
1467	ACAAUCUU G CUGAGCAU	346	ATGCTCAG GGCTAGCTACAACGA AAGATTGT	2048
1472	CUUGCUGA G CAUAAAC	347	GTTTATG GGCTAGCTACAACGA TCAGCAAG	2049
1474	UGCUGAGC A UAAACAG	348	CTGTTTGA GGCTAGCTACAACGA GCTCAGCA	2050
1479	AGCAUAAA A CAGUCAAA	349	TTTGACTG GGCTAGCTACAACGA TTTATGCT	2051
1482	AUAAACA G UCAAAUGU	350	ACATTTGA GGCTAGCTACAACGA TGTTTTAT	2052
1487	ACAGUCAA A UGUGUUUA	351	TAAACACA GGCTAGCTACAACGA TTGACTGT	2053
1489	AGUCAAAU G UGUUAAA	352	TTTAAACA GGCTAGCTACAACGA ATTTGACT	2054
1491	UCAAAUGU G UUUAAAA	353	TTTTTAAA GGCTAGCTACAACGA ACATTTGA	2055
1499	GUUUAAA A CCUCACUG	354	CAGTGAGG GGCTAGCTACAACGA TTTTAAAC	2056
1504	AAAACCUC A CUGCCACU	355	AGTGGCAG GGCTAGCTACAACGA GAGGTTTT	2057
1507	ACCUCACU G CCACUCUA	356	TAGAGTGG GGCTAGCTACAACGA AGTGAGGT	2058
1510	UCACUGCC A CUCUAAU	357	AATTAGAG GGCTAGCTACAACGA GGCAGTGA	2059
1516	CCACUCUA A UUGUCAU	358	ATTGACAA GGCTAGCTACAACGA TAGAGTGG	2060
1519	CUCUAAU G UCAAUUG	359	CACATTGA GGCTAGCTACAACGA AATTAGAG	2061
1523	AAUUGUCA A UUGAAAC	360	GTTTCACA GGCTAGCTACAACGA TGACAATT	2062

1525	UUGUCAU G UGAAACCC	361	GGGTTTCA GGCTAGCTACAACGA ATTGACAA	2063
1530	AAUGUGAA A CCCAGAU	362	ATCTGGGG GGCTAGCTACAACGA TTCACATT	2064
1537	AACCCAG A UUACGAA	363	TTCTGAAA GGCTAGCTACAACGA CTGGGGTT	2065
1541	CCAGAUU A CGAAAAG	364	CCTTTTCG GGCTAGCTACAACGA AAATCTGG	2066
1549	ACGAAAAG G CCGUGUCA	365	TGACACGG GGCTAGCTACAACGA CTTTTCGT	2067
1552	AAAAGGCC G UGUCAUCG	366	CGATGACA GGCTAGCTACAACGA GGCCTTTT	2068
1554	AAGGCCGU G UCAUCGUU	367	AACGATGA GGCTAGCTACAACGA ACGGCCTT	2069
1557	GCCGUGUC A UCGUUUCC	368	GGAAACGA GGCTAGCTACAACGA GACACGGC	2070
1560	GUGUCAUC G UUCCAGA	369	TCTGAAA GGCTAGCTACAACGA GATGACAC	2071
1568	GUUCCAG A CCCGGCUC	370	GAGCCGGG GGCTAGCTACAACGA CTGGAAC	2072
1573	CAGACCCG G CUCUCUAC	371	GTAGAGAG GGCTAGCTACAACGA CGGGCTG	2073
1580	GGCUCUCU A CCCACUGG	372	CCAGTGGG GGCTAGCTACAACGA AGAGAGCC	2074
1584	CUCUACCC A CUGGGCAG	373	CTGCCAG GGCTAGCTACAACGA GGGTAGAG	2075
1589	CCCACUGG G CAGCAGAC	374	GTCTGCTG GGCTAGCTACAACGA CCAGTGGG	2076
1592	ACUGGGCA G CAGACAA	375	TTTGTCTG GGCTAGCTACAACGA TGCCCACT	2077
1596	GGCAGCAG A CAAAUCCU	376	AGGATTG GGCTAGCTACAACGA CTGCTGCC	2078
1600	GCAGACAA A UCCUGACU	377	AGTCAGGA GGCTAGCTACAACGA TTGTCTGC	2079
1606	AAAUCCUG A CUUGUACC	378	GGTACAAG GGCTAGCTACAACGA CAGGATT	2080
1610	CCUGACUU G UACCGCAU	379	ATGCGGTA GGCTAGCTACAACGA AAGTCAGG	2081
1612	UGACUUGU A CCGCAUUA	380	ATATGCGG GGCTAGCTACAACGA ACAAGTCA	2082
1615	CUUGUACC G CAUAUGGU	381	ACCATATG GGCTAGCTACAACGA GGTACAAG	2083
1617	UGUACCGC A UAUGGUUA	382	ATACCATA GGCTAGCTACAACGA GCGGTACA	2084
1619	UACCGCAU A UGUUAUCC	383	GGATACCA GGCTAGCTACAACGA ATGCGGTA	2085
1622	CGCAUAUG G UAUCCUC	384	GAGGGATA GGCTAGCTACAACGA CATATGCG	2086
1624	CAUAUGGU A UCCCUCAA	385	TTGAGGGA GGCTAGCTACAACGA ACCATATG	2087
1632	AUCCCUCA A CCUACAAU	386	ATTGTAGG GGCTAGCTACAACGA TGAGGGAT	2088
1636	CUCAACCU A CAAUCAAG	387	CTTGATTG GGCTAGCTACAACGA AGGTTGAG	2089
1639	AACCUACA A UCAAGUGG	388	CCACTTGA GGCTAGCTACAACGA TGTAGGTT	2090
1644	ACAAUCAA G UGGUUCUG	389	CAGAACCA GGCTAGCTACAACGA TTGATTGT	2091
1647	AUCAAGUG G UUCUGGCA	390	TGCCAGAA GGCTAGCTACAACGA CACTTGAT	2092
1653	UGGUUCUG G CACCCUG	391	CAGGGGTG GGCTAGCTACAACGA CAGAACCA	2093
1655	GUUCUGGC A CCCUGUA	392	TACAGGGG GGCTAGCTACAACGA GCCAGAAC	2094
1661	GCACCCCU G UAACCAUA	393	TATGGTTA GGCTAGCTACAACGA AGGGGTGC	2095
1664	CCCGUGUA A CCAUAUDC	394	GATTATGG GGCTAGCTACAACGA TACAGGGG	2096
1667	CUGUAACC A UAUCAUU	395	AATGATTA GGCTAGCTACAACGA GGTACAG	2097
1670	UAACCAUA A UCAUCCG	396	CGGAATGA GGCTAGCTACAACGA TATGGTTA	2098
1673	CCAUAUAC A UUCGAAG	397	CTTCGGAA GGCTAGCTACAACGA GATTATGG	2099
1681	AUCCGAA G CAAGGUGU	398	ACACCTTG GGCTAGCTACAACGA TTCGGAAT	2100
1686	GAAGCAAG G UGUGACUU	399	AAGTCACA GGCTAGCTACAACGA CTTGCTTC	2101
1688	AGCAAGGU G UGACUUUU	400	AAAAGTCA GGCTAGCTACAACGA ACCTTGCT	2102
1691	AAGGUGUG A CUUUUGUU	401	AACAAAAG GGCTAGCTACAACGA CACACCTT	2103
1697	UGACUUUU G UCCAAUA	402	TATTGGAA GGCTAGCTACAACGA AAAAGTCA	2104
1703	UUGUCCA A UAUAGAAG	403	CTTCATTA GGCTAGCTACAACGA TGGAACAA	2105
1706	UUCAUAUA A UGAAGAGU	404	ACTCTTCA GGCTAGCTACAACGA TATTGGAA	2106
1713	AAUGAAGA G UCCUUUAU	405	ATAAAGGA GGCTAGCTACAACGA TCTTCATT	2107
1720	AGUCCUUU A UCCUGGAU	406	ATCCAGGA GGCTAGCTACAACGA AAAGGACT	2108
1727	UAUCCUGG A UGCUGACA	407	TGTCAGCA GGCTAGCTACAACGA CCAGGATA	2109
1729	UCCUGGAU G CUGACAGC	408	GCTGTCAG GGCTAGCTACAACGA ATCCAGGA	2110
1733	GGAUGCUG A CAGCAACA	409	TGTTGCTG GGCTAGCTACAACGA CAGCATCC	2111
1736	UGCUGACA G CAACUUGG	410	CCATGTTG GGCTAGCTACAACGA TGTCAGCA	2112
1739	UGACAGCA A CAUGGGAA	411	TTCCCATG GGCTAGCTACAACGA TGCTGTCA	2113
1741	ACAGCAAC A UGGGAAAC	412	GTTTCCCA GGCTAGCTACAACGA GTTGCTGT	2114

1748	CAUGGGAA A CAGAAUUG	413	CAATTCTG GGCTAGCTACAACGA TTCCCATG	2115
1753	GAAACAGA A UUGAGAGC	414	GCTCTCAA GGCTAGCTACAACGA TCTGTTTC	2116
1760	AAUUGAGA G CAUCACUC	415	GAGTGATG GGCTAGCTACAACGA TCTCAATT	2117
1762	UUGAGAGC A UCACUCAG	416	CTGAGTGA GGCTAGCTACAACGA GCTCTCAA	2118
1765	AGAGCAUC A CUCAGCGC	417	GCGCTGAG GGCTAGCTACAACGA GATGCTCT	2119
1770	AUCACUCA G CGCAUGGC	418	GCCATGCG GGCTAGCTACAACGA TGAGTGAT	2120
1772	CACUCAGC G CAUGGCAA	419	TTGCCATG GGCTAGCTACAACGA GCTGAGTG	2121
1774	CUCAGCGC A UGGCAUA	420	TATTGCCA GGCTAGCTACAACGA GCGCTGAG	2122
1777	AGCGCAUG G CAAUAAUA	421	TATTATTG GGCTAGCTACAACGA CATGCGCT	2123
1780	GCAUGGCA A UAAUAGAA	422	TTCTATTA GGCTAGCTACAACGA TGCCATGC	2124
1783	UGGCAUA A UAGAAGGA	423	TCCTCTTA GGCTAGCTACAACGA TATTGCCA	2125
1796	AGGAAAGA A UAAGAUGG	424	CCATCTTA GGCTAGCTACAACGA TCTTTCCT	2126
1801	AGAAUAAG A UGGCUAGC	425	GCTAGCCA GGCTAGCTACAACGA CTTATTCT	2127
1804	AUAAGAUG G CUAGCACC	426	GGTGCTAG GGCTAGCTACAACGA CATCTTAT	2128
1808	GAUGGCUA G CACCUUGG	427	CCAAGGTG GGCTAGCTACAACGA TAGCCATC	2129
1810	UGGCUAGC A CCUUGGUU	428	AACCAAGG GGCTAGCTACAACGA GCTAGCCA	2130
1816	GCACCUUG G UUGUGGCU	429	AGCCACAA GGCTAGCTACAACGA CAAGGTGC	2131
1819	CCUUGGUU G UGGCUGAC	430	GTCAGCCA GGCTAGCTACAACGA AACCAAGG	2132
1822	UGGUGUG G CUGACUCU	431	AGAGTCAG GGCTAGCTACAACGA CACAACCA	2133
1826	UGUGGCUG A CUCUAGAA	432	TTCTAGAG GGCTAGCTACAACGA CAGCCACA	2134
1834	ACUCUAGA A UUUCUGGA	433	TCCAGAAA GGCTAGCTACAACGA TCTAGAGT	2135
1843	UUUCUGGA A UCUAUAU	434	AATGTAGA GGCTAGCTACAACGA TCCAGAAA	2136
1847	UGGAAUCU A CAUUUGCA	435	TGCAATG GGCTAGCTACAACGA AGATTCCA	2137
1849	GAUCUAC A UUUGCAUA	436	TATGCAAA GGCTAGCTACAACGA GTAGATTG	2138
1853	CUACAUAU G CAUAGCUU	437	AAGCTATG GGCTAGCTACAACGA AAATGTAG	2139
1855	ACAUAUGC A UAGCUUCC	438	GGAAGCTA GGCTAGCTACAACGA GCAATGT	2140
1858	UUUGCAUA G CUUCCAUA	439	ATTGGAAG GGCTAGCTACAACGA TATGCAAA	2141
1865	AGCUUCCA A UAAAGUUG	440	CAACTTTA GGCTAGCTACAACGA TGGAAGCT	2142
1870	CCAAUAAA G UUGGGACU	441	AGTCCCAA GGCTAGCTACAACGA TTTATTGG	2143
1876	AAGUUGGG A CUGUGGGA	442	TCCCACAG GGCTAGCTACAACGA CCCAATT	2144
1879	UUGGGACU G UGGGAAGA	443	TCTTCCCA GGCTAGCTACAACGA AGTCCCAA	2145
1889	GGGAAGAA A CAUAAGCU	444	AGCTTATG GGCTAGCTACAACGA TTCTTCCC	2146
1891	GAAGAAAC A UAAGCUUU	445	AAAGCTTA GGCTAGCTACAACGA GTTCTTTC	2147
1895	AAACAUA A CUUUUAUA	446	TATAAAG GGCTAGCTACAACGA TTATGTTT	2148
1901	AAGCUUUU A UAUCACAG	447	CTGTGATA GGCTAGCTACAACGA AAAAGCTT	2149
1903	GUUUUAU A UCACAGAU	448	ATCTGTGA GGCTAGCTACAACGA ATAAAGG	2150
1906	UUUAUAUC A CAGAUUG	449	CACATCTG GGCTAGCTACAACGA GATATAAA	2151
1910	UAUCACAG A UGUGCCAA	450	TTGGCACA GGCTAGCTACAACGA CTGTGATA	2152
1912	UCACAGAU G UGCCAAU	451	ATTGGCA GGCTAGCTACAACGA ATCTGTGA	2153
1914	ACAGAUU G CCAAUUGG	452	CCATTTGG GGCTAGCTACAACGA ACATCTGT	2154
1919	UGUGCCAA A UGGGUUUC	453	GAAACCCA GGCTAGCTACAACGA TTGGCACA	2155
1923	CCAAUUGG G UUUCAUGU	454	ACATGAAA GGCTAGCTACAACGA CCATTTGG	2156
1928	UGGUUUC A UGUUAACU	455	AGTTAACA GGCTAGCTACAACGA GAAACCCA	2157
1930	GGUUUCAU G UUAACUUG	456	CAAGTTAA GGCTAGCTACAACGA ATGAAACC	2158
1934	UCAUGUUA A CUUGGAAA	457	TTTCCAAG GGCTAGCTACAACGA TAACATGA	2159
1945	UGGAAAAA A UGCCGACG	458	CGTCGGCA GGCTAGCTACAACGA TTTTCCCA	2160
1947	GAAAAAAU G CCGACGGA	459	TCCGTCGG GGCTAGCTACAACGA ATTTTTTC	2161
1951	AAUUGCCG A CGGAAGGA	460	TCCTTCCG GGCTAGCTACAACGA CGGCATTT	2162
1964	AGGAGAGG A CCUGAAAC	461	GTTTCAGG GGCTAGCTACAACGA CCTCTCCT	2163
1971	GACCUGAA A CUGUCUUG	462	CAAGACAG GGCTAGCTACAACGA TTCAGGTC	2164
1974	CUGAAACU G UCUUGCAC	463	GTGCAAGA GGCTAGCTACAACGA AGTTTCAG	2165
1979	ACUGUCUU G CACAGUUA	464	TAAGTGTG GGCTAGCTACAACGA AAGACAGT	2166

1981	UGUCUUGC A CAGUUAAC	465	GTTAAC TG GGCTAGCTACAACGA GCAAGACA	2167
1984	CUUGCACA G UUAACAAG	466	CTTGTTAA GGCTAGCTACAACGA TGTGCAAG	2168
1988	CACAGUUA A CAAGUUCU	467	AGAACTTG GGCTAGCTACAACGA TAAGTGTG	2169
1992	GUUAACAA G UUCUUAUA	468	TATAAGAA GGCTAGCTACAACGA TTGTTAAC	2170
1998	AAGUUCUU A UACAGAGA	469	TCTCTGTA GGCTAGCTACAACGA AAGAACTT	2171
2000	GUUCUUAU A CAGAGACG	470	CGTCTCTG GGCTAGCTACAACGA ATAAGAAC	2172
2006	AUACAGAG A CGUUAUU	471	AAGTAACG GGCTAGCTACAACGA CTCTGTAT	2173
2008	ACAGAGAC G UUACUUGG	472	CCAAGTAA GGCTAGCTACAACGA GTCTCTGT	2174
2011	GAGACGUU A CUUGGAUU	473	AATCCAAG GGCTAGCTACAACGA AACGTCTC	2175
2017	UUACUUGG A UUUUACUG	474	CAGTAAAA GGCTAGCTACAACGA CCAAGTAA	2176
2022	UGGAUUUU A CUGCGGAC	475	GTCCGCAG GGCTAGCTACAACGA AAAATCCA	2177
2025	AUUUUACU G CGGACAGU	476	ACTGTCCG GGCTAGCTACAACGA AGTAAAT	2178
2029	UACUGCGG A CAGUUAU	477	ATTAAC TG GGCTAGCTACAACGA CCGCAGTA	2179
2032	UGCGGACA G UUAUAAC	478	GTTATTAA GGCTAGCTACAACGA TGTCCGCA	2180
2036	GACAGUUA A UACAGAA	479	TTCTGTTA GGCTAGCTACAACGA TAAGTGTG	2181
2039	AGUUAUA A CAGAACAA	480	TTGTTCTG GGCTAGCTACAACGA TATTAACT	2182
2044	AUAACAGA A CAUACAC	481	GTGCATTG GGCTAGCTACAACGA TCTGTTAT	2183
2047	ACAGAACA A UGCACUAC	482	GTAGTGCA GGCTAGCTACAACGA TGTTCGTG	2184
2049	AGAACA AU G CACUACAG	483	CTGTAGTG GGCTAGCTACAACGA ATTGTTCT	2185
2051	AACA AU GC A CUACAGUA	484	TACTGTAG GGCTAGCTACAACGA GCATTGTT	2186
2054	AAUGCACU A CAGUAUA	485	TAATACTG GGCTAGCTACAACGA AGTGCATT	2187
2057	GCACUACA G UAUAGCA	486	TGCTAATA GGCTAGCTACAACGA TGTAGTGC	2188
2059	ACUACAGU A UAGCAAG	487	CTTGCTAA GGCTAGCTACAACGA ACTGTAGT	2189
2063	CAGUAUA G CAGCAAA	488	TTTGCTTG GGCTAGCTACAACGA TAATACTG	2190
2067	AUUAGCAA G CAAAAAU	489	ATTTTTTG GGCTAGCTACAACGA TTGCTAAT	2191
2074	AGCAAAAA A UGCGCAUC	490	GATGGCCA GGCTAGCTACAACGA TTTTGTCT	2192
2077	AAAAAUUG G CCAUCACU	491	AGTGATGG GGCTAGCTACAACGA CATTTTTT	2193
2080	AAAUUGCC A UCACUAAG	492	CTTAGTGA GGCTAGCTACAACGA GGCCATT	2194
2083	UGGCCAUC A CUAAGGAG	493	CTCCTTAG GGCTAGCTACAACGA GATGGCCA	2195
2091	ACUAAGGA G CACUCCAU	494	ATGGAGTG GGCTAGCTACAACGA TCCTTAGT	2196
2093	UAAGGAGC A CUCCAUC	495	TGATGGAG GGCTAGCTACAACGA GCTCCTTA	2197
2098	AGCACUCC A UCACUCU	496	AAGAGTGA GGCTAGCTACAACGA GGAGTGTG	2198
2101	ACUCCAUC A CUCUAAU	497	ATTAAGAG GGCTAGCTACAACGA GATGGAGT	2199
2108	CACUCUUA A UCUUACCA	498	TGGTAAGA GGCTAGCTACAACGA TAAGAGTG	2200
2113	UUAAUUCU A CCAUCAUG	499	CATGATGG GGCTAGCTACAACGA ARGATTAA	2201
2116	AUCUUAAC A UCAUGAAU	500	ATTCATGA GGCTAGCTACAACGA GGTAAAGAT	2202
2119	UUACCAUC A UGA AUGUU	501	AACATTCA GGCTAGCTACAACGA GATGGTAA	2203
2123	CAUCAUGA A UGUUCCC	502	GGGAAACA GGCTAGCTACAACGA TCATGATG	2204
2125	UCAUGAAU G UUUCCUG	503	CAGGGAAA GGCTAGCTACAACGA ATTCATGA	2205
2133	GUUCCCU G CAGAUUC	504	GAATCTTG GGCTAGCTACAACGA AGGGAAAC	2206
2138	CCUGCAAG A UUCAGGCA	505	TGCCTGAA GGCTAGCTACAACGA CTTGCAGG	2207
2144	AGAUCAG G CACUAUG	506	CATAGGTG GGCTAGCTACAACGA CTGAATCT	2208
2146	AUUCAGGC A CUAUGCC	507	GGCATAGG GGCTAGCTACAACGA GCCTGAAT	2209
2150	AGGCACCU A UGCCUGCA	508	TGCAGGCA GGCTAGCTACAACGA AGGTGCCT	2210
2152	GCACCUAU G CCUGCAGA	509	TCTGCAGG GGCTAGCTACAACGA ATAGGTGC	2211
2156	CUAUGCCU G CAGAGCCA	510	TGGCTCTG GGCTAGCTACAACGA AGGCATAG	2212
2161	CCUGCAGA G CCAGGAU	511	ATTCCTGG GGCTAGCTACAACGA TCTGCAGG	2213
2168	AGCCAGGA A UGUUAACA	512	TGTATACA GGCTAGCTACAACGA TCCTGGCT	2214
2170	CCAGGAU G UAUACACA	513	TGTGTATA GGCTAGCTACAACGA ATTCCTGG	2215
2172	AGGAUGU A UACACAGG	514	CCTGTGTA GGCTAGCTACAACGA ACATTCCT	2216
2174	GAUUGUAU A CACAGGGG	515	CCCCTGTG GGCTAGCTACAACGA ATACATTC	2217
2176	AUGUAUAC A CAGGGGAA	516	TTCCCTGT GGCTAGCTACAACGA GTATACAT	2218

2188	GGGAAGAA A UCCUCCAG	517	CTGGAGGA GGCTAGCTACAACGA TTCTTCCC	2219
2206	AGAAAGAA A UUACAAUC	518	GATTGTAA GGCTAGCTACAACGA TTCTTTCT	2220
2209	AAGAAAUU A CAAUCAGA	519	TCTGATTG GGCTAGCTACAACGA AATTTCCT	2221
2212	AAAUUACA A UCAGAGAU	520	ATCTCTGA GGCTAGCTACAACGA TGTAATTT	2222
2219	AAUCAGAG A UCAGGAAG	521	CTTCTCTGA GGCTAGCTACAACGA CTCTGATT	2223
2227	AUCAGGAA G CACCAUAC	522	GTATGGTG GGCTAGCTACAACGA TTCCTGAT	2224
2229	CAGGAAGC A CCAUACCU	523	AGGTATGG GGCTAGCTACAACGA GCTTCCTG	2225
2232	GAAGCACC A UACCUCCU	524	AGGAGGTA GGCTAGCTACAACGA GGTGCTTC	2226
2234	AGCACCAU A CCUCCUGC	525	GCAGGAGG GGCTAGCTACAACGA ATGGTGCT	2227
2241	UACCUCCU G CGAAACCU	526	AGGTTTCG GGCTAGCTACAACGA AGGAGGTA	2228
2246	CCUGCGAA A CCUCAGUG	527	CACTGAGG GGCTAGCTACAACGA TTCGCAGG	2229
2252	AAACCUCA G UGAUCACA	528	TGTGATCA GGCTAGCTACAACGA TGAGGTTT	2230
2255	CCUCAGUG A UCACACAG	529	CTGTGTGA GGCTAGCTACAACGA CACTGAGG	2231
2258	CAGUGAUC A CACAGUGG	530	CCACTGTG GGCTAGCTACAACGA GATCACTG	2232
2260	GUGAUCAC A CAGUGGCC	531	GGCCACTG GGCTAGCTACAACGA GTGATCAC	2233
2263	AUCACACA G UGGCCAUC	532	GATGGCCA GGCTAGCTACAACGA TGTGTGAT	2234
2266	ACACAGUG G CCAUCAGC	533	GCTGATGG GGCTAGCTACAACGA CACTGTGT	2235
2269	CAGUGGCC A UCAGCAGU	534	ACTGCTGA GGCTAGCTACAACGA GGCCACTG	2236
2273	GGCCAUCA G CAGUCCA	535	TGGAAGTG GGCTAGCTACAACGA TGATGGCC	2237
2276	CAUCAGCA G UUCCACCA	536	TGGTGGAA GGCTAGCTACAACGA TGCTGATG	2238
2281	GCAGUCC A CCACUUUA	537	TAAAGTGG GGCTAGCTACAACGA GGAAGTGC	2239
2284	GUUCCACC A CUUAGAC	538	GTCTAAG GGCTAGCTACAACGA GGTGGAAC	2240
2291	CACUUAG A CUGUCAUG	539	TAGACAG GGCTAGCTACAACGA CTAAAGTG	2241
2294	UUUAGACU G UCAUGCUA	540	TAGCATGA GGCTAGCTACAACGA AGTCTAAA	2242
2297	AGACUGUC A UGCUAUUG	541	CATTAGCA GGCTAGCTACAACGA GACAGTCT	2243
2299	ACUGUCAU G CUAAUGGU	542	ACCATTAG GGCTAGCTACAACGA ATGACAGT	2244
2303	UCAUGCUA A UGGUGUCC	543	GGACACCA GGCTAGCTACAACGA TAGCATGA	2245
2306	UGCUAUUG G UGUCCCCG	544	CGGGGACA GGCTAGCTACAACGA CATTAGCA	2246
2308	CUAAUGGU G UCCCCGAG	545	CTCGGGGA GGCTAGCTACAACGA ACCATTAG	2247
2316	GUCCCCGA G CCUCAGAU	546	ATCTGAGG GGCTAGCTACAACGA TCGGGGAC	2248
2323	AGCCUCAG A UCACUUGG	547	CCAAGTGA GGCTAGCTACAACGA CTGAGGCT	2249
2326	CUCAGAU A CUUGGUUU	548	AAACCAAG GGCTAGCTACAACGA GATCTGAG	2250
2331	AUCACUUG G UUUAAAAA	549	TTTTTAAA GGCTAGCTACAACGA CAAGTGAT	2251
2339	GUUUAAAA A CAACCACA	550	TGTGGTTG GGCTAGCTACAACGA TTTTAAAC	2252
2342	UAAAAACA A CCACAAA	551	TTTGTGTTG GGCTAGCTACAACGA TGTTTTAA	2253
2345	AAACAACC A CAAAUAUC	552	GTATTTTG GGCTAGCTACAACGA GGTGTGTT	2254
2350	ACCACAAA A UACAACAA	553	TTGTTGTA GGCTAGCTACAACGA TTTGTGTT	2255
2352	CACAAAUA A CAACAAGA	554	TCTTGTGTTG GGCTAGCTACAACGA ATTTGTG	2256
2355	AAAUAACA A CAAGAGCC	555	GGCTCTTG GGCTAGCTACAACGA TGTATTTT	2257
2361	CAACAAGA G CCUGGAU	556	ATTCCAGG GGCTAGCTACAACGA TCTTGTG	2258
2368	AGCCUGGA A UUAUUUA	557	TAAAATAA GGCTAGCTACAACGA TCCAGGCT	2259
2371	CUGGAUUU A UUUUAGGA	558	TCCTAAAA GGCTAGCTACAACGA AATTCCAG	2260
2379	AUUUUAGG A CCAGGAAG	559	CTTCCTGG GGCTAGCTACAACGA CCTAAAAT	2261
2387	ACCAGGAA G CAGCACGC	560	GCCTGCTG GGCTAGCTACAACGA TTCCTGGT	2262
2390	AGGAAGCA G CACGUGU	561	ACAGCGTG GGCTAGCTACAACGA TGCTTCCT	2263
2392	GAAGCAGC A CGCUGUU	562	AAACAGCG GGCTAGCTACAACGA GCTGCTTC	2264
2394	AGCAGCAC G CUGUUUUA	563	ATAAACAG GGCTAGCTACAACGA GTGCTGCT	2265
2397	AGCACGCU G UUUUUGA	564	TCAATAAA GGCTAGCTACAACGA AGCGTGCT	2266
2401	CGCUGUUU A UUGAAAGA	565	TCTTTCAA GGCTAGCTACAACGA AAACAGCG	2267
2410	UUGAAAGA G UCACAGAA	566	TTCTGTGA GGCTAGCTACAACGA TCTTTCAA	2268
2413	AAAGAGUC A CAGAAGAG	567	CTCTTCTG GGCTAGCTACAACGA GACTCTTT	2269
2423	AGAAGAGG A UGAAGGUG	568	CACCTTCA GGCTAGCTACAACGA CCTCTTCT	2270

2429	GGAUGAAG G UGUCUAUC	569	GATAGACA GGCTAGCTACAACGA CTTTCATCC	2271
2431	AUGAAGGU G UCUAUCAC	570	GTGATAGA GGCTAGCTACAACGA ACCTTCAT	2272
2435	AGGUGUCU A UCACUGCA	571	TGCAGTGA GGCTAGCTACAACGA AGACACCT	2273
2438	UGUCUAUC A CUGCAAAG	572	CTTTGCAG GGCTAGCTACAACGA GATAGACA	2274
2441	CUAUCACU G CAAAGCCA	573	TGGCTTTG GGCTAGCTACAACGA AGTGATAG	2275
2446	ACUGCAA G CCACCAAC	574	GTTGGTGG GGCTAGCTACAACGA TTTGCAGT	2276
2449	GCAAAGCC A CCAACCAG	575	CTGGTTGG GGCTAGCTACAACGA GGCTTTGC	2277
2453	AGCCACCA A CCAGAAGG	576	CCTTCTGG GGCTAGCTACAACGA TGGTGGCT	2278
2462	CCAGAAGG G CUCUGUGG	577	CCACAGAG GGCTAGCTACAACGA CCTTCTGG	2279
2467	AGGGCUCU G UGGAAAGU	578	ACTTTCCA GGCTAGCTACAACGA AGAGCCCT	2280
2474	UGUGGAAA G UUCAGCAU	579	ATGCTGAA GGCTAGCTACAACGA TTTCCACA	2281
2479	AAAGUUCA G CAUACCUC	580	GAGGTATG GGCTAGCTACAACGA TGAACCTT	2282
2481	AGUUCAGC A UACCUCAC	581	GTGAGGTA GGCTAGCTACAACGA GCTGAACT	2283
2483	UUCAGCAU A CCUCACUG	582	CAGTGAGG GGCTAGCTACAACGA ATGCTGAA	2284
2488	CAUACCUC A CUGUUCAA	583	TTGAACAG GGCTAGCTACAACGA GAGGTATG	2285
2491	ACCUCACU G UUCAAGGA	584	TCCTTGAA GGCTAGCTACAACGA AGTGAGGT	2286
2500	UUCAAGGA A CCUCGGAC	585	GTCCGAGG GGCTAGCTACAACGA TCCTTGAA	2287
2507	AACCUCGG A CAAGUCUA	586	TAGACTTG GGCTAGCTACAACGA CCGAGGTT	2288
2511	UCGGACAA G UCUAUUCU	587	AGATTAGA GGCTAGCTACAACGA TTGTCCGA	2289
2516	CAAGUCUA A UCUGGAGC	588	GCTCCAGA GGCTAGCTACAACGA TAGACTTG	2290
2523	AAUCUGGA G CUGAUCAC	589	GTGATCAG GGCTAGCTACAACGA TCCAGATT	2291
2527	UGGAGCUG A UCACUCUA	590	TAGAGTGA GGCTAGCTACAACGA CAGCTCCA	2292
2530	AGCUGAUC A CUCUAACA	591	TGTTAGAG GGCTAGCTACAACGA GATCAGCT	2293
2536	UCACUCUA A CAUGCACC	592	GGTGCAATG GGCTAGCTACAACGA TAGAGTGA	2294
2538	ACUCUAAC A UGCACCUG	593	CAGGTGCA GGCTAGCTACAACGA GTTAGAGT	2295
2540	UCUAACAU G CACCUGUG	594	CACAGGTG GGCTAGCTACAACGA ATGTTAGA	2296
2542	UAACAUGC A CCUGUGUG	595	CACACAGG GGCTAGCTACAACGA GCATGTTA	2297
2546	AUGCACCU G UGUGGUG	596	CAGCCACA GGCTAGCTACAACGA AGGTGCAT	2298
2548	GCACCUGU G UGGCUGCG	597	CGCAGCCA GGCTAGCTACAACGA ACAGGTGC	2299
2551	CCUGUGUG G CUGCGACU	598	AGTCGCAG GGCTAGCTACAACGA CACACAGG	2300
2554	GUGUGGCU G CGACUCUC	599	GAGAGTCG GGCTAGCTACAACGA AGCCACAC	2301
2557	UGGCUGCG A CUCUCUUC	600	GAAGAGAG GGCTAGCTACAACGA CGCAGCCA	2302
2568	CUCUUCUG G CUCCUADU	601	AATAGGAG GGCTAGCTACAACGA CAGAAGAG	2303
2574	UGGCUCCU A UUAACCCU	602	AGGGTTAA GGCTAGCTACAACGA AGGAGCCA	2304
2578	UCCUAUUA A CCUCCUU	603	AAGGAGGG GGCTAGCTACAACGA TAATAGGA	2305
2587	CCUCCUU A UCCGAAAA	604	TTTTCGGA GGCTAGCTACAACGA AAGGAGGG	2306
2596	UCCGAAAA A UGAAAAGG	605	CCTTTTCA GGCTAGCTACAACGA TTTTCGGA	2307
2604	AUGAAAAG G UCUUCUUC	606	GAAGAAGA GGCTAGCTACAACGA CTTTTCAT	2308
2617	CUUCUGAA A UAAAGACU	607	AGTCTTTA GGCTAGCTACAACGA TTCAGAAG	2309
2623	AAAUAAAG A CUGACUAC	608	GTAGTCAG GGCTAGCTACAACGA CTTTATTT	2310
2627	AAAGACUG A CUACCUAU	609	ATAGGTAG GGCTAGCTACAACGA CAGTCTTT	2311
2630	GACUGACU A CUAUCAA	610	TTGATAGG GGCTAGCTACAACGA AGTCAGTC	2312
2634	GACUACCU A UCAUUAU	611	ATAATTGA GGCTAGCTACAACGA AGGTAGTC	2313
2638	ACCUAUCA A UUAUAUUG	612	CATTATAA GGCTAGCTACAACGA TGATAGGT	2314
2641	UAUCAAU A UAAUGGAC	613	GTCCATTA GGCTAGCTACAACGA AATTGATA	2315
2644	CAAUUAU A UGGACCCA	614	TGGGTCCA GGCTAGCTACAACGA TATAATTG	2316
2648	UAUAUUGG A CCCAGAUG	615	CATCTGGG GGCTAGCTACAACGA CCATTATA	2317
2654	GGACCCAG A UGAAGUUC	616	GAACTTCA GGCTAGCTACAACGA CTGGGTCC	2318
2659	CAGAUGAA G UCCCUUUG	617	CAAAGGAA GGCTAGCTACAACGA TTCATCTG	2319
2669	UCCUUUGG A UGAGCAGU	618	ACTGCTCA GGCTAGCTACAACGA CCAAAGGA	2320
2673	UUGGAUGA G CAGUGUGA	619	TCACACTG GGCTAGCTACAACGA TCATCCAA	2321
2676	GAUGAGCA G UGUGAGCG	620	CGCTCACA GGCTAGCTACAACGA TGCTCATC	2322

2678	UGAGCAGU G UGAGCGGC	621	GCCGCTCA GGCTAGCTACAACGA ACTGCTCA	2323
2682	CAGUGUGA G CGGCUCCC	622	GGGAGCCG GGCTAGCTACAACGA TCACACTG	2324
2685	UGUGAGCG G CUCCCUUA	623	TAAGGGAG GGCTAGCTACAACGA CGCTCACA	2325
2693	GCUCCCUU A UGAUGCCA	624	TGGCATCA GGCTAGCTACAACGA AAGGGAGC	2326
2696	CCCUUAUG A UGCCAGCA	625	TGCTGGCA GGCTAGCTACAACGA CATAAGGG	2327
2698	CUUAUGAU G CCAGCAAG	626	CTTGCTGG GGCTAGCTACAACGA ATCATAAG	2328
2702	UGADGCCA G CAAGUGGG	627	CCCACCTG GGCTAGCTACAACGA TGGCATCA	2329
2706	GCCAGCAA G UGGGAGUU	628	AACTCCCA GGCTAGCTACAACGA TTGCTGGC	2330
2712	AAGUGGGA G UUUGCCCG	629	CGGGCAAA GGCTAGCTACAACGA TCCCACTT	2331
2716	GGGAGUUU G CCCGGGAG	630	CTCCCGGG GGCTAGCTACAACGA AAACCTCC	2332
2727	CGGAGAG A CUUAAACU	631	AGTTTAAG GGCTAGCTACAACGA CTCTCCCG	2333
2733	AGACUUA A CUGGGCAA	632	TTGCCAG GGCTAGCTACAACGA TTAAGTCT	2334
2738	UAAACUGG G CAAAUAC	633	GTGATTG GGCTAGCTACAACGA CCAGTTTA	2335
2742	CUGGGCAA A UCACUUGG	634	CCAAGTGA GGCTAGCTACAACGA TTGCCAG	2336
2745	GGCAAUUC A CUUGGAAG	635	CTTCCAAG GGCTAGCTACAACGA GATTGCCC	2337
2758	GAAGAGGG G CUUUUGGA	636	TCCAAAAG GGCTAGCTACAACGA CCCTCTTC	2338
2770	UUGGAAAA G UGGUUCAA	637	TGAACCA GGCTAGCTACAACGA TTTTCCAA	2339
2773	GAAAAGUG G UUCAAGCA	638	TGCTTGAA GGCTAGCTACAACGA CACTTTTC	2340
2779	UGGUUCAA G CAUCAGCA	639	TGCTGATG GGCTAGCTACAACGA TTGAACCA	2341
2781	GUUCAAGC A UCAGCAU	640	AATGCTGA GGCTAGCTACAACGA GCTTGAAC	2342
2785	AAGCAUCA G CAUUUGGC	641	GCCAAATG GGCTAGCTACAACGA TGATGCTT	2343
2787	GCAUCAGC A UUUGGCAU	642	ATGCCAAA GGCTAGCTACAACGA GCTGATGC	2344
2792	AGCAUUUG G CAUUAAGA	643	TCTTAATG GGCTAGCTACAACGA CAAATGCT	2345
2794	CAUUUGGC A UUAAGAAA	644	TTTCTTAA GGCTAGCTACAACGA GCCAAATG	2346
2802	AUUAAGAA A UCACCUAC	645	GTAGGTGA GGCTAGCTACAACGA TTCTTAAT	2347
2805	AAGAAAU C CCUACGUG	646	CACGTAGG GGCTAGCTACAACGA GATTCTTT	2348
2809	AAUCACCU A CGUGCCGG	647	CCGGCACG GGCTAGCTACAACGA AGGTGATT	2349
2811	UCACCUAC G UGCCGGAC	648	GTCCGGCA GGCTAGCTACAACGA GTAGGTGA	2350
2813	ACCUCAGU G CCGGACUG	649	CAGTCCGG GGCTAGCTACAACGA ACGTAGGT	2351
2818	CGUGCCGG A CUGUGGCU	650	AGCCACAG GGCTAGCTACAACGA CCGGCACG	2352
2821	GCCGGACTU G UGGCUGUG	651	CACAGCCA GGCTAGCTACAACGA AGTCCGGC	2353
2824	GGACUGUG G CUGUGAAA	652	TTTCACAG GGCTAGCTACAACGA CACAGTCC	2354
2827	CUGUGGCU G UGAAAUG	653	CATTTTCA GGCTAGCTACAACGA AGCCACAG	2355
2833	CUGUGAAA A UGUGAAA	654	TTTCAGCA GGCTAGCTACAACGA TTTCACAG	2356
2835	GUGAAAAU G CUGAAAGA	655	TCTTTCAG GGCTAGCTACAACGA ATTTTCAC	2357
2848	AAGAGGGG G CCACGGCC	656	GGCCGTGG GGCTAGCTACAACGA CCCCTCTT	2358
2851	AGGGGGCC A CGGCCAGC	657	GCTGGCCG GGCTAGCTACAACGA GGCCCCCT	2359
2854	GGGCCACG G CCAGCGAG	658	CTCGCTGG GGCTAGCTACAACGA CGTGGCCC	2360
2858	CACGGCCA G CGAGUACA	659	TGTAICTG GGCTAGCTACAACGA TGGCCGTG	2361
2862	GCCAGCGA G UACAAAGC	660	GCTTTGTA GGCTAGCTACAACGA TCGCTGGC	2362
2864	CAGCGAGU A CAAAGCUC	661	GAGCTTGG GGCTAGCTACAACGA ACTCGCTG	2363
2869	AGUACAAA G CUCUGAUG	662	CATCAGAG GGCTAGCTACAACGA TTTGTACT	2364
2875	AAGCUCUG A UGACUGAG	663	CTCAGTCA GGCTAGCTACAACGA CAGAGCTT	2365
2878	CUCUGAUG A CUGAGCUA	664	TAGCTCAG GGCTAGCTACAACGA CATCAGAG	2366
2883	AUGACUGA G CUAAAAU	665	ATTTTTAG GGCTAGCTACAACGA TCAGTCAT	2367
2890	AGCUAAAA A UCUUGACC	666	GGTCAAGA GGCTAGCTACAACGA TTTTAGCT	2368
2896	AAAUUCUG A CCCACAUU	667	AATGTGGG GGCTAGCTACAACGA CAAGATTT	2369
2900	CUUGACCC A CAUUGGCC	668	GGCCAATG GGCTAGCTACAACGA GGGTCAG	2370
2902	UGACCCAC A UUGGCCAC	669	GTGGCCAA GGCTAGCTACAACGA GTGGGTCA	2371
2906	CCACAUUG G CCACCAUC	670	GATGGTGG GGCTAGCTACAACGA CAATGTGG	2372
2909	CAUUGGCC A CCAUCUGA	671	TCAGATGG GGCTAGCTACAACGA GGCCAATG	2373
2912	UGGCCACC A UCUGAAGC	672	CGTTCAGA GGCTAGCTACAACGA GGTGGCCA	2374



2918	CCAUCUGA A CGUGGUUA	673	TAACCACG GGCTAGCTACAACGA TCAGATGG	2375
2920	AUCUGAAC G UGUUUAAC	674	GTTAACCA GGCTAGCTACAACGA GTTCAGAT	2376
2923	UGAACGUG G UUAACCUG	675	CAGGTAA GGCTAGCTACAACGA CACGTTCA	2377
2927	CGUGGUUA A CCUGCUGG	676	CCAGCAGG GGCTAGCTACAACGA TAACCACG	2378
2931	GUUAACCU G CUGGGAGC	677	GCTCCCAG GGCTAGCTACAACGA AGGTTAAC	2379
2938	UGCUGGGA G CCUGCACC	678	GGTGCAGG GGCTAGCTACAACGA TCCAGCA	2380
2942	GGGAGCCU G CACCAAGC	679	GCTTGGTG GGCTAGCTACAACGA AGGCTCCC	2381
2944	GAGCCUGC A CCAAGCAA	680	TTGCTTGG GGCTAGCTACAACGA GCAGGCTC	2382
2949	UGCACCAA G CAAGGAGG	681	CCTCCTTG GGCTAGCTACAACGA TTGGTGCA	2383
2958	CAAGGAGG G CCUCUGAU	682	ATCAGAGG GGCTAGCTACAACGA CCTCCTTG	2384
2965	GGCCUCUG A UGGUGAUU	683	AATCACCA GGCTAGCTACAACGA CAGAGGCC	2385
2968	CUCUGAUG G UGAUUGUU	684	AACAATCA GGCTAGCTACAACGA CATCAGAG	2386
2971	UGAUGGUG A UGUUGAA	685	TTCAACAA GGCTAGCTACAACGA CACCATCA	2387
2974	UGUGAUU G UGAUUAAC	686	GTATTCAA GGCTAGCTACAACGA AATCACCA	2388
2979	AUUGUGA A UACUGCAA	687	TTGCAGTA GGCTAGCTACAACGA TCAACAAT	2389
2981	UGUUGAAU A CUGCAAU	688	ATTTCAG GGCTAGCTACAACGA ATTCAACA	2390
2984	UGAAUACU G CAAAUUG	689	CATATTTG GGCTAGCTACAACGA AGTATTCA	2391
2988	UACUGCAA A UAUGGAAA	690	TTTCCATA GGCTAGCTACAACGA TTGCAGTA	2392
2990	CUGCAAU A UGAAAUC	691	GATTTCGA GGCTAGCTACAACGA ATTTGCAG	2393
2996	AUAUGGAA A UCUCUCCA	692	TGGAGAGA GGCTAGCTACAACGA TTCCATAT	2394
3005	UCUCUCCA A CUACCUCA	693	TGAGGTAG GGCTAGCTACAACGA TGGAGAGA	2395
3008	CUCCAACU A CCUCAAGA	694	TCTTGAGG GGCTAGCTACAACGA AGTTGGAG	2396
3017	CCUCAAGA G CAAACGUG	695	CACGTTTG GGCTAGCTACAACGA TCTTGAGG	2397
3021	AAGAGCAA A CGUGACUU	696	AAGTCACG GGCTAGCTACAACGA TTGCTCTT	2398
3023	GAGCAAAC G UGACUUAU	697	ATAAGTCA GGCTAGCTACAACGA GTTTGCTC	2399
3026	CAAACGUG A CUUAUUUU	698	AAAATAAG GGCTAGCTACAACGA CACGTTTG	2400
3030	CGUGACUU A UUUUUUCU	699	AGAAAAAA GGCTAGCTACAACGA AAGTCACG	2401
3041	UUUUCUCA A CAAGGAUG	700	CATCCTTG GGCTAGCTACAACGA TGAGAAAA	2402
3047	CAACAAGG A UGCAGCAC	701	GTGCTGCA GGCTAGCTACAACGA CCTTGTG	2403
3049	ACAAGGAU G CAGCACUA	702	TAGTGCTG GGCTAGCTACAACGA ATCCTTGT	2404
3052	AGGAUGCA G CACUACAC	703	GTGTAGTG GGCTAGCTACAACGA TGCATCCT	2405
3054	GAUGCAGC A CUACACAU	704	ATGTGTAG GGCTAGCTACAACGA GCTGCATC	2406
3057	GCAGCACU A CACAUGGA	705	TCCATGTG GGCTAGCTACAACGA AGTGCTGC	2407
3059	AGCACUAC A CAUGGAGC	706	GCTCCATG GGCTAGCTACAACGA GTAGTGCT	2408
3061	CACUACAC A UGGAGCCU	707	AGGCTCCA GGCTAGCTACAACGA GTGTAGTG	2409
3066	CACAUGGA G CCUAAGAA	708	TTCTTAGG GGCTAGCTACAACGA TCCATGTG	2410
3082	AAGAAAAA A UGGAGCCA	709	TGGCTCCA GGCTAGCTACAACGA TTTTCTTT	2411
3087	AAA AUGGA G CCAGGCCU	710	AGGCCTGG GGCTAGCTACAACGA TCCATTTT	2412
3092	GGAGCCAG G CCUGGAAC	711	GTTCCAGG GGCTAGCTACAACGA CTGGCTCC	2413
3099	GGCCUGGA A CAAGGCAA	712	TTGCCTTG GGCTAGCTACAACGA TCCAGGCC	2414
3104	GGAACAAG G CAAGAAAC	713	GTTTCTTG GGCTAGCTACAACGA CTGTGTC	2415
3111	GGCAAGAA A CCAAGACU	714	AGTCTTGG GGCTAGCTACAACGA TTCTTGCC	2416
3117	AAACCAAG A CUAGAUG	715	CTATCTAG GGCTAGCTACAACGA CTGGTTT	2417
3122	AAGACUAG A UAGCGUCA	716	TGACGCTA GGCTAGCTACAACGA CTAGTCTT	2418
3125	ACUAGAUA G CGUCACCA	717	TGGTGACG GGCTAGCTACAACGA TATCTAGT	2419
3127	UAGAUAAG G UCACCAGC	718	GCTGGTGA GGCTAGCTACAACGA GCTATCTA	2420
3130	AUAGCGUC A CCAGCAGC	719	GCTGCTGG GGCTAGCTACAACGA GACGCTAT	2421
3134	CGUCACCA G CAGCGAAA	720	TTTCGCTG GGCTAGCTACAACGA TGGTGACG	2422
3137	CACCAGCA G CGAAAGCU	721	AGCTTTCG GGCTAGCTACAACGA TGCTGGTG	2423
3143	CAGCGAAA G CUUUGCGA	722	TCGCAAGG GGCTAGCTACAACGA TTTTCGCTG	2424
3148	AAAGCUUU G CGAGCUCC	723	GGAGCTCG GGCTAGCTACAACGA AAAGCTTT	2425
3152	CUUUGCGA G CUCCGGCU	724	AGCCGGAG GGCTAGCTACAACGA TCGCAAG	2426

3158	GAGUCCG G CUUUCAGG	725	CCTGAAAG GGCTAGCTACAACGA CGGAGCTC	2427
3170	UCAGGAAG A UAAAAGUC	726	GACTTTTA GGCTAGCTACAACGA CTTCCTGA	2428
3176	AGAUAAAA G UCUGAGUG	727	CACTCAGA GGCTAGCTACAACGA TTTTATCT	2429
3182	AAGUCUGA G UGAUGUUG	728	CAACATCA GGCTAGCTACAACGA TCAGACTT	2430
3185	UCUGAGUG A UGUUGAGG	729	CCTCAACA GGCTAGCTACAACGA CACTCAGA	2431
3187	UGAGUGAU G UUGAGGAA	730	TTCTCTCA GGCTAGCTACAACGA ATCACTCA	2432
3203	AGAGGAGG A UUCUGACG	731	CGTCAGAA GGCTAGCTACAACGA CCTCCTCT	2433
3209	GGAUUCUG A CGGUUUCU	732	AGAAACCG GGCTAGCTACAACGA CAGAATCC	2434
3212	UUCUGACG G UUCUACA	733	TGTAGAAA GGCTAGCTACAACGA CGTCAGAA	2435
3218	CGGUUUCU A CAAGGAGC	734	GTCTCTTG GGCTAGCTACAACGA AGAAACCG	2436
3225	UACAAGGA G CCAUCAC	735	GTGATGGG GGCTAGCTACAACGA TCCTTGTA	2437
3229	AGGAGCCC A UCACUAG	736	CATAGTGA GGCTAGCTACAACGA GGGCTCCT	2438
3232	AGCCCAUC A CUUUGGAA	737	TTCCATAG GGCTAGCTACAACGA GATGGGCT	2439
3235	CCAUCACU A UGGAAGAU	738	ATCTTCCA GGCTAGCTACAACGA AGTGATGG	2440
3242	UAUGGAAG A UCUGAUUU	739	AAATCAGA GGCTAGCTACAACGA CTTCCTATA	2441
3247	AAGAUCUG A UUCUUUAC	740	GTAAGAAA GGCTAGCTACAACGA CAGATCTT	2442
3254	GAUUUCUU A CAGUUUUC	741	GAAAACTG GGCTAGCTACAACGA AAGAAATC	2443
3257	GUUUUACA G UUUUCAAG	742	CTTGAAAA GGCTAGCTACAACGA TGTAGAA	2444
3265	GUUUUCAA G UGGCCAGA	743	TCTGGCCA GGCTAGCTACAACGA TTGAAAC	2445
3268	UUCAAGUG G CCAGAGGC	744	GCCTCTGG GGCTAGCTACAACGA CACTTGAA	2446
3275	GGCCAGAG G CAUGGAGU	745	ACTCCATG GGCTAGCTACAACGA CTCTGGCC	2447
3277	CCAGAGGC A UGGAGUUC	746	GAATCCA GGCTAGCTACAACGA GCCTCTGG	2448
3282	GGCAUGGA G UUCCUGUC	747	GACAGGAA GGCTAGCTACAACGA TCCATGCC	2449
3288	GAGUUCU G UCUUCCAG	748	CTGGAAGA GGCTAGCTACAACGA AGGAATC	2450
3300	UCCAGAAA G UGCAUUA	749	TGAATGCA GGCTAGCTACAACGA TTTCTGGA	2451
3302	CAGAAAGU G CAUUAUC	750	GATGAATG GGCTAGCTACAACGA ACTTCTG	2452
3304	GAAAGUGC A UUCAUCGG	751	CCGATGAA GGCTAGCTACAACGA GCATTTTC	2453
3308	GUGCAUUC A UCGGGACC	752	GGTCCCGA GGCTAGCTACAACGA GAATGCAC	2454
3314	UCAUCGGG A CCUGGCAG	753	CTGCCAGG GGCTAGCTACAACGA CCCGATGA	2455
3319	GGGACCUG G CAGCGAGA	754	TCTCGCTG GGCTAGCTACAACGA CAGGTCCC	2456
3322	ACCUGGCA G CGAGAAAC	755	GTTTCTCG GGCTAGCTACAACGA TGCCAGGT	2457
3329	AGCGAGAA A CAUUCUUU	756	AAAGAATG GGCTAGCTACAACGA TTCTCGCT	2458
3331	CGAGAAAC A UUCUUUUA	757	TAAAAGAA GGCTAGCTACAACGA GTTCTCG	2459
3339	AUUCUUUU A UCUGAGAA	758	TTCTCAGA GGCTAGCTACAACGA AAAAGAAT	2460
3347	AUCUGAGA A CAACGUGG	759	CCACGTTG GGCTAGCTACAACGA TCTCAGAT	2461
3350	UGAGAACA A CGUGGUGA	760	TCACCACG GGCTAGCTACAACGA TGTCTCA	2462
3352	AGAACAAC G UGGUGAAG	761	CTTCACCA GGCTAGCTACAACGA GTTGTCT	2463
3355	ACAACGUG G UGAAGAUU	762	AATCTTCA GGCTAGCTACAACGA CACGTTGT	2464
3361	UGGUGAAG A UUUGUGAU	763	ATCACAAA GGCTAGCTACAACGA CTTCACCA	2465
3365	GAAGAUUU G UGAUUUUG	764	CAAAATCA GGCTAGCTACAACGA AAATCTTC	2466
3368	GAUUUGUG A UUUUGGCC	765	GGCCAAAA GGCTAGCTACAACGA CACAAATC	2467
3374	UGAUUUUG G CCUGGCC	766	GGGCAAGG GGCTAGCTACAACGA CAAAATCA	2468
3379	UUGGCCUU G CCGGGAU	767	ATCCCGGG GGCTAGCTACAACGA AAGGCCAA	2469
3386	UGCCCGGG A UAUUAUA	768	TATAAATA GGCTAGCTACAACGA CCCGGGCA	2470
3388	CCCGGGAU A UUAUAAG	769	CTTATAAA GGCTAGCTACAACGA ATCCGGG	2471
3392	GGAUUUUU A UAAGAACC	770	GGTTCTTA GGCTAGCTACAACGA AAATATCC	2472
3398	UUAUAAGA A CCCGGAU	771	AATCGGGG GGCTAGCTACAACGA TCTTATAA	2473
3404	GAACCCCG A UUAUGUGA	772	TCACATAA GGCTAGCTACAACGA CGGGGTTT	2474
3407	CCCGGAU A UGUGAGAA	773	TTCTCACA GGCTAGCTACAACGA AATCGGGG	2475
3409	CCGAUUUAU G UGAGAAAA	774	TTTTCTCA GGCTAGCTACAACGA ATAATCGG	2476
3422	AAAAGGAG A UACUCGAC	775	GTGAGTA GGCTAGCTACAACGA CTCCTTTT	2477
3424	AAGGAGAU A CUCGACUU	776	AAGTCGAG GGCTAGCTACAACGA ATCTCCTT	2478

3429	GAUACUCG A CUUCCUCU	777	AGAGGAAG GGCTAGCTACAACGA CGAGTATC	2479
3441	CCUCUGAA A UGGAUGGC	778	GCCATCCA GGCTAGCTACAACGA TTCAGAGG	2480
3445	UGAAAUGG A UGGCUCCC	779	GGGAGCCA GGCTAGCTACAACGA CCATTTCA	2481
3448	AAUGGAUG G CUCCCGAA	780	TTCCGGAG GGCTAGCTACAACGA CATCCATT	2482
3456	GCUCCCGA A UCUAUCUU	781	AAGATAGA GGCTAGCTACAACGA TCGGGAGC	2483
3460	CCGAAUCU A UCUUUGAC	782	GTCAAAGA GGCTAGCTACAACGA AGATTCCG	2484
3467	UAUCUUUG A CAAAUCU	783	AGATTTTG GGCTAGCTACAACGA CAAAGATA	2485
3472	UUGACAAA A UCUACAGC	784	GCTGTAGA GGCTAGCTACAACGA TTTGTCAA	2486
3476	CAAAUCU A CAGCACCA	785	TGGTGCTG GGCTAGCTACAACGA AGATTTTG	2487
3479	AAUCUACA G CACCAAGA	786	TCTTGGTG GGCTAGCTACAACGA TGTAGATT	2488
3481	UCUACAGC A CCAAGAGC	787	GCTCTTGG GGCTAGCTACAACGA GCTGTAGA	2489
3488	CACCAAGA G CGACGUGU	788	ACACGTCG GGCTAGCTACAACGA TCTTGGTG	2490
3491	CAAGAGCG A CGUGUGGU	789	ACCACACG GGCTAGCTACAACGA CGCTCTTG	2491
3493	AGAGCGAC G UGUGGUCU	790	AGACCACA GGCTAGCTACAACGA GTCGCTCT	2492
3495	AGCGACGU G UGGUCUUA	791	TAAGACCA GGCTAGCTACAACGA ACGTCGCT	2493
3498	GACGUGUG G UCUUACGG	792	CCGTAAGA GGCTAGCTACAACGA CACACGTC	2494
3503	GUGGUCUU A CGGAGUUA	793	ATACTCCG GGCTAGCTACAACGA AAGACCAC	2495
3508	CUUACGGA G UAUUGCUG	794	CAGCAATA GGCTAGCTACAACGA TCCGTAAG	2496
3510	UACGGAGU A UUGCUGUG	795	CACAGCAA GGCTAGCTACAACGA ACTCCGTA	2497
3513	GGAGUAUU G CUGUGGGA	796	TCCCACAG GGCTAGCTACAACGA AATACTCC	2498
3516	GUUUGCU G UGGGAAAU	797	ATTTCCCA GGCTAGCTACAACGA AGCAATAC	2499
3523	UGUGGGAA A UCUUCUCC	798	GGAGAAGA GGCTAGCTACAACGA TTCCCA	2500
3536	CUCCUUG G UGGGUCUC	799	GAGACCCA GGCTAGCTACAACGA CTAAGGAG	2501
3540	UUAGGUGG G UCUCUAUA	800	TATGGAGA GGCTAGCTACAACGA CCACCTAA	2502
3546	GGGUCUCC A UACCCAGG	801	CCTGGGTA GGCTAGCTACAACGA GGAGACCC	2503
3548	GUCUCAU A CCCAGGAG	802	CTCTGGG GGCTAGCTACAACGA ATGGAGAC	2504
3556	ACCCAGGA G UACAAUG	803	CATTGTGA GGCTAGCTACAACGA TCCTGGGT	2505
3558	CCAGGAGU A CAAUUGGA	804	TCCATTTG GGCTAGCTACAACGA ACTCCTGG	2506
3562	GAGUACAA A UGGAUGAG	805	CTCATCCA GGCTAGCTACAACGA TTGTACTC	2507
3566	ACAAUUGG A UGAGGACU	806	AGTCCTCA GGCTAGCTACAACGA CCATTTGT	2508
3572	GGAUGAGG A CUUUUGCA	807	TGCCAAAG GGCTAGCTACAACGA CCTCATCC	2509
3578	GGACUUUU G CAGUCGCC	808	TGCGACTG GGCTAGCTACAACGA AAAAGTCC	2510
3581	CUUUUGCA G UCGCCUGA	809	TCAGGCGA GGCTAGCTACAACGA TGCAAAAG	2511
3584	UUGCAGUC G CCUGAGGG	810	CCCTCAGG GGCTAGCTACAACGA GACTGCAA	2512
3596	GAGGGAAG G CAUGAGGA	811	TCCTCATG GGCTAGCTACAACGA CTTCCCTC	2513
3598	GGGAAGGC A UGAGGAUG	812	CATCCTCA GGCTAGCTACAACGA GCCTTCCC	2514
3604	GCAUGAGG A UGAGAGCU	813	AGCTCTCA GGCTAGCTACAACGA CCTCATGC	2515
3610	GGAUGAGA G CUCCUGAG	814	CTCAGGAG GGCTAGCTACAACGA TCTCATCC	2516
3618	GCUCUGA G UACUCUAC	815	GTAGAGTA GGCTAGCTACAACGA TCAGGAGC	2517
3620	UCCUGAGU A CUCUACUC	816	GAGTAGAG GGCTAGCTACAACGA ACTCAGGA	2518
3625	AGUACUCU A CUCCUGAA	817	TTCAGGAG GGCTAGCTACAACGA AGAGTACT	2519
3634	CUCCUGAA A UCUAUCAG	818	CTGATAGA GGCTAGCTACAACGA TTCAGGAG	2520
3638	UGAAAUUCU A UCAGAUCA	819	TGATCTGA GGCTAGCTACAACGA AGATTTCA	2521
3643	UCUAUCAG A UCAUGCUG	820	CAGCATGA GGCTAGCTACAACGA CTGATAGA	2522
3646	AUCAGAUC A UGCUGGAC	821	GTCCAGCA GGCTAGCTACAACGA GATCTGAT	2523
3648	CAGAUCAU G CUGGACUG	822	CAGTCCAG GGCTAGCTACAACGA ATGATCTG	2524
3653	CAUGCUGG A CUGCUGGC	823	GCCAGCAG GGCTAGCTACAACGA CCAGCATG	2525
3656	GCUGGACU G CUGGCACA	824	TGTGCCAG GGCTAGCTACAACGA AGTCCAGC	2526
3660	GACUGCUG G CACAGAGA	825	TCTCTGTG GGCTAGCTACAACGA CAGCAGTC	2527
3662	CUGCUGGC A CAGAGACC	826	GGTCTCTG GGCTAGCTACAACGA GCCAGCAG	2528
3668	GCACAGAG A CCAAAAG	827	CTTTTGGG GGCTAGCTACAACGA CTCTGTGC	2529
3681	AAAGAAAG G CCAAGAUU	828	AATCTTGG GGCTAGCTACAACGA CTTTCTTT	2530

3687	AGGCCAAG A UUUGCAGA	829	TCTGCAAA GGCTAGCTACAACGA CTTGGCCT	2531
3691	CAAGAUUU G CAGAACUU	830	AAGTTCTG GGCTAGCTACAACGA AAATCTTG	2532
3696	UUUGCAGA A CUUGUGGA	831	TCCACAAG GGCTAGCTACAACGA TCTGCAAA	2533
3700	CAGAACUU G UGGA AAAA	832	TTTTTCCA GGCTAGCTACAACGA AAGTTCTG	2534
3708	GUGGAAAA A CUAGGUGA	833	TCACCTAG GGCTAGCTACAACGA TTTCCAC	2535
3713	AAAACUAG G UGAUUUGC	834	GCAAATCA GGCTAGCTACAACGA CTAGTTT	2536
3716	ACUAGGUG A UUUGCUUC	835	GAAGCAAA GGCTAGCTACAACGA CACCTAGT	2537
3720	GGUGAUUU G CUUCAAGC	836	GCTTGAAG GGCTAGCTACAACGA AAATCACC	2538
3727	UGCUUCA A G CAAUGUA	837	TACATTTG GGCTAGCTACAACGA TTGAAGCA	2539
3731	UCAAGCAA A UGUACAAC	838	GTGTGACA GGCTAGCTACAACGA TTGCTTGA	2540
3733	AAGCAAU G UACAACAG	839	CTGTGTGA GGCTAGCTACAACGA ATTTGCTT	2541
3735	GCAAUGU A CAACAGGA	840	TCCTGTTG GGCTAGCTACAACGA ACATTTGC	2542
3738	AAUGUACA A CAGGAUGG	841	CCATCCTG GGCTAGCTACAACGA TGTACATT	2543
3743	ACAACAGG A UGGUAAAG	842	CTTTACCA GGCTAGCTACAACGA CCTGTTGT	2544
3746	ACAGGAUG G UAAAGACU	843	AGTCTTTA GGCTAGCTACAACGA CATCCTGT	2545
3752	UGGUAAG A CUACAUC	844	GGATGTAG GGCTAGCTACAACGA CTTTACCA	2546
3755	UAAAGACU A CAUCCCAA	845	TTGGGATG GGCTAGCTACAACGA AGTCTTTA	2547
3757	AAGACUAC A UCCCAAUC	846	GATTGGGA GGCTAGCTACAACGA GTAGTCTT	2548
3763	ACAUCCCA A UCAAUGCC	847	GGCATTGA GGCTAGCTACAACGA TGGGATGT	2549
3767	CCCAAUCA A UGCCAUAC	848	GTATGGCA GGCTAGCTACAACGA TGATTGGG	2550
3769	CAAUCAAU G CCAUACUG	849	CAGTATGG GGCTAGCTACAACGA ATTGATTG	2551
3772	UCAAUGCC A UACUGACA	850	TGTCAGTA GGCTAGCTACAACGA GGCATTGA	2552
3774	AAUGCCAU A CUGACAGG	851	CCTGTGAG GGCTAGCTACAACGA ATGGCATT	2553
3778	CCAUACUG A CAGGAAAU	852	ATTTCCTG GGCTAGCTACAACGA CAGTATGG	2554
3785	GACAGGAA A UAGUGGGU	853	ACCCACTA GGCTAGCTACAACGA TTCCTGTC	2555
3788	AGGAAAU A G UGGGUUA	854	TAAACCCA GGCTAGCTACAACGA TATTTCTT	2556
3792	AAUAGUGG G UUUACAU	855	TATGTAAG GGCTAGCTACAACGA CCACTATT	2557
3796	GUGGGUUU A CAUACUCA	856	TGAGTATG GGCTAGCTACAACGA AAACCCAC	2558
3798	GGGUUUAC A UACUCAAC	857	GTGAGTA GGCTAGCTACAACGA GTAAACCC	2559
3800	GUUUACAU A CUCAACUC	858	GAGTTGAG GGCTAGCTACAACGA ATGTAAC	2560
3805	CAUACUCA A CUCCUGCC	859	GGCAGGAG GGCTAGCTACAACGA TGAGTATG	2561
3811	CAACUCCU G CCUUCUCU	860	AGAGAAGG GGCTAGCTACAACGA AGGAGTTG	2562
3824	CUCUGAGG A CUUCUUA	861	TGAAGAAG GGCTAGCTACAACGA CCTCAGAG	2563
3839	CAAGGAAA G UAUUUCAG	862	CTGAAATA GGCTAGCTACAACGA TTTCTCTG	2564
3841	AGGAAAGU A UUUCAGCU	863	AGCTGAAA GGCTAGCTACAACGA ACTTTCTT	2565
3847	GUUUUUA G CUCCGAAG	864	CTTCGGAG GGCTAGCTACAACGA TGAATAC	2566
3855	GCUCCGAA G UUUAAUUC	865	GAATTAAA GGCTAGCTACAACGA TTCGGAGC	2567
3860	GAAGUUUA A UUCAGGAA	866	TTCTTGAA GGCTAGCTACAACGA TAAACTTC	2568
3869	UUCAGGAA G CUCUGAUG	867	CATCAGAG GGCTAGCTACAACGA TTCCTGAA	2569
3875	AAGCUCUG A UGAUGUCA	868	TGACATCA GGCTAGCTACAACGA CAGAGCTT	2570
3878	CUCUGAUG A UGUCAGAU	869	ATCTGACA GGCTAGCTACAACGA CATCAGAG	2571
3880	CUGAUGAU G UCAGAUAU	870	ATATCTGA GGCTAGCTACAACGA ATCATCAG	2572
3885	GAUGUCAG A UAUGUAAA	871	TTTACATA GGCTAGCTACAACGA CTGACATC	2573
3887	UGUCAGAU A UGUAAAUG	872	CATTTACA GGCTAGCTACAACGA ATCTGACA	2574
3889	UCAGAUAU G UAAUUGCU	873	AGCATTTA GGCTAGCTACAACGA ATATCTGA	2575
3893	AUAUGUAA A UGCUUUA	874	TGAAAGCA GGCTAGCTACAACGA TTACATAT	2576
3895	AUGUAAAU G CUUUAAG	875	CTTGAAAG GGCTAGCTACAACGA ATTTACAT	2577
3903	GCUUUAAG A UUCAUGAG	876	CTCATGAA GGCTAGCTACAACGA TTGAAAGC	2578
3907	UCAAGUUC A UGAGCCUG	877	CAGGCTCA GGCTAGCTACAACGA GAACTTGA	2579
3911	GUUCAUGA G CCUGGAAA	878	TTTCCAGG GGCTAGCTACAACGA TCAATGAC	2580
3922	UGGAAAGA A UCAAAACC	879	GGTTTTGA GGCTAGCTACAACGA TCTTTCCA	2581
3928	GAAUCAAA A CCUUGAA	880	TTCAAAGG GGCTAGCTACAACGA TTTGATTG	2582

3939	UUUGAAGA A CUUUUACC	881	GGTAAAAG GGCTAGCTACAACGA TCTTCAAA	2583
3945	GAACUUUU A CCGAAUGC	882	GCATTTCGG GGCTAGCTACAACGA AAAAGTTC	2584
3950	UUUACCGA A UGCCACCU	883	AGGTGGCA GGCTAGCTACAACGA TCGGTAAA	2585
3952	UACCGAAU G CCACCUCC	884	GGAGGTGG GGCTAGCTACAACGA ATTGGTA	2586
3955	CGAAUGCC A CCUCCAUG	885	CATGGAGG GGCTAGCTACAACGA GGCATTGG	2587
3961	CCACCUCC A UGUUUGAU	886	ATCAAACA GGCTAGCTACAACGA GGAGGTGG	2588
3963	ACCUCCAU G UUUGAUGA	887	TCATCAAA GGCTAGCTACAACGA ATGGAGGT	2589
3968	CAUGUUUG A UGACUACC	888	GGTAGTCA GGCTAGCTACAACGA CAAACATG	2590
3971	GUUUGAUG A CUACCAGG	889	CCTGGTAG GGCTAGCTACAACGA CATCAAAC	2591
3974	UGAUGACU A CCAGGGCG	890	CGCCCTGG GGCTAGCTACAACGA AGTCATCA	2592
3980	CUACCAGG G CGACAGCA	891	TGCTGTCTG GGCTAGCTACAACGA CCTGGTAG	2593
3983	CCAGGGCG A CAGCAGCA	892	TGCTGTCTG GGCTAGCTACAACGA CGCCCTGG	2594
3986	GGGCGACA G CAGCACUC	893	GAGTGTCTG GGCTAGCTACAACGA TGTGCGCC	2595
3989	CGACAGCA G CACUCUGU	894	ACAGAGTG GGCTAGCTACAACGA TGCTGTCTG	2596
3991	ACAGCAGC A CUCUGUUG	895	CAACAGAG GGCTAGCTACAACGA GCTGTCTGT	2597
3996	AGCACUCU G UUGGCCUC	896	GAGGCCAA GGCTAGCTACAACGA AGAGTGCT	2598
4000	CUCUGUUG G CCUCUCCC	897	GGGAGAGG GGCTAGCTACAACGA CAACAGAG	2599
4009	CCUCUCCC A UGCUGAAG	898	CTTCAGCA GGCTAGCTACAACGA GGGAGAGG	2600
4011	UCUCCCAU G CUGAAGCG	899	CGCTTCAG GGCTAGCTACAACGA ATGGGAGA	2601
4017	AUGCUGAA G CGCUUCAC	900	GTGAAGCG GGCTAGCTACAACGA TTCAGCAT	2602
4019	GCUGAAGC G CUUACCU	901	AGGTGAAG GGCTAGCTACAACGA GCTTCAGC	2603
4024	AGCGCUUC A CUUGGACU	902	AGTCCAGG GGCTAGCTACAACGA GAAGCGCT	2604
4030	UCACCUGG A CUGACAGC	903	GCTGTCAG GGCTAGCTACAACGA CCAGGTGA	2605
4034	CUGGACUG A CAGCAAAC	904	GTTTGCTG GGCTAGCTACAACGA CAGTCCAG	2606
4037	GACUGACA G CAAACCCA	905	TGGGTTTG GGCTAGCTACAACGA TGTCAGTC	2607
4041	GACAGCAA A CCAAGGC	906	GCCTTGGG GGCTAGCTACAACGA TTGCTGTC	2608
4048	AACCCAAG G CCUCGCUC	907	GAGCGAGG GGCTAGCTACAACGA CTTGGGTT	2609
4053	AAGGCCUC G CUCAAGAU	908	ATCTTGAG GGCTAGCTACAACGA GAGGCCTT	2610
4060	CGCUCAAG A UUGACUUG	909	CAAGTCAA GGCTAGCTACAACGA CTTGAGCG	2611
4064	CAAGAUUG A CUUGAGAG	910	CTCTCAAG GGCTAGCTACAACGA CAATCTTG	2612
4072	ACUUGAGA G UAACCAGU	911	ACTGGTTA GGCTAGCTACAACGA TCTCAAGT	2613
4075	UGAGAGUA A CCAGUAAA	912	TTTACTGG GGCTAGCTACAACGA TACTCTCA	2614
4079	AGUAACCA G UAAAGUA	913	TACTTTTA GGCTAGCTACAACGA TGGTTACT	2615
4085	CAGUAAA A UAAGGAGU	914	ACTCCTTA GGCTAGCTACAACGA TTTTACTG	2616
4092	AGUAAGGA G UCGGGGCU	915	AGCCCCGA GGCTAGCTACAACGA TCCTTACT	2617
4098	GAGUCGGG G CUGUCUGA	916	TCAGACAG GGCTAGCTACAACGA CCCGACTC	2618
4101	UCGGGGCU G UCUGAUGU	917	ACATCAGA GGCTAGCTACAACGA AGCCCCGA	2619
4106	GCUGUCUG A UGUCAGCA	918	TGCTGACA GGCTAGCTACAACGA CAGACAGC	2620
4108	UGUCUGAU G UCAGCAGG	919	CCTGCTGA GGCTAGCTACAACGA ATCAGACA	2621
4112	UGAUGUCA G CAGGCCCA	920	TGGGCCTG GGCTAGCTACAACGA TGACATCA	2622
4116	GUCAGCAG G CCCAGUUU	921	AAACTGGG GGCTAGCTACAACGA CTGCTGAC	2623
4121	CAGGCCCA G UUUCUGCC	922	GGCAGAAA GGCTAGCTACAACGA TGGGCCTG	2624
4127	CAGUUUCU G CCAUUGCA	923	TGGAATGG GGCTAGCTACAACGA AGAAACTG	2625
4130	UUUCUGCC A UUCAGCU	924	AGCTGGAA GGCTAGCTACAACGA GGCAGAAA	2626
4136	CCAUUGCA G CUGUGGGC	925	GCCACAG GGCTAGCTACAACGA TGGAAATG	2627
4139	UUCAGCU G UGGGCACG	926	CGTGCCCA GGCTAGCTACAACGA AGCTGGAA	2628
4143	AGCUGUGG G CAGCUCAG	927	CTGACGTG GGCTAGCTACAACGA CCACAGCT	2629
4145	CUGUGGGC A CGUCAGCG	928	CGCTGACG GGCTAGCTACAACGA GCCCACAG	2630
4147	GUGGGCAC G UCAGCGAA	929	TTGCTGTA GGCTAGCTACAACGA GTGCCCCAC	2631
4151	GCACGUCA G CGAAGGCA	930	TGCTCTCG GGCTAGCTACAACGA TGACGTGC	2632
4157	CAGCGAAG G CAAGCGCA	931	TGCGCTTG GGCTAGCTACAACGA CTTGCTG	2633
4161	GAAGGCAA G CGCAGGUU	932	AACCTGCG GGCTAGCTACAACGA TTGCTTTC	2634

4163	AGGCAAGC G CAGGUUCA	933	TGAACCTG GGCTAGCTACAACGA GCTTGCCT	2635
4167	AAGCGCAG G UUCACCUA	934	TAGGTGAA GGCTAGCTACAACGA CTGCGCTT	2636
4171	GCAGGUUC A CCUACGAC	935	GTCGTAGG GGCTAGCTACAACGA GAACCTGC	2637
4175	GUUCACCU A CGACCAG	936	CGTGGTCG GGCTAGCTACAACGA AGGTGAAC	2638
4178	CACCUACG A CCACGUG	937	CAGCGTGG GGCTAGCTACAACGA CGTAGGTG	2639
4181	CUACGACC A CGCUGAGC	938	GCTCAGCG GGCTAGCTACAACGA GGTGCTAG	2640
4183	ACGACCAC G CUGAGCUG	939	CAGCTCAG GGCTAGCTACAACGA GTGGTCGT	2641
4188	CACGUGA G CUGAAAG	940	CTTTCCAG GGCTAGCTACAACGA TCAGCGTG	2642
4201	AAAGGAAA A UCGCGUGC	941	GCACGCGA GGCTAGCTACAACGA TTTCCTTT	2643
4204	GGAAAAUC G CGUGCUGC	942	GCAGCAGG GGCTAGCTACAACGA GATTTTCC	2644
4206	AAAUCGCG G UGCUGCUC	943	GAGCAGCA GGCTAGCTACAACGA GCGATTTT	2645
4208	AAUCGCGU G CUGCUGCC	944	GGGAGCAG GGCTAGCTACAACGA ACGCGATT	2646
4211	CGCGUGCU G CUGCCCGC	945	GCGGGGAG GGCTAGCTACAACGA AGCAGCGG	2647
4218	UGCUGCCC G CCCCCAGA	946	TCTGGGGG GGCTAGCTACAACGA GGGGAGCA	2648
4226	GCCCCCAG A CUACAACU	947	AGTTGTAG GGCTAGCTACAACGA CTGGGGGC	2649
4229	CCCAGACU A CAACUCGG	948	CCGAGTTG GGCTAGCTACAACGA AGTCTGGG	2650
4232	AGACUACA A CUCGGUGG	949	CCACCGAG GGCTAGCTACAACGA TGTAGTCT	2651
4237	ACAACUCG G UGGUCCUG	950	CAGGACCA GGCTAGCTACAACGA CGAGTTGT	2652
4240	ACUCGGUG G UCCUGUAC	951	GTACAGGA GGCTAGCTACAACGA CACCGAGT	2653
4245	GUGGUCCU G UACUCCAC	952	GTGGAGTA GGCTAGCTACAACGA AGGACCAC	2654
4247	GGUCCUGU A CUCCACCC	953	GGGTGGAG GGCTAGCTACAACGA ACAGGACC	2655
4252	UGUACUCC A CCCCACCC	954	GGGTGGGG GGCTAGCTACAACGA GGAGTACA	2656
4257	UCCACCCC A CCCAUCUA	955	TAGATGGG GGCTAGCTACAACGA GGGGTGGA	2657
4261	CCCCACCC A UCUGAGU	956	ACTCTAGA GGCTAGCTACAACGA GGGTGGGG	2658
4268	CAUCUAGA G UUUGACAC	957	GTGTCAA GGCTAGCTACAACGA TCTAGATG	2659
4273	AGAGUUUG A CACGAAGC	958	GCTTCGTG GGCTAGCTACAACGA CAACTCT	2660
4275	AGUUUGAC A CGAAGCCU	959	AGGCTTCG GGCTAGCTACAACGA GTCAAACT	2661
4280	GACACGAA G CCUUAUUU	960	AAATAAGG GGCTAGCTACAACGA TTCGTGTC	2662
4285	GAAGCCUU A UUUCUAGA	961	TCTAGAAA GGCTAGCTACAACGA AAGGCTTC	2663
4295	UUCUAGAA G CACAUGUG	962	CACATGTG GGCTAGCTACAACGA TTCTAGAA	2664
4297	CUAGAAGC A CAUGUGUA	963	TACACATG GGCTAGCTACAACGA GCTTCTAG	2665
4299	AQAAGCAC A UGUGUAUU	964	AATACACA GGCTAGCTACAACGA GTGCTTCT	2666
4301	AAGCACAU G UGUUAUUU	965	TAAATACA GGCTAGCTACAACGA ATGTGCTT	2667
4303	GCACAUUG G UAUUAUAU	966	TATAATA GGCTAGCTACAACGA ACATGTGC	2668
4305	ACAUGUGU A UUAUACC	967	GGTATAAA GGCTAGCTACAACGA ACACATGT	2669
4309	GUGUAUUU A UACCCCA	968	TGGGGGTA GGCTAGCTACAACGA AAATACAC	2670
4311	GUUUUUU A CCCCAGG	969	CCTGGGGG GGCTAGCTACAACGA ATAAATAC	2671
4322	CCAGGAA A CUAGCUUU	970	AAAGCTAG GGCTAGCTACAACGA TTCCTGGG	2672
4326	GGAAACUA G CUUUUGCC	971	GGCAAAAG GGCTAGCTACAACGA TAGTTTCC	2673
4332	UAGCUUUU G CCAGUAUU	972	AATACTGG GGCTAGCTACAACGA AAAAGCTA	2674
4336	UUUUGCCA G UAUUAUGC	973	GCATAATA GGCTAGCTACAACGA TGGCAAAA	2675
4338	UUGCCAGU A UUAUGCAU	974	ATGCATAA GGCTAGCTACAACGA ACTGGCAA	2676
4341	CCAGUAUU A UGCAUUAU	975	TATATGCA GGCTAGCTACAACGA AATACTGG	2677
4343	AGUAUUU G CAUAUUAU	976	TATATATG GGCTAGCTACAACGA ATAACTAT	2678
4345	UAUUUUGC A UUAUAAG	977	CTTATATA GGCTAGCTACAACGA GCATAATA	2679
4347	UUAUGCAU A UUAAGUU	978	AACTTATA GGCTAGCTACAACGA ATGCATAA	2680
4349	AUGCAUUA A UAAGUUUA	979	TAACTTA GGCTAGCTACAACGA ATATGCAT	2681
4353	AUAUAUA A UUUACACC	980	GGTGTAAG GGCTAGCTACAACGA TTATATAT	2682
4357	AUAAGUUU A CACCUUA	981	TAAAGGTG GGCTAGCTACAACGA AACTTAT	2683
4359	AAGUUUAC A CCUUUAUC	982	GATAAAGG GGCTAGCTACAACGA GTAACTT	2684
4365	ACACCUUU A UCUUCCA	983	TGGAAGA GGCTAGCTACAACGA AAAGGTGT	2685
4373	AUCUUUCC A UGGGAGCC	984	GGCTCCCA GGCTAGCTACAACGA GGAAAGAT	2686

4379	CCAUGGGA G CCAGCUGC	985	GCAGCTGG GGCTAGCTACAACGA TCCCATGG	2687
4383	GGGAGCCA G CUGCUUUU	986	AAAAGCAG GGCTAGCTACAACGA TGGCTCCC	2688
4386	AGCCAGCU G CUUUUUGU	987	ACAAAAG GGCTAGCTACAACGA AGCTGGCT	2689
4393	UGCUUUU G UGAUUUUU	988	AAAAATCA GGCTAGCTACAACGA AAAAAGCA	2690
4396	UUUUUGUG A UUUUUUA	989	TAAAAAA GGCTAGCTACAACGA CAAAAAA	2691
4405	UUUUUUA A UAGUGCUU	990	AAGCACTA GGCTAGCTACAACGA TAAAAAA	2692
4408	UUUUAUA G UGCUUUU	991	AAAAAGCA GGCTAGCTACAACGA TATTAAAA	2693
4410	UUAAUAGU G CUUUUUU	992	AAAAAAG GGCTAGCTACAACGA ACTATTAA	2694
4424	UUUUUUUG A CUAACAAG	993	CTTGTTAG GGCTAGCTACAACGA CAAAAAA	2695
4428	UUUGACUA A CAAGAAUG	994	CATTCTTG GGCTAGCTACAACGA TAGTCAA	2696
4434	UAACAAGA A UGUACUC	995	GAGTTACA GGCTAGCTACAACGA TCTTGTTA	2697
4436	ACAAGAAU G UAACUCCA	996	TGGAGTTA GGCTAGCTACAACGA ATTCTTGT	2698
4439	AGAAUGUA A CUCCAGAU	997	ATCTGGAG GGCTAGCTACAACGA TACATTCT	2699
4446	AACUCCAG A UAGAGAAA	998	TTTCTCTA GGCTAGCTACAACGA CTGGAGTT	2700
4454	AUAGAGAA A UAGUGACA	999	TGTCACCTA GGCTAGCTACAACGA TTCTCTAT	2701
4457	GAGAAUA G UGACAAGU	1000	ACTTGTCA GGCTAGCTACAACGA TATTCTCT	2702
4460	AAAUAGUG A CAAGUGAA	1001	TTCACTTG GGCTAGCTACAACGA CACTATTT	2703
4464	AGUGACAA G UGAAGAAC	1002	GTTCTTCA GGCTAGCTACAACGA TTGTCACT	2704
4471	AGUGAAGA A CACUACUG	1003	CAGTAGTG GGCTAGCTACAACGA TCTTCACT	2705
4473	UGAAGAAC A CUACUGCU	1004	AGCAGTAG GGCTAGCTACAACGA GTTCTTCA	2706
4476	AGAACACU A CUGCUAAA	1005	TTTAGCAG GGCTAGCTACAACGA AGTGTCT	2707
4479	ACACUACU G CUAAAUCC	1006	GGATTTAG GGCTAGCTACAACGA AGTAGTGT	2708
4484	ACUGCUAA A UCCUCAUG	1007	CATGAGGA GGCTAGCTACAACGA TAGCAGT	2709
4490	AAAUCCUC A UGUUACUC	1008	GAGTAACA GGCTAGCTACAACGA GAGGATTT	2710
4492	AUCCUCAU G UUACUCAG	1009	CTGAGTAA GGCTAGCTACAACGA ATGAGGAT	2711
4495	CUCAUGUU A CUCAGUGU	1010	ACACTGAG GGCTAGCTACAACGA AACATGAG	2712
4500	GUUACUCA G UGUUAGAG	1011	CTCTAACA GGCTAGCTACAACGA TGAGTAAC	2713
4502	UACUCAGU G UUAGAGAA	1012	TTCTCTAA GGCTAGCTACAACGA ACTGAGTA	2714
4511	UUAGAGAA A UCCUCCU	1013	AGGAAGGA GGCTAGCTACAACGA TTCTCTAA	2715
4522	CUUCCUAA A CCCAUGA	1014	TCATTGGG GGCTAGCTACAACGA TTAGGAAG	2716
4527	UAAACCCA A UGACUUC	1015	GGAAGTCA GGCTAGCTACAACGA TGGGTTTA	2717
4530	ACCCAAUG A CUUCCUG	1016	CAGGGAAG GGCTAGCTACAACGA CATTTGGT	2718
4538	ACUUCCCU G CUCCAACC	1017	GGTTGGAG GGCTAGCTACAACGA AGGGAAGT	2719
4544	CUGCUCCA A CCCCAGCC	1018	GGCGGGGG GGCTAGCTACAACGA TGGAGCAG	2720
4550	CAACCCCC G CCACCUCA	1019	TGAGGTGG GGCTAGCTACAACGA GGGGGTTG	2721
4553	CCCCCGCC A CCUCAGGG	1020	CCCTGAGG GGCTAGCTACAACGA GGCAGGGG	2722
4561	ACCUCAGG G CACGCAGG	1021	CCTGCGTG GGCTAGCTACAACGA CCTGAGGT	2723
4563	CUCAGGGC A CGCAGGAC	1022	GTCTGCGG GGCTAGCTACAACGA GCCCTGAG	2724
4565	CAGGGCAC G CAGGACCA	1023	TGGTCCTG GGCTAGCTACAACGA GTGCCCTG	2725
4570	CACGCAGG A CCAGUUUG	1024	CAAACCTG GGCTAGCTACAACGA CCTGCGTG	2726
4574	CAGGACCA G UUUGAUUG	1025	CAATCAA GGCTAGCTACAACGA TGGTCCTG	2727
4579	CCAGUUUG A UUGAGGAG	1026	CTCCTCAA GGCTAGCTACAACGA CAACTGG	2728
4587	AUUGAGGA G CUGCACUG	1027	CAGTGCGG GGCTAGCTACAACGA TCCTCAAT	2729
4590	GAGGAGCU G CACUGAUC	1028	GATCAGTG GGCTAGCTACAACGA AGCTCTCT	2730
4592	GGAGCUGC A CUGAUCAC	1029	GTGATCAG GGCTAGCTACAACGA GCAGCTCC	2731
4596	CUGCACUG A UCACCCAA	1030	TTGGGTGA GGCTAGCTACAACGA CAGTGCGG	2732
4599	CACUGAUC A CCCAAUGC	1031	GCATTGGG GGCTAGCTACAACGA GATCAGTG	2733
4604	AUCACCCA A UGCAUCAC	1032	GTGATGCA GGCTAGCTACAACGA TGGGTGAT	2734
4606	CACCCAAU G CAUCACGU	1033	ACGTGATG GGCTAGCTACAACGA ATTGGGTG	2735
4608	CCCACCAU A UCACGUAC	1034	GTACGTGA GGCTAGCTACAACGA GCATTGGG	2736
4611	AAUGCAUC A CGUACCCC	1035	GGGGTACG GGCTAGCTACAACGA GATGCATT	2737
4613	UGCAUCAC G UACCCAC	1036	GTGGGGTA GGCTAGCTACAACGA GTGATGCA	2738

4615	CAUCACGU A CCCACUG	1037	CAGTGGGG GGCTAGCTACAACGA ACGTGATG	2739
4620	CGUACCCC A CUGGGCCA	1038	TGGCCCAG GGCTAGCTACAACGA GGGGTACG	2740
4625	CCCACUGG G CCAGCCCU	1039	AGGGCTGG GGCTAGCTACAACGA CCACTGGG	2741
4629	CUGGGCCA G CCCUGCAG	1040	CTGCAGGG GGCTAGCTACAACGA TGGCCCAG	2742
4634	CCAGCCCU G CAGCCCAA	1041	TTGGGCTG GGCTAGCTACAACGA AGGGCTGG	2743
4637	GCCCUGCA G CCCAAAC	1042	GTFTTGGG GGCTAGCTACAACGA TGCAGGGC	2744
4644	AGCCCAA A CCCAGGGC	1043	GCCCTGGG GGCTAGCTACAACGA TTGGGGCT	2745
4651	AACCCAGG G CAACAAGC	1044	GCTTGTG GGCTAGCTACAACGA CCTGGGTT	2746
4654	CCAGGGCA A CAAGCCCG	1045	CGGGCTTG GGCTAGCTACAACGA TGCCCTGG	2747
4658	GGCAACAA G CCGGUUAG	1046	CTAACGGG GGCTAGCTACAACGA TTGTTGCC	2748
4662	ACAAGCCC G UUAGCCCC	1047	GGGGCTAA GGCTAGCTACAACGA GGGCTTGT	2749
4666	GCCCGUUA G CCCAGGG	1048	CCCTGGGG GGCTAGCTACAACGA TAACGGGC	2750
4676	CCCAGGGG A UCACUGGC	1049	GCCAGTGA GGCTAGCTACAACGA CCCCTGGG	2751
4679	AGGGGAUC A CUGGCUGG	1050	CCAGCCAG GGCTAGCTACAACGA GATCCCCT	2752
4683	GAUCACUG G CUGGCCUG	1051	CAGGCCAG GGCTAGCTACAACGA CAGTGATC	2753
4687	ACUGGCUG G CCUGAGCA	1052	TGCTCAGG GGCTAGCTACAACGA CAGCCAGT	2754
4693	UGGCCUGA G CAACAUCU	1053	AGATGTTG GGCTAGCTACAACGA TCAGGCCA	2755
4696	CCUGAGCA A CAUCUGGG	1054	CCGAGATG GGCTAGCTACAACGA TGCTCAGG	2756
4698	UGAGCAAC A UCUCGGGA	1055	TCCCAGGA GGCTAGCTACAACGA GTTGCTCA	2757
4707	UCUCGGGA G UCCUCUAG	1056	CTAGAGGA GGCTAGCTACAACGA TCCCAGGA	2758
4715	GUCCUCUA G CAGGCCUA	1057	TAGGCCCTG GGCTAGCTACAACGA TAGAGGAC	2759
4719	UCUAGCAG G CCUAAGAC	1058	GTCTTAGG GGCTAGCTACAACGA CTGCTAGA	2760
4726	GGCCUAAG A CAUGUGAG	1059	CTCACATG GGCTAGCTACAACGA CTTAGGCC	2761
4728	CCUAAGAC A UGUGAGGA	1060	TCCTCACA GGCTAGCTACAACGA GTCTTAGG	2762
4730	UAAGACAU G UGAGGAGG	1061	CCTCCTCA GGCTAGCTACAACGA ATGTCTTA	2763
4752	GAAAAAAA G CAAAAAGC	1062	GCTTTTTC GGCTAGCTACAACGA TTTTTC	2764
4759	AGCAAAAA G CAAGGGAG	1063	CTCCCTTG GGCTAGCTACAACGA TTTTGTCT	2765
4777	AAAGAGAA A CCGGGAGA	1064	TCTCCCGG GGCTAGCTACAACGA TTCTCTTT	2766
4788	GGGAGAAG G CAUGAGAA	1065	TTCTCATG GGCTAGCTACAACGA CTCTCTCC	2767
4790	GAGAAGGC A UGAGAAAG	1066	CTTCTCA GGCTAGCTACAACGA GCCTCTC	2768
4800	GAGAAAGA A UUUGAGAC	1067	GTCTCAA GGCTAGCTACAACGA TCTTCTC	2769
4807	AAUUUGAG A CGCACCAU	1068	ATGGTGCG GGCTAGCTACAACGA CTCAAATT	2770
4809	UUUGAGAC G CACCAUGU	1069	ACATGGTG GGCTAGCTACAACGA GTCTCAA	2771
4811	UGAGACG A CCAUGUGG	1070	CCACATGG GGCTAGCTACAACGA GCGTCTCA	2772
4814	GACGCACC A UGUGGGCA	1071	TGCCACA GGCTAGCTACAACGA GGTGCGTC	2773
4816	CGCACCAU G UGGGCACG	1072	CGTGCCCA GGCTAGCTACAACGA ATGGTGCG	2774
4820	CCAUGUGG G CACGGAGG	1073	CCTCCGTG GGCTAGCTACAACGA CCACATGG	2775
4822	AUGUGGGC A CGGAGGGG	1074	CCCTCCG GGCTAGCTACAACGA GCCACAT	2776
4832	GGAGGGGG A CGGGGCUC	1075	GAGCCCCG GGCTAGCTACAACGA CCCCTCC	2777
4837	GGGACGGG G CUCAGCAA	1076	TTGCTGAG GGCTAGCTACAACGA CCGTCCC	2778
4842	GGGGCUCA G CAAUGCCA	1077	TGGCATTG GGCTAGCTACAACGA TGAGCCCC	2779
4845	GCUCAGCA A UGCCAUUU	1078	AAATGGCA GGCTAGCTACAACGA TGCTGAGC	2780
4847	UCAGCAAU G CCAUUUCA	1079	TGAAATGG GGCTAGCTACAACGA ATTGCTGA	2781
4850	GCAAUGCC A UUUCAGUG	1080	CACTGAAA GGCTAGCTACAACGA GGCATTGC	2782
4856	CCAUUUCA G UGGCUUCC	1081	GGAGGCCA GGCTAGCTACAACGA TGAAATGG	2783
4859	UUUCAGUG G CUUCCAG	1082	CTGGGAAG GGCTAGCTACAACGA CACTGAAA	2784
4867	GCUUCCCA G CUCUGACC	1083	GGTCAGAG GGCTAGCTACAACGA TGGGAAGC	2785
4873	CAGCUCUG A CCCUUCUA	1084	TAGAAGGG GGCTAGCTACAACGA CAGAGCTG	2786
4881	ACCCUUCU A CAUUUGAG	1085	CTCAAATG GGCTAGCTACAACGA AGAAGGGT	2787
4883	CCUUCUAC A UUUGAGGG	1086	CCCTCAA GGCTAGCTACAACGA GTAGAAGG	2788
4891	AUUUGAGG G CCCAGCCA	1087	TGGCTGGG GGCTAGCTACAACGA CCTCAAAT	2789
4896	AGGGCCCA G CCAGGAGC	1088	GCTCCTGG GGCTAGCTACAACGA TGGGCCCT	2790



4903	AGCCAGGA G CAGAUUGA	1089	TCCATCTG GGCTAGCTACAACGA TCCTGGCT	2791
4907	AGGAGCAG A UGGACAGC	1090	GCTGTCCA GGCTAGCTACAACGA CTGCTCCT	2792
4911	GCAGAUUG A CAGCGAUG	1091	CATCGCTG GGCTAGCTACAACGA CCATCTGC	2793
4914	GAUGGACA G CGAUGAGG	1092	CCTCATCG GGCTAGCTACAACGA TGTCCATC	2794
4917	GGACAGCG A UGAGGGGA	1093	TCCCCTCA GGCTAGCTACAACGA CGCTGTCC	2795
4925	AUGAGGGG A CAUUUUCU	1094	AGAAAATG GGCTAGCTACAACGA CCCCTCAT	2796
4927	GAGGGGAC A UUUUCUGG	1095	CCAGAAAA GGCTAGCTACAACGA GTCCCCTC	2797
4936	UUUUCUGG A UUCUGGGA	1096	TCCCAGAA GGCTAGCTACAACGA CCAGAAAA	2798
4946	UCUGGGAG G CAAGAAAA	1097	TTTTCTTG GGCTAGCTACAACGA CTCCCAGA	2799
4957	AGAAAAGG A CAAAUUUC	1098	GATATTTG GGCTAGCTACAACGA CCTTTTCT	2800
4961	AAGGACAA A UAUCUUUU	1099	AAAAGATA GGCTAGCTACAACGA TTGTCCTT	2801
4963	GGACAAAU A UCUUUUUU	1100	AAAAAAGA GGCTAGCTACAACGA ATTTGTCC	2802
4975	UUUUUGGA A CUAAGCA	1101	TGCTTTAG GGCTAGCTACAACGA TCCAAAAA	2803
4981	GAACUAAA G CAAUUUUU	1102	AAAATTTG GGCTAGCTACAACGA TTTAGTTC	2804
4985	UAAAGCAA A UUUUAGAC	1103	GTCTAAAA GGCTAGCTACAACGA TTGCTTTA	2805
4992	AAUUUUAG A CCUUUACC	1104	GGTAAAGG GGCTAGCTACAACGA CTAATAAT	2806
4998	AGACUUUU A CCUAUGGA	1105	TCCATAGG GGCTAGCTACAACGA AAAGGTCT	2807
5002	CUUUACCU A UGGAAGUG	1106	CACCTCCA GGCTAGCTACAACGA AGGTAAAG	2808
5008	CUAUGGAA G UGGUUCUA	1107	TAGAACCA GGCTAGCTACAACGA TTCCATAG	2809
5011	UGGAAGUG G UUCUAUGU	1108	ACATAGAA GGCTAGCTACAACGA CACTTCCA	2810
5016	GUGGUUCU A UGUCCAUU	1109	AATGGACA GGCTAGCTACAACGA AGAACCCAC	2811
5018	GGUUCUAI G UCCAUCU	1110	AGAATGGA GGCTAGCTACAACGA ATAGAACC	2812
5022	CUAUGUCC A UUCUCAUU	1111	AATGAGAA GGCTAGCTACAACGA GGACATAG	2813
5028	CCAUCUC A UUCUGGCG	1112	GCCACGAA GGCTAGCTACAACGA GAGAATGG	2814
5032	UCUCAUUC G UGCAUGU	1113	ACATGCCA GGCTAGCTACAACGA GAATGAGA	2815
5035	CAUUCGUG G CAUGUUUU	1114	AAAACATG GGCTAGCTACAACGA CACGAATG	2816
5037	UUCUGGCG A UGUUUUGA	1115	TCAAAACA GGCTAGCTACAACGA GCCACGAA	2817
5039	CGUGGCAU G UUUUGAUU	1116	AATCAAAA GGCTAGCTACAACGA ATGCCACG	2818
5045	AUGUUUUG A UUUGUAGC	1117	GCTACAAA GGCTAGCTACAACGA CAAAACAT	2819
5049	UUUGAUUU G UAGCACUG	1118	CAGTGCTA GGCTAGCTACAACGA AAATCAAA	2820
5052	GAUUUGUA G CACUGAGG	1119	CCTCAGTG GGCTAGCTACAACGA TACAAATC	2821
5054	UUUGUAGC A CUGAGGGU	1120	ACCCTCAG GGCTAGCTACAACGA GCTACAAA	2822
5061	CACUGAGG G UGGCACUC	1121	GAGTGCCA GGCTAGCTACAACGA CCTCAGTG	2823
5064	UGAGGGUG G CACUCAAC	1122	GTTGAGTG GGCTAGCTACAACGA CACCCTCA	2824
5066	AGGGUGGC A CUCAACUC	1123	GAGTTGAG GGCTAGCTACAACGA GCCACCCT	2825
5071	GGCACUCA A CUCUGAGC	1124	GCTCAGAG GGCTAGCTACAACGA TGAGTGCC	2826
5078	AACUCUGA G CCCAUACU	1125	AGTATGGG GGCTAGCTACAACGA TCAGAGTT	2827
5082	CUGAGCCC A UACUUUUG	1126	CAAAAGTA GGCTAGCTACAACGA GGGCTCAG	2828
5084	GAGCCCAU A CUUUUGGC	1127	GCCAAAAG GGCTAGCTACAACGA ATGGGCTC	2829
5091	UACUUUUG G CUCCUCUA	1128	TAGAGGAG GGCTAGCTACAACGA CAAAAGTA	2830
5100	CUCCUCUA G UAAGAUGC	1129	GCATCTTA GGCTAGCTACAACGA TAGAGGAG	2831
5105	CUAGUAAG A UGCACUGA	1130	TCAGTGCA GGCTAGCTACAACGA CTTACTAG	2832
5107	AGUAAGAU G CACUGAAA	1131	TTTCAGTG GGCTAGCTACAACGA ATCTTACT	2833
5109	UAAGAUGC A CUGAAAAC	1132	GTTTTTCAG GGCTAGCTACAACGA GCATCTTA	2834
5116	CACUGAAA A CUUAGCCA	1133	TGGCTAAG GGCTAGCTACAACGA TTTCAGTG	2835
5121	AAAACUUA G CCAGAGUU	1134	AACTCTGG GGCTAGCTACAACGA TAAGTTTT	2836
5127	UAGCCAGA G UUAGGUUG	1135	CAACCTAA GGCTAGCTACAACGA TCTGGCTA	2837
5132	AGAGUUAG G UUGUCUCC	1136	GGAGACAA GGCTAGCTACAACGA CTAACCTC	2838
5135	GUUAGGUU G UCUCAGG	1137	CCTGGAGA GGCTAGCTACAACGA AACCTAAC	2839
5143	GUCUCCAG G CCAUGAUG	1138	CATCATGG GGCTAGCTACAACGA CTGGAGAC	2840
5146	UCCAGGCC A UGAUGGCC	1139	GGCCATCA GGCTAGCTACAACGA GGCCTGGA	2841
5149	AGGCCAUG A UGGCCUUA	1140	TAAGGCCA GGCTAGCTACAACGA CATGGCCT	2842

5152	CCAUGAUG G CCUACAC	1141	GTGTAAGG GGCTAGCTACAACGA CATCATGG	2843
5157	AUGGCCUU A CACUGAAA	1142	TTTCAGTG GGCTAGCTACAACGA AAGGCCAT	2844
5159	GGCCUAC A CUGAAA AU	1143	ATTTTCAG GGCTAGCTACAACGA GTAAGGCC	2845
5166	CACUGAAA A UGUCACAU	1144	ATGTGACA GGCTAGCTACAACGA TTTCAGTG	2846
5168	CUGAAA AU G UCACAUUC	1145	GAATGTGA GGCTAGCTACAACGA ATTTTCAG	2847
5171	AAA AUGUC A CAUUCU AU	1146	ATAGAATG GGCTAGCTACAACGA GACATTTT	2848
5173	A AUGUCAC A UUCU AUU	1147	AAATAGAA GGCTAGCTACAACGA GTGACATT	2849
5178	CACAUUCU A UUUUGGGU	1148	ACCCAAA GGCTAGCTACAACGA AGAATGTG	2850
5185	UAUUUUGG G UAUAUAUA	1149	TATTAATA GGCTAGCTACAACGA CCAAAATA	2851
5187	UUUUGGGU A UUAUAUA	1150	TATATTAA GGCTAGCTACAACGA ACCCAAAA	2852
5191	GGUAUAUA A UAUAUAGU	1151	ACTATATA GGCTAGCTACAACGA TAATACCC	2853
5193	GUUAUAUA A UAUAUAGU	1152	GGACTATA GGCTAGCTACAACGA ATTAATAC	2854
5195	AUAUAUAUA A UAGUCCAG	1153	CTGGACTA GGCTAGCTACAACGA ATATTAT	2855
5198	AAUAUAUA G UCCAGACA	1154	TGTCTGGA GGCTAGCTACAACGA TATATATT	2856
5204	UAGUCCAG A CACUUAAC	1155	GTTAAGTG GGCTAGCTACAACGA CTGGACTA	2857
5206	GUCCAGAC A CUUAACUC	1156	GAGTTAAG GGCTAGCTACAACGA GTCTGGAC	2858
5211	GACACUUA A CUCAAUUU	1157	AAATTGAG GGCTAGCTACAACGA TAAGTGTC	2859
5216	UUAACUCA A UUUUCUGG	1158	CCAAAGAA GGCTAGCTACAACGA TGAGTTAA	2860
5224	AUUUCUUG G UAUAUAUC	1159	GAATAATA GGCTAGCTACAACGA CAAGAAAT	2861
5226	UUCUUGGU A UUAUUCUG	1160	CAGAATAA GGCTAGCTACAACGA ACCAAGAA	2862
5229	UUGGUUUA A UUCUGUUU	1161	AAACAGAA GGCTAGCTACAACGA AATACCAA	2863
5234	AUAUAUCU G UUUUGCAC	1162	GTGCAAAA GGCTAGCTACAACGA AGAATAAT	2864
5239	UCUGUUUU G CACAGUUA	1163	TAAGTGTG GGCTAGCTACAACGA AAAACAGA	2865
5241	UGUUUUGC A CAGUUAGU	1164	ACTAACTG GGCTAGCTACAACGA GCAAAACA	2866
5244	UUUGCACA G UUAGUUGU	1165	ACAACATA GGCTAGCTACAACGA TGTGCATA	2867
5248	CACAGUUA G UUGUGAAA	1166	TTTCACAA GGCTAGCTACAACGA TAAGTGTG	2868
5251	AGUUAGUU G UGAAAGAA	1167	TTCTTTCA GGCTAGCTACAACGA AACTAACT	2869
5261	GAAAGAAA G CUGAGAAG	1168	CTTCTCAG GGCTAGCTACAACGA TTTCTTTC	2870
5271	UGAGAAGA A UGAAAAUG	1169	CATTTTCA GGCTAGCTACAACGA TCTTCTCA	2871
5277	GAAUGAAA A UGCAGUCC	1170	GGACTGCA GGCTAGCTACAACGA TTTCTTTC	2872
5279	AUGAAA AU G CAGUCCUG	1171	CAGGACTG GGCTAGCTACAACGA ATTTTCAT	2873
5282	AAA AUGCA G UCCUGAGG	1172	CTCAGGA GGCTAGCTACAACGA TGCATTTT	2874
5294	UGAGGAGA G UUUUCUCC	1173	GCAGAAAA GGCTAGCTACAACGA TCTCTCTA	2875
5303	UUUUCUCC A UAUCAAAA	1174	TTTGTATA GGCTAGCTACAACGA GGAGAAAA	2876
5305	UUCUCCAU A UCAAAACG	1175	CGTTTGA GGCTAGCTACAACGA ATGGAGAA	2877
5311	AUAUCAAA A CGAGGGCU	1176	AGCCCTCG GGCTAGCTACAACGA TTTGATAT	2878
5317	AAACGAGG G CUGAUGGA	1177	TCCATCAG GGCTAGCTACAACGA CCTCGTTT	2879
5321	GAGGGCUG A UGGAGGAA	1178	TTCTCTCA GGCTAGCTACAACGA CAGCCCTC	2880
5334	GGAAAAAG G UCAUAUAG	1179	CTTATTGA GGCTAGCTACAACGA CTTTTCCT	2881
5338	AAAGGUCA A UAAGGUCA	1180	TGACCTTA GGCTAGCTACAACGA TGACCTTT	2882
5343	UCAUAUAG G UCAAGGGA	1181	TCCCTTGA GGCTAGCTACAACGA CTTATTGA	2883
5354	AAGGGAAG A CCCCUCU	1182	AGACGGGG GGCTAGCTACAACGA CTTCCCTT	2884
5359	AAGACCCC G UCUCUUA	1183	TATAGAGA GGCTAGCTACAACGA GGGGTCTT	2885
5365	CCGUCUCU A UACCAACC	1184	GGTTGGTA GGCTAGCTACAACGA AGAGACGG	2886
5367	GUCUCUUA A CCAACCAA	1185	TTGGTTGG GGCTAGCTACAACGA ATAGAGAC	2887
5371	CUAUACCA A CCAACCAA	1186	TGGTTTGG GGCTAGCTACAACGA TGGTATAG	2888
5376	CCAACCAA A CCAAUUCA	1187	TGAATTGG GGCTAGCTACAACGA TTGGTTGG	2889
5380	CCAACCAA A UUCACCAA	1188	TTGGTGAA GGCTAGCTACAACGA TGGTTTGG	2890
5384	ACCAAUUC A CCAACACA	1189	TGTGTTGG GGCTAGCTACAACGA GAATTGGT	2891
5388	AUUCACCA A CACAGUUG	1190	CAACTGTG GGCTAGCTACAACGA TGGTGAAT	2892
5390	UCACCAAC A CAGUUGGG	1191	CCCAACTG GGCTAGCTACAACGA GTTGGTGA	2893
5393	CCAACACA G UUGGGACC	1192	GGTCCCAA GGCTAGCTACAACGA TGTGTTGG	2894

5399	CAGUUGGG A CCCAAAC	1193	GTTTTGGG GGCTAGCTACAACGA CCCAACTG	2895
5406	GACCCAAA A CACAGGAA	1194	TTCCTGTG GGCTAGCTACAACGA TTTGGGTC	2896
5408	CCCAAAAC A CAGGAAGU	1195	ACTTCCTG GGCTAGCTACAACGA GTTTTGGG	2897
5415	CACAGGAA G UCAGUCAC	1196	GTGACTGA GGCTAGCTACAACGA TTCCTGTG	2898
5419	GGAGUCA G UCAGUUU	1197	AAACGTGA GGCTAGCTACAACGA TGACTTCC	2899
5422	AGUCAGUC A CGUUUCCU	1198	AGGAAACG GGCTAGCTACAACGA GACTGACT	2900
5424	UCAGUCAC G UUUCUUU	1199	AAAGGAAA GGCTAGCTACAACGA GTGACTGA	2901
5435	UCCUUUUC A UUUAUUGG	1200	CCATTAAA GGCTAGCTACAACGA GAAAAGGA	2902
5440	UUCAUUUA A UGGGGAUU	1201	AATCCCCA GGCTAGCTACAACGA TAAATGAA	2903
5446	UUAUGGGG A UUCCACUA	1202	TAGTGGAA GGCTAGCTACAACGA CCCATTA	2904
5451	GGGADUCC A CUUUCUCA	1203	TGAGATAG GGCTAGCTACAACGA GGAATCCC	2905
5454	AUUCACU A UCUCACAC	1204	GTGTGAGA GGCTAGCTACAACGA AGTGGAAT	2906
5459	ACUAUCUC A CACUAUUC	1205	GATTAGTG GGCTAGCTACAACGA GAGATAGT	2907
5461	UAUCUCAC A CUAAUCUG	1206	CAGATTAG GGCTAGCTACAACGA GTGAGATA	2908
5465	UCACACUA A UCUGAAAG	1207	CTTTCAGA GGCTAGCTACAACGA TAGTGTGA	2909
5475	CUGAAAGG A UGUGGAAG	1208	CTTCACA GGCTAGCTACAACGA CCTTTCAG	2910
5477	GAAAGGAU G UGGAAGAG	1209	CTCTTCCA GGCTAGCTACAACGA ATCCTTTC	2911
5485	GUGGAAGA G CAUUAGCU	1210	AGCTAATG GGCTAGCTACAACGA TCTTCCAC	2912
5487	GGAGAGC A UUAGCUGG	1211	CCAGCTAA GGCTAGCTACAACGA GCTCTTCC	2913
5491	GAGCAUUA G CUGGCACA	1212	TGCGCCAG GGCTAGCTACAACGA TAATGCTC	2914
5495	AUUAGCUG G CGCAUUAU	1213	AATATGCG GGCTAGCTACAACGA CAGCTAAT	2915
5497	UAGCUGGC G CAUAUUA	1214	TTAATATG GGCTAGCTACAACGA GCCAGCTA	2916
5499	GCUGGCGC A UAUUAAGC	1215	GCTTAATA GGCTAGCTACAACGA GCGCCAGC	2917
5501	UGGCGCAU A UUAAGCAC	1216	GTGCTTAA GGCTAGCTACAACGA ATGCGCCA	2918
5506	CAUAUUA G CACUUUA	1217	TTAAAGTG GGCTAGCTACAACGA TTAATATG	2919
5508	UAUUAAGC A CUUUAAGC	1218	GCCTAAAG GGCTAGCTACAACGA GCTTAATA	2920
5515	CACUUUA G CUCCUUGA	1219	TCAAGGAG GGCTAGCTACAACGA TTAAGTG	2921
5524	CUCCUUGA G UAAAAGG	1220	CCTTTTTA GGCTAGCTACAACGA TCAAGGAG	2922
5532	GUAAAAG G UGUUAUGU	1221	ACATACCA GGCTAGCTACAACGA CTTTTAC	2923
5535	AAAAGGUG G UAUGUAU	1222	ATTACATA GGCTAGCTACAACGA CACCTTTT	2924
5537	AAGGUGGU A UGUUAUUU	1223	AAATTACA GGCTAGCTACAACGA ACCACCTT	2925
5539	GGUGGUAU G UAUUUUA	1224	ATAAATTA GGCTAGCTACAACGA ATACCACC	2926
5542	GGUAUGUA A UUUAUGCA	1225	TGCATAAA GGCTAGCTACAACGA TACATACC	2927
5546	UGUAUUU A UGCAAGGU	1226	ACCTTGCA GGCTAGCTACAACGA AAATTACA	2928
5548	UAUUUUU G CAAGGUU	1227	ATACCTTG GGCTAGCTACAACGA ATAAATTA	2929
5553	UAUGCAAG G UAUUCUC	1228	GAGAAATA GGCTAGCTACAACGA CTTGCATA	2930
5555	UGCAAGGU A UUUCUCCA	1229	TGGAGAAA GGCTAGCTACAACGA ACCTTGCA	2931
5564	UUUCUCCA G UUGGGACU	1230	AGTCCCAA GGCTAGCTACAACGA TGGAGAAA	2932
5570	CAGUUGGG A CUCAGGAU	1231	ATCCTGAG GGCTAGCTACAACGA CCCAACTG	2933
5577	GACUCAGG A UAUUAGUU	1232	AACTAATA GGCTAGCTACAACGA CCTGAGTC	2934
5579	CUCAGGAU A UUAGUUA	1233	TTAACTAA GGCTAGCTACAACGA ATCCTGAG	2935
5583	GGUAUUA A UUAUGAG	1234	CTCATTAA GGCTAGCTACAACGA TAATATCC	2936
5587	AUUAGUUA A UGAGCAU	1235	ATGGCTCA GGCTAGCTACAACGA TAACTAAT	2937
5591	GUUAAUGA G CCAUCACU	1236	AGTGATGG GGCTAGCTACAACGA TCATTAA	2938
5594	AAUGAGCC A UCACUAGA	1237	TCTAGTGA GGCTAGCTACAACGA GGCTCATT	2939
5597	GAGCCAUC A CUAGAAGA	1238	TCTTCTAG GGCTAGCTACAACGA GATGGCTC	2940
5609	GAAGAAA G CCCAUUU	1239	AAAATGGG GGCTAGCTACAACGA TTTTCTTC	2941
5613	AAAAGCCC A UUUCUAC	1240	GTTGAAA GGCTAGCTACAACGA GGGCTTTT	2942
5620	CAUUUUA A CUGCUUUG	1241	CAAAGCAG GGCTAGCTACAACGA TGAAAATG	2943
5623	UUUCAACU G CUUUGAAA	1242	TTTCAAAG GGCTAGCTACAACGA AGTTGAAA	2944
5631	GCUUUGAA A CUUGCCUG	1243	CAGGCAAG GGCTAGCTACAACGA TTCAAAGC	2945
5635	UGAAACUU G CCUGGGGU	1244	ACCCAGG GGCTAGCTACAACGA AAGTTTCA	2946

5642	UGCCUGGG G UCUGAGCA	1245	TGCTCAGA GGCTAGCTACAACGA CCCAGGCA	2947
5648	GGGUCUGA G CAUGAUGG	1246	CCATCATG GGCTAGCTACAACGA TCAGACCC	2948
5650	GUCUGAGC A UGAUGGGA	1247	TCCCATCA GGCTAGCTACAACGA GCTCAGAC	2949
5653	UGAGCAUG A UGGGAUA	1248	TATTCCCA GGCTAGCTACAACGA CATGCTCA	2950
5659	UGAUGGGA A UAGGGAGA	1249	TCTCCCTA GGCTAGCTACAACGA TCCCATCA	2951
5667	AUAGGGAG A CAGGGUAG	1250	CTACCCTG GGCTAGCTACAACGA CTCCCTAT	2952
5672	GAGACAGG G UAGGAAAG	1251	CTTTCCTA GGCTAGCTACAACGA CCTGTCTC	2953
5682	AGGAAAGG G CGCCUACU	1252	AGTAGGCG GGCTAGCTACAACGA CCTTTCCT	2954
5684	GAAAGGGC G CCUACUCU	1253	AGAGTAGG GGCTAGCTACAACGA GCCCTTTC	2955
5688	GGCGCCCU A CUCUUCAG	1254	CTGAAGAG GGCTAGCTACAACGA AGGCGCCC	2956
5698	UCUUCAGG G UCUAAGA	1255	TCTTTAGA GGCTAGCTACAACGA CCTGAAGA	2957
5706	GUCUAAAG A UCAAGUGG	1256	CCACTTGA GGCTAGCTACAACGA CTTTAGAC	2958
5711	AAGAUCAA G UGGGCCUU	1257	AAGGCCCA GGCTAGCTACAACGA TTGATCTT	2959
5715	UCAAGUGG G CCUUGGAU	1258	ATCCAAGG GGCTAGCTACAACGA CCACTTGA	2960
5722	GGCCUUGG A UCGCUAAG	1259	CTTAGCGA GGCTAGCTACAACGA CCAAGGCC	2961
5725	CUUGGAUC G CUAAGCUG	1260	CAGCTTAG GGCTAGCTACAACGA GATCCAAG	2962
5730	AUCGCUAA G CUGGCUCU	1261	AGAGCCAG GGCTAGCTACAACGA TTAGCGAT	2963
5734	CUAAGCUG G CUCUGUUU	1262	AAACAGAG GGCTAGCTACAACGA CAGCTTAG	2964
5739	CUGGCUCU G UUUGAUGC	1263	GCATCAAA GGCTAGCTACAACGA AGAGCCAG	2965
5744	UCUGUUUG A UGCUAUUU	1264	AAATAGCA GGCTAGCTACAACGA CAAACAGA	2966
5746	UGUUUGAU G CUUUUAU	1265	ATAAATAG GGCTAGCTACAACGA ATCAAACA	2967
5749	UUGAUGCU A UUUUUGCA	1266	TGCATAAA GGCTAGCTACAACGA AGCATCAA	2968
5753	UGCUAUUU A UGCAAGUU	1267	AACTTGCA GGCTAGCTACAACGA AAATAGCA	2969
5755	CUUUUAU G CAAGUUAG	1268	CTAACTTG GGCTAGCTACAACGA ATAAATAG	2970
5759	UUUUGCAA G UUAGGGUC	1269	GACCCTAA GGCTAGCTACAACGA TTGCATAA	2971
5765	AAGUUAGG G UCUAUGUA	1270	TACATAGA GGCTAGCTACAACGA CCTAACTT	2972
5769	UAGGGUCU A UGUUUUA	1271	TAAATACA GGCTAGCTACAACGA AGACCCTA	2973
5771	GGGUCUAU G UAUUUAGG	1272	CCTAAATA GGCTAGCTACAACGA ATAGACCC	2974
5773	GUCUAUGU A UUUAGGAU	1273	ATCCTAAA GGCTAGCTACAACGA ACATAGAC	2975
5780	UAUUUAGG A UGCGCCUA	1274	TAGGCGCA GGCTAGCTACAACGA CCTAAATA	2976
5782	UUUAGGAU G CGCCUACU	1275	AGTAGGCG GGCTAGCTACAACGA ATCCTAAA	2977
5784	UAGGAUGC G CCUACUCU	1276	AGAGTAGG GGCTAGCTACAACGA GCATCCTA	2978
5788	AUGCGCCU A CUCUUCAG	1277	CTGAAGAG GGCTAGCTACAACGA AGGCGCAT	2979
5798	UCUUCAGG G UCUAAGA	1278	TCTTTAGA GGCTAGCTACAACGA CCTGAAGA	2980
5806	GUCUAAAG A UCAAGUGG	1279	CCACTTGA GGCTAGCTACAACGA CTTTAGAC	2981
5811	AAGAUCAA G UGGGCCUU	1280	AAGGCCCA GGCTAGCTACAACGA TTGATCTT	2982
5815	UCAAGUGG G CCUUGGAU	1281	ATCCAAGG GGCTAGCTACAACGA CCACTTGA	2983
5822	GGCCUUGG A UCGCUAAG	1282	CTTAGCGA GGCTAGCTACAACGA CCAAGGCC	2984
5825	CUUGGAUC G CUAAGCUG	1283	CAGCTTAG GGCTAGCTACAACGA GATCCAAG	2985
5830	AUCGCUAA G CUGGCUCU	1284	AGAGCCAG GGCTAGCTACAACGA TTAGCGAT	2986
5834	CUAAGCUG G CUCUGUUU	1285	AAACAGAG GGCTAGCTACAACGA CAGCTTAG	2987
5839	CUGGCUCU G UUUGAUGC	1286	GCATCAAA GGCTAGCTACAACGA AGAGCCAG	2988
5844	UCUGUUUG A UGCUAUUU	1287	AAATAGCA GGCTAGCTACAACGA CAAACAGA	2989
5846	UGUUUGAU G CUUUUAU	1288	ATAAATAG GGCTAGCTACAACGA ATCAAACA	2990
5849	UUGAUGCU A UUUUUGCA	1289	TGCATAAA GGCTAGCTACAACGA AGCATCAA	2991
5853	UGCUAUUU A UGCAAGUU	1290	AACTTGCA GGCTAGCTACAACGA AAATAGCA	2992
5855	CUUUUAU G CAAGUUAG	1291	CTAACTTG GGCTAGCTACAACGA ATAAATAG	2993
5859	UUUUGCAA G UUAGGGUC	1292	GACCCTAA GGCTAGCTACAACGA TTGCATAA	2994
5865	AAGUUAGG G UCUAUGUA	1293	TACATAGA GGCTAGCTACAACGA CCTAACTT	2995
5869	UAGGGUCU A UGUUUUA	1294	TAAATACA GGCTAGCTACAACGA AGACCCTA	2996
5871	GGGUCUAU G UAUUUAGG	1295	CCTAAATA GGCTAGCTACAACGA ATAGACCC	2997
5873	GUCUAUGU A UUUAGGAU	1296	ATCCTAAA GGCTAGCTACAACGA ACATAGAC	2998

5880	UAUUUAGG A UGUCUGCA	1297	TGCAGACA GGCTAGCTACAACGA CCTAAATA	2999
5882	UUUAGGAU G UCUGCACC	1298	GGTGCAGA GGCTAGCTACAACGA ATCCTAAA	3000
5886	GAUGUCU G CACCUUCU	1299	AGAAGGTG GGCTAGCTACAACGA AGACATCC	3001
5888	AUGUCUGC A CCUUCUGC	1300	GCAGAAGG GGCTAGCTACAACGA GCAGACAT	3002
5895	CACCUUCU G CAGCCAGU	1301	ACTGGCTG GGCTAGCTACAACGA AGAAGGTG	3003
5898	CUUCUGCA G CCAGUCAG	1302	CTGACTGG GGCTAGCTACAACGA TGCAGAAG	3004
5902	UGCAGCCA G UCAGAAGC	1303	GCTTCTGA GGCTAGCTACAACGA TGGCTGCA	3005
5909	AGUCAGAA G CUGGAGAG	1304	CTCTCCAG GGCTAGCTACAACGA TTCTGACT	3006
5918	CUGGAGAG G CAACAGUG	1305	CACGTGTT GGCTAGCTACAACGA CTCTCCAG	3007
5921	GAGAGGCA A CAGUGGAU	1306	ATCCACTG GGCTAGCTACAACGA TGCTCTCT	3008
5924	AGGCAACA G UGGAUUGC	1307	GCAATCCA GGCTAGCTACAACGA TGTTCGCT	3009
5928	AACAGUGG A UUGCUGCU	1308	AGCAGCAA GGCTAGCTACAACGA CCACTGTT	3010
5931	AGUGGAUU G CUGCUUCU	1309	AGAAGCAG GGCTAGCTACAACGA AATCCACT	3011
5934	GAUUGCU G CUUCUUGG	1310	CCAAGAAG GGCTAGCTACAACGA AGCAATCC	3012
5951	GGAGAAGA G UAUCUUC	1311	GAAGCATA GGCTAGCTACAACGA TCTTCTCC	3013
5953	AGAAGAGU A UGCUUCCU	1312	AGGAAGCA GGCTAGCTACAACGA ACTCTTCT	3014
5955	AAGAUUUA G CUUCUUUU	1313	AAAGGAAG GGCTAGCTACAACGA ATACTCTT	3015
5965	UUCUUUUU A UCCAUGUA	1314	TACATGGA GGCTAGCTACAACGA AAAAGGAA	3016
5969	UUUUAUCC A UGUAAUUU	1315	AAATTACA GGCTAGCTACAACGA GGATAAAA	3017
5971	UUUAUCCAU G UAAUUUAA	1316	TTAAATTA GGCTAGCTACAACGA ATGGATAA	3018
5974	UCCAUGUA A UUUAACUG	1317	CAGTTAAA GGCTAGCTACAACGA TACATGGA	3019
5979	GUAAUUUA A CUGUAGAA	1318	TTCTACAG GGCTAGCTACAACGA TAAATTAC	3020
5982	AUUUAACU G UAGAACCU	1319	AGTTTCTA GGCTAGCTACAACGA AGTTAAAT	3021
5987	ACUGUAGA A CCUGAGCU	1320	AGCTCAGG GGCTAGCTACAACGA TCTACAGT	3022
5993	GAACCUGA G CUCUAAGU	1321	ACTTAGAG GGCTAGCTACAACGA TCAGGTTC	3023
6000	AGCUCUAA G UAACCGAA	1322	TTCCGTTA GGCTAGCTACAACGA TTAGAGCT	3024
6003	UCUAAGUA A CCGAAGAA	1323	TTCTTCGG GGCTAGCTACAACGA TACTTAGA	3025
6011	ACCGAAGA A UGUUAGCC	1324	GGCATACA GGCTAGCTACAACGA TCTTCGGT	3026
6013	CGAAGAAU G UAUGCCUC	1325	GAGGCATA GGCTAGCTACAACGA ATTCTTCG	3027
6015	AAGAAUGU A UGCCUCUG	1326	CAGAGGCA GGCTAGCTACAACGA ACATTCTT	3028
6017	GAUUGUUA G CCUCUGUU	1327	AACAGAGG GGCTAGCTACAACGA ATACATTC	3029
6023	AUGCCUCU G UUCUUAUG	1328	CATAAGAA GGCTAGCTACAACGA AGAGGCAT	3030
6029	CUGUUCUU A UGUGCCAC	1329	GTGGCACA GGCTAGCTACAACGA AAGAACAG	3031
6031	GUUCUUUA G UGCCACAU	1330	ATGTGGCA GGCTAGCTACAACGA ATAAGAAC	3032
6033	UCUUAUGU G CCACAUCC	1331	GGATGTGG GGCTAGCTACAACGA ACATAAGA	3033
6036	UAUGUGCC A CAUCCUUG	1332	CAAGGATG GGCTAGCTACAACGA GGCACATA	3034
6038	UGUGCCAC A UCCUUGUU	1333	AACAAGGA GGCTAGCTACAACGA GTGGCACA	3035
6044	ACAUCCUU G UUUAAAGG	1334	CCTTTAAA GGCTAGCTACAACGA AAGGATGT	3036
6052	GUUUAAAG G CUCUCUGU	1335	ACAGAGAG GGCTAGCTACAACGA CTTTAAAC	3037
6059	GGCUCUCU G UAUGAAGA	1336	TCTTCATA GGCTAGCTACAACGA AGAGAGCC	3038
6061	CUCUCUGU A UGAAGAGA	1337	TCTCTTCA GGCTAGCTACAACGA ACAGAGAG	3039
6069	AUGAAGAG A UGGGACCG	1338	CGGTCCCA GGCTAGCTACAACGA CTCTTCAT	3040
6074	GAGAUGGG A CCGUCAUC	1339	GATGACGG GGCTAGCTACAACGA CCCATCTC	3041
6077	AUGGGACC G UCAUCAGC	1340	GCTGATGA GGCTAGCTACAACGA GGTCCCAT	3042
6080	GGACCGUC A UCAGCACA	1341	TGTGCTGA GGCTAGCTACAACGA GACGGTCC	3043
6084	CGUCAUCA G CACAUUCC	1342	GGAATGTG GGCTAGCTACAACGA TGATGACG	3044
6086	UCAUCAGC A CAUCCCUA	1343	AGGGAAAT GGCTAGCTACAACGA GCTGATGA	3045
6088	AUCAGCAC A UUCCCUAG	1344	CTAGGGAA GGCTAGCTACAACGA GTGCTGAT	3046
6096	AUUCUUUA G UGAGCCUA	1345	TAGGCTCA GGCTAGCTACAACGA TAGGGAAT	3047
6100	CCUACUGA G CCUACUGG	1346	CCAGTAGG GGCTAGCTACAACGA TCACTAGG	3048
6104	GUGAGCCU A CUGGCUC	1347	GGAGCCAG GGCTAGCTACAACGA AGGCTCAC	3049
6108	GCCUACUG G CUCCUGGC	1348	GCCAGGAG GGCTAGCTACAACGA CAGTAGGC	3050

6115	GGCUCUG G CAGCGCU	1349	AGCCGCTG GGCTAGCTACAACGA CAGGAGCC	3051
6118	UCCUGGCA G CGGCUUU	1350	AAAAGCCG GGCTAGCTACAACGA TGCCAGGA	3052
6121	UGGCAGCG G CUUUUGUG	1351	CACAAAAG GGCTAGCTACAACGA CGCTGCCA	3053
6127	CGCUCUUU G UGGAAGAC	1352	GTCTTCCA GGCTAGCTACAACGA AAAAGCCG	3054
6134	UGUGGAAG A CUCACUAG	1353	CTAGTGAG GGCTAGCTACAACGA CTTCCACA	3055
6138	GAAGACUC A CUAGCCAG	1354	CTGGCTAG GGCTAGCTACAACGA GAGTCITC	3056
6142	ACUCACUA G CCAGAAGA	1355	TCTTCTGG GGCTAGCTACAACGA TAGTGAGT	3057
6156	AGAAGAGG A UGGGACAG	1356	CTGTCCCA GGCTAGCTACAACGA TCCTCTCT	3058
6161	GGAGUGGG A CAGUCCUC	1357	GAGGACTG GGCTAGCTACAACGA CCCACTCC	3059
6164	GUGGAGCA G UCCUCUCC	1358	GGAGAGGA GGCTAGCTACAACGA TGTCCAC	3060
6173	UCCUCUCC A CCAAGAUC	1359	GATCTTGG GGCTAGCTACAACGA GGGAGAGGA	3061
6179	CCACCAAG A UCUAAUUC	1360	GATTTAGA GGCTAGCTACAACGA CTTGGTGG	3062
6185	AGAUCUAA A UCCAAACA	1361	TGTTTGA GGCTAGCTACAACGA TTAGATCT	3063
6191	AAAUCCAA A CAAAAGCA	1362	TGCTTTG GGCTAGCTACAACGA TTGGATTT	3064
6197	AAACAAA G CAGGCUAG	1363	CTAGCCTG GGCTAGCTACAACGA TTTGTTT	3065
6201	AAAAGCAG G CUAGAGCC	1364	GGCTCTAG GGCTAGCTACAACGA CTGCTTTT	3066
6207	AGGCUAGA G CCAGAAGA	1365	TCTTCTGG GGCTAGCTACAACGA TCTAGCCT	3067
6220	AAGAGAGG A CAAAUUU	1366	AAGATTG GGCTAGCTACAACGA CCTCTCTT	3068
6224	GAGGACAA A UCUUUGUU	1367	AACAAAGA GGCTAGCTACAACGA TTGTCCTC	3069
6230	AAAUUUU G UUGUCCU	1368	AGGAACAA GGCTAGCTACAACGA AAAGATT	3070
6233	UCUUGUU G UUCUCUU	1369	AAGAGGAA GGCTAGCTACAACGA AACAAAGA	3071
6246	UCUUCUU A CACAUACG	1370	CGTATGTG GGCTAGCTACAACGA AAAGAAGA	3072
6248	UUCUUUAC A CAUACGCA	1371	TGCGTATG GGCTAGCTACAACGA GTAAAGAA	3073
6250	CUUUACAC A UACGCAA	1372	TTTGCCTA GGCTAGCTACAACGA GTGTAAAG	3074
6252	UUCACAU A CGCAAACC	1373	GGTTTGGG GGCTAGCTACAACGA ATGTGTAA	3075
6254	ACACAUAC G CAAACCAC	1374	GTGGTTTG GGCTAGCTACAACGA GTATGTGT	3076
6258	AUACGCAA A CCACCUGU	1375	ACAGGTGG GGCTAGCTACAACGA TTGCGTAT	3077
6261	CGCAAACC A CCUGUGAC	1376	GTCAAGG GGCTAGCTACAACGA GGTTTGCG	3078
6265	AACCACCU G UGACAGCU	1377	AGCTGTCA GGCTAGCTACAACGA AGGTGGTT	3079
6268	CACCUGUG A CAGCUGG	1378	GCCAGCTG GGCTAGCTACAACGA CACAGGTG	3080
6271	CUGUGACA G CUGGCAU	1379	ATTGCCAG GGCTAGCTACAACGA TGTACAG	3081
6275	GACAGCUG G CAAUUUA	1380	TAAATTG GGCTAGCTACAACGA CAGCTGTC	3082
6278	AGCUGGCA A UUUUAUA	1381	TTATAAAA GGCTAGCTACAACGA TGCCAGCT	3083
6283	GCAUUUU A UAAUCAG	1382	CTGATTGA GGCTAGCTACAACGA AAAATTGC	3084
6287	UUUUUAUA A UCAGGUA	1383	TTACCTGA GGCTAGCTACAACGA TTATAAAA	3085
6292	UAAUCAG G UAACUGA	1384	TCCAGTTA GGCTAGCTACAACGA CTGATTGA	3086
6295	AUCAGGUA A CUGGAAGG	1385	CCTTCCAG GGCTAGCTACAACGA TACCTGAT	3087
6306	GGAAGGAG G UUAACUC	1386	GAGTTTAA GGCTAGCTACAACGA CTCCTTCC	3088
6311	GAGGUUA A CUCAGAA	1387	TTTCTGAG GGCTAGCTACAACGA TTAACCTC	3089
6327	AAAAGAAG A CCUCAGUC	1388	GACTGAGG GGCTAGCTACAACGA CTTCTTTT	3090
6333	AGACCUCA G UCAUUCU	1389	AGAATTGA GGCTAGCTACAACGA TGAGGTCT	3091
6337	CUCAGUCA A UUCUCUAC	1390	GTAGAGAA GGCTAGCTACAACGA TGAAGTCT	3092
6344	AAUUCUCU A CUUUUUU	1391	AAAAAAG GGCTAGCTACAACGA AGAGAATT	3093
6366	UUUCCAA A UCAGAUAA	1392	TTATCTGA GGCTAGCTACAACGA TTGGAAAA	3094
6371	CAAUCAG A UAAUAGCC	1393	GGCTATTA GGCTAGCTACAACGA CTGATTGG	3095
6374	AUCAGAU A UAGCCAG	1394	CTGGGCTA GGCTAGCTACAACGA TATCTGAT	3096
6377	AGAUAAU G CCCAGCA	1395	TTGCTGGG GGCTAGCTACAACGA TATTATCT	3097
6382	AUAGCCCA G CAAUAGU	1396	ACTATTGG GGCTAGCTACAACGA TGGGCTAT	3098
6386	CCCAGCAA A UAGUGAU	1397	TATCACTA GGCTAGCTACAACGA TTGCTGGG	3099
6389	AGCAAUA G UGAUACA	1398	TGTTATCA GGCTAGCTACAACGA TATTGGCT	3100
6392	AAAUAGUG A UAACAAU	1399	ATTTGTTA GGCTAGCTACAACGA CACTATTT	3101
6395	UAGUGAU A CAAUAAA	1400	TTTATTGG GGCTAGCTACAACGA TATCACTA	3102

6399	GAUAACAA A UAAACCU	1401	AGGTTTGA GGCTAGCTACAACGA TTGTTATC	3103
6404	CAAAUAAA A CCUAGCU	1402	AGCTAAGG GGCTAGCTACAACGA TTTATTTG	3104
6410	AAACCUUA G CUGUUAU	1403	ATGAACAG GGCTAGCTACAACGA TAAGGTTT	3105
6413	CCUAGCU G UUCAUGUC	1404	GACATGAA GGCTAGCTACAACGA AGCTAAGG	3106
6417	AGCUGUUC A UGUCUUGA	1405	TCAAGACA GGCTAGCTACAACGA GAACAGCT	3107
6419	CUGUUAU G UCUUGAUU	1406	AATCAAGA GGCTAGCTACAACGA ATGAACAG	3108
6425	AUGUCUUG A UUUCAAUA	1407	TATTGAAA GGCTAGCTACAACGA CAAGACAT	3109
6431	UGAUUUA A UAAUUAU	1408	ATTAATTA GGCTAGCTACAACGA TGAAATCA	3110
6434	UUUCAAUA A UUAUUCU	1409	AGAATTAA GGCTAGCTACAACGA TATTGAAA	3111
6438	AAUAAUUA A UUCUUAU	1410	ATTAAGAA GGCTAGCTACAACGA TAATTATT	3112
6445	AAUUCUUA A UCAUUAAG	1411	CTTAATGA GGCTAGCTACAACGA TAAGAATT	3113
6448	UCUUAUUC A UUAAGAGA	1412	TCTCTTAA GGCTAGCTACAACGA GATTAAGA	3114
6456	AUUAAGAG A CCAUAAUA	1413	TATTATGG GGCTAGCTACAACGA CTCTTAAT	3115
6459	AAGAGACC A UAAUAAU	1414	ATTTATTA GGCTAGCTACAACGA GGTCCTCT	3116
6462	AGACCAUA A UAAUACU	1415	AGTATTTA GGCTAGCTACAACGA TATGGTCT	3117
6466	CAUAAUAA A UACUCCU	1416	AAGGAGTA GGCTAGCTACAACGA TTATTATG	3118
6468	UAUAAAU A CUCCUUU	1417	AAAAGGAG GGCTAGCTACAACGA ATTTATTA	3119
6487	AGAGAAAA G CAAACCA	1418	TGGTTTGG GGCTAGCTACAACGA TTTTCTCT	3120
6492	AAAGCAAA A CCAUAGA	1419	TCTAATGG GGCTAGCTACAACGA TTTGCTTT	3121
6495	GCAAAACC A UUAGAAU	1420	AATTCTAA GGCTAGCTACAACGA GGTTTTCG	3122
6501	CCAUUAGA A UUGUUAU	1421	AGTAACAA GGCTAGCTACAACGA TCTAATGG	3123
6504	UUAGAAU G UUAUCAG	1422	CTGAGTAA GGCTAGCTACAACGA AATTCTAA	3124
6507	GAAUUGUU A CUCAGCUC	1423	GAGCTGAG GGCTAGCTACAACGA AACAATTG	3125
6512	GUUACUCA G CUCCUUA	1424	TGAAGGAG GGCTAGCTACAACGA TGAGTAAC	3126
6522	UCCUUCAA A CUCAGGU	1425	AACCTGAG GGCTAGCTACAACGA TTGAAGGA	3127
6528	AAACUCAG G UUUGUAGC	1426	GCTACAAA GGCTAGCTACAACGA CTGAGTTT	3128
6532	UCAGGUUU G UAGCAUAC	1427	GTATGCTA GGCTAGCTACAACGA AAACCTGA	3129
6535	GGUUUGUA G CAUACAUG	1428	CATGTATG GGCTAGCTACAACGA TACAACCC	3130
6537	UUUGUAGC A UACAUGAG	1429	CTCATGTA GGCTAGCTACAACGA GCTACAAA	3131
6539	UGUAGCAU A CAUGAGUC	1430	GACTCATG GGCTAGCTACAACGA ATGCTACA	3132
6541	UAGCAUAC A UGAGUCCA	1431	TGGACTCA GGCTAGCTACAACGA GTATGCTA	3133
6545	AUACAUGA G UCCAUCCA	1432	TGGATGGA GGCTAGCTACAACGA TCATGTAT	3134
6549	AUGAGUCC A UCAUCAG	1433	CTGATGGA GGCTAGCTACAACGA GGACTCAT	3135
6553	GUCCAUGC A UCAGUCAA	1434	TTGACTGA GGCTAGCTACAACGA GGATGGAC	3136
6557	AUCCAUCA G UCAAAGAA	1435	TTCTTTGA GGCTAGCTACAACGA TGATGGAT	3137
6565	GUCAAAGA A UGGUCCA	1436	TGGAACCA GGCTAGCTACAACGA TCTTTGAC	3138
6568	AAAGAAUG G UUCAUCU	1437	AGATGGAA GGCTAGCTACAACGA CATTCTTT	3139
6573	AUGGUUCC A UCUGGAGU	1438	ACTCCAGA GGCTAGCTACAACGA GGAACCAT	3140
6580	CAUCUGGA G UCUUAAUG	1439	CATTAAGA GGCTAGCTACAACGA TCCAGATG	3141
6586	GAGUCUUA A UGUAGAAA	1440	TTTCTACA GGCTAGCTACAACGA TAAGACTC	3142
6588	GUCUUAU G UAGAAAGA	1441	TCTTTCTA GGCTAGCTACAACGA ATTAAGAC	3143
6600	AAAGAAAA A UGGAGACU	1442	AGTCTCCA GGCTAGCTACAACGA TTTTCTTT	3144
6606	AAUUGGAG A CUUGAAU	1443	ATTACAAG GGCTAGCTACAACGA CTCCATTT	3145
6610	GGAGACUU G UAAUAAUG	1444	CATTATTA GGCTAGCTACAACGA AAGTCTCC	3146
6613	GACUUGUA A UAAUGAGC	1445	GCTCATTA GGCTAGCTACAACGA TACAAGTC	3147
6616	UUGUAAUA A UGAGCUAG	1446	CTAGCTCA GGCTAGCTACAACGA TATTACAA	3148
6620	AAUAAUGA G CUAGUUA	1447	GTAACCTG GGCTAGCTACAACGA TCAATTAT	3149
6624	AUGAGCUA G UUAACAAG	1448	CTTTGTAA GGCTAGCTACAACGA TAGTCAT	3150
6627	AGCUAGUU A CAAAGUGC	1449	GCACTTTG GGCTAGCTACAACGA AACTAGCT	3151
6632	GUUACAAA G UGCUUGUU	1450	AACAAGCA GGCTAGCTACAACGA TTTGTAAC	3152
6634	UACAAAGU G CUUGUUA	1451	TGAACAAG GGCTAGCTACAACGA ACTTTGTA	3153
6638	AAGUGCUU G UUCAUUA	1452	TTAATGAA GGCTAGCTACAACGA AAGCACTT	3154

6642	GCUUGUUC A UUA AAAUA	1453	TATTTTAA GGCTAGCTACAACGA GAACAAGC	3155
6648	UCAUUA AA A UAGCACUG	1454	CAGTGCTA GGCTAGCTACAACGA TTTAATGA	3156
6651	UUA AAAUA G CACUGAAA	1455	TTTCAGTG GGCTAGCTACAACGA TATTTTAA	3157
6653	AAAAUAGC A CUGAAA AU	1456	ATTTTCAG GGCTAGCTACAACGA GCTATTTT	3158
6660	CACUGAAA A UUGAAACA	1457	TGTTTCAA GGCTAGCTACAACGA TTTCAGTG	3159
6666	AAAUUGAA A CAUGAAU	1458	AATTCATG GGCTAGCTACAACGA TTCAATTT	3160
6668	AUUGAAAC A UGA AUUA	1459	TTAATTCA GGCTAGCTACAACGA GTTTCAT	3161
6672	AAACAUGA A UUAACUGA	1460	TCAGTTAA GGCTAGCTACAACGA TCATGTTT	3162
6676	AUGAAUUA A CUGAUAAU	1461	ATTATCAG GGCTAGCTACAACGA TAATTCAT	3163
6680	AUUAACUG A UAAUAUUC	1462	GAATATTA GGCTAGCTACAACGA CAGTTAAT	3164
6683	AACUGAUA A UAUUCCAA	1463	TTGGAATA GGCTAGCTACAACGA TATCAGTT	3165
6685	CUGAUAAU A UUCCA AUC	1464	GATTGGAA GGCTAGCTACAACGA ATTATCAG	3166
6691	AUAUCCA A UCAUUGC	1465	GCAATGA GGCTAGCTACAACGA TGGAATAT	3167
6694	UUCCA AUC A UUGCCA U	1466	ATGGCAAA GGCTAGCTACAACGA GATTGGAA	3168
6698	AAUCAUUU G CCAUUAU	1467	ATAAATGG GGCTAGCTACAACGA AAATGATT	3169
6701	CAUUGCC A UUAUGAC	1468	GTCATAAA GGCTAGCTACAACGA GGCAATG	3170
6705	UGCCAUUU A UGACAAA	1469	TTTGTGCA GGCTAGCTACAACGA AAATGGCA	3171
6708	CAUUAUG A CAAAAUG	1470	CATTTTGG GGCTAGCTACAACGA CATAATG	3172
6714	UGACAAA A UGUUGGC	1471	GCCAACCA GGCTAGCTACAACGA TTTGTGCA	3173
6717	CAAAAUG G UUGGCACU	1472	AGTGCCAA GGCTAGCTACAACGA CATTTTGG	3174
6721	AAUGGUUG G CACUACA	1473	TGTTAGTG GGCTAGCTACAACGA CAACCATT	3175
6723	UGGUUGGC A CUAACAA	1474	TTTGTTAG GGCTAGCTACAACGA GCCAACCA	3176
6727	UGGCACUA A CAAAGAAC	1475	GTTCCTTG GGCTAGCTACAACGA TAGTGCCA	3177
6734	AACAAAGA A CGAGCACU	1476	AGTGCTCG GGCTAGCTACAACGA TCCTTGTT	3178
6738	AAGAACGA G CACUCCU	1477	AGGAAGTG GGCTAGCTACAACGA TCCTTGTT	3179
6740	GAACGAGC A CUUCCUU	1478	AAAGGAAG GGCTAGCTACAACGA GCTCGTTC	3180
6753	CUUCAGAG G UUCUGAG	1479	CTCAGAAA GGCTAGCTACAACGA TCTGAAAG	3181
6762	UUUCUGAG A UAAUGUAC	1480	GTACATTA GGCTAGCTACAACGA CTCAGAAA	3182
6765	CUGAGAU A UGUACGUG	1481	CACGTACA GGCTAGCTACAACGA TATCTCAG	3183
6767	GAGUAUAU G UACUGGGA	1482	TCCACGTA GGCTAGCTACAACGA ATTATCTC	3184
6769	GAUAUGU A CGUGGAAC	1483	GTTCACAG GGCTAGCTACAACGA ACATTATC	3185
6771	UAUUGUAC G UGGAACAG	1484	CTGTTCCA GGCTAGCTACAACGA GTACATTA	3186
6776	UACUGGGA A CAGUCUGG	1485	CCAGACTG GGCTAGCTACAACGA TCCACGTA	3187
6779	GUGGAACA G UCUGGGUG	1486	CACCCAGA GGCTAGCTACAACGA TGTTCAC	3188
6785	CAGUCUGG G UGGAUUGG	1487	CCATTCCA GGCTAGCTACAACGA CCAGACTG	3189
6790	UGGUGGGA A UGGGCGUG	1488	CAGCCCCA GGCTAGCTACAACGA TCCACCCA	3190
6795	GGAAUGGG G CUGAAACC	1489	GGTTTCAG GGCTAGCTACAACGA CCCATTCC	3191
6801	GGGUGAA A CCAUGUGC	1490	GCACATGG GGCTAGCTACAACGA TTCAGCCC	3192
6804	CUGAAACC A UGUGCAAG	1491	CTTGCA CA GGCTAGCTACAACGA GGTTTCAG	3193
6806	GAAACCAU G UGCAAGUC	1492	GACTTGCA GGCTAGCTACAACGA ATGGTTTC	3194
6808	AACCAUGU G CAAGUCUG	1493	CAGACTTG GGCTAGCTACAACGA ACATGGTT	3195
6812	AUGUGCAA G UCUGUGUC	1494	GACACAGA GGCTAGCTACAACGA TTGCACAT	3196
6816	GCAAGUCU G UGUCUUGU	1495	ACAAGACA GGCTAGCTACAACGA AGACTTGC	3197
6818	AAGUCUGU G UCUUGUCA	1496	TGACAAGA GGCTAGCTACAACGA ACAGACTT	3198
6823	UGUGUCUU G UCAGUCCA	1497	TGACTGA GGCTAGCTACAACGA AAGACACA	3199
6827	UCUUGUCA G UCCAAGAA	1498	TTCTTGGA GGCTAGCTACAACGA TGACAAGA	3200
6836	UCCAAGAA G UGACACCG	1499	CGGTGTCA GGCTAGCTACAACGA TTCTTGGA	3201
6839	AAGAAGUG A CACCGAGA	1500	TCTCGGTG GGCTAGCTACAACGA CACTTCTT	3202
6841	GAAGUGAC A CCGAGAUG	1501	CACTCTCG GGCTAGCTACAACGA GTCACTTC	3203
6847	ACACCGAG A UGUAAUU	1502	AATTAACA GGCTAGCTACAACGA CTCGGTGT	3204
6849	ACCGAGAU G UUAUUUU	1503	AAATTAACA GGCTAGCTACAACGA ATCTCGGT	3205
6853	AGAUGUUA A UUUUAGGG	1504	CCCTAAAA GGCTAGCTACAACGA TAACATCT	3206



6862	UUUUAGGG A CCCGUGCC	1505	GGCACGGG GGCTAGCTACAACGA CCCTAAAA	3207
6866	AGGGACCC G UGCCUUGU	1506	ACAAGGCA GGCTAGCTACAACGA GGGTCCCT	3208
6868	GGACCCGU G CCUUGUUU	1507	AAACAAGG GGCTAGCTACAACGA ACGGGTCC	3209
6873	CGUGCCUU G UUUCCUAG	1508	CTAGGAAA GGCTAGCTACAACGA AAGGCACG	3210
6881	GUUCCUA G CCCACAAG	1509	CTTGTGGG GGCTAGCTACAACGA TAGGAAAC	3211
6885	CCUAGCCC A CAAGAAUG	1510	CATTCTTG GGCTAGCTACAACGA GGGCTAGG	3212
6891	CCACAAGA A UGCAACA	1511	TGTTTGCA GGCTAGCTACAACGA TCTTGTGG	3213
6893	ACAAGAAU G CAAACAUC	1512	GATGTTTG GGCTAGCTACAACGA ATTCTTGT	3214
6897	GAUGCAA A CAUCAAAC	1513	GTTTGATG GGCTAGCTACAACGA TTGCATTG	3215
6899	AUGCAAAC A UCAACACG	1514	CTGTTTGA GGCTAGCTACAACGA GTTTCATG	3216
6904	AACAUCAA A CAGAUACU	1515	AGTATCTG GGCTAGCTACAACGA TTGATGTT	3217
6908	UCAACAG A UACUCGCU	1516	AGCGAGTA GGCTAGCTACAACGA CTGTTTGA	3218
6910	AAACAGAU A CUCGCUAG	1517	CTAGCGAG GGCTAGCTACAACGA ATCTGTTT	3219
6914	AGAUACUC G CUAGCCUC	1518	GAGGCTAG GGCTAGCTACAACGA GAGTATCT	3220
6918	ACUCGCUA G CCUCAUUU	1519	AAATGAGG GGCTAGCTACAACGA TAGCGAGT	3221
6923	CUAGCCUC A UUUAUUU	1520	AATTTAAA GGCTAGCTACAACGA GAGGCTAG	3222
6929	UCAUUUAA A UUGAUUAA	1521	TTAATCAA GGCTAGCTACAACGA TTAATGA	3223
6933	UUAAAUUG A UUAAGGA	1522	TCCTTTAA GGCTAGCTACAACGA CAATTTAA	3224
6945	AAGGAGGA G UGCAUCUU	1523	AAGATGCA GGCTAGCTACAACGA TCCTCCTT	3225
6947	GGAGGAGU G CAUCUUUG	1524	CAAAGATG GGCTAGCTACAACGA ACTCCTCC	3226
6949	AGGAGUGC A UCUUUGGC	1525	GCCAAAGA GGCTAGCTACAACGA GCCTCCTT	3227
6956	CAUCUUUG G CCGACAGU	1526	ACTGTCGG GGCTAGCTACAACGA CAAAGATG	3228
6960	UUUGGCCG A CAGUGGUG	1527	CACCACTG GGCTAGCTACAACGA CGGCCAAA	3229
6963	GGCCGACA G UGGUGUAA	1528	TTACACCA GGCTAGCTACAACGA TGTGGGCC	3230
6966	CGACAGUG G UGUAAUCG	1529	CAGTTACA GGCTAGCTACAACGA CACTGTGG	3231
6968	ACAGUGGU G UAACUGUG	1530	CACAGTTA GGCTAGCTACAACGA ACCACTGT	3232
6971	GUGGUGUA A CUGUGUGU	1531	ACACACAG GGCTAGCTACAACGA TACACCAC	3233
6974	GUGUAACU G UGUGUGUG	1532	CACACACA GGCTAGCTACAACGA AGTTACAC	3234
6976	GUAACUGU G UGUGUGUG	1533	CACACACA GGCTAGCTACAACGA ACAGTTAC	3235
6978	AACUGUGU G UGUGUGUG	1534	CACACACA GGCTAGCTACAACGA ACACAGTT	3236
6980	CUGUGUGU G UGUGUGUG	1535	CACACACA GGCTAGCTACAACGA ACACACAG	3237
6982	GUGUGUGU G UGUGUGUG	1536	CACACACA GGCTAGCTACAACGA ACACACAC	3238
6984	GUGUGUGU G UGUGUGUG	1537	CACACACA GGCTAGCTACAACGA ACACACAC	3239
6986	GUGUGUGU G UGUGUGUG	1538	CACACACA GGCTAGCTACAACGA ACACACAC	3240
6988	GUGUGUGU G UGUGUGUG	1539	CACACACA GGCTAGCTACAACGA ACACACAC	3241
6990	GUGUGUGU G UGUGUGUG	1540	CACACACA GGCTAGCTACAACGA ACACACAC	3242
6992	GUGUGUGU G UGUGUGUG	1541	CACACACA GGCTAGCTACAACGA ACACACAC	3243
6994	GUGUGUGU G UGUGUGUG	1542	CACACACA GGCTAGCTACAACGA ACACACAC	3244
6996	GUGUGUGU G UGUGUGUG	1543	CACACACA GGCTAGCTACAACGA ACACACAC	3245
6998	GUGUGUGU G UGUGUGUG	1544	CACACACA GGCTAGCTACAACGA ACACACAC	3246
7000	GUGUGUGU G UGUGUGUG	1545	CACACACA GGCTAGCTACAACGA ACACACAC	3247
7002	GUGUGUGU G UGUGUGUG	1546	CACACACA GGCTAGCTACAACGA ACACACAC	3248
7004	GUGUGUGU G UGUGUGUG	1547	CACACACA GGCTAGCTACAACGA ACACACAC	3249
7006	GUGUGUGU G UGUGUGUG	1548	CACACACA GGCTAGCTACAACGA ACACACAC	3250
7008	GUGUGUGU G UGUGUGUG	1549	CCCACACA GGCTAGCTACAACGA ACACACAC	3251
7010	GUGUGUGU G UGUGUGUG	1550	CACCCACA GGCTAGCTACAACGA ACACACAC	3252
7012	GUGUGUGU G UGUGUGUG	1551	CACACCCA GGCTAGCTACAACGA ACACACAC	3253
7016	GUGUGUGG G UGUGUGUG	1552	CACCCACA GGCTAGCTACAACGA CCACACAC	3254
7018	GUGUGUGG G UGUGUGUA	1553	TACACCCA GGCTAGCTACAACGA ACCACAC	3255
7022	GGGUGUGG G UGUUUGUG	1554	CACATACA GGCTAGCTACAACGA CCACACCC	3256
7024	GUGUGUGG G UAUGUGUG	1555	CACACATA GGCTAGCTACAACGA ACCACAC	3257
7026	GUGGUGUGU A UGUGUGUU	1556	AACACACA GGCTAGCTACAACGA ACACCCAC	3258

7028	GGGUGUAU G UGUGUUUU	1557	AAAACACA GGCTAGCTACAACGA ATACACCC	3259
7030	GUGUAUGU G UGUUUUGU	1558	ACAAAACA GGCTAGCTACAACGA ACATACAC	3260
7032	GUAUGUGU G UUUUGUGC	1559	GCACAAAA GGCTAGCTACAACGA ACACATAC	3261
7037	UGUGUUUU G UGCAUAAC	1560	GTTATGCA GGCTAGCTACAACGA AAAACACA	3262
7039	UGUUUUGU G CAUAACUA	1561	TAGTTATG GGCTAGCTACAACGA ACAAACA	3263
7041	UUUUGUGC A UAACUAU	1562	AATAGTTA GGCTAGCTACAACGA GCACAAAA	3264
7044	UGUGCAUA A CUUUUAA	1563	TTAAATAG GGCTAGCTACAACGA TATGCACA	3265
7047	GCAUAACU A UUUAAAGGA	1564	TCCTTAAA GGCTAGCTACAACGA AGTTATGC	3266
7057	UUAAGGAA A CUGGAUU	1565	AATTCCAG GGCTAGCTACAACGA TTCCTTAA	3267
7063	AAACUGGA A UUUUAAAG	1566	CTTTAAAA GGCTAGCTACAACGA TCCAGTTT	3268
7071	AUUUUAAA G UUACUUUU	1567	AAAAGTAA GGCTAGCTACAACGA TTTAAAAT	3269
7074	UUAAGUUU A CUUUUAUA	1568	TATAAAGG GGCTAGCTACAACGA AACTTTAA	3270
7080	UUACUUUU A UACAAACC	1569	GOTTTGTA GGCTAGCTACAACGA AAAAGTAA	3271
7082	ACUUUUUA A CAAACCAA	1570	TTGGTTTG GGCTAGCTACAACGA ATAAAAGT	3272
7086	UUUAACAA A CCAAGAAU	1571	ATTCTTGG GGCTAGCTACAACGA TTGTATAA	3273
7093	AACCAAGA A UAUAUGCU	1572	AGCATATA GGCTAGCTACAACGA TCTTGGTT	3274
7095	CCAAGAAU A UAUGCUC	1573	GTAGCATA GGCTAGCTACAACGA ATTCTTGG	3275
7097	AAGAUAU A UGCUACAG	1574	CTGTAGCA GGCTAGCTACAACGA ATATTCTT	3276
7099	GAUAUAU G CUACAGAU	1575	ATCTGTAG GGCTAGCTACAACGA ATATATTC	3277
7102	UAUAUGCU A CAGAUUA	1576	TATATCTG GGCTAGCTACAACGA AGCATATA	3278
7106	UGCUACAG A UAUAAGAC	1577	GTCTTATA GGCTAGCTACAACGA CTGTAGCA	3279
7108	CUACAGAU A UAAGACAG	1578	CTGTCTTA GGCTAGCTACAACGA ATCTGTAG	3280
7113	GAUAUAAG A CAGACAUG	1579	CATGTCTG GGCTAGCTACAACGA CTTATATC	3281
7117	UAAGACAG A CAUGGUUU	1580	AAACCATG GGCTAGCTACAACGA CTGTCTTA	3282
7119	AGACAGAC A UGGUUUGG	1581	CCAAACCA GGCTAGCTACAACGA GTCTGTCT	3283
7122	CAGACAUG G UUUGGUCC	1582	GGACCAA GGCTAGCTACAACGA CATGTCTG	3284
7127	AUGGUUUG G UCCUAUAU	1583	ATATAGGA GGCTAGCTACAACGA CAAACCAT	3285
7132	UUGGUCCU A UAUUUCUA	1584	TAGAAATA GGCTAGCTACAACGA AGGACCAA	3286
7134	GGUCCUAU A UUUCUAGU	1585	ACTAGAAA GGCTAGCTACAACGA ATAGGACC	3287
7141	UAUUUCUA G UCAUGAUG	1586	CATCATGA GGCTAGCTACAACGA TAGAAATA	3288
7144	UUUCUAGU A UGAUGAAU	1587	ATTCATCA GGCTAGCTACAACGA GACTAGAA	3289
7147	UAGUCAUG A UGAUGUA	1588	TACATTCA GGCTAGCTACAACGA CATGACTA	3290
7151	CAUGAUGA A UGUUUUUU	1589	AAAATACA GGCTAGCTACAACGA TCATCATG	3291
7153	UGAUGAAU G UAUUUUGU	1590	ACAAAATA GGCTAGCTACAACGA ATTCATCA	3292
7155	AUGAAUGU A UUUUGUAU	1591	ATACAAAA GGCTAGCTACAACGA ACATTCAT	3293
7160	UGUAUUUU G UAUACCAU	1592	ATGGTATA GGCTAGCTACAACGA AAAATACA	3294
7162	UAUUUUGU A UACCAUCU	1593	AGATGGTA GGCTAGCTACAACGA ACAAATA	3295
7164	UUUUGUAU A CCAUCUUC	1594	GAAGATGG GGCTAGCTACAACGA ATACAAAA	3296
7167	UGUAUACC A UCUUCAUA	1595	TATGAAGA GGCTAGCTACAACGA GGTATACA	3297
7173	CCAUCUUC A UAUAUAU	1596	ATATTATA GGCTAGCTACAACGA GAAGATGG	3298
7175	AUCUUCAU A UAAUAUAC	1597	GTATATTA GGCTAGCTACAACGA ATGAAGAT	3299
7178	UUCAUAUA A UAUACUUA	1598	TAAGTATA GGCTAGCTACAACGA TATATGAA	3300
7180	CAUAUAUA A UACUAAA	1599	TTTAAGTA GGCTAGCTACAACGA ATTATATG	3301
7182	UAUAUAUA A CUUAAAA	1600	TTTTTAAG GGCTAGCTACAACGA ATATTATA	3302
7190	ACUAAAAA A UAUUCUU	1601	AAGAAATA GGCTAGCTACAACGA TTTTAAGT	3303
7192	UUAAAAAU A UUUCUUA	1602	TTAAGAAA GGCTAGCTACAACGA ATTTTAA	3304
7200	AUUUCUUA A UUGGAUU	1603	AATCCCAA GGCTAGCTACAACGA TAAGAAAT	3305
7206	UAAUUGG A UUUGUAU	1604	ATTACAAA GGCTAGCTACAACGA CCCAATTA	3306
7210	UGGGAUUU G UAAUCGUA	1605	TACGATTA GGCTAGCTACAACGA AAATCCCA	3307
7213	GAUUUGUA A UCGUACCA	1606	TGGTACGA GGCTAGCTACAACGA TACAAATC	3308
7216	UUGUAUUC G UACCAACU	1607	AGTTGGTA GGCTAGCTACAACGA GATTACAA	3309
7218	GUAUUCGU A CCAACUUA	1608	TAAGTTGG GGCTAGCTACAACGA ACGATTAC	3310

7222	UCGUACCA A CUUAAUUG	1609	CAATTAAG GGCTAGCTACAACGA TGGTACGA	3311
7227	CCAACUUA A UUGAUAAA	1610	TTTATCAA GGCTAGCTACAACGA TAAGTTGG	3312
7231	CUUAAUUG A UAAACUUG	1611	CAAGTTTA GGCTAGCTACAACGA CAATTAAG	3313
7235	AUUGAUAA A CUUGGCAA	1612	TTGCCAAG GGCTAGCTACAACGA TTATCAAT	3314
7240	UAAACUUG G CAACUGCU	1613	AGCAGTTG GGCTAGCTACAACGA CAAGTTTA	3315
7243	ACUUGGCA A CUGCUUUU	1614	AAAAGCAG GGCTAGCTACAACGA TGCCAAGT	3316
7246	UGGCAACU G CUUUUAUG	1615	CATAAAAG GGCTAGCTACAACGA AGTTGCCA	3317
7252	CUGCUUUU A UGUUCUGU	1616	ACAGAACA GGCTAGCTACAACGA AAAAGCAG	3318
7254	GCUUUUAU G UUCUGUCU	1617	AGACAGAA GGCTAGCTACAACGA ATAAAAGC	3319
7259	UAUGUUCU G UCUCUUC	1618	GAAGGAGA GGCTAGCTACAACGA AGAACATA	3320
7269	CUCCUUCU A UAAAUUUU	1619	AAAATTTA GGCTAGCTACAACGA GGAAGGAG	3321
7273	UCCAUUAA A UUUUUCAA	1620	TTGAAAAA GGCTAGCTACAACGA TTATGGAA	3322
7283	UUUUCAAA A UACUAAUU	1621	AATTAGTA GGCTAGCTACAACGA TTTGAAAA	3323
7285	UUCAAAAU A CUAAUUCA	1622	TGAATTAG GGCTAGCTACAACGA ATTTTGAA	3324
7289	AAAUACUA A UUCAACAA	1623	TTGTTGAA GGCTAGCTACAACGA TAGTATTT	3325
7294	CUAAUUCA A CAAAGAAA	1624	TTTCTTTG GGCTAGCTACAACGA TGAATTAG	3326
7305	AAGAAAAA G CUCUUUUU	1625	AAAAAGAG GGCTAGCTACAACGA TTTTCTTT	3327
7323	UUCUAAAA A UAAACUCA	1626	TGAGTTTA GGCTAGCTACAACGA TTTAGGAA	3328
7327	UAAAAUAA A CUCAAAUU	1627	AATTTGAG GGCTAGCTACAACGA TTATTTTA	3329
7333	AAACUCAA A UUUAUCCU	1628	AGGATAAA GGCTAGCTACAACGA TTGAGTTT	3330
7337	UCAAAUUU A UCCUUGUU	1629	AACAAGGA GGCTAGCTACAACGA AAATTTGA	3331
7343	UUAUCCUU G UUUAGAGC	1630	GCTCTAAA GGCTAGCTACAACGA AAGGATAA	3332
7350	UGUUUAGA G CAGAGAAA	1631	TTTCTCTG GGCTAGCTACAACGA TCTAAACA	3333
7360	AGAGAAAA A UUAAGAAA	1632	TTTCTTAA GGCTAGCTACAACGA TTTTCTCT	3334
7370	UAAGAAAA A CUUUGAAA	1633	TTTCAAAG GGCTAGCTACAACGA TTTTCTTA	3335
7378	ACUUUGAA A UGGUCUCA	1634	TGAGACCA GGCTAGCTACAACGA TTCAAAGT	3336
7381	UUGAAAUG G UCUCAAAA	1635	TTTGTAGA GGCTAGCTACAACGA CATTTCAA	3337
7391	CUCAAAAA A UUGCUIAA	1636	TTTAGCAA GGCTAGCTACAACGA TTTTGTAG	3338
7394	AAAAAAUU G CUAAAUUU	1637	ATATTTAG GGCTAGCTACAACGA AATTTTTT	3339
7399	AUUGCUIA A UAUUUUUA	1638	TGAAAATA GGCTAGCTACAACGA TTAGCAAT	3340
7401	UGCUIAAU A UUUUCAUU	1639	ATTGAAAA GGCTAGCTACAACGA ATTAGCAA	3341
7408	UAUUUUUA A UGGAAAAAC	1640	GTTTTCCA GGCTAGCTACAACGA TGAAAAATA	3342
7415	AAUGGAAA A CUAAAUUG	1641	ACATTTAG GGCTAGCTACAACGA TTTCCATT	3343
7420	AAACUAAA A UGUUAGUU	1642	AACTAACA GGCTAGCTACAACGA TTAGTTTT	3344
7422	AACUAAAU G UUAGUUUA	1643	TAAACTAA GGCTAGCTACAACGA ATTAGTTT	3345
7426	AAUGUUUA G UUUAGCUG	1644	CAGCTAAA GGCTAGCTACAACGA TAACATTT	3346
7431	UUAGUUUA G CUGAUUGU	1645	ACAATCAG GGCTAGCTACAACGA TAACTAA	3347
7435	UUUAGCUG A UUGUAUGG	1646	CCATACAA GGCTAGCTACAACGA CAGCTAAA	3348
7438	AGCUGAUU G UAUGGGGU	1647	ACCCATAA GGCTAGCTACAACGA AATCAGCT	3349
7440	CUGAUUGU A UGGGGUUU	1648	AAACCCCA GGCTAGCTACAACGA ACAATCAG	3350
7445	UGUAUGGG G UUUUCGAA	1649	TTGAAAAA GGCTAGCTACAACGA CCCATACA	3351
7453	GUUUUCGA A CCUUCAC	1650	GTGAAAGG GGCTAGCTACAACGA TCGAAAAAC	3352
7460	AACCUUUC A CUUUUUGU	1651	ACAAAAAG GGCTAGCTACAACGA GAAAGGTT	3353
7467	CACUUUUU G UUUUUUUU	1652	AAAACAAA GGCTAGCTACAACGA AAAAAGTG	3354
7471	UUUUGUUU G UUUUACCU	1653	AGGTAAAA GGCTAGCTACAACGA AAACAAAA	3355
7476	UUUGUUUU A CCUAAUUC	1654	GAAATAGG GGCTAGCTACAACGA AAAACAAA	3356
7480	UUUUACCU A UUUCACAA	1655	TTGTGAAA GGCTAGCTACAACGA AGGTAAAA	3357
7485	CCUAAUUC A CAACUGUG	1656	CACAGTTG GGCTAGCTACAACGA GAAATAGG	3358
7488	AUUUCACA A CUGUGUAA	1657	TTACACAG GGCTAGCTACAACGA TGTGAAAT	3359
7491	UCACAACU G UGUAAAUU	1658	AATTTACA GGCTAGCTACAACGA AGTTGTGA	3360
7493	ACAACUGU G UAAAUUGC	1659	GCAATTTA GGCTAGCTACAACGA ACAGTTGT	3361
7497	CUGUGUAA A UUGCCA AU	1660	ATTGGCAA GGCTAGCTACAACGA TTACACAG	3362

7500	UGUAAAUU G CCAAUAAU	1661	ATTATTGG GGCTAGCTACAACGA AATTTACA	3363
7504	AAUUGCCA A UAAUCCU	1662	AGGAATTA GGCTAGCTACAACGA TGGCAATT	3364
7507	UGCCAAUA A UUCUGUC	1663	GACAGGAA GGCTAGCTACAACGA TATTGGCA	3365
7513	UAAUCCU G UCCAUGAA	1664	TTCATGGA GGCTAGCTACAACGA AGGAATTA	3366
7517	UCCUGUCC A UGAAAUG	1665	CATTTTCA GGCTAGCTACAACGA GGACAGGA	3367
7523	CCAUGAAA A UGCAAUU	1666	AATTTGCA GGCTAGCTACAACGA TTTTCATG	3368
7525	AUGAAAUA G CAAAUUAU	1667	ATAATTGG GGCTAGCTACAACGA ATTTTCAT	3369
7529	AAUUGCAA A UUAUCCAG	1668	CTGGATAA GGCTAGCTACAACGA TTGCATTT	3370
7532	UGCAAAUJ A UCCAGUGU	1669	ACACTGGA GGCTAGCTACAACGA AATTTGCA	3371
7537	AUUAUCCA G UGUAGADA	1670	TATCTACA GGCTAGCTACAACGA TGGATAAT	3372
7539	UAUCCAGU G UAGAUUA	1671	TATATCTA GGCTAGCTACAACGA ACTGGATA	3373
7543	CAGUGUAG A UAUUUUG	1672	CAAATATA GGCTAGCTACAACGA CTACACTG	3374
7545	GUGUAGAU A UAUUGAC	1673	GTCAAATA GGCTAGCTACAACGA ATCTACAC	3375
7547	GUAGAUU A UUUGACCA	1674	TGGTCAAA GGCTAGCTACAACGA ATATCTAC	3376
7552	UAUUAUUG A CCAUCACC	1675	GGTGTATG GGCTAGCTACAACGA CAAATATA	3377
7555	AUUUGACC A UCACCCUA	1676	TAGGGTGA GGCTAGCTACAACGA GGTCAAAT	3378
7558	UGACCAUC A CCCUAGG	1677	CCATAGGG GGCTAGCTACAACGA GATGGTCA	3379
7563	AUCACCCU A UGGAUUAU	1678	AATATCCA GGCTAGCTACAACGA AGGGTGAT	3380
7567	CCCUAUGG A UAUUGGU	1679	AGCCAATA GGCTAGCTACAACGA CCATAGGG	3381
7569	CUAUGGAU A UUGGCUAG	1680	CTAGCCAA GGCTAGCTACAACGA ATCCATAG	3382
7573	GGAUUUG G CUAGUUU	1681	AAAAC TAG GGCTAGCTACAACGA CAATATCC	3383
7577	AUUGGCUA G UUUUGCCU	1682	AGGCCAAA GGCTAGCTACAACGA TAGCCAAT	3384
7582	CUAGUUU G CCUUUAU	1683	AATAAAGG GGCTAGCTACAACGA AAAACTAG	3385
7588	UUGCCUUU A UUAAGCAA	1684	TTGCTTAA GGCTAGCTACAACGA AAAGGCAA	3386
7593	UUUAUUAA G CAAAUUCA	1685	TGAATTGG GGCTAGCTACAACGA TTAATAAA	3387
7597	UUAAGCAA A UUCAUUC	1686	GAAATGAA GGCTAGCTACAACGA TTGCTTAA	3388
7601	GCAAAUUC A UUUCAGCC	1687	GGCTGAAA GGCTAGCTACAACGA GAATTTGC	3389
7607	UCAUUUCA G CCUGAAUG	1688	CATTCAGG GGCTAGCTACAACGA TGAATGTA	3390
7613	CAGCCUGA A UGUCUGCC	1689	GGCAGACA GGCTAGCTACAACGA TCAGGCTG	3391
7615	GCCUGAAU G UCUGCCUA	1690	TAGGCAGA GGCTAGCTACAACGA ATTCAGGC	3392
7619	GAAUGUCU G CCUAUAUA	1691	TATATAGG GGCTAGCTACAACGA AGACATTC	3393
7623	GUCUGCCU A UAUUUUCU	1692	AGAATATA GGCTAGCTACAACGA AGGCAGAC	3394
7625	CUGCCUAU A UAUUCUCU	1693	AGAGAATA GGCTAGCTACAACGA ATAGGCAG	3395
7627	GCCUAUAU A UUCUCUGC	1694	GCAGAGAA GGCTAGCTACAACGA ATATAGGC	3396
7634	UAUUCUCU G CUCUUUGU	1695	ACAAAGAG GGCTAGCTACAACGA AGAGAATA	3397
7641	UGCUCUUU G UAUUCUCC	1696	GGAGAATA GGCTAGCTACAACGA AAAGAGCA	3398
7643	CUCUUUGU A UUCUCCU	1697	AAGGAGAA GGCTAGCTACAACGA ACAAAGAG	3399
7655	UCCUUUGA A CCCGUUAA	1698	TTAACGGG GGCTAGCTACAACGA TCAAAGGA	3400
7659	UUGAACCC G UUAACA	1699	TGTTTAA GGCTAGCTACAACGA GGGTTCAA	3401
7665	CCGUUAAA A CAUCCUGU	1700	ACAGGATG GGCTAGCTACAACGA TTTAACGG	3402
7667	GUUAAAAC A UCCUGUGG	1701	CCACAGGA GGCTAGCTACAACGA GTTTTAAC	3403
7672	AACAUCU G UGGCACUC	1702	GAGTGCCA GGCTAGCTACAACGA AGGATGTT	3404

Input Sequence = HSFLT. Cut Site = R/Y

Arm Length = 8. Core Sequence = GGCTAGCTACAACGA

HSFLT (Human flt mRNA for receptor-related tyrosine kinase.; Acc# X51602; 7680 bp)

Table VI: Human KDR DNzyme and Substrate sequence

Pos	Substrate	Seq ID No	DNzyme	Seq ID No
14	GUCCCGGG A CCCCGGA	3405	TCCCGGGG GGCTAGCTACAACGA CCCGGGAC	4691
25	CCGGGAGA G CGGUCAGU	3406	ACTGACCG GGCTAGCTACAACGA TCTCCCGG	4692
28	GGAGAGCG G UCAGUGUG	3407	CACACTGA GGCTAGCTACAACGA CGCTCTCC	4693
32	AGCGGUCA G UGUGUGGU	3408	ACCACACA GGCTAGCTACAACGA TGACCGCT	4694
34	CGGUCAGU G UGUGGUCG	3409	CGACCACA GGCTAGCTACAACGA ACTGACCG	4695
36	GUCAGUGU G UGGUCGCU	3410	AGCGACCA GGCTAGCTACAACGA AACTGAC	4696
39	AGUGUGUG G UCGCUGCG	3411	CGCAGCGA GGCTAGCTACAACGA CACACACT	4697
42	GUGUGGUC G CUGCGUUU	3412	AAACGCAG GGCTAGCTACAACGA GACCACAC	4698
45	UGGUCGCU G CGUUUCCU	3413	AGGAAACG GGCTAGCTACAACGA AGCGACCA	4699
47	GUCGCGCG G UUUCUCU	3414	AGAGGAAA GGCTAGCTACAACGA GCAGCGAC	4700
56	UUUCUCU G CCUGCGCC	3415	GGCGCAGG GGCTAGCTACAACGA AGAGGAAA	4701
60	CUCUGCCU G CGCCGGGC	3416	GCCCGCGG GGCTAGCTACAACGA AGGCAGAG	4702
62	CUGCCUGC G CCGGGCAU	3417	ATGCCCGG GGCTAGCTACAACGA GCAGGCAG	4703
67	UGCGCCGG G CAUCACUU	3418	AAGTGATG GGCTAGCTACAACGA CCGGCGCG	4704
69	CGCCGGGC A UCACUUGC	3419	GCAAGTGA GGCTAGCTACAACGA GCCCGGCG	4705
72	CGGGCAUC A CUUGCGCG	3420	CGCGCAAG GGCTAGCTACAACGA GATGCCCG	4706
76	AUCACUU G CGCGCCG	3421	GCGGCGCG GGCTAGCTACAACGA AAGTGATG	4707
78	UCACUUGC G CGCCGAG	3422	CTGCGCGG GGCTAGCTACAACGA GCAAGTGA	4708
80	ACUUGCGC G CCGCAGAA	3423	TTCTGCGG GGCTAGCTACAACGA GCGCAAGT	4709
83	UGCGCGCC G CAGAAAGU	3424	ACTTCTG GGCTAGCTACAACGA GCGCGCA	4710
90	CGCAGAAA G UCCGUCUG	3425	CAGACGGA GGCTAGCTACAACGA TTTCTGCG	4711
94	GAAAGUCC G UCUGGCAG	3426	CTGCCAGA GGCTAGCTACAACGA GGAATTTC	4712
99	UCCGUCUG G CAGCCUGG	3427	CCAGGCTG GGCTAGCTACAACGA CAGACGGA	4713
102	GUCUGGCA G CCUGGAUA	3428	TATCCAGG GGCTAGCTACAACGA TGCCAGAC	4714
108	CAGCCUGG A UAUCUCU	3429	AGAGGATA GGCTAGCTACAACGA CCAGGCTG	4715
110	GCCUGGAU A UCCUCUCC	3430	GGAGAGGA GGCTAGCTACAACGA ATCCAGGC	4716
120	CCUCUCCU A CCGGCACC	3431	GGTGCCGG GGCTAGCTACAACGA AGGAGAGG	4717
124	UCCUACCG G CACCCGCA	3432	TGCGGGTG GGCTAGCTACAACGA CGGTAGGA	4718
126	CUACCGGC A CCCGAGA	3433	TCTGCGGG GGCTAGCTACAACGA GCCGGTAG	4719
130	CGGCACCC G CAGACGCC	3434	GGCGTCTG GGCTAGCTACAACGA GGGTGCCG	4720
134	ACCCGAG A CGCCCUUG	3435	CAGGGGCG GGCTAGCTACAACGA CTGCGGGT	4721
136	CCGCAGAC G CCCUGCA	3436	TGCAGGGG GGCTAGCTACAACGA GTCTGCGG	4722
142	ACGCCCU G CAGCCGCC	3437	GGCGGCTG GGCTAGCTACAACGA AGGGGCGT	4723
145	CCCCUGCA G CCGCCGCU	3438	ACCGGCGG GGCTAGCTACAACGA TGCAGGGG	4724
148	CUGCAGCC G CCGGUCGG	3439	CCGACCGG GGCTAGCTACAACGA GGCTGCAG	4725
152	AGCCGCGG G UCGGCGCC	3440	GGCGCCGA GGCTAGCTACAACGA CGGCGGCT	4726
156	GCCGUGCG G CGCCCGGG	3441	CCCGGGCG GGCTAGCTACAACGA CGACCGGC	4727
158	CGGUCGGC G CCCGGGCU	3442	AGCCCGGG GGCTAGCTACAACGA GCCGACCG	4728
164	GCGCCCGG G CUCCCUAG	3443	CTAGGGAG GGCTAGCTACAACGA CCGGGCGC	4729
172	GTUCCCUA G CCCUGUC	3444	GCACAGGG GGCTAGCTACAACGA TAGGGAGC	4730
177	CUAGCCCU G UGCGCUCA	3445	TGAGCGCA GGCTAGCTACAACGA AGGGCTAG	4731
179	AGCCUGU G CGCUAAC	3446	GTGAGCG GGCTAGCTACAACGA ACAGGGCT	4732
181	CCUGUGC G CUCAACUG	3447	CAGTTGAG GGCTAGCTACAACGA GCACAGGG	4733
186	UGCGCUCA A CUGUCCUG	3448	CAGGACAG GGCTAGCTACAACGA TGAGCGCA	4734
189	GUCAACU G UCCUGCGC	3449	GCGCAGGA GGCTAGCTACAACGA AGTTGAGC	4735
194	ACUGUCCU G CGCUGCGG	3450	CCGCAGCG GGCTAGCTACAACGA AGGACAGT	4736
196	UGUCCUGC G CUGCGGGG	3451	CCCCGCAG GGCTAGCTACAACGA GCAGGACA	4737
199	CCUGCGCU G CGGGGUGC	3452	GCACCCCG GGCTAGCTACAACGA AGCGCAGG	4738
204	GUUGCGGG G UGCCGCGA	3453	TCGCGGCA GGCTAGCTACAACGA CCCGCGAC	4739

206	UGCGGGGU G CCGCGAGU	3454	ACTCGCGG GGCTAGCTACAACGA ACCCGGCA	4740
209	GGGGUGCC G CGAGUUC	3455	GGAACCTG GGCTAGCTACAACGA GGCACCCC	4741
213	UGCCGCGA G UCCACCU	3456	AGGTGGAA GGCTAGCTACAACGA TCGCGGCA	4742
218	CGAGUUC A CCUCCGG	3457	CGCGGAGG GGCTAGCTACAACGA GGAACCTG	4743
224	CCACCUCC G CGCCUCCU	3458	AGGAGGCG GGCTAGCTACAACGA GGAGGTGG	4744
226	ACCUCGCG G CCUCCUUC	3459	GAAGGAGG GGCTAGCTACAACGA GCGGAGGT	4745
240	UUCUCUAG A CAGGCGCU	3460	AGCGCCTG GGCTAGCTACAACGA CTAGAGAA	4746
244	CUAGACAG G CGCUGGA	3461	TCCACGCG GGCTAGCTACAACGA CTGTCTAG	4747
246	AGACAGGC G CUGGGAGA	3462	TCTCCAGG GGCTAGCTACAACGA GCCTGTCT	4748
259	GAGAAAG A CCGGCUCC	3463	GGAGCCGG GGCTAGCTACAACGA TCTTTCTC	4749
263	AAGAACC G CUCCCGAG	3464	CTCGGGAG GGCTAGCTACAACGA CGGTCTCT	4750
271	GCUCCGA G UUCUGGGC	3465	GCCAGAA GGCTAGCTACAACGA TCGGGAGC	4751
278	AGUUCUGG G CAUUCGCG	3466	GCGAAATG GGCTAGCTACAACGA CCAGAACT	4752
280	UUCUGGG G UUUCGCCC	3467	GGCGGAAA GGCTAGCTACAACGA GCCCAGAA	4753
285	GGCAUUC G CCGGCGUC	3468	GAGCCGGG GGCTAGCTACAACGA GAAATGCC	4754
290	UUCGCCCC G CUCGAGGU	3469	ACCTCGAG GGCTAGCTACAACGA CGGGCGAA	4755
297	GGCUCGAG G UGCAGGAU	3470	ATCCTGCA GGCTAGCTACAACGA CTCGAGCC	4756
299	CUCGAGGU G CAGGAUGC	3471	GCATCTTG GGCTAGCTACAACGA ACCTCGAG	4757
304	GGUGCAGG A UGCAGAGC	3472	GCTCTGCA GGCTAGCTACAACGA CCTGCACC	4758
306	UGCAGGAU G CAGAGCAA	3473	TTGCTCTG GGCTAGCTACAACGA ATCCTGCA	4759
311	GAUGCAGA G CAAGGUGC	3474	GCACCTTG GGCTAGCTACAACGA TCTGCATC	4760
316	AGAGCAAG G UGCUGCUG	3475	CAGCAGCA GGCTAGCTACAACGA CTGTCTCT	4761
318	AGCAAGGU G CUGCUGGC	3476	GCCAGCAG GGCTAGCTACAACGA ACCTTGCT	4762
321	AAGGUGCU G CUGGCCGU	3477	ACGGCCAG GGCTAGCTACAACGA AGCACCTT	4763
325	UGCUGCUG G CCGUCGCC	3478	GGCGACGG GGCTAGCTACAACGA CAGCAGCA	4764
328	UGCUGGCC G UCGCCUG	3479	CAGGGCGA GGCTAGCTACAACGA GGCCAGCA	4765
331	UGGCCGUC G CCCUGUGG	3480	CCACAGGG GGCTAGCTACAACGA GACGGCCA	4766
336	GUCGCCCU G UGGCUCUG	3481	CAGAGCCA GGCTAGCTACAACGA AGGGCGAC	4767
339	GCCUCUG G CUCUGCGU	3482	ACGCAGAG GGCTAGCTACAACGA CACAGGGC	4768
344	GUGGUCUG G CGUGGAGA	3483	TCTCCACG GGCTAGCTACAACGA AGAGCCAC	4769
346	GGCUCUGC G UGGAGACC	3484	GGTCTCCA GGCTAGCTACAACGA GCAGAGCC	4770
352	GCGUGGAG A CCCGGGCC	3485	GGCCCGGG GGCTAGCTACAACGA CTCCACGC	4771
358	AGACCCGG G CCGCCUCU	3486	AGAGGCGG GGCTAGCTACAACGA CCGGGTCT	4772
361	CCCGGGCC G CCUCUGUG	3487	CACAGAGG GGCTAGCTACAACGA GGCCCGGG	4773
367	CCGCCUCU G UGGGUUUG	3488	CAAACCCA GGCTAGCTACAACGA AGAGGCGG	4774
371	CUCUGUGG G UUUGCCUA	3489	TAGGCAAA GGCTAGCTACAACGA CCACAGAG	4775
375	GUGGGUUU G CCUAGUGU	3490	ACACTAGG GGCTAGCTACAACGA AAACCCAC	4776
380	UUUGCCUA G UGUUUCUC	3491	GAGAAACA GGCTAGCTACAACGA TAGGCAAA	4777
382	UGCCUAGU G UUUCUCUU	3492	AAGAGAAA GGCTAGCTACAACGA ACTAGGCA	4778
392	UUCUCUUG A UCUGCCCA	3493	TGGGCAGA GGCTAGCTACAACGA CAAGAGAA	4779
396	CUUGAUUC G CCCAGGCU	3494	AGCCTGGG GGCTAGCTACAACGA AGATCAAG	4780
402	CUGCCCAG G CUCAGCAU	3495	ATGCTGAG GGCTAGCTACAACGA CTGGGCAG	4781
407	CAGGCUCA G CAUACAAA	3496	TTTGTATG GGCTAGCTACAACGA TGAGCCTG	4782
409	GGCUCAGC A UACAAAAA	3497	TTTTTGTG GGCTAGCTACAACGA GCTGAGCC	4783
411	CUCAGCAU A CAAAAAGA	3498	TCTTTTGT GGCTAGCTACAACGA ATGCTGAG	4784
419	ACAAAAAG A CAUACUUA	3499	TAAGTATG GGCTAGCTACAACGA CTTTTTGT	4785
421	AAAAAGAC A UACUUAUA	3500	TGTAAGTA GGCTAGCTACAACGA GTCTTTT	4786
423	AAAGACAU A CUUACAUA	3501	ATTGTAAG GGCTAGCTACAACGA ATGTCTTT	4787
427	ACAUACUU A CAUUAAG	3502	CTTAATTG GGCTAGCTACAACGA AGTATGTT	4788
430	UACUUACA A UUAAGGCU	3503	AGCCTTAA GGCTAGCTACAACGA TGTAAGTA	4789
436	CRAUUAAG G CUAAUACA	3504	TGTATTAG GGCTAGCTACAACGA CTTAATTG	4790
440	UAAGGCUA A UACAACUC	3505	GAGTTGTA GGCTAGCTACAACGA TAGCCTTA	4791
442	AGGCUAUA A CAACUCUU	3506	AAGAGTTG GGCTAGCTACAACGA ATTAGCCT	4792

445	CUAUACA A CUCUCAA	3507	TTGAAGAG GGCTAGCTACAACGA TGTATTAG	4793
454	CUCUCAA A UUACUUGC	3508	GCAAGTAA GGCTAGCTACAACGA TTGAAGAG	4794
457	UUCAAAU A CUUGCAGG	3509	CCTGCAAG GGCTAGCTACAACGA AATTTGAA	4795
461	AAUUAUU G CAGGGGAC	3510	GTCCCTG GGCTAGCTACAACGA AAGTAATT	4796
468	UGCAGGGG A CAGAGGGA	3511	TCCCTCTG GGCTAGCTACAACGA CCCCTGCA	4797
476	ACAGAGGG A CUUGGACU	3512	AGTCCAAG GGCTAGCTACAACGA CCCTCTGT	4798
482	GGACUUGG A CUGGCUUU	3513	AAAGCCAG GGCTAGCTACAACGA CCAAGTCC	4799
486	UUGGACUG G CUUUGGCC	3514	GGCCAAAG GGCTAGCTACAACGA CAGTCCAA	4800
492	UGGCUUUG G CCCAAUAA	3515	TTATTGGG GGCTAGCTACAACGA CAAAGCCA	4801
497	UUGGCCCA A UAAUCAGA	3516	TCTGATTA GGCTAGCTACAACGA TGGGCCAA	4802
500	GCCCAAUA A UCAGAGUG	3517	CACCTCTG GGCTAGCTACAACGA TATTGGGC	4803
506	UAAUCAGA G UGGCAGUG	3518	CACCTGCA GGCTAGCTACAACGA TCTGATTA	4804
509	UCAGAGUG G CAGUGAGC	3519	GCTCACTG GGCTAGCTACAACGA CACTCTGA	4805
512	GAGUGGCA G UGAGCAAA	3520	TTTGCTCA GGCTAGCTACAACGA TGCCACTC	4806
516	GGCAGUGA G CAAAGGGU	3521	ACCCTTTG GGCTAGCTACAACGA TCACTGCC	4807
523	AGCAAAGG G UGAGGUG	3522	CACCTCCA GGCTAGCTACAACGA CCTTTGCT	4808
529	GGGUGGAG G UGACUGAG	3523	CTCAGTCA GGCTAGCTACAACGA CTCCACCC	4809
532	UGGAGGUG A CUGAGUGC	3524	GCACTCAG GGCTAGCTACAACGA CACCTCCA	4810
537	GUGACUGA G UGCAGCGA	3525	TCGCTGCA GGCTAGCTACAACGA TCAGTCAC	4811
539	GACUGAGU G CAGCGAUG	3526	CATCGCTG GGCTAGCTACAACGA ACTCAGTC	4812
542	UGAGUGCA G CGAUGGCC	3527	GGCCATCG GGCTAGCTACAACGA TGCACTCA	4813
545	GUGCAGCG A UGGCCUCU	3528	AGAGGCCA GGCTAGCTACAACGA CGCTGCAC	4814
548	CAGCGAUG G CCUCUUCU	3529	AGAAGAGG GGCTAGCTACAACGA CATCGCTG	4815
557	CCUCUUCU G UAAGACAC	3530	GTGTCTTA GGCTAGCTACAACGA AGAAGAGG	4816
562	UCUGUAAG A CACUCACA	3531	TGTAGATG GGCTAGCTACAACGA CTTACAGA	4817
564	UGUAAGAC A CUCACAAU	3532	ATTGTGAG GGCTAGCTACAACGA GTCTTACA	4818
568	AGACACUC A CAAUCCA	3533	TGGAATTG GGCTAGCTACAACGA GAGTGTCT	4819
571	CACUCACA A UUCCAAA	3534	TTTGGGAA GGCTAGCTACAACGA TGTAGTGT	4820
580	UUCCAAA G UGAUCGGA	3535	TCCGATCA GGCTAGCTACAACGA TTTTGGAA	4821
583	CAAAAGUG A UCGGAAAU	3536	ATTTCGGA GGCTAGCTACAACGA CACTTTTG	4822
590	GAUCGGAA A UGACACUG	3537	CAGTGTCA GGCTAGCTACAACGA TTCCGATC	4823
593	CGAAADG A CACUGGAG	3538	CTCCAGTG GGCTAGCTACAACGA CATTTCG	4824
595	GAAUAGAC A CUGGAGCC	3539	GGCTCCAG GGCTAGCTACAACGA GTCATTTC	4825
601	ACACUGGA G CCUACAAG	3540	CTGTAGG GGCTAGCTACAACGA TCCAGTGT	4826
605	UGGAGCCU A CAAGUGCU	3541	AGCACTTG GGCTAGCTACAACGA AGGCTCCA	4827
609	GCCUACAA G UGCUUCUA	3542	TAGAAGCA GGCTAGCTACAACGA TTGTAGGC	4828
611	CUACAAGU G CUUCUACC	3543	GGTAGAAG GGCTAGCTACAACGA ACTTGTAG	4829
617	GUGCUUCU A CCGGAAA	3544	TTTCCCGG GGCTAGCTACAACGA AGAAGCAC	4830
625	ACCGGGAA A CUGACUUG	3545	CAAGTCAG GGCTAGCTACAACGA TTCCCGGT	4831
629	GGAAACUG A CUUGGCCU	3546	AGGCCAAG GGCTAGCTACAACGA CAGTTTCC	4832
634	CUGACUUG G CCUCGUC	3547	GACCGAGG GGCTAGCTACAACGA CAAGTCAG	4833
640	UGGCCUCG G UCAUUUAU	3548	ATAAATGA GGCTAGCTACAACGA CGAGGCCA	4834
643	CCUCGGUC A UUAUUGUC	3549	GACATAAA GGCTAGCTACAACGA GACCGAGG	4835
647	GGUCAUUU A UGUUAUG	3550	CATAGACA GGCTAGCTACAACGA AAATGACC	4836
649	UCAUUUAU G UCUAUGUU	3551	AACATAGA GGCTAGCTACAACGA ATAAATGA	4837
653	UUUUGUCU A UGUUCAAG	3552	CTTGAACA GGCTAGCTACAACGA AGACATAA	4838
655	AUGUCUAU G UUCAAGAU	3553	ATCTTGAA GGCTAGCTACAACGA ATAGACAT	4839
662	UGUUAAG A UUACAGAU	3554	ATCTGTAA GGCTAGCTACAACGA CTTGAACA	4840
665	UCAAGAUU A CAGAUUC	3555	GAGATCTG GGCTAGCTACAACGA AATCTTGA	4841
669	GAUUACAG A UCUCUAU	3556	AATGGAGA GGCTAGCTACAACGA CTGTAATC	4842
675	AGAUCUCC A UUAUUGC	3557	GCAATAAA GGCTAGCTACAACGA GGAGATCT	4843
679	CUCCAUUU A UUGCUUCU	3558	AGAAGCAA GGCTAGCTACAACGA AAATGGAG	4844
682	CAUUUAUU G CUUCUGUU	3559	AACAGAAG GGCTAGCTACAACGA AATAAATG	4845

688	UUGCUCU G UUAGUGAC	3560	GTCATAA GGCTAGCTACAACGA AGAAGCAA	4846
692	UUCUGUUA G UGACCAAC	3561	GTTGGTCA GGCTAGCTACAACGA TAACAGAA	4847
695	UGUUGUG A CCAACAUG	3562	CATGTTGG GGCTAGCTACAACGA CACTAACA	4848
699	AGUGACCA A CAUGGAGU	3563	ACTCCATG GGCTAGCTACAACGA TGGTCACT	4849
701	UGACCAAC A UGGAGUCG	3564	CGACTCCA GGCTAGCTACAACGA GTTGGTCA	4850
706	AACAUGGA G UCGUGUAC	3565	GTACACGA GGCTAGCTACAACGA TCCATGTT	4851
709	AUGGAGUC G UGUACAUU	3566	AATGTACA GGCTAGCTACAACGA GACTCCAT	4852
711	GGAGUCGU G UACAUUAC	3567	GTAATGTA GGCTAGCTACAACGA ACGACTCC	4853
713	AGUCGUGU A CAUACUG	3568	CAGTAATG GGCTAGCTACAACGA ACACGACT	4854
715	UCGUGUAC A UUACUGAG	3569	CTCAGTAA GGCTAGCTACAACGA GTACACGA	4855
718	UGUACAUU A CUGAGAAC	3570	GTTCTCAG GGCTAGCTACAACGA AATGTACA	4856
725	UACUGAGA A CAAAAACA	3571	TGTTTTTG GGCTAGCTACAACGA TCTCAGTA	4857
731	GAACAAA A CAAACUG	3572	CAGTTTTG GGCTAGCTACAACGA TTTGTTTC	4858
736	AAAACAAA A CUGUGGUG	3573	CACCACAG GGCTAGCTACAACGA TTTGTTTT	4859
739	ACAAAACU G UGGUGAUU	3574	AATCACCA GGCTAGCTACAACGA AGTTTGT	4860
742	AAACUGUG G UGAUCCA	3575	TGGAATCA GGCTAGCTACAACGA CACAGTTT	4861
745	CUGUGGUG A UUCCAUGU	3576	ACATGGAA GGCTAGCTACAACGA CACCACAG	4862
750	GUGAUUCC A UGUCUGG	3577	CCGAGACA GGCTAGCTACAACGA GGAATCAC	4863
752	GAUUCUCC A UCUCGGU	3578	ACCCGAGA GGCTAGCTACAACGA ATGGAATC	4864
759	UGUCUGG G UCCAUUUC	3579	GAAATGGA GGCTAGCTACAACGA CCGAGACA	4865
763	UCGGGUCC A UUUCAAU	3580	ATTGAAA GGCTAGCTACAACGA GGACCCGA	4866
770	CAUUUCA A UCUCACG	3581	CGTTGAGA GGCTAGCTACAACGA TTGAAATG	4867
776	AAAUUCA A CGUGUCAC	3582	GTGACACG GGCTAGCTACAACGA TGAGATTT	4868
778	AUCUCAAC G UGUACAUU	3583	AAGTGACA GGCTAGCTACAACGA GTTGAGAT	4869
780	CUCAACGU G UCAUUUG	3584	CAAAGTGA GGCTAGCTACAACGA ACGTTGAG	4870
783	AACGUGUC A CUUGUGC	3585	GCACAAAG GGCTAGCTACAACGA GACACGTT	4871
788	GUCACUUU G UGCAAGAU	3586	ATCTTGCA GGCTAGCTACAACGA AAAGTGAC	4872
790	CACUUUGU G CAAGAUAC	3587	GTATCTTG GGCTAGCTACAACGA ACAAGTG	4873
795	UGUGCAAG A UACCCAGA	3588	TCTGGGTA GGCTAGCTACAACGA CTGACACA	4874
797	UGCAAGAU A CCCAGAAA	3589	TTTCTGGG GGCTAGCTACAACGA ATCTTGCA	4875
810	GAAAAGAG A UUUGUCC	3590	GGAACAAA GGCTAGCTACAACGA CTCTTTTC	4876
814	AGAGAUUU G UUCUGAU	3591	ATCAGGAA GGCTAGCTACAACGA AAATCTCT	4877
821	UGUCCUG A UGUUACA	3592	TGTTACCA GGCTAGCTACAACGA CAGGAACA	4878
824	UCCUGAUG G UAACAGAA	3593	TTCTGTTA GGCTAGCTACAACGA CATCAGGA	4879
827	UGAUGGUA A CAGAAUUU	3594	AAATTCTG GGCTAGCTACAACGA TACCATCA	4880
832	GUAACAGA A UUCCUGG	3595	CCAGGAAA GGCTAGCTACAACGA TCTGTTAC	4881
842	UUCCUGGG A CAGCAAGA	3596	TCTTGCTG GGCTAGCTACAACGA CCCAGGAA	4882
845	CUGGGACA G CAAGAAGG	3597	CCTTCTTG GGCTAGCTACAACGA TGTCCAG	4883
854	CAAGAAGG G CUUACUA	3598	TAGTAAAG GGCTAGCTACAACGA CCTTCTTG	4884
859	AGGGCUUU A CUUUCUCC	3599	GGGAATAG GGCTAGCTACAACGA AAAGCCCT	4885
862	GUUUUACU A UUCCAGC	3600	GCTGGGAA GGCTAGCTACAACGA AGTAAAGC	4886
869	UAUUCUCC A CUACUGA	3601	TCATGTAG GGCTAGCTACAACGA TGGGAATA	4887
872	UCCAGCU A CAUGAUA	3602	TGATCATG GGCTAGCTACAACGA AGCTGGGA	4888
874	CCAGCUAC A UGAUCAGC	3603	GCTGTACA GGCTAGCTACAACGA GTAGCTGG	4889
877	GCUACAU A UCAGCUAU	3604	ATAGCTGA GGCTAGCTACAACGA CATGTAGC	4890
881	CAUGAUA G CUAGCUG	3605	CAGCATAG GGCTAGCTACAACGA TGATCATG	4891
884	GAUCAGCU A UGUGGCA	3606	TGCCAGCA GGCTAGCTACAACGA AGCTGATC	4892
886	UCAGCUAU G CUGGCAUG	3607	CATGCCAG GGCTAGCTACAACGA ATAGCTGA	4893
890	CUAUGCUG G CAUGGUCU	3608	AGACCATG GGCTAGCTACAACGA CAGCATAG	4894
892	AUGCUGGC A UGGUCUUC	3609	GAAGACCA GGCTAGCTACAACGA GCCAGCAT	4895
895	CUGGCAUG G UCUUCUGU	3610	ACAGAGAA GGCTAGCTACAACGA CATGCCAG	4896
902	GGUCUUCU G UGAAGCAA	3611	TTGCTTCA GGCTAGCTACAACGA AGAAGACC	4897
907	UCUGUGAA G CAAAAAU	3612	AATTTTTG GGCTAGCTACAACGA TTCACAGA	4898



913	AAGCAAAA A UUAUAGAU	3613	ATCATTA A GGCTAGCTACAACGA TTTTGCTT	4899
917	AAAAAUUA A UGAUGAAA	3614	TTTCATCA GGCTAGCTACAACGA TAATTTT	4900
920	AAUUAUUG A UGAAAGUU	3615	AACTTTCA GGCTAGCTACAACGA CATTAATT	4901
926	UGAUGAAA G UUACCAU	3616	ACTGGTAA GGCTAGCTACAACGA TTTCATCA	4902
929	UGAAAGUU A CCAGUCUA	3617	TAGACTGG GGCTAGCTACAACGA AACTTTCA	4903
933	AGUUAACA G UCUAUUUA	3618	ATAATAGA GGCTAGCTACAACGA TGGTAACT	4904
937	ACCAGUCU A UUAUGUAC	3619	GTACATAA GGCTAGCTACAACGA AGACTGGT	4905
940	AGUCUAUU A UGUACAUA	3620	TATGTACA GGCTAGCTACAACGA AATAGACT	4906
942	UCUAUUUA G UACAUAGU	3621	ACTATGTA GGCTAGCTACAACGA ATAATAGA	4907
944	UAUUAUGU A CAUAGUUG	3622	CAACTATG GGCTAGCTACAACGA ACATAATA	4908
946	UUAUGUAC A UAGUUGUC	3623	GACAACTA GGCTAGCTACAACGA GTACATAA	4909
949	UGUACAUA G UUGUCGUU	3624	AACGACAA GGCTAGCTACAACGA TATGTACA	4910
952	ACAUAGUU G UCGUUGUA	3625	TACAACGA GGCTAGCTACAACGA AACTATGT	4911
955	UAGUUGUC G UUGUAGGG	3626	CCCTACAA GGCTAGCTACAACGA GACAACTA	4912
958	UUGUCGUU G UAGGGUUA	3627	ATACCCTA GGCTAGCTACAACGA AACGACAA	4913
963	GUUGUAGG G UAUAGGAU	3628	ATCCTATA GGCTAGCTACAACGA CCTACAAC	4914
965	UGUAGGGU A UAGGAUUU	3629	AAATCCTA GGCTAGCTACAACGA ACCCTACA	4915
970	GGUAUAGG A UUAUAGAU	3630	ATCATAAA GGCTAGCTACAACGA CCTATACC	4916
974	UAGGAUUU A UGAUGUGG	3631	CCACATCA GGCTAGCTACAACGA AAATCCTA	4917
977	GAUUUAUG A UGUGGUUC	3632	GAACCACA GGCTAGCTACAACGA CATAAATC	4918
979	UUUAUGAU G UGUUCUGG	3633	CAGAACCA GGCTAGCTACAACGA ATCATAAA	4919
982	AUGAUGUG G UUCUGAGU	3634	ACTCAGAA GGCTAGCTACAACGA CACATCAT	4920
989	GGUUCUGA G UCCGUCUC	3635	GAGACGGA GGCTAGCTACAACGA TCAGAACC	4921
993	CUGAGUCC G UCUCAUUG	3636	CCATGAGA GGCTAGCTACAACGA GGACTCAG	4922
998	UCCGUCUC A UGGAUUUG	3637	CAATTCCA GGCTAGCTACAACGA GAGACGGA	4923
1003	CUCAUUGA A UUGAACUA	3638	TAGTTCAA GGCTAGCTACAACGA TCCATGAG	4924
1008	GGAAUUGA A CUUUCUGU	3639	ACAGATAG GGCTAGCTACAACGA TCAATTCC	4925
1011	AUUGAACU A UCUGUUGG	3640	CCAACAGA GGCTAGCTACAACGA AGTTCAAT	4926
1015	AACUAUCU G UUGGAGAA	3641	TTCTCCAA GGCTAGCTACAACGA AGATAGTT	4927
1026	GGAGAAAA G CUUGUCUU	3642	AAGACAAG GGCTAGCTACAACGA TTTTCTCC	4928
1030	AAAAGCUU G UCUAUAAU	3643	ATTTAAGA GGCTAGCTACAACGA AAGCTTTT	4929
1037	UGUCUUA A UUGUACAG	3644	CTGTACAA GGCTAGCTACAACGA TTAAGACA	4930
1040	CUUAAAUU G UACAGCAA	3645	TTGCTGTA GGCTAGCTACAACGA AATTTAAG	4931
1042	UAAAUUGU A CAGCAAGA	3646	TCTTGCTG GGCTAGCTACAACGA ACAATTTA	4932
1045	AUUGUACA G CAAGAACU	3647	AGTTCTTG GGCTAGCTACAACGA TGTACAAT	4933
1051	CAGCAAGA A CUGAACUA	3648	TAGTTCAG GGCTAGCTACAACGA TCCTGCTG	4934
1056	AGAACUGA A CUAAUUGU	3649	ACATTTAG GGCTAGCTACAACGA TCAGTTCT	4935
1061	UGAACUAA A UGUGGGGA	3650	TCCCCACA GGCTAGCTACAACGA TTAGTTCA	4936
1063	AACUAAAU G UGGGGAUU	3651	AATCCCCA GGCTAGCTACAACGA ATTTAGTT	4937
1069	AUGUGGGG A UUGACUUC	3652	GAAGTCAA GGCTAGCTACAACGA CCCCACAT	4938
1073	GGGGAUUG A CUUCAACU	3653	AGTTGAAG GGCTAGCTACAACGA CAATCCCC	4939
1079	UGACUUCA A CUGGGAAU	3654	ATTCCCAG GGCTAGCTACAACGA TGAAGTCA	4940
1086	AACUGGGA A UACCCUUC	3655	GAAGGGTA GGCTAGCTACAACGA TCCCAGTT	4941
1088	CUGGGAAU A CCCUUCUU	3656	AAGAAGGG GGCTAGCTACAACGA ATTCCCAG	4942
1101	UCUUCGAA G CAUCAGCA	3657	TGCTGATG GGCTAGCTACAACGA TTCGAAGA	4943
1103	UUCGAAGC A UCAGCAUA	3658	TATGCTGA GGCTAGCTACAACGA GCTTCGAA	4944
1107	AAGCAUCA G CAUAAGAA	3659	TTCTTATG GGCTAGCTACAACGA TGATGCTT	4945
1109	GCAUCAGC A UAAGAAAC	3660	GTTTCTTA GGCTAGCTACAACGA GCTGATGC	4946
1116	CAUAAGAA A CUUGUAAA	3661	TTTACAAG GGCTAGCTACAACGA TTCTTATG	4947
1120	AGAAACUU G UAAACCGA	3662	TCGGTTTA GGCTAGCTACAACGA AAGTTTCT	4948
1124	ACUUGUAA A CCGAGACC	3663	GGTCTCGG GGCTAGCTACAACGA TTACAAGT	4949
1130	AAACCGAG A CCUAAAAA	3664	TTTTTAGG GGCTAGCTACAACGA CTCGGTTT	4950
1138	ACCUAAAA A CCCAGUCU	3665	AGACTGGG GGCTAGCTACAACGA TTTTAGGT	4951

1143	AAAACCCA G UCUGGGAG	3666	CTCCCAGA GGCTAGCTACAACGA TGGGTTTT	4952
1151	GUCUGGGA G UGAGAUGA	3667	TCATCTCA GGCTAGCTACAACGA TCCCAGAC	4953
1156	GGAGUGAG A UGAAGAAA	3668	TTCTTTCA GGCTAGCTACAACGA CTCCTCC	4954
1164	AUGAAGAA A UUUUUGAG	3669	CTCAAAAA GGCTAGCTACAACGA TTCTTCAT	4955
1172	AUUUUGA G CACCUUAA	3670	TTAAGGTG GGCTAGCTACAACGA TCAAAAAT	4956
1174	UUUUGAGC A CCUUAACU	3671	AGTTAAGG GGCTAGCTACAACGA GCTCAAAA	4957
1180	GCACCUUA A CUUAAGAU	3672	ATCTATAG GGCTAGCTACAACGA TAAGGTGC	4958
1183	CCUUAACU A UAGAUUGU	3673	ACCATCTA GGCTAGCTACAACGA AGTTAAGG	4959
1187	AACUAUAG A UGGUGUAA	3674	TTACACCA GGCTAGCTACAACGA CTATAGTT	4960
1190	UAUAGAUG G UGUAAACC	3675	GGTTTACA GGCTAGCTACAACGA CATCTATA	4961
1192	UAGAUGGU G UAACCCGG	3676	CCGGGTTA GGCTAGCTACAACGA ACCATCTA	4962
1195	AUGGUGUA A CCCGGAGU	3677	ACTCCGGG GGCTAGCTACAACGA TACCCAT	4963
1202	AACCCGGA G UGACCAAG	3678	CTTGGTCA GGCTAGCTACAACGA TCCGGGTT	4964
1205	CCGGAGUG A CCAAGGAU	3679	ATCCTTGG GGCTAGCTACAACGA CACTCCGG	4965
1212	GACCAAGG A UUGUACAC	3680	GTGTACAA GGCTAGCTACAACGA CCTTGGTC	4966
1215	CAAGGAUU G UACACUG	3681	CAGGTGTA GGCTAGCTACAACGA AATCCTTG	4967
1217	AGGAUUGU A CACCUUG	3682	CACAGGTG GGCTAGCTACAACGA ACAATCCT	4968
1219	GAUUGUAC A CCUGUGCA	3683	TGCACAGG GGCTAGCTACAACGA GTACAATC	4969
1223	GUACACCU G UGCAGCAU	3684	ATGCTGCA GGCTAGCTACAACGA AGGTGTAC	4970
1225	ACACCUUG G CAGCAUCC	3685	GGATGCTG GGCTAGCTACAACGA ACAGGTGT	4971
1228	CCUGUGCA G CAUCCAGU	3686	ACTGGATG GGCTAGCTACAACGA TGCACAGG	4972
1230	UGUGCAGC A UCCAGUGG	3687	CCACTGGA GGCTAGCTACAACGA GCTGCACA	4973
1235	AGCAUCCA G UGGGCUGA	3688	TCAGCCCA GGCTAGCTACAACGA TGGATGCT	4974
1239	UCCAGUGG G CUGAUGAC	3689	GTCATCAG GGCTAGCTACAACGA CCACTGGA	4975
1243	GUGGCUG A UGACCAAG	3690	CTTGGTCA GGCTAGCTACAACGA CAGCCCAC	4976
1246	GGCUGAUG A CCAAGAAG	3691	CTTCTTGG GGCTAGCTACAACGA CATCAGCC	4977
1256	CAAGAAGA A CAGCACAU	3692	ATGTGCTG GGCTAGCTACAACGA TCTTCTTG	4978
1259	GAAGAACA G CACAUUUG	3693	CAAAATGT GGCTAGCTACAACGA TGTCTTCT	4979
1261	AGAACAGC A CAUUGUC	3694	GACAAATG GGCTAGCTACAACGA GCTGTTCT	4980
1263	AACAGCAG A UUUGUCAG	3695	CTGACAAA GGCTAGCTACAACGA GTGCTGTT	4981
1267	GCACAUUU G UCAGGGUC	3696	GACCCCTG GGCTAGCTACAACGA AAATGTGC	4982
1273	UUGUCAGG G UCCAUGAA	3697	TTCAATGA GGCTAGCTACAACGA CCTGACAA	4983
1277	CAGGGUCC A UGAAAAAC	3698	GTTTTTCA GGCTAGCTACAACGA GGACCCCTG	4984
1284	CAUGAAAA A CCUUUUGU	3699	ACAAAAGG GGCTAGCTACAACGA TTTTCATG	4985
1291	AACCUUUU G UUGCUUUU	3700	AAAAGCAA GGCTAGCTACAACGA AAAAGGTT	4986
1294	CUUUUGUU G CUUUUGGA	3701	TCCAAAAG GGCTAGCTACAACGA AACAAAAG	4987
1304	UUUUGGAA G UGGCAUGG	3702	CCATGCCA GGCTAGCTACAACGA TTCCAAA	4988
1307	UGGAAGUG G CAUGGAU	3703	ATTCCATG GGCTAGCTACAACGA CACTTCCA	4989
1309	GAAGUGGC A UGGAUUCU	3704	AGATTCCA GGCTAGCTACAACGA GCCACTTC	4990
1314	GGCAUGGA A UCUCUGGU	3705	ACCAGAGA GGCTAGCTACAACGA TCCATGCC	4991
1321	AAUCUCUG G UGGAAGCC	3706	GGCTTCCA GGCTAGCTACAACGA CAGAGATT	4992
1327	UGGUGGAA G CCACGGUG	3707	CACCGTGG GGCTAGCTACAACGA TTCCACCA	4993
1330	UGGAAGCC A CGUGGGG	3708	CCCCACCG GGCTAGCTACAACGA GGCTTCCA	4994
1333	AAGCCACG G UGGGGGAG	3709	CTCCCCCA GGCTAGCTACAACGA CGTGGCTT	4995
1341	GUGGGGGA G CGUGUCAG	3710	CTGACACG GGCTAGCTACAACGA TCCCCCAC	4996
1343	GGGGGAGC G UGUCAGAA	3711	TTCTGACA GGCTAGCTACAACGA GCTCCCCC	4997
1345	GGGAGCGU G UCAGAAUC	3712	GATTCTGA GGCTAGCTACAACGA ACGCTCCC	4998
1351	GUGUCAGA A UCCUGCG	3713	CGCAGGGA GGCTAGCTACAACGA TCTGACAC	4999
1357	GAAUCCCU G CGAAGUAC	3714	GTACTTCG GGCTAGCTACAACGA AGGGATTTC	5000
1362	CCUGCGAA G UACCUUGG	3715	CCAAGGTA GGCTAGCTACAACGA TTGCGAGG	5001
1364	UGCGAAGU A CCUUGGUU	3716	AACCAAGG GGCTAGCTACAACGA ACTTCGCA	5002
1370	GUACCUUG G UUACCCAC	3717	GTGGGTAA GGCTAGCTACAACGA CAAGGTAC	5003
1373	CCUUGGUU A CCCACCCC	3718	GGGGTGGG GGCTAGCTACAACGA AACCAAGG	5004

1377	GGUUAACC A CCCCAGA	3719	TCTGGGGG GGCTAGCTACAACGA GGGTAACC	5005
1387	CCCCAGAA A UAAAUGG	3720	CCATTTTA GGCTAGCTACAACGA TTCTGGGG	5006
1392	GAAAUAAA A UGUUAUA	3721	TTATACCA GGCTAGCTACAACGA TTTATTTT	5007
1395	AUAAAAUG G UAUAAAA	3722	TTTTTATA GGCTAGCTACAACGA CATTTTAT	5008
1397	AAAAUGGU A UAAAAUG	3723	CATTTTTA GGCTAGCTACAACGA ACCATTTT	5009
1403	GUUAAAAA A UGGAUAC	3724	GTATTCCA GGCTAGCTACAACGA TTTTATAC	5010
1408	AAAAUGGA A UACCCCUU	3725	AAGGGGTA GGCTAGCTACAACGA TCCATTTT	5011
1410	AAUGGAU A CCCCUGA	3726	TCAAGGGG GGCTAGCTACAACGA ATTCCATT	5012
1419	CCCCUGA G UCCAAUCA	3727	TGATTGGA GGCTAGCTACAACGA TCAAGGGG	5013
1424	UGAGUCCA A UCACACAA	3728	TTGTGTGA GGCTAGCTACAACGA TGGACTCA	5014
1427	GUCCAUC A CACAAUA	3729	TAATTGTG GGCTAGCTACAACGA GATTGGAC	5015
1429	CCAAUCAC A CAUAUAAA	3730	TTTAATTG GGCTAGCTACAACGA GTGATTGG	5016
1432	AUCACACA A UUAAGCG	3731	CGCTTTAA GGCTAGCTACAACGA TGTGTGAT	5017
1438	CAAUUAAA G CGGGGCAU	3732	ATGCCCGG GGCTAGCTACAACGA TTTAATTG	5018
1443	AAAGCGGG G CAUGUACU	3733	AGTACATG GGCTAGCTACAACGA CCCGCTTT	5019
1445	AGCGGGGC A UGUACUGA	3734	TCAGTACA GGCTAGCTACAACGA GCCCCGCT	5020
1447	CGGGGCAU G UACUGACG	3735	CGTCAGTA GGCTAGCTACAACGA ATGCCCGG	5021
1449	GGGCAUGU A CUGACGAU	3736	ATCGTCAG GGCTAGCTACAACGA ACATGCCC	5022
1453	AUGUACUG A CGAUUAUG	3737	CATAATCG GGCTAGCTACAACGA CAGTACAT	5023
1456	UACUGACG A UUAUGGAA	3738	TTCCATAA GGCTAGCTACAACGA CGTCAGTA	5024
1459	UGACGAU A UGGAAGUG	3739	CACTTCCA GGCTAGCTACAACGA AATCGTCA	5025
1465	UUAUGGAA G UGAGUGAA	3740	TTCACCTA GGCTAGCTACAACGA TTCCATAA	5026
1469	GGAAGUGA G UGAAGAG	3741	CTCTTTCA GGCTAGCTACAACGA TCACTTCC	5027
1478	UGAAGAG A CACAGGAA	3742	TTCTGTG GGCTAGCTACAACGA CTCTTTCA	5028
1480	AAAGAGAC A CAGGAAU	3743	ATTCCTTG GGCTAGCTACAACGA GTCTCTTT	5029
1487	CACAGGAA A UUACACUG	3744	CAGTGTA GGCTAGCTACAACGA TTCTGTG	5030
1490	AGGAAAU A CACUGUCA	3745	TGACAGTG GGCTAGCTACAACGA AATTCCT	5031
1492	GAAAUUAC A CUGUCAUC	3746	GATGACAG GGCTAGCTACAACGA GTAATTTT	5032
1495	AUUACACU G UCAUCCUU	3747	AAGGATGA GGCTAGCTACAACGA AGTGAAT	5033
1498	ACACUGUC A UCCUUACC	3748	GGTAAGGA GGCTAGCTACAACGA GACAGTGT	5034
1504	UCAUCCUU A CCAUCCCC	3749	GGGATTGG GGCTAGCTACAACGA AAGGATGA	5035
1508	CCUUAACA A UCCCAUUU	3750	AAATGGGA GGCTAGCTACAACGA TGGTAAGG	5036
1513	CCAUCCCC A UUUCAAAG	3751	CTTGAAA GGCTAGCTACAACGA GGGATTGG	5037
1527	AAGGAGAA G CAGAGCCA	3752	TGGCTCTG GGCTAGCTACAACGA TTCTCCTT	5038
1532	GAAGCAGA G CCAUGUGG	3753	CCACATGG GGCTAGCTACAACGA TCTGCTTC	5039
1535	GCAGAGCC A UGUGGUCU	3754	AGACCACA GGCTAGCTACAACGA GGCTCTGC	5040
1537	AGAGCCAU G UGGUCUCU	3755	AGAGACCA GGCTAGCTACAACGA ATGGCTCT	5041
1540	GCCAUGUG G UCUCUCUG	3756	CAGAGAGA GGCTAGCTACAACGA CACATGGC	5042
1549	UCUCUCUG G UUGUGUAU	3757	ATACACAA GGCTAGCTACAACGA CAGAGAGA	5043
1552	CUCUGGUU G UGUUUGUC	3758	GACATACA GGCTAGCTACAACGA AACCAGAG	5044
1554	CUGGUUGU G UAUGUCCC	3759	GGGACATA GGCTAGCTACAACGA ACAACCAG	5045
1556	GGUUGUGU A UGUCCCAC	3760	GTGGGACA GGCTAGCTACAACGA ACACAACC	5046
1558	UUGUGUAU G UCCCACCC	3761	GGGTGGGA GGCTAGCTACAACGA ATACACAA	5047
1563	UAUGUCCC A CCCCAGAU	3762	ATCTGGGG GGCTAGCTACAACGA GGGACATA	5048
1570	CACCCCAG A UUGGUGAG	3763	CTCACCAG GGCTAGCTACAACGA CTGGGGTG	5049
1574	CCAGAUUG G UGAGAAU	3764	ATTTCTCA GGCTAGCTACAACGA CAATCTGG	5050
1581	GGUGAGAA A UCUCUAAU	3765	ATTAGAGA GGCTAGCTACAACGA TTCTCACC	5051
1588	AAUCUCUA A UCUCUCU	3766	AGGAGAGA GGCTAGCTACAACGA TAGAGATT	5052
1597	UCUCUCU G UGGAUCC	3767	GGAATCCA GGCTAGCTACAACGA AGGAGAGA	5053
1601	UCCUGUGG A UUCUACC	3768	GGTAGGAA GGCTAGCTACAACGA CCACAGGA	5054
1607	GGAUUCU A CCAUACG	3769	CGTACTGG GGCTAGCTACAACGA AGGAATCC	5055
1611	UCCUACCA G UACGGCAC	3770	GTGCCGTA GGCTAGCTACAACGA TGGTAGGA	5056
1613	CUACCAGU A CGGCACCA	3771	TGGTGCCG GGCTAGCTACAACGA ACTGGTAG	5057

1616	CCAGUACG G CACCACUC	3772	GAGTGGTG GGCTAGCTACAACGA CGTACTGG	5058
1618	AGUACGGC A CCACUCAA	3773	TTGAGTGG GGCTAGCTACAACGA GCCGTACT	5059
1621	ACGGCACC A CUCAAACG	3774	CGTTTGAG GGCTAGCTACAACGA GGTGCCGT	5060
1627	CCACUCAA A CGCUGACA	3775	TGTCAGCG GGCTAGCTACAACGA TTGAGTGG	5061
1629	ACUCAAC G CUGACAUG	3776	CATGTCAG GGCTAGCTACAACGA GTTTGAGT	5062
1633	AAACGUG A CAUGUACG	3777	CGTACATG GGCTAGCTACAACGA CAGCGTTT	5063
1635	ACGCGUAC A UGUACGGU	3778	ACCGTACA GGCTAGCTACAACGA GTCAGCGT	5064
1637	GCUGACAU G UACGGUCU	3779	AGACCGTA GGCTAGCTACAACGA ATGTCAGC	5065
1639	UGACAUGU A CGGUCUUA	3780	ATAGACCG GGCTAGCTACAACGA ACATGTCA	5066
1642	CAUGUACG G UCUAUGCC	3781	GGCATAGA GGCTAGCTACAACGA CGTACATG	5067
1646	UACGGUCU A UGCCAUUC	3782	GAATGGCA GGCTAGCTACAACGA AGACCGTA	5068
1648	CGGUCUUA G CCAUUCU	3783	AGGAATGG GGCTAGCTACAACGA ATAGACCG	5069
1651	UCUAUGCC A UCCUCCCC	3784	GGGAGGAA GGCTAGCTACAACGA GGCATAGA	5070
1662	CCUCCCC G CAUCACAU	3785	ATGTGATG GGCTAGCTACAACGA GGGGGAGG	5071
1664	UCCCCCGC A UCACAUCC	3786	GGATGTGA GGCTAGCTACAACGA GCGGGGGA	5072
1667	CCCGCAUC A CAUCCACU	3787	AGTGGATG GGCTAGCTACAACGA GATGCGGG	5073
1669	CGCAUCAC A UCCACUGG	3788	CCAGTGA GGCTAGCTACAACGA GTGATGCG	5074
1673	UCACAUCC A CUGGUUAU	3789	AATACCAG GGCTAGCTACAACGA GGATGTGA	5075
1677	AUCCACUG G UAUUGGCA	3790	TGCCAATA GGCTAGCTACAACGA CAGTGGAT	5076
1679	CCACUGGU A UUGGCAGU	3791	ACTGCCAA GGCTAGCTACAACGA ACCAGTGG	5077
1683	UGGUUUG G CAGUUGGA	3792	TCCAAC TG GGCTAGCTACAACGA CAATACCA	5078
1686	UAUUGGCA G UUGGAGGA	3793	TCCTCCAA GGCTAGCTACAACGA TGCCAATA	5079
1698	GAGGAAGA G UGCGCCAA	3794	TTGGCGCA GGCTAGCTACAACGA TCTTCCTC	5080
1700	GGAGAGU G CGCCAAAG	3795	CGTTGGCG GGCTAGCTACAACGA ACTCTTCC	5081
1702	AAGAGUGC G CCAACGAG	3796	CTCGTTGG GGCTAGCTACAACGA GCACTCTT	5082
1706	GUGCGCCA A CGAGCCCA	3797	TGGGCTCG GGCTAGCTACAACGA TGGCGCAC	5083
1710	GCCAACGA G CCCAGCCA	3798	TGGCTGGG GGCTAGCTACAACGA TCGTTGGC	5084
1715	CGAGCCCA G CCAAGCUG	3799	CAGCTTGG GGCTAGCTACAACGA TGGGCTCG	5085
1720	CCAGCCAA G CUGUCUCA	3800	TGAGACAG GGCTAGCTACAACGA TTGGCTGG	5086
1723	GCCAAGCU G UCUCAGUG	3801	CACTGAGA GGCTAGCTACAACGA AGCTTGGC	5087
1729	CUGUCUCA G UGACAAAC	3802	GTTTGTCA GGCTAGCTACAACGA TGAGACAG	5088
1732	UCUCAGUG A CAAACCCA	3803	TGGGTTTG GGCTAGCTACAACGA CACTGAGA	5089
1736	AGUGACAA A CCCAUACC	3804	GGTATGGG GGCTAGCTACAACGA TTGTCACT	5090
1740	ACAAACCC A UACCCUUG	3805	CAAGGGTA GGCTAGCTACAACGA GGGTTTGT	5091
1742	AAACCCAU A CCCUUGUG	3806	CACAAGGG GGCTAGCTACAACGA ATGGGTTT	5092
1748	AUACCCU G UGAAGAAU	3807	ATTCTTCA GGCTAGCTACAACGA AAGGGTAT	5093
1755	UGUGAAGA A UGAGAAAG	3808	CTTCTCCA GGCTAGCTACAACGA TCTTCACA	5094
1763	AUGGAGAA G UGUGGAGG	3809	CCTCCACA GGCTAGCTACAACGA TTCTCCAT	5095
1765	GGAGAAGU G UGAGGAGC	3810	GTCTCCA GGCTAGCTACAACGA ACTTCTCC	5096
1772	UGUGGAGG A CUUCCAGG	3811	CCTGGAAG GGCTAGCTACAACGA CCTCCACA	5097
1787	GGGAGGAA A UAAAAUUG	3812	CAATTTTA GGCTAGCTACAACGA TTCTCTCC	5098
1792	GAAAUAAA A UUGAAGUU	3813	AACTTCAA GGCTAGCTACAACGA TTTATTTT	5099
1798	AAAUUGAA G UUAUUAAA	3814	TTTATTAA GGCTAGCTACAACGA TTCAATTT	5100
1802	UGAAGUUA A UAAAAUUC	3815	GATTTTTA GGCTAGCTACAACGA TAACTTCA	5101
1808	UAUUAAAA A UCAAUUUG	3816	CAAATTGA GGCTAGCTACAACGA TTTTATTA	5102
1812	AAAAAUCA A UUUCUCU	3817	AGAGCAAA GGCTAGCTACAACGA TGATTTTT	5103
1816	AUCAAUUU G CUCUAAUU	3818	AATTAGAG GGCTAGCTACAACGA AAATGTAT	5104
1822	UUGCUCUA A UUGAAGGA	3819	TCCTTCAA GGCTAGCTACAACGA TAGAGCAA	5105
1835	AGGAAAAA A CAAACUG	3820	CAGTTTGG GGCTAGCTACAACGA TTTTTCCT	5106
1840	AAAACAAA A CUGUAAGU	3821	ACTTACAG GGCTAGCTACAACGA TTTGTTTT	5107
1843	ACAAACU G UAAGUACC	3822	GGTACTTA GGCTAGCTACAACGA AGTTTGTG	5108
1847	AACUGUAA G UACCCUUG	3823	CAAGGGTA GGCTAGCTACAACGA TTACAGTT	5109
1849	CUGUAAGU A CCCUUGUU	3824	AACAAGGG GGCTAGCTACAACGA ACTTACAG	5110

1855	GUACCCUU G UUAUCCAA	3825	TTGGATAA GGCTAGCTACAACGA AAGGGTAC	5111
1858	CCCUGUUU A UCCAAGCG	3826	CGCTTGGA GGCTAGCTACAACGA AACAGGGG	5112
1864	UUAUCCAA G CGGCAAAU	3827	ATTGCGCG GGCTAGCTACAACGA TTGGATAA	5113
1867	UCCAAGCG G CAAUGUG	3828	CACATTTG GGCTAGCTACAACGA CGCTTGGA	5114
1871	AGCGGCAA A UGUGUCAG	3829	CTGACACA GGCTAGCTACAACGA TTGCCGCT	5115
1873	CGGCAAAU G UGUCAGCU	3830	AGCTGACA GGCTAGCTACAACGA ATTTGCGG	5116
1875	GCAAUGU G UCAGCUUU	3831	AAAGCTGA GGCTAGCTACAACGA ACATTGTC	5117
1879	AUGUGUCA G CUUGUAC	3832	GTACAAAG GGCTAGCTACAACGA TGACACAT	5118
1884	UCAGCUUU G UACAAAU	3833	CATTGTGA GGCTAGCTACAACGA AAAGCTGA	5119
1886	AGCUUGU A CAAUGUG	3834	CACATTTG GGCTAGCTACAACGA ACAAGCT	5120
1890	UGUACAA A UGUGAGC	3835	GCTTCACA GGCTAGCTACAACGA TTGTACAA	5121
1892	GUACAAAU G UGAAGCG	3836	CCGCTTCA GGCTAGCTACAACGA ATTTGTAC	5122
1897	AAUGUGAA G CGGUCAAC	3837	GTTGACCG GGCTAGCTACAACGA TTCACATT	5123
1900	GUGAAGCG G UCAACAA	3838	TTTGTGTA GGCTAGCTACAACGA CGCTTCAC	5124
1904	AGCGGUCA A CAAAGUCG	3839	CGACTTTG GGCTAGCTACAACGA TGACCGCT	5125
1909	UCAACAA G UCGGGAGA	3840	TCTCCCGA GGCTAGCTACAACGA TTTGTTGA	5126
1927	GAGAGAGG G UGAUCUCC	3841	GGAGATCA GGCTAGCTACAACGA CCTCTCTC	5127
1930	AGAGGGUG A UCUCUUC	3842	GAAGGAGA GGCTAGCTACAACGA CACCCTCT	5128
1940	CUCCUUC A CGUGACCA	3843	TGGTCACG GGCTAGCTACAACGA GGAAGGAG	5129
1942	CCUCCAC G UGACCAGG	3844	CCTGGTCA GGCTAGCTACAACGA GTGGAAGG	5130
1945	UCCACGUG A CCAGGGGU	3845	ACCCCTGG GGCTAGCTACAACGA CACGTGGA	5131
1952	GACCAGGG G UCCUGAAA	3846	TTTCAGGA GGCTAGCTACAACGA CCCTGGTC	5132
1960	GUCCUGAA A UUACUUUG	3847	CAAAGTAA GGCTAGCTACAACGA TTCAGGAC	5133
1963	CUGAAAUU A CUUGCAA	3848	TTGCAAAG GGCTAGCTACAACGA AATTTCAG	5134
1968	AUUACUUU G CAACCUGA	3849	TCAGGTTG GGCTAGCTACAACGA AAAGTAAT	5135
1971	ACUUUGCA A CCUGACAU	3850	ATGTCAGG GGCTAGCTACAACGA TGCAAAGT	5136
1976	GCAACCUG A CAUGCAGC	3851	GCTGCATG GGCTAGCTACAACGA CAGGTTGC	5137
1978	AACCUGAC A UGCAGCCC	3852	GGGCTGCA GGCTAGCTACAACGA GTCAGGTT	5138
1980	CCUGACAU G CAGCCAC	3853	GTGGGCTG GGCTAGCTACAACGA ATGTCAGG	5139
1983	GACAUGCA G CCCACUGA	3854	TCAGTGGG GGCTAGCTACAACGA TGCACTGC	5140
1987	UGCAGCCC A CUGAGCAG	3855	CTGCTCAG GGCTAGCTACAACGA GGGCTGCA	5141
1992	CCACUGA G CAGGAGAG	3856	CTCTCCTG GGCTAGCTACAACGA TCAGTGGG	5142
2000	GCAGGAGA G CGUGUCUU	3857	AAGACACG GGCTAGCTACAACGA TCTCCTGC	5143
2002	AGGAGAGC G UGUUUUG	3858	CAAAGACA GGCTAGCTACAACGA GCTCTCCT	5144
2004	GAGAGCGU G UCUUUGUG	3859	CACAAAGA GGCTAGCTACAACGA ACGCTCTC	5145
2010	GUGUCUUU G UGGUGCAC	3860	GTGCACCA GGCTAGCTACAACGA AAAGACAC	5146
2013	UCUUUGUG G UGCACUGC	3861	GCAGTGCA GGCTAGCTACAACGA CACAAAGA	5147
2015	UUUGUGGU G CACUGCAG	3862	CTGCAGTG GGCTAGCTACAACGA ACCACAAA	5148
2017	UGUGGUGC A CUGCAGAC	3863	GTCTGCAG GGCTAGCTACAACGA GCACCACA	5149
2020	GGUGCACU G CAGACAGA	3864	TCTGTCTG GGCTAGCTACAACGA AGTGCACC	5150
2024	CACUGCAG A CAGAUCUA	3865	TAGATCTG GGCTAGCTACAACGA CTGCAGTG	5151
2028	GCAGACAG A UCUACGUU	3866	AACGTAGA GGCTAGCTACAACGA CTGTCTGC	5152
2032	ACAGAUCU A CGUUUGAG	3867	CTCAAACG GGCTAGCTACAACGA AGATCTGT	5153
2034	AGAUCUAC G UUUGAGAA	3868	TTCTCAA A GGCTAGCTACAACGA GTAGATCT	5154
2042	GUUUGAGA A CCUCACAU	3869	ATGTGAGG GGCTAGCTACAACGA TCTCAAA	5155
2047	AGAACCUC A CAUGGUAC	3870	GTACCATG GGCTAGCTACAACGA GAGGTTCT	5156
2049	AACCUCAC A UGUUACAA	3871	TTGTACCA GGCTAGCTACAACGA GTGAGGTT	5157
2052	CUCACAU G UACAAGCU	3872	AGCTTGTA GGCTAGCTACAACGA CATGTGAG	5158
2054	CACAUGGU A CAAGCUUG	3873	CAAGCTTG GGCTAGCTACAACGA ACCATGTG	5159
2058	UGGUACAA G CUUGGCC	3874	GGGCCAAG GGCTAGCTACAACGA TTGTACCA	5160
2063	CAAGCUUG G CCCACAGC	3875	GCTGTGGG GGCTAGCTACAACGA CAAGCTTG	5161
2067	CUUGGCC A CAGCCUCU	3876	AGAGGCTG GGCTAGCTACAACGA GGGCCAAG	5162
2070	GGCCACA G CCUCUGCC	3877	GGCAGAGG GGCTAGCTACAACGA TGTGGGCC	5163

2076	CAGCCUCU G CCAAUCCA	3878	TGGATTGG GGCTAGCTACAACGA AGAGGCTG	5164
2080	CUCUGCCA A UCCAUGUG	3879	CACATGGA GGCTAGCTACAACGA TGGCAGAG	5165
2084	GCCAAUCC A UGUGGGAG	3880	CTCCACA GGCTAGCTACAACGA GGATTGGC	5166
2086	CAAUCCAU G UGGGAGAG	3881	CTCTCCCA GGCTAGCTACAACGA ATGGATTG	5167
2094	GUGGAGA G UUGCCAC	3882	GTGGGCAA GGCTAGCTACAACGA TCTCCAC	5168
2097	GGAGAGUU G CCCACACC	3883	GGTGTGGG GGCTAGCTACAACGA AACTCTCC	5169
2101	AGUUGCCC A CACCUGUU	3884	AACAGGTG GGCTAGCTACAACGA GGGCAACT	5170
2103	UUGCCAC A CCUGUUUG	3885	CAACAGG GGCTAGCTACAACGA GTGGGCAA	5171
2107	CCACACCU G UUUGCAAG	3886	CTTGCAA GGCTAGCTACAACGA AGGTGTGG	5172
2111	ACCUGUUU G CAAGAACU	3887	AGTTCTTG GGCTAGCTACAACGA AACAGGT	5173
2117	UUGCAAGA A CUUGGAUA	3888	TATCCAAG GGCTAGCTACAACGA TCTTGCAA	5174
2123	GAACUUGG A UACUCUUU	3889	AAAGAGTA GGCTAGCTACAACGA CCAAGTTC	5175
2125	ACUUGGAU A CUCUUUG	3890	CCAAAGAG GGCTAGCTACAACGA ATCCAAGT	5176
2136	CUUUGGAA A UGAAUUG	3891	GCATTCAA GGCTAGCTACAACGA TTCCAAAG	5177
2141	GAAAUUGA A UGCCACCA	3892	TGGTGGCA GGCTAGCTACAACGA TCAATTTC	5178
2143	AAUUGAAU G CCACCAUG	3893	CATGGTGG GGCTAGCTACAACGA ATTCAATT	5179
2146	UGAAUGCC A CCAUGUUC	3894	GAACATGG GGCTAGCTACAACGA GGCATTCA	5180
2149	AUGCCACC A UGUUCUCU	3895	AGAGAACA GGCTAGCTACAACGA GGTGGCAT	5181
2151	GCCACCAU G UUCUCUAA	3896	TTAGAGAA GGCTAGCTACAACGA ATGGTGGC	5182
2159	GUUCUCUA A UAGCACAA	3897	TTGTGCTA GGCTAGCTACAACGA TAGAGAAC	5183
2162	CUCUAAUA G CACAAUUG	3898	CATTTGTG GGCTAGCTACAACGA TATTAGAG	5184
2164	CUAAUAGC A CAAUUGAC	3899	GTCATTTG GGCTAGCTACAACGA GCTATTAG	5185
2168	UAGCACAA A UGACAUUU	3900	AAATGTCA GGCTAGCTACAACGA TTGTGCTA	5186
2171	CACAAUUG A CAUUUGA	3901	TCAAATG GGCTAGCTACAACGA CATTTGTG	5187
2173	CAAUUGAC A UUUUGAUC	3902	GATCAAAA GGCTAGCTACAACGA GTCATTTG	5188
2179	ACAUUUUG A UCAUGGAG	3903	CTCCATGA GGCTAGCTACAACGA CAAAATGT	5189
2182	UUUUGAUC A UGGAGCUU	3904	AAGCTCCA GGCTAGCTACAACGA GATCAAAA	5190
2187	AUCAUGGA G CUUAAGAA	3905	TTCTTAAG GGCTAGCTACAACGA TCCATGAT	5191
2195	GCUUAAGA A UGCAUCCU	3906	AGGATGCA GGCTAGCTACAACGA TCTTAAGC	5192
2197	UUAAGAAU G CAUCCUUG	3907	CAAGGATG GGCTAGCTACAACGA ATTCTTAA	5193
2199	AAGAAUGC A UCCUUGCA	3908	TGCAAGGA GGCTAGCTACAACGA GCATTCTT	5194
2205	GCAUCCUU G CAGGACCA	3909	TGGTCCTG GGCTAGCTACAACGA AAGGATGC	5195
2210	CUUGCAGG A CCAAGGAG	3910	CTCCTTGG GGCTAGCTACAACGA CCTGCAAG	5196
2219	CCAAGGAG A CUUUGUCU	3911	AGACATAG GGCTAGCTACAACGA CTCCTTGG	5197
2222	AGGAGACU A UGUUGGCC	3912	GGCAGACA GGCTAGCTACAACGA AGTCTCCT	5198
2224	GAGACUUA G UCUGCCUU	3913	AAGGCAGA GGCTAGCTACAACGA ATAGTCTC	5199
2228	CUUUGUCU G CCUUGCUC	3914	GAGCAAGG GGCTAGCTACAACGA AGACATAG	5200
2233	UCUGCCUU G CUCAAGAC	3915	GTCTTGAG GGCTAGCTACAACGA AAGGCAGA	5201
2240	UGCUCUAG A CAGGAAGA	3916	TCTTCCTG GGCTAGCTACAACGA CTTGAGCA	5202
2248	ACAGGAAG A CCAAGAAA	3917	TTTCTTGG GGCTAGCTACAACGA CTTCTGT	5203
2259	AAGAAAAG A CAUUGCGU	3918	ACGCAATG GGCTAGCTACAACGA CTTTCTT	5204
2261	GAAAAGAC A UUGCGUGG	3919	CCACGCAA GGCTAGCTACAACGA GTCTTTTC	5205
2264	AAGACAUU G CGUGGUCA	3920	TGACCAAG GGCTAGCTACAACGA AATGTCTT	5206
2266	GACAUUGC G UGGUCAGG	3921	CCTGACCA GGCTAGCTACAACGA GCAATGTC	5207
2269	AUUGCGUG G UCAGGCAG	3922	CTGCCTGA GGCTAGCTACAACGA CACGCAAT	5208
2274	GUGGUCAG G CAGCUCAC	3923	GTGAGCTG GGCTAGCTACAACGA CTGACCAC	5209
2277	GUCAGGCA G CUCACAGU	3924	ACTGTGAG GGCTAGCTACAACGA TGCCTGAC	5210
2281	GGCAGCUC A CAGUCCUA	3925	TAGGACTG GGCTAGCTACAACGA GAGCTGCC	5211
2284	AGCUCACA G UCCUAGAG	3926	CTCTAGGA GGCTAGCTACAACGA TGTGAGCT	5212
2292	GUCCUAGA G CGUGUGGC	3927	GCCACACG GGCTAGCTACAACGA TCTAGGAC	5213
2294	CCUAGAGC G UGUGGCAC	3928	GTGCCACA GGCTAGCTACAACGA GCTCTAG	5214
2296	UAGAGCGU G UGGCACCC	3929	GGGTGCCA GGCTAGCTACAACGA ACGCTCTA	5215
2299	AGCGUGUG G CACCCACG	3930	CGTGGGTG GGCTAGCTACAACGA CACACGCT	5216

2301	CGUGUGGC A CCCACGAU	3931	ATCGTGGG GGCTAGCTACAACGA GCCACACG	5217
2305	UGGCACCC A CGAUCACA	3932	TGTGATCG GGCTAGCTACAACGA GGGTGCCA	5218
2308	CACCCACG A UCACAGGA	3933	TCCTGTGA GGCTAGCTACAACGA CGTGGGTG	5219
2311	CCACGAUC A CAGGAAAC	3934	GTTTCCTG GGCTAGCTACAACGA GATCGTGG	5220
2318	CACAGGAA A CCUGGAGA	3935	TCTCCAGG GGCTAGCTACAACGA TTCCTGTG	5221
2327	CCUGGAGA A UCAGACGA	3936	TGCTCTGA GGCTAGCTACAACGA TCTCCAGG	5222
2332	AGAAUCAG A CGACAAGU	3937	ACTTGTCT GGCTAGCTACAACGA CTGATTCT	5223
2335	AUCAGACG A CAAGUAU	3938	AATACTTG GGCTAGCTACAACGA CGTCTGAT	5224
2339	GACGACAA G UAUUGGGG	3939	CCCAATA GGCTAGCTACAACGA TTGTCGTC	5225
2341	CGACAAGU A UUGGGGAA	3940	TTCCCCAA GGCTAGCTACAACGA ACTTGTCT	5226
2351	UGGGGAAA G CAUCGAAG	3941	CTTCGATG GGCTAGCTACAACGA TTTCCCCA	5227
2353	GGGAAAGC A UCGAAGUC	3942	GACTTCGA GGCTAGCTACAACGA GCTTTCCC	5228
2359	GCAUCGAA G UCUCAU	3943	GCATGAGA GGCTAGCTACAACGA TTCGATGC	5229
2364	GAAGUCUC A UGCACGGC	3944	GCCGTGCA GGCTAGCTACAACGA GAGACTTC	5230
2366	AGUCUCAU G CACGGCAU	3945	ATGCCGTG GGCTAGCTACAACGA ATGAGACT	5231
2368	UCUCAUGC A CGGCAUCU	3946	AGATGCCG GGCTAGCTACAACGA GCATGAGA	5232
2371	CAUGCACG G CAUCUGGG	3947	CCCAGATG GGCTAGCTACAACGA CGTGCATG	5233
2373	UGCACGGC A UCUGGGAA	3948	TTCCCAGA GGCTAGCTACAACGA GCCGTGCA	5234
2381	AUCUGGGA A UCCCCUC	3949	GAGGGGGA GGCTAGCTACAACGA TCCCAGAT	5235
2391	CCCCUCC A CAGAUCAU	3950	ATGATCTG GGCTAGCTACAACGA GGAGGGGG	5236
2395	CUCCACAG A UCAUGUGG	3951	CCACATGA GGCTAGCTACAACGA CTGTGGAG	5237
2398	CACAGAUC A UGUGGUUU	3952	AAACCACA GGCTAGCTACAACGA GATCTGTG	5238
2400	CAGAUCAU G UGUUUUAA	3953	TTAAACCA GGCTAGCTACAACGA ATGATCTG	5239
2403	AUCAUGUG G UUUAAAGA	3954	TCTTTAAA GGCTAGCTACAACGA CACATGAT	5240
2411	GUUUAAG A UAAUGAGA	3955	TCTCATTG GGCTAGCTACAACGA CTTTAAAC	5241
2414	UAAAGAAU A UGAGACCC	3956	GGGTCTCA GGCTAGCTACAACGA TATCTTTA	5242
2419	AUAUGAG A CCCUUGUA	3957	TACAAGGG GGCTAGCTACAACGA CTCATTAT	5243
2425	AGACCCUU G UAGAAGAC	3958	GTCTTCTA GGCTAGCTACAACGA AAGGGTCT	5244
2432	UGUAGAAG A CUCAGGCA	3959	TGCCTGAG GGCTAGCTACAACGA CTTCTACA	5245
2438	AGACUCAG G CAUUGUAU	3960	ATACAATG GGCTAGCTACAACGA CTGAGTCT	5246
2440	ACUCAGGC A UUGUAUUG	3961	CAATACAA GGCTAGCTACAACGA GCCTGAGT	5247
2443	CAGGCAU G UAUUGAAG	3962	CTTCAATA GGCTAGCTACAACGA AATGCCCTG	5248
2445	GGCAUUGU A UUGAAGGA	3963	TCCTTCAA GGCTAGCTACAACGA ACAATGCC	5249
2453	AUUGAAGG A UGGGAACC	3964	GGTTCCCA GGCTAGCTACAACGA CCTTCAAT	5250
2459	GGAUGGGA A CCGGAACC	3965	GTTTCCGG GGCTAGCTACAACGA TCCCATCC	5251
2465	GAACCGGA A CCUCACUA	3966	TAGTGAGG GGCTAGCTACAACGA TCCGGTTC	5252
2470	GGAACCUC A CUAUCCGC	3967	GCGGATAG GGCTAGCTACAACGA GAGGTTCC	5253
2473	ACCUCACU A UCCGCAGA	3968	TCTGCGGA GGCTAGCTACAACGA AGTGAGGT	5254
2477	CACUAUCC G CAGAGUGA	3969	TCACTCTG GGCTAGCTACAACGA GGATAGTG	5255
2482	UCCGCAGA G UGAGGAAG	3970	CTTCTCTA GGCTAGCTACAACGA TCTGCGGA	5256
2495	GAAGGAGG A CGAAGGCC	3971	GGCCTTCG GGCTAGCTACAACGA CCTCCTTC	5257
2501	GGACGAAG G CCUCUACA	3972	TGTAGAGG GGCTAGCTACAACGA CTTCGTCC	5258
2507	AGGCCUCU A CACCUGCC	3973	GGCAGGTG GGCTAGCTACAACGA AGAGGCCT	5259
2509	GCCUCUAC A CCUGCCAG	3974	CTGGCAGG GGCTAGCTACAACGA GTAGAGGC	5260
2513	CUACACCU G CCAGGCAU	3975	ATGCCCTG GGCTAGCTACAACGA AGGTGTAG	5261
2518	CCUGCCAG G CAUGCAGU	3976	ACTGCATG GGCTAGCTACAACGA CTGGCAGG	5262
2520	UGCCAGGC A UGCAGUGU	3977	ACACTGCA GGCTAGCTACAACGA GCCTGGCA	5263
2522	CCAGGCAU G CAGUGUUC	3978	GAACACTG GGCTAGCTACAACGA ATGCCCTG	5264
2525	GGCAUGCA G UGUUCUUG	3979	CAAGAACA GGCTAGCTACAACGA TGCATGCC	5265
2527	CAUGCAGU G UUCUUGGC	3980	GCCAAGAA GGCTAGCTACAACGA ACTGCATG	5266
2534	UGUUCUUG G CUGUGCAA	3981	TTGCACAG GGCTAGCTACAACGA CAAGAACA	5267
2537	UCUUGGCU G UGCAAAAG	3982	CTTTTGCA GGCTAGCTACAACGA AGCCAAGA	5268
2539	UUGGCUGU G CAAAAGUG	3983	CACTTTTC GGCTAGCTACAACGA ACAGCCAA	5269

2545	GUGCAAAA G UGGAGGCA	3984	TGCCTCCA GGCTAGCTACAACGA TTTTGCAC	5270
2551	AAGUGGAG G CAUUUUUC	3985	GAAAAATG GGCTAGCTACAACGA CTCCACTT	5271
2553	GUGGAGGC A UUUUUCAU	3986	ATGAAAAA GGCTAGCTACAACGA GCCTCCAC	5272
2560	CAUUUUUC A UAADAGAA	3987	TTCTATTA GGCTAGCTACAACGA GAAAAATG	5273
2563	UUUUCAU A UAGAAGGU	3988	ACCTTCTA GGCTAGCTACAACGA TATGAAAA	5274
2570	AAUAGAAG G UGCCAGG	3989	CCTGGGCA GGCTAGCTACAACGA CTTCCTATT	5275
2572	UAGAAGGU G CCCAGGAA	3990	TTCCTGGG GGCTAGCTACAACGA ACCTTCTA	5276
2584	AGGAAAAA G CGAACUUG	3991	CAAGTTCG GGCTAGCTACAACGA CTTCCTCT	5277
2588	AAAGACGA A CUUGGAAA	3992	TTTCCAAG GGCTAGCTACAACGA TCGTCTTT	5278
2596	ACUUGGAA A UCAUUUUU	3993	AATAATGA GGCTAGCTACAACGA TTCCAAGT	5279
2599	UGGAAUUC A UUAUUCUA	3994	TAGATATA GGCTAGCTACAACGA GATTTCCT	5280
2602	AAAUCAU A UUCUAGUA	3995	TACTAGAA GGCTAGCTACAACGA AATGATTT	5281
2608	UUAUUCUA G UAGGCACG	3996	CGTGCCTA GGCTAGCTACAACGA TAGATATA	5282
2612	UCUAGUAG G CACGCGCG	3997	CCGCCGTG GGCTAGCTACAACGA CTACTAGA	5283
2614	UAGUAGGC A CGGCGGUG	3998	CACCGCCG GGCTAGCTACAACGA GCCTACTA	5284
2617	UAGGCACG G CGGUGAUU	3999	AATCACCG GGCTAGCTACAACGA CGTGCCTA	5285
2620	GCACGCGG G UGAUUGCC	4000	GGCAATCA GGCTAGCTACAACGA CGCCGTGC	5286
2623	CGGCGGUG A UUGCCAUG	4001	CATGGCAA GGCTAGCTACAACGA CACCGCGG	5287
2626	CGGUGAUU G CCAUGUUC	4002	GAACATGG GGCTAGCTACAACGA AATCACCG	5288
2629	UGAUUGCC A UGUUCUUC	4003	GAAGAACA GGCTAGCTACAACGA GGCAATCA	5289
2631	AUUGCCAU G UUCUUCUG	4004	CAGAAGAA GGCTAGCTACAACGA ATGGCAAT	5290
2640	UUCUUCUG G CUACUUCU	4005	AGAAGTAG GGCTAGCTACAACGA CAGAAGAA	5291
2643	UUCUGGCU A CUUCUUGU	4006	ACAAGAAG GGCTAGCTACAACGA AGCCAGAA	5292
2650	UACUUCUU G UCAUCAUC	4007	GATGATGA GGCTAGCTACAACGA AAGAAGTA	5293
2653	UUCUUGUC A UCAUCCUA	4008	TAGGATGA GGCTAGCTACAACGA GACAAGAA	5294
2656	UUGUCAUC A UCCUACCG	4009	CCGTAGGA GGCTAGCTACAACGA GATGACAA	5295
2661	AUCAUCCU A CGGACCGU	4010	ACGGTCCG GGCTAGCTACAACGA AGGATGAT	5296
2665	UCCUACGG A CCGUUAAG	4011	CTTAACGG GGCTAGCTACAACGA CCGTAGGA	5297
2668	UACGGAAC G UUAAGCGG	4012	CCGCTTAA GGCTAGCTACAACGA GGTCCTGA	5298
2673	ACCGUUA A CGGCCCCA	4013	TTGGCCCG GGCTAGCTACAACGA TTAACGGT	5299
2677	UUAAGCGG G CCAUUGGA	4014	TCCATTGG GGCTAGCTACAACGA CCGCTTAA	5300
2681	GCGGGCCA A UGGAGGGG	4015	CCCCTCCA GGCTAGCTACAACGA TGGCCCGC	5301
2691	GGAGGGGA A CUGAAGAC	4016	GTCTTCAG GGCTAGCTACAACGA TCCCCTCC	5302
2698	AACUGAAG A CAGGCUAC	4017	GTAGCCTG GGCTAGCTACAACGA CTTCAGTT	5303
2702	GAAGACAG G CUACUUGU	4018	ACAAGTAG GGCTAGCTACAACGA CTGTCTTC	5304
2705	GACAGGCU A CUUGUCCA	4019	TGGACAAG GGCTAGCTACAACGA AGCCTGTC	5305
2709	GGCUACUU G UCCAUCGU	4020	ACGATGGA GGCTAGCTACAACGA AAGTAGCC	5306
2713	ACUUGUCC A UCGUCAUG	4021	CATGACGA GGCTAGCTACAACGA GGACAAGT	5307
2716	UGUCCAUC G UCAUGGAU	4022	ATCCATGA GGCTAGCTACAACGA GATGGACA	5308
2719	CCAUCGUC A UGGAUCCA	4023	TGGATCCA GGCTAGCTACAACGA GACGATGG	5309
2723	CGUCAUGG A UCCAGAUG	4024	CATCTGGA GGCTAGCTACAACGA CCATGACG	5310
2729	GGAUCCAG A UGAACUCC	4025	GGAGTTCA GGCTAGCTACAACGA CTGGATCC	5311
2733	CCAGAUGA A CUCCCAUU	4026	AATGGGAG GGCTAGCTACAACGA TCATCTGG	5312
2739	GAACUCCC A UUGGAUGA	4027	TCATCCAA GGCTAGCTACAACGA GGGAGTTC	5313
2744	CCCAUUGG A UGAACAUU	4028	AATGTTCA GGCTAGCTACAACGA CCAATGGG	5314
2748	UUGGAUGA A CAUUGUGA	4029	TCACAATG GGCTAGCTACAACGA TCATCCAA	5315
2750	GGAUGAAC A UUGUGAAC	4030	GTTCACAA GGCTAGCTACAACGA GTTCATCC	5316
2753	UGAACAUU G UGAACGAC	4031	GTCGTTCA GGCTAGCTACAACGA AATGTTCA	5317
2757	CAUUGUGA A CGACUGCC	4032	GGCAGTCG GGCTAGCTACAACGA TCACAATG	5318
2760	UGUGAACG A CUGCCUUA	4033	TAAGGCAG GGCTAGCTACAACGA CGTTCACA	5319
2763	GAACGACU G CCUUAUGA	4034	TCATAAGG GGCTAGCTACAACGA AGTCGTTC	5320
2768	ACUGCCUU A UGAUGCCA	4035	TGGCATCA GGCTAGCTACAACGA AAGGCAGT	5321
2771	GCCUUAUG A UGCCAGCA	4036	TGCTGGCA GGCTAGCTACAACGA CATAAGGC	5322



2773	CUUAUGAU G CCAGCAA	4037	TTTGCTGG GGCTAGCTACAACGA ATCATAAG	5323
2777	UGAUGCCA G CAAUUGGG	4038	CCCATTTG GGCTAGCTACAACGA TGGCATCA	5324
2781	GCCAGCAA A UGGGAUU	4039	AATTCCCA GGCTAGCTACAACGA TTGCTGGC	5325
2787	AAUUGGA A UCCCCAG	4040	CTGGGGAA GGCTAGCTACAACGA TCCCATT	5326
2798	CCCCAGAG A CCGCUGA	4041	TCAGCCGG GGCTAGCTACAACGA CTCTGGGG	5327
2802	AGAGACCG G CUGAAGCU	4042	AGCTTCAG GGCTAGCTACAACGA CGTCTCT	5328
2808	CGGUGAA G CUAGGUA	4043	TTACCTAG GGCTAGCTACAACGA TTCAGCCG	5329
2813	GAAGCUAG G UAAGCCUC	4044	GAGGCTTA GGCTAGCTACAACGA CTAGCTTC	5330
2817	CUAGGUA G CCUCUUG	4045	CCAAGAGG GGCTAGCTACAACGA TTACCTAG	5331
2825	GCCUCUUG G CCGUGUG	4046	CACCACGG GGCTAGCTACAACGA CAAGAGGC	5332
2828	UCUUGGCC G UGGUGCCU	4047	AGGCACCA GGCTAGCTACAACGA GGCCAAGA	5333
2831	UGGCGUG G UGCCUUUG	4048	CAAAGGCA GGCTAGCTACAACGA CACGGCCA	5334
2833	GCCGUGGU G CCUUUGGC	4049	GCCAAAGG GGCTAGCTACAACGA ACCACGGC	5335
2840	UGCCUUUG G CCAAGUGA	4050	TCACCTGG GGCTAGCTACAACGA CAAAGGCA	5336
2845	UUGGCCAA G UGAUUGAA	4051	TTCAATCA GGCTAGCTACAACGA TTGGCCAA	5337
2848	GCCAAGUG A UUGAAGCA	4052	TGCTTCAA GGCTAGCTACAACGA CACTTGGC	5338
2854	UGAUUGAA G CAGAUGCC	4053	GGCATCTG GGCTAGCTACAACGA TTCAATCA	5339
2858	UGAAGCAG A UGCCUUUG	4054	CAAAGGCA GGCTAGCTACAACGA CTGCTTCA	5340
2860	AAGCAGAU G CCUUUGGA	4055	TCCAAAGG GGCTAGCTACAACGA ATCTGCTT	5341
2869	CCUUUGGA A UUGACAAG	4056	CTGTGCTA GGCTAGCTACAACGA TCCAAAGG	5342
2873	UGGAUUUG A CAAGACAG	4057	CTGTCTTG GGCTAGCTACAACGA CAATTCCA	5343
2878	UUGACAAG A CAGCAACU	4058	AGTTGCTG GGCTAGCTACAACGA CTGTGCTA	5344
2881	ACAAGACA G CAACUUGC	4059	GCAAGTTG GGCTAGCTACAACGA TGTCTTGT	5345
2884	AGACAGCA A CUUGCAGG	4060	CCTGCAAG GGCTAGCTACAACGA TGCTGTCT	5346
2888	AGCAACUU G CAGGACAG	4061	CTGTCTTG GGCTAGCTACAACGA AAGTTGCT	5347
2893	CUUGCAGG A CAGUAGCA	4062	TGCTACTG GGCTAGCTACAACGA CCTGCAAG	5348
2896	GCAGGACA G UAGCAGUC	4063	GACTGCTA GGCTAGCTACAACGA TGTCTGCT	5349
2899	GGACAGUA G CAGUCAA	4064	TTGACTG GGCTAGCTACAACGA TACTGTCC	5350
2902	CAGUAGCA G UCAAAUG	4065	CATTTTGA GGCTAGCTACAACGA TGCTACTG	5351
2908	CAGUCAA A UGUUGAA	4066	TTTCAACA GGCTAGCTACAACGA TTTGACTG	5352
2910	GUCAAAUA G UUGAAAGA	4067	TCTTTCAA GGCTAGCTACAACGA ATTTTGAC	5353
2923	AAGAAGGA G CAACACAC	4068	GTGTGTTG GGCTAGCTACAACGA TCCTTCTT	5354
2926	AAGGAGCA A CACACAGU	4069	ACTGTGTG GGCTAGCTACAACGA TGCTCCTT	5355
2928	GGAGCAAC A CACAGUGA	4070	TCCTGTG GGCTAGCTACAACGA GTTGCTCC	5356
2930	AGCAACAC A CAGUGAGC	4071	GCTCACTG GGCTAGCTACAACGA GTGTTGCT	5357
2933	AACACACA G UGAGCAUC	4072	GATGCTCA GGCTAGCTACAACGA TGTGTGTT	5358
2937	CACAGUGA G CAUCGAGC	4073	GCTCGATG GGCTAGCTACAACGA TCACTGTG	5359
2939	CAGUGAGC A UCGAGCUC	4074	GAGCTCGA GGCTAGCTACAACGA GCTCACTG	5360
2944	AGCAUCGA G CUCUCAUG	4075	CATGAGAG GGCTAGCTACAACGA TCGATGCT	5361
2950	GAGCUCUC A UGUGUGAA	4076	TTCAAGCA GGCTAGCTACAACGA GAGAGCTC	5362
2952	GCUCUCAU G UCUGAACU	4077	AGTTTCAA GGCTAGCTACAACGA ATGAGAGC	5363
2958	AUGUCUGA A CUCAAGAU	4078	ATCTTGAG GGCTAGCTACAACGA TCAGACAT	5364
2965	AACUCAAG A UCCUCAU	4079	AATGAGGA GGCTAGCTACAACGA CTTGAGTT	5365
2971	AGAUCCUC A UUCAUAU	4080	AATATGAA GGCTAGCTACAACGA GAGGATCT	5366
2975	CCUCAUUC A UAUUGGUC	4081	GACCAATA GGCTAGCTACAACGA GAATGAGG	5367
2977	UCAUUAU A UUGGUCAC	4082	GTGACCAA GGCTAGCTACAACGA ATGAATGA	5368
2981	UCAUAUUG G UCACCAUC	4083	GATGGTGA GGCTAGCTACAACGA CAATATGA	5369
2984	UAUUGGUC A CCAUCUCA	4084	TGAGATGG GGCTAGCTACAACGA GACCAATA	5370
2987	UGGUCACC A UCUCUAUG	4085	CATTGAGA GGCTAGCTACAACGA GGTGACCA	5371
2993	CCAUCUCA A UUGGUGCA	4086	TGACCACA GGCTAGCTACAACGA TGAGATGG	5372
2995	AUCUCAAU G UGGUCAAC	4087	GTTGACCA GGCTAGCTACAACGA ATTGAGAT	5373
2998	UCAAUUG G UCAACCUU	4088	AAGGTTGA GGCTAGCTACAACGA CACATTGA	5374
3002	UGUGGUGA A CCUUCUAG	4089	CTAGAAGG GGCTAGCTACAACGA TGACCACA	5375

3011	CCUUCUAG G UGCCUGUA	4090	TACAGGCA GGCTAGCTACAACGA CTAGAAGG	5376
3013	UUCUAGGU G CCUGUACC	4091	GGTACAGG GGCTAGCTACAACGA ACCTAGAA	5377
3017	AGGUGCCU G UACCAAGC	4092	GCTTGGA GGCTAGCTACAACGA AGGCACCT	5378
3019	GUGCCUGU A CCAAGCCA	4093	TGGCTTGG GGCTAGCTACAACGA ACAGGCAC	5379
3024	UGUACCAA G CCAGGAGG	4094	CCTCCTGG GGCTAGCTACAACGA TTGGTACA	5380
3033	CCAGGAGG G CCACUCAU	4095	ATGAGTGG GGCTAGCTACAACGA CCTCCTGG	5381
3036	GGAGGGCC A CUCAUGGU	4096	ACCATGAG GGCTAGCTACAACGA GGCCCTCC	5382
3040	GGCCACUC A UGGUGAUU	4097	AATCACCA GGCTAGCTACAACGA GAGTGGCC	5383
3043	CACUCAUG G UGAUUGUG	4098	CACAATCA GGCTAGCTACAACGA CATGAGTG	5384
3046	UCAUGGUG A UUGUGGAA	4099	TTCCACAA GGCTAGCTACAACGA CACCATGA	5385
3049	UGGUGAUU G UGGAUUC	4100	GAATTCCA GGCTAGCTACAACGA AATCACCA	5386
3054	AUUGUGGA A UUCUGCAA	4101	TTGCAGAA GGCTAGCTACAACGA TCCACAAT	5387
3059	GGAAUUCU G CAAAUUUG	4102	CAAAATTG GGCTAGCTACAACGA AGAATTCC	5388
3063	UUCUGCAA A UUUGGAA	4103	TTTCCAAA GGCTAGCTACAACGA TTGCAGAA	5389
3071	AUUUGGAA A CCUGUCCA	4104	TGGACAGG GGCTAGCTACAACGA TTCCAAAT	5390
3075	GGAAACCU G UCCACUUA	4105	TAAGTGGG GGCTAGCTACAACGA AGGTTTCC	5391
3079	ACCUGUCC A CUUACCUG	4106	CAGGTAAG GGCTAGCTACAACGA GGACAGGT	5392
3083	GUCCACUU A CCUGAGGA	4107	TCCTCAGG GGCTAGCTACAACGA AAGTGGAC	5393
3092	CCUGAGGA G CAAGAGAA	4108	TTCTCTTG GGCTAGCTACAACGA TCCTCAGG	5394
3101	CAAGAGAA A UGAUUUUG	4109	CAAAATCA GGCTAGCTACAACGA TTCTCTTG	5395
3105	AGAAUUGA A UUUGUCCC	4110	GGGACAAA GGCTAGCTACAACGA TCATTTCT	5396
3109	AUGAAUUU G UCCCCUAC	4111	GTAGGGGA GGCTAGCTACAACGA AAATTCAT	5397
3116	UGUCCCCU A CAAGACCA	4112	TGGTCTTG GGCTAGCTACAACGA AGGGGACA	5398
3121	CUUACAAG A CCAAGGGG	4113	CCCTTTGG GGCTAGCTACAACGA CTGTAGG	5399
3130	CCAAGGGG G CACGAUUC	4114	GAATCGTG GGCTAGCTACAACGA CCCTTTGG	5400
3132	AAAGGGGC A CGAUUCCG	4115	CGGAATCG GGCTAGCTACAACGA GCCCCTTT	5401
3135	GGGGCAGG A UUCCGUCA	4116	TGACGGAA GGCTAGCTACAACGA CGTGCCCC	5402
3140	ACGAUUCG G UCAAGGGA	4117	TCCCTTGA GGCTAGCTACAACGA GGAATCGT	5403
3152	AGGGAAAG A CUACGUUG	4118	CAACGTAG GGCTAGCTACAACGA CTTTCCCT	5404
3155	GAAAGACU A CGUUGGAG	4119	CTCCAACG GGCTAGCTACAACGA AGTCTTTC	5405
3157	AAGACTAC G UUGGAGCA	4120	TGCTCCAA GGCTAGCTACAACGA GTAGTCTT	5406
3163	ACGUUGGA G CAAUCCCU	4121	AGGGATTG GGCTAGCTACAACGA TCCAACGT	5407
3166	UUGGAGCA A UCCUGUG	4122	CACAGGGA GGCTAGCTACAACGA TGCTCCAA	5408
3172	CAAUCCCU G UGGAUCUG	4123	CAGATCCA GGCTAGCTACAACGA AGGGATTG	5409
3176	CCCUGUGG A UCUGAAAC	4124	GTTTCAGA GGCTAGCTACAACGA CCACAGGG	5410
3183	GAUCUGAA A CGGCBCUU	4125	AAGCGCCG GGCTAGCTACAACGA TTCAGATC	5411
3186	CUGAAACG G CGCUUGGA	4126	TCCAAGCG GGCTAGCTACAACGA CGTTTCAG	5412
3188	GAAACGGC G CUUGGACA	4127	TGTCCAAG GGCTAGCTACAACGA GCCGTTTC	5413
3194	GCGCUUGG A CAGCAUCA	4128	TGATGCTG GGCTAGCTACAACGA CCAAGCGC	5414
3197	CUUGGACA G CAUCACCA	4129	TGGTGATG GGCTAGCTACAACGA TGTCCAAG	5415
3199	UGGACAGC A UCACCAGU	4130	ACTGGTGA GGCTAGCTACAACGA GCTGTCCA	5416
3202	ACAGCAUC A CCAGUAGC	4131	GCTACTGG GGCTAGCTACAACGA GATGCTGT	5417
3206	CAUCACCA G UAGCCAGA	4132	TCTGGCTA GGCTAGCTACAACGA TGGTGATG	5418
3209	CACCAGUA G CCAGAGCU	4133	AGCTCTGG GGCTAGCTACAACGA TACTGGTG	5419
3215	UAGCCAGA G CUCAGCCA	4134	TGGCTGAG GGCTAGCTACAACGA TCTGGCTA	5420
3220	AGAGCUCA G CCAGCUCU	4135	AGAGCTGG GGCTAGCTACAACGA TGAGCTCT	5421
3224	CUCAGCCA G CUCUGGAU	4136	ATCCAGAG GGCTAGCTACAACGA TGGCTGAG	5422
3231	AGCUCUGG A UUUGUGGA	4137	TCCACAAA GGCTAGCTACAACGA CCAGAGCT	5423
3235	CUGGAUUU G UGGAGGAG	4138	CTCCTCCA GGCTAGCTACAACGA AAATCCAG	5424
3246	GAGGAGAA G UCCUCAG	4139	CTGAGGGA GGCTAGCTACAACGA TTCTCCTC	5425
3254	GUCCCCUG A UGAUGUAG	4140	CTACATCA GGCTAGCTACAACGA TGAGGGAC	5426
3257	CCUCAGUG A UGUAGAAG	4141	CTTCTACA GGCTAGCTACAACGA CACTGAGG	5427
3259	UCAGUGAU G UAGAAGAA	4142	TTCTTCTA GGCTAGCTACAACGA ATCACTGA	5428

3274	AAGAGGAA G CUCCUGAA	4143	TTCAGGAG GGCTAGCTACAACGA TTCCTCTT	5429
3284	UCCUGAAG A UCUGUAUA	4144	TATACAGA GGCTAGCTACAACGA CTTCAGGA	5430
3288	GAAGAUCU G UAUAAGGA	4145	TCCTTATA GGCTAGCTACAACGA AGATCTTC	5431
3290	AGAUCUGU A UAAGGACU	4146	AGTCCTTA GGCTAGCTACAACGA ACAGATCT	5432
3296	GUUAAGG A CUUCCUGA	4147	TCAGGAAG GGCTAGCTACAACGA CCTTATAC	5433
3304	ACUUCCUG A CCUUGGAG	4148	CTCCAAGG GGCTAGCTACAACGA CAGGAAGT	5434
3312	ACCUUGGA G CAUCUCAU	4149	ATGAGATG GGCTAGCTACAACGA TCCAAGGT	5435
3314	CUUGGAGC A UCUCAUCU	4150	AGATGAGA GGCTAGCTACAACGA GCTCCAAG	5436
3319	AGCAUCUC A UCUGUUAU	4151	GTAACAGA GGCTAGCTACAACGA GAGATGCT	5437
3323	UCUCAUCU G UUAACAGU	4152	AGCTGTAA GGCTAGCTACAACGA AGATGAGA	5438
3326	CAUCUGUU A CAGCUUCC	4153	GGAAGCTG GGCTAGCTACAACGA AACAGATG	5439
3329	CUGUACA G CUUCCAAG	4154	CTTGAAG GGCTAGCTACAACGA TGTAAACAG	5440
3337	GCUCCAA G UGGCUAAG	4155	CTTAGCCA GGCTAGCTACAACGA TTGGAAGC	5441
3340	UCCAAGUG G CUAAGGGC	4156	GCCCTTAG GGCTAGCTACAACGA CACTTGGA	5442
3347	GGCUAAGG G CAUGGAGU	4157	ACTCCATG GGCTAGCTACAACGA CCTTAGCC	5443
3349	CUAAGGGC A UGGAGUUC	4158	GAATCCA GGCTAGCTACAACGA GCCCTTAG	5444
3354	GGCAUGGA G UUCUUGGC	4159	GCCAAGAA GGCTAGCTACAACGA TCCATGCC	5445
3361	AGUUCUUG G CAUCGCGA	4160	TCGCGATG GGCTAGCTACAACGA CAAGAACT	5446
3363	UUCUUGGC A UCGCGAAA	4161	TTTCGCGA GGCTAGCTACAACGA GCCAAGAA	5447
3366	UUGGCAUC G CGAAAGUG	4162	CACTTTCG GGCTAGCTACAACGA GATGCCAA	5448
3372	UCGCGAAA G UGUUCCA	4163	TGGATACA GGCTAGCTACAACGA TTTCGCGA	5449
3374	GCGAAAGU G UAUCCACA	4164	TGTGGATA GGCTAGCTACAACGA ACTTTCGC	5450
3376	GAAAGUGU A UCCACAGG	4165	CCTGTGGA GGCTAGCTACAACGA ACACTTTC	5451
3380	GUGUAUCC A CAGGGACC	4166	GGTCCCTG GGCTAGCTACAACGA GGATACAC	5452
3386	CCACAGGG A CCUGGCGG	4167	CCGCCAGG GGCTAGCTACAACGA CCCTGTGG	5453
3391	GGGACCUG G CGGCACGA	4168	TCGTGCCG GGCTAGCTACAACGA CAGGTCCC	5454
3394	ACCUGGCG G CACGAAAU	4169	ATTTCTGT GGCTAGCTACAACGA CGCCAGGT	5455
3396	CUGGCGG A CGAAUAU	4170	ATATTTCG GGCTAGCTACAACGA GCCGCCAG	5456
3401	GGCAGGAA A UAUCCUCU	4171	AGAGGATA GGCTAGCTACAACGA TTCGTGCC	5457
3403	CACGAAAU A UCCUCUUA	4172	TAAGAGGA GGCTAGCTACAACGA ATTTCTGT	5458
3411	AUCCUCUU A UCGGAGAA	4173	TTCTCCGA GGCTAGCTACAACGA AAGAGGAT	5459
3422	GGAGAAGA A CGUGGUUA	4174	TAACCACG GGCTAGCTACAACGA TCTTCTCC	5460
3424	AGAAGAAC G UGGUUAUA	4175	TTTAACCA GGCTAGCTACAACGA GTTCTTCT	5461
3427	AGAACGUG G UUAUAUUC	4176	GATTTTAA GGCTAGCTACAACGA CACGTTCT	5462
3433	UGGUUAUA A UCUGUGAC	4177	GTCACAGA GGCTAGCTACAACGA TTTAACCA	5463
3437	UAAUAUCU G UGACUUUG	4178	CAAAGTCA GGCTAGCTACAACGA AGATTTTA	5464
3440	AAUCUGUG A CUUUGGCU	4179	AGCCAAAG GGCTAGCTACAACGA CACAGATT	5465
3446	UGACUUUG G CUUGGCCC	4180	GGGCCAAG GGCTAGCTACAACGA CAAAGTCA	5466
3451	UUGGCUUG G CCCGGGAU	4181	ATCCCGGG GGCTAGCTACAACGA CAAGCCAA	5467
3458	GGCCCGGG A UAUUUAUA	4182	TATAATA GGCTAGCTACAACGA CCCGGGCC	5468
3460	CCCGGGAU A UUUUAUAA	4183	TTTATAAA GGCTAGCTACAACGA ATCCCGGG	5469
3464	GGUAUUAU A UAAAGAU	4184	GATCTTTA GGCTAGCTACAACGA AAATATCC	5470
3470	UUAUAAG A UCCAGAUU	4185	AATCTGGA GGCTAGCTACAACGA CTTTATAA	5471
3476	AGAUCAG A UUAUGUCA	4186	TGACATAA GGCTAGCTACAACGA CTGGATCT	5472
3479	UCCAGAUU A UGUCAGAA	4187	TTCTGACA GGCTAGCTACAACGA AATCTGGA	5473
3481	CAGAUUAU G UCAGAAA	4188	TTTCTGTA GGCTAGCTACAACGA ATAATCTG	5474
3494	AAAAGGAG A UGCUCGCC	4189	GGCGAGCA GGCTAGCTACAACGA CTCCTTTT	5475
3496	AAGGAGAU G CUCGCCUC	4190	GAGGCGAG GGCTAGCTACAACGA ATCTCCTT	5476
3500	AGAUGCUC G CCUCCUUU	4191	AAGGGAGG GGCTAGCTACAACGA GAGCATCT	5477
3513	CCUUGGAA A UGGAUGGC	4192	GCCATCCA GGCTAGCTACAACGA TTCAAAGG	5478
3517	UGAAUUGG A UGGCCCCA	4193	TGGGGCCA GGCTAGCTACAACGA CCATTTC	5479
3520	AAUGGAUG G CCCAGAA	4194	TTCTGGGG GGCTAGCTACAACGA CATCCATT	5480
3529	CCCCAGAA A CAAUUUUU	4195	AAAATTG GGCTAGCTACAACGA TTCTGGGG	5481

3532	CAGAAACA A UUUUGAC	4196	GTCAAAA GGCTAGCTACAACGA TGTTCTG	5482
3539	AAUUUUUG A CAGAGUGU	4197	ACACTCTG GGCTAGCTACAACGA CAAAAATT	5483
3544	UUGACAGA G UGUACACA	4198	TGTGTACA GGCTAGCTACAACGA TCTGTCAA	5484
3546	GACAGAGU G UACACAAU	4199	ATTGTGTA GGCTAGCTACAACGA ACTCTGTC	5485
3548	CAGAGUGU A CACAAUCC	4200	GGATTGTG GGCTAGCTACAACGA ACACTCTG	5486
3550	GAGUGUAC A CAUCCAG	4201	CTGGATTG GGCTAGCTACAACGA GTACACTC	5487
3553	UGUACACA A UCCAGAGU	4202	ACTCTGGA GGCTAGCTACAACGA TGTGTACA	5488
3560	AAUCCAGA G UGACGUCU	4203	AGACGTCA GGCTAGCTACAACGA TCTGGATT	5489
3563	CCAGAGUG A CGUCUGGU	4204	ACCAGACG GGCTAGCTACAACGA CACTCTGG	5490
3565	AGAGUGAC G UCUGGUCU	4205	AGACCAGA GGCTAGCTACAACGA GTCACCTT	5491
3570	GACGUCUG G UCUUUUGG	4206	CCAAAAGA GGCTAGCTACAACGA CAGACGTC	5492
3578	GUCUUUUG G UGUUUUGC	4207	GCAAAACA GGCTAGCTACAACGA CAAAAGAC	5493
3580	CUUUUGGU G UUUUGCUG	4208	CAGCAAAA GGCTAGCTACAACGA ACCAAAAG	5494
3585	GGUGUUUU G CUGUGGGA	4209	TCCCACAG GGCTAGCTACAACGA AAAACACC	5495
3588	GUUUUGCU G UGGGAAAU	4210	ATTTCCCA GGCTAGCTACAACGA AGCAAAAC	5496
3595	UGUGGGAA A UAUUUUCC	4211	GGAAATA GGCTAGCTACAACGA TTTCCACA	5497
3597	UGGGAUU A UUUUCCUU	4212	AAGGAAAA GGCTAGCTACAACGA ATTTCCCA	5498
3608	UUCUUUAG G UGUUUCUC	4213	GAGAAGCA GGCTAGCTACAACGA CTAAGGAA	5499
3610	CCUUAGGU G CUUCUCCA	4214	TGGAGAAG GGCTAGCTACAACGA ACCTAAGG	5500
3618	GUUCUCC A UAUCUGG	4215	CCAGGATA GGCTAGCTACAACGA GGAGAAGC	5501
3620	UUCUCCAU A UCCUGGGG	4216	CCCAGGA GGCTAGCTACAACGA ATGGAGAA	5502
3628	AUCCUGGG G UAAAGAUU	4217	AATCTTTA GGCTAGCTACAACGA CCCAGGAT	5503
3634	GGGUAAG A UUGAUGAA	4218	TTCAATCA GGCTAGCTACAACGA CTTTACCC	5504
3638	AAAGAUUG A UGAAGAAU	4219	ATTCTTCA GGCTAGCTACAACGA CAATCTTT	5505
3645	GAUGAAGA A UUUUGUAG	4220	CTACAAAA GGCTAGCTACAACGA TCTTCATC	5506
3650	AGAAUUUU G UAGGCGAU	4221	ATCGCTTA GGCTAGCTACAACGA AAAATTCT	5507
3654	UUUUGUAG G CGAUUGAA	4222	TTCAATCG GGCTAGCTACAACGA CTACAAAA	5508
3657	UGUAGGCG A UUGAAAGA	4223	TCTTTCAA GGCTAGCTACAACGA CGCTTACA	5509
3670	AAGAAGGA A CUAGAAUG	4224	CATTCTAG GGCTAGCTACAACGA TCCTTCTT	5510
3676	GAACUAGA A UGAGGGCC	4225	GGCCCTCA GGCTAGCTACAACGA TCTAGTTC	5511
3682	GRAUGAGG G CCCUGAU	4226	ATCAGGGG GGCTAGCTACAACGA CCTCATTC	5512
3689	GGCCCCUG A UUAUACUA	4227	TAGTATAA GGCTAGCTACAACGA CAGGGGCC	5513
3692	CCCUGAUU A UACUACAC	4228	GTGTAGTA GGCTAGCTACAACGA AATCAGGG	5514
3694	CUGAUUAA A CUACACCA	4229	TGGTGTAG GGCTAGCTACAACGA ATAATCAG	5515
3697	AUAUACU A CACCAGAA	4230	TTCTGGTG GGCTAGCTACAACGA AGTATAAT	5516
3699	UAUACUAC A CCAGAAAU	4231	ATTTCTGG GGCTAGCTACAACGA GTAGTATA	5517
3706	CACCAGAA A UGUACCAG	4232	CTGGTACA GGCTAGCTACAACGA TTCTGGTG	5518
3708	CCAGAAAU G UACCAGAC	4233	GTCTGGTA GGCTAGCTACAACGA ATTTCTGG	5519
3710	AGAAAUUG A CCAGACCA	4234	TGGTCTGG GGCTAGCTACAACGA ACATTTCT	5520
3715	UGUACCAG A CCAUGCUG	4235	CAGCATGG GGCTAGCTACAACGA CTGGTACA	5521
3718	ACCAGACC A UGUGGAC	4236	GTCCAGCA GGCTAGCTACAACGA GGTCTGGT	5522
3720	CAGACCAU G CUGGACUG	4237	CAGTCCAG GGCTAGCTACAACGA ATGGTCTG	5523
3725	CAUGCUGG A CUGCUGGC	4238	GCCAGCAG GGCTAGCTACAACGA CCAGCATG	5524
3728	GCUGGACU G CUGGCACG	4239	CGTGCCAG GGCTAGCTACAACGA AGTCCAGC	5525
3732	GACUGCUG G CACGGGGA	4240	TCCCCGTG GGCTAGCTACAACGA CAGCAGTC	5526
3734	CUGCUGGC A CGGGGAGC	4241	GCTCCCCG GGCTAGCTACAACGA GCCAGCAG	5527
3741	CACGGGGA G CCCAGUCA	4242	TGACTGGG GGCTAGCTACAACGA TCCCCGTG	5528
3746	GGAGCCCA G UCAGAGAC	4243	GTCTCTGA GGCTAGCTACAACGA TGGGCTCC	5529
3753	AGUCAGAG A CCCACGUU	4244	AACGTGGG GGCTAGCTACAACGA CTCTGACT	5530
3757	AGAGACCC A CGUUUUCA	4245	TGAAAACG GGCTAGCTACAACGA GGGTCTCT	5531
3759	AGACCCAC G UUUUCAGA	4246	TCTGAAAA GGCTAGCTACAACGA GTGGGTCT	5532
3768	UUUUCAGA G UUGUGGGA	4247	TCCACCAA GGCTAGCTACAACGA TCTGAAAA	5533
3772	CAGAGUUG G UGGAACAU	4248	ATGTTCCA GGCTAGCTACAACGA CAACTCTG	5534

3777	UUGGUGGA A CAUUGGG	4249	CCCAAATG GGCTAGCTACAACGA TCCACCAA	5535
3779	GGUGGAAC A UUUGGGAA	4250	TTCCCAAA GGCTAGCTACAACGA GTTCCACC	5536
3788	UUUGGGAA A UCUCUUGC	4251	GCAAGAGA GGCTAGCTACAACGA TTCCCAAA	5537
3795	AAUCUCUU G CAAGCUAA	4252	TTAGCTTG GGCTAGCTACAACGA AAGAGATT	5538
3799	UCUUGCAA G CUAUUGCU	4253	AGCATTAG GGCTAGCTACAACGA TTGCAAGA	5539
3803	GCAAGCUA A UGCUCAGC	4254	GCTGAGCA GGCTAGCTACAACGA TAGCTTGC	5540
3805	AAGCUAAU G CUCAGCAG	4255	CTGCTGAG GGCTAGCTACAACGA ATTAGCTT	5541
3810	AAUGCUCA G CAGGAUGG	4256	CCATCCTG GGCTAGCTACAACGA TGAGCATT	5542
3815	UCAGCAGG A UGGCAAAG	4257	CTTTGCCA GGCTAGCTACAACGA CCTGCTGA	5543
3818	GCAGGAUG G CAAAGACU	4258	AGTCTTTG GGCTAGCTACAACGA CATCCTGC	5544
3824	UGGCAAAG A CUACAUUG	4259	CAATGTAG GGCTAGCTACAACGA CTTTGCCA	5545
3827	CAAAGACU A CAUUGUUC	4260	GAACAATG GGCTAGCTACAACGA AGTCTTTG	5546
3829	AAGACUAC A UUGUUCUU	4261	AAGAACAA GGCTAGCTACAACGA GTAGTCTT	5547
3832	ACUACAUU G UUCUCCG	4262	CGGAAGAA GGCTAGCTACAACGA AATGTAGT	5548
3841	UUCUCCG A UAUCAGAG	4263	CTCTGATA GGCTAGCTACAACGA CGGAAGAA	5549
3843	CUUCCGAU A UCAGAGAC	4264	GTCTCTGA GGCTAGCTACAACGA ATCGGAAG	5550
3850	UAUCAGAG A CUUUGAGC	4265	GCTCAAAG GGCTAGCTACAACGA CTCTGATA	5551
3857	GACUUUGA G CAUGGAAG	4266	CTTCCATG GGCTAGCTACAACGA TCAAAGTC	5552
3859	CUUUGAGC A UGGAAGAG	4267	CTCTTCCA GGCTAGCTACAACGA GCTCAAAG	5553
3869	GGAAGAGG A UUCUGGAC	4268	GTCCAGAA GGCTAGCTACAACGA CCTCTTCC	5554
3876	GAUUCUGG A CUCUCUCU	4269	AGAGAGAG GGCTAGCTACAACGA CCAGAATC	5555
3885	CUCUCUCU G CCUACCUC	4270	GAGGTAGG GGCTAGCTACAACGA AGAGAGAG	5556
3889	CUCUGCCU A CCUCACCU	4271	AGGTGAGG GGCTAGCTACAACGA AGGCAGAG	5557
3894	CCUACCUC A CCUGUUUC	4272	GAAACAGG GGCTAGCTACAACGA GAGGTAGG	5558
3898	CCUCACCU G UUUCUGU	4273	ACAGGAAA GGCTAGCTACAACGA AGGTGAGG	5559
3905	UGUUUCCU G UAUGGAGG	4274	CCTCCATA GGCTAGCTACAACGA AGGAAACA	5560
3907	UUUCCUGU A UGGAGGAG	4275	CTCCTCCA GGCTAGCTACAACGA ACAGGAAA	5561
3922	AGGAGGAA G UAUGUGAC	4276	GTCACATA GGCTAGCTACAACGA TTCCTCCT	5562
3924	GAGGAAGU A UGUGACCC	4277	GGGTCACA GGCTAGCTACAACGA ACTTCCTC	5563
3926	GGAAGUAA G UGACCCCA	4278	TGGGGTCA GGCTAGCTACAACGA ATACTTCC	5564
3929	AGUAUGUG A CCCCAAU	4279	ATTTGGGG GGCTAGCTACAACGA CACATACT	5565
3936	GACCCCAA A UUCAUAU	4280	TAATGGAA GGCTAGCTACAACGA TTGGGGTC	5566
3941	CAAAUUC A UUAUGACA	4281	TGTCATAA GGCTAGCTACAACGA GGAATTTG	5567
3944	AUUCCAU A UGACAACA	4282	TGTTGTCA GGCTAGCTACAACGA AATGGAAT	5568
3947	CAUUAUG A CAACACAG	4283	CTGTGTTG GGCTAGCTACAACGA CATAATGG	5569
3950	UUAUGACA A CACAGCAG	4284	CTGCTGTG GGCTAGCTACAACGA TGTCATAA	5570
3952	AUGACAAC A CAGCAGGA	4285	TCCTGCTG GGCTAGCTACAACGA GTTGTTCAT	5571
3955	ACAACACA G CAGGAAUC	4286	GATTCTTG GGCTAGCTACAACGA TGTGTGTG	5572
3961	CAGCAGGA A UCAGUCAG	4287	CTGACTGA GGCTAGCTACAACGA TCCTGCTG	5573
3965	AGGAUAUA G UCAGUAUC	4288	GATACTGA GGCTAGCTACAACGA TGATTTCCT	5574
3969	AUCAGUCA G UAUCUGCA	4289	TGCAGATA GGCTAGCTACAACGA TGA CTGAT	5575
3971	CAGUCAGU A UCUGCAGA	4290	TCTGCAGA GGCTAGCTACAACGA ACTGACTG	5576
3975	CAGUAUCU G CAGAACAG	4291	CTGTTCTG GGCTAGCTACAACGA AGATACTG	5577
3980	UCUGCAGA A CAGUAAGC	4292	GCTTACTG GGCTAGCTACAACGA TCTGCAGA	5578
3983	GCAGAACA G UAAGCGAA	4293	TTGCTTA GGCTAGCTACAACGA TGTTCCTG	5579
3987	AACAGUAA G CGAAAGAG	4294	CTCTTTCG GGCTAGCTACAACGA TTA CTGTT	5580
3995	GCGAAAGA G CCGGCCUG	4295	CAGGCCGG GGCTAGCTACAACGA TCTTTTCG	5581
3999	AAGAGCCG G CCUGUGAG	4296	CTCACAGG GGCTAGCTACAACGA CGGCTCTT	5582
4003	GCCGCCCU G UGAGUGUA	4297	TACACTCA GGCTAGCTACAACGA AGGCCGGC	5583
4007	GCCUGUGA G UGUAAAA	4298	TTTTTACA GGCTAGCTACAACGA TCACAGGC	5584
4009	CUGUGAGU G UAAAAACA	4299	TGTTTTTA GGCTAGCTACAACGA ACTCACAG	5585
4015	GUGUAAAA A CAUUUGAA	4300	TTCAAATG GGCTAGCTACAACGA TTTTACAC	5586
4017	GUAAAAAC A UUUGAAGA	4301	TCTTCAAA GGCTAGCTACAACGA GTTTTTAC	5587

4025	AUUUGAAG A UAUCCCGU	4302	ACGGGATA GGCTAGCTACAACGA CTTCAAAT	5588
4027	UUGAAGAU A UCCCGUUA	4303	TAACGGGA GGCTAGCTACAACGA ATCTTCAA	5589
4032	GADAUCCC G UUAGAAGA	4304	TCTTCTAA GGCTAGCTACAACGA GGGATATC	5590
4041	UUAGAAGA A CCAGAAGU	4305	ACTTCTGG GGCTAGCTACAACGA TCTTCTAA	5591
4048	AACCAGAA G UAAAAGUA	4306	TACTTTTA GGCTAGCTACAACGA TTCTGGTT	5592
4054	AAGUAAAA G UAAUCCCA	4307	TGGGATTA GGCTAGCTACAACGA TTTTACTT	5593
4057	UAAAAGUA A UCCCAGAU	4308	ATCTGGGA GGCTAGCTACAACGA TACTTTTA	5594
4064	AAUCCAG A UGACAACC	4309	GGTTGTCA GGCTAGCTACAACGA CTGGGATT	5595
4067	CCCAGAU G CAACCAGA	4310	TCTGGTTG GGCTAGCTACAACGA CATCTGGG	5596
4070	AGAUGACA A CCAGACGG	4311	CCGTCTGG GGCTAGCTACAACGA TGTCTATC	5597
4075	ACAACCG A CGGACAGU	4312	ACTGTCCG GGCTAGCTACAACGA CTGGTTGT	5598
4079	CCAGACGG A CAGUGGUA	4313	TACCACTG GGCTAGCTACAACGA CCGTCTGG	5599
4082	GACGGACA G UGUUAUGG	4314	CCATACCA GGCTAGCTACAACGA TGTCCGTC	5600
4085	GGACAGUG G UAUGGUUC	4315	GAACCATA GGCTAGCTACAACGA CACTGTCC	5601
4087	ACAGUGGU A UGUUUCU	4316	AAGAACCA GGCTAGCTACAACGA ACCACTGT	5602
4090	GUGGUAUG G UUCUUGCC	4317	GGCAAGAA GGCTAGCTACAACGA CATAACCAC	5603
4096	UGGUUCU G CCUCAGAA	4318	TTCTGAGG GGCTAGCTACAACGA AAGAACCA	5604
4107	UCAGAAGA G CUGAAAC	4319	GTTTTCAG GGCTAGCTACAACGA TCTTCTGA	5605
4114	AGCUGAAA A CUUUGGAA	4320	TTCCAAAG GGCTAGCTACAACGA TTTCAGCT	5606
4124	UUUGGAAG A CAGAACCA	4321	TGGTCTG GGCTAGCTACAACGA CTTCCAAA	5607
4129	AAGACAGA A CCAAUUA	4322	TAATTTGG GGCTAGCTACAACGA TCTGTCTT	5608
4134	AGAACCAA A UUAUCUCC	4323	GGAGATAA GGCTAGCTACAACGA TTGGTTCT	5609
4137	ACCAAU A UCUCUCC	4324	GATGGAGA GGCTAGCTACAACGA AATTGGT	5610
4143	UUAUCUCC A UCUUUUGG	4325	CCAAAAGA GGCTAGCTACAACGA GGAGATAA	5611
4151	AUCUUUUG G UGGAAUGG	4326	CCATTCCA GGCTAGCTACAACGA CAAAAGAT	5612
4156	UUGGUGGA A UGGUGCCC	4327	GGGCACCA GGCTAGCTACAACGA TCCACCAA	5613
4159	GUGGAAUG G UGCCCAGC	4328	GCTGGGCA GGCTAGCTACAACGA CATTCCAC	5614
4161	GGAUUGGU G CCCAGCAA	4329	TTGCTGGG GGCTAGCTACAACGA ACCATTCC	5615
4166	GGUGCCCA G CAAAAGCA	4330	TGCTTTTG GGCTAGCTACAACGA TGGGCACC	5616
4172	CAGCAAAA G CAGGGAGU	4331	ACTCCCTG GGCTAGCTACAACGA TTTTGCTG	5617
4179	AGCAGGGA G UCUGUGGC	4332	GCCACAGA GGCTAGCTACAACGA TCCCTGCT	5618
4183	GGGAGUCU G UGGCAUCU	4333	AGATGCCA GGCTAGCTACAACGA AGACTCCC	5619
4186	AGUCUGUG G CAUCUGAA	4334	TTCAGATG GGCTAGCTACAACGA CACAGACT	5620
4188	UCUGUGGC A UCUGAAGG	4335	CCTTCAGA GGCTAGCTACAACGA GCCACAGA	5621
4196	AUCUGAAG G CUCAAACC	4336	GGTTTGAG GGCTAGCTACAACGA CTTCAGAT	5622
4202	AGGCUCAA A CCAGACAA	4337	TTGTCTGG GGCTAGCTACAACGA TTGAGCCT	5623
4207	CAAACCG A CAAGCGGC	4338	GCCGCTTG GGCTAGCTACAACGA CTGGTTTG	5624
4211	CCAGACAA G CGGCUACC	4339	GGTAGCCG GGCTAGCTACAACGA TTGTCTGG	5625
4214	GACAAGCG G CUACCAGU	4340	ACTGGTAG GGCTAGCTACAACGA CGCTTGTC	5626
4217	AAGCGGCU A CCAGUCCG	4341	CGGACTGG GGCTAGCTACAACGA AGCCGCTT	5627
4221	GGCUACCA G UCCGGAUA	4342	TATCCGGA GGCTAGCTACAACGA TGGTAGCC	5628
4227	CAGUCCGG A UAUCACUC	4343	GAGTGATA GGCTAGCTACAACGA CCGGACTG	5629
4229	GUCCGGAU A UCACUCCG	4344	CGGAGTGA GGCTAGCTACAACGA ATCCGGAC	5630
4232	CGGAUAUC A CUCCGAGG	4345	CATCGGAG GGCTAGCTACAACGA GATATCCG	5631
4238	UCACUCCG A UGACACAG	4346	CTGTGTCA GGCTAGCTACAACGA CGGAGTGA	5632
4241	CUCCGAGU A CACAGACA	4347	TGTCTGTG GGCTAGCTACAACGA CATCGGAG	5633
4243	CCGAUGAC A CAGACACC	4348	GGTGTCTG GGCTAGCTACAACGA GTCATCGG	5634
4247	UGACACAG A CACCACCG	4349	CGGTGGTG GGCTAGCTACAACGA CTGTGTCA	5635
4249	ACACAGAC A CCACCGUG	4350	CACGGTGG GGCTAGCTACAACGA GTCTGTGT	5636
4252	CAGACACC A CCGUGUAC	4351	GTACACGG GGCTAGCTACAACGA GGTGTCTG	5637
4255	ACACCACC G UGUACUCC	4352	GGAGTACA GGCTAGCTACAACGA GGTGGTGT	5638
4257	ACCACCGU G UACUCCAG	4353	CTGGAGTA GGCTAGCTACAACGA ACGGTGGT	5639
4259	CACCGUGU A CUCCAGUG	4354	CACTGGAG GGCTAGCTACAACGA ACACGGTG	5640

4265	GUACUCCA G UGAGGAAG	4355	CTTCCTCA GGCTAGCTACAACGA TGGAGTAC	5641
4273	GUGAGGAA G CAGAACUU	4356	AAGTTCTG GGCTAGCTACAACGA TTCCTCAC	5642
4278	GAAGCAGA A CUUUUAAA	4357	TTTAAAAG GGCTAGCTACAACGA TCTGCTTC	5643
4287	CUUUUAAA G CUGAUAGA	4358	TCTATCAG GGCTAGCTACAACGA TTTAAAAG	5644
4291	UAAAGCUG A UAGAGAUU	4359	AATCTCTA GGCTAGCTACAACGA CAGCTTTA	5645
4297	UGAUAGAG A UUGGAGUG	4360	CACTCCAA GGCTAGCTACAACGA CTCTATCA	5646
4303	AGAUGGA G UGCAAACC	4361	GGTTTGCA GGCTAGCTACAACGA TCCAATCT	5647
4305	AUUGGAGU G CAAACCGG	4362	CCGGTTTG GGCTAGCTACAACGA ACTCCAAT	5648
4309	GAGUGCAA A CCGUAGC	4363	GCTACCGG GGCTAGCTACAACGA TTGCACTC	5649
4313	GCAAACCG G UAGCACAG	4364	CTGTGCTA GGCTAGCTACAACGA CGGTTTTC	5650
4316	AACCGGUA G CACAGCCC	4365	GGGCTGTG GGCTAGCTACAACGA TACCGGTT	5651
4318	CCGUAGC A CAGCCAG	4366	CTGGGCTG GGCTAGCTACAACGA GCTACCGG	5652
4321	GUAGCACA G CCCAGAUU	4367	AATCTGGG GGCTAGCTACAACGA TGTGCTAC	5653
4327	CAGCCAG A UUCUCCAG	4368	CTGGAGAA GGCTAGCTACAACGA CTGGGCTG	5654
4335	AUUCUCCA G CCUGACUC	4369	GAGTCAGG GGCTAGCTACAACGA TGGAGAAT	5655
4340	CCAGCCUG A CUCGGGGA	4370	TCCCGGAG GGCTAGCTACAACGA CAGGCTGG	5656
4348	ACUCGGGG A CCACACUG	4371	CAGTGTGG GGCTAGCTACAACGA CCCCAGT	5657
4351	CGGGGACC A CACUGAGC	4372	GCTCAGTG GGCTAGCTACAACGA GGTCCCCG	5658
4353	GGGACCAC A CUGAGCUC	4373	GAGCTCAG GGCTAGCTACAACGA GTGGTCCC	5659
4358	CACACUGA G CUCUCCUC	4374	GAGGAGAG GGCTAGCTACAACGA TCAGTGTG	5660
4369	CUCCUCCU G UUUAAAAG	4375	CTTTTAAA GGCTAGCTACAACGA AGGAGGAG	5661
4381	AAAAGGAA G CAUCCACA	4376	TGTGGATG GGCTAGCTACAACGA TTCCTTTT	5662
4383	AAGGAAGC A UCCACACC	4377	GGTGTGGA GGCTAGCTACAACGA GCTTCCTT	5663
4387	AAGCAUCC A CACCCCAA	4378	TTGGGGTG GGCTAGCTACAACGA GGATGCTT	5664
4389	GCAUCCAC A CCCCAACU	4379	AGTTGGGG GGCTAGCTACAACGA GTGGATGC	5665
4395	ACACCCCA A CUCCCGGA	4380	TCCGGGAG GGCTAGCTACAACGA TGGGGTGT	5666
4403	ACUCCCGG A CAUCACAU	4381	ATGTGATG GGCTAGCTACAACGA CCGGGAGT	5667
4405	UCCCGGAC A UCACAUGA	4382	TCATGTGA GGCTAGCTACAACGA GTCCGGGA	5668
4408	CGGACAUC A CAUGAGAG	4383	CTCTCATG GGCTAGCTACAACGA GATGTCCG	5669
4410	GACAUCAC A UGAGAGGU	4384	ACCTCTCA GGCTAGCTACAACGA GTGATGTC	5670
4417	CAUGAGAG G UCUGCUCA	4385	TGAGCAGA GGCTAGCTACAACGA CTCTCATG	5671
4421	AGAGGUCU G CUCAGAUU	4386	AATCTGAG GGCTAGCTACAACGA AGACCTCT	5672
4427	CUGCUCAG A UUUUGAAG	4387	CTTCAAAA GGCTAGCTACAACGA CTGAGCAG	5673
4435	AUUUGUAA G UGUUGUUC	4388	GAACAACA GGCTAGCTACAACGA TTCAAAAT	5674
4437	UUUGAAGU G UUGUUCUU	4389	AAGAACAA GGCTAGCTACAACGA ACTTCAAA	5675
4440	GAAGUGUU G UUCUUUCC	4390	GGAAAGAA GGCTAGCTACAACGA AACACTTC	5676
4449	UUCUUUCC A CCAGCAGG	4391	CCTGCTGG GGCTAGCTACAACGA GGAAAGAA	5677
4453	UUCACCA G CAGGAAGU	4392	ACTTCCTG GGCTAGCTACAACGA TGGTGGAA	5678
4460	AGCAGGAA G UAGCCGCA	4393	TGCGGCTA GGCTAGCTACAACGA TTCCTGCT	5679
4463	AGGAAGUA G CCGCAUUU	4394	AAATGCGG GGCTAGCTACAACGA TACTTCCT	5680
4466	AAGUAGCC G CAUUUGAU	4395	ATCAAATG GGCTAGCTACAACGA GGCTACTT	5681
4468	GUAGCCGC A UUUGAUUU	4396	AAATCAAA GGCTAGCTACAACGA GCGGCTAC	5682
4473	CGCAUUUG A UUUCAUU	4397	AATGAAAA GGCTAGCTACAACGA CAAATGCG	5683
4479	UGAUUUUC A UUUCGACA	4398	TGTCGAAA GGCTAGCTACAACGA GAAAATCA	5684
4485	UCAUUUCG A CAACAGAA	4399	TTCTGTTG GGCTAGCTACAACGA CGAAATGA	5685
4488	UUUCGACA A CAGAAAAA	4400	TTTTTCTG GGCTAGCTACAACGA TGTGAAA	5686
4499	GAAAAAGG A CCUCGGAC	4401	GTCCGAGG GGCTAGCTACAACGA CCTTTTTC	5687
4506	GACCUCGG A CUGCAGGG	4402	CCCTGCAG GGCTAGCTACAACGA CCGAGGTC	5688
4509	CUCGGACU G CAGGGAGC	4403	GCTCCCTG GGCTAGCTACAACGA AGTCCGAG	5689
4516	UGCAGGGA G CCAGUCUU	4404	AAGACTGG GGCTAGCTACAACGA TCCCTGCA	5690
4520	GGGAGCCA G UCUUCUAG	4405	CTAGAAGA GGCTAGCTACAACGA TGGCTCCC	5691
4529	UCUUCUAG G CAUAUCCU	4406	AGGATATG GGCTAGCTACAACGA CTAGAAGA	5692
4531	UUCUAGGC A UAUCUUGG	4407	CCAGGATA GGCTAGCTACAACGA GCCTAGAA	5693

4533	CUAGGCAU A UCCUGGAA	4408	TTCCAGGA GGCTAGCTACAACGA ATGCCTAG	5694
4545	UGGAAGAG G CUUGUGAC	4409	GTCACAAG GGCTAGCTACAACGA CTCTTCCA	5695
4549	AGAGGCUU G UGACCCAA	4410	TTGGGTCA GGCTAGCTACAACGA AAGCCTCT	5696
4552	GGCUUGUG A CCCAAGAA	4411	TTCTTGGG GGCTAGCTACAACGA CACAAGCC	5697
4560	ACCCAAGA A UGUGUCUG	4412	CAGACACA GGCTAGCTACAACGA TCTTGGGT	5698
4562	CCAAGAAU G UGUCUGUG	4413	CACAGACA GGCTAGCTACAACGA ATTCTTGG	5699
4564	AAGAAUGU G UCUGUGUC	4414	GACACAGA GGCTAGCTACAACGA ACATTCTT	5700
4568	AUGUGUCU G UGUCUUCU	4415	AGAAGACA GGCTAGCTACAACGA AGACACAT	5701
4570	GUUGUCUGU G UCUUCUCC	4416	GGAGAAGA GGCTAGCTACAACGA ACAGACAC	5702
4581	UUCUCCCA G UGUUGACC	4417	GGTCAACA GGCTAGCTACAACGA TGGGAGAA	5703
4583	CUCCAGU G UUGACCUG	4418	CAGGTCAA GGCTAGCTACAACGA ACTGGGAG	5704
4587	CAGUGUUG A CCUGAUCC	4419	GGATCAGG GGCTAGCTACAACGA CAACACTG	5705
4592	UUGACCUG A UCCUCUUU	4420	AAAGAGGA GGCTAGCTACAACGA CAGGTCAA	5706
4605	CUUUUUUC A UUCAUUUA	4421	TAAATGAA GGCTAGCTACAACGA GAAAAAAG	5707
4609	UUUCAUUC A UUUAAAAA	4422	TTTTTAAA GGCTAGCTACAACGA GAATGAAA	5708
4618	UUUAAAAA G CAUUAUCA	4423	TGATAATG GGCTAGCTACAACGA TTTTTAAA	5709
4620	UAAAAAGC A UUAUCAUG	4424	CATGATAA GGCTAGCTACAACGA GCTTTTTA	5710
4623	AAAGCAUU A UCAUGCCC	4425	GGGCATGA GGCTAGCTACAACGA AATGCTTT	5711
4626	GCAUUAUC A UGCCCCUG	4426	CAGGGGCA GGCTAGCTACAACGA GATAATGC	5712
4628	AUUAUCAU G CCCUGCU	4427	AGCAGGGG GGCTAGCTACAACGA ATGATAAT	5713
4634	AUGCCCUU G CUGCGGGU	4428	ACCCGCAG GGCTAGCTACAACGA AGGGGCAT	5714
4637	CCCUGCU G CGGGUCUC	4429	GAGACCCG GGCTAGCTACAACGA AGCAGGGG	5715
4641	UGCUGCGG G UCUCACCA	4430	TGGTGAGA GGCTAGCTACAACGA CCGCAGCA	5716
4646	CGGGUCUC A CCAUGGGU	4431	ACCCATGG GGCTAGCTACAACGA GAGACCCG	5717
4649	GUCUCACC A UGGGUUUA	4432	TAAACCCA GGCTAGCTACAACGA GGTGAGAC	5718
4653	CACCAUGG G UUUAGAAC	4433	GTCTTAAA GGCTAGCTACAACGA CCATGGTG	5719
4660	GGUUUAGA A CAAAGAGC	4434	GCTCTTTG GGCTAGCTACAACGA TCTAAACC	5720
4667	AACAAAGA G CUUCAAGC	4435	GCTTGAAG GGCTAGCTACAACGA TCTTTGTT	5721
4674	AGCUUCAA G CAUUGGCC	4436	GGCCATTG GGCTAGCTACAACGA TTGAAGCT	5722
4677	UUAAGCA A UGGCCCCA	4437	TGGGGCCA GGCTAGCTACAACGA TGCTTGAA	5723
4680	AAGCAUG G CCCCAUCC	4438	GGATGGGG GGCTAGCTACAACGA CATTGCTT	5724
4685	AUGGCCCC A UCCUAAA	4439	TTTGAGGA GGCTAGCTACAACGA GGGGCCAT	5725
4697	UCAAGAA G UAGCAGUA	4440	TACTGCTA GGCTAGCTACAACGA TTCTTTGA	5726
4700	AAGAAGUA G CAGUACCU	4441	AGGTACTG GGCTAGCTACAACGA TACTTCTT	5727
4703	AAGUAGCA G UACCUGGG	4442	CCCAGGTA GGCTAGCTACAACGA TGCTACTT	5728
4705	GUAGCAGU A CCUGGGGA	4443	TCCCCAGG GGCTAGCTACAACGA ACTGCTAC	5729
4714	CCUGGGGA G CUGACACU	4444	AGTGTGAG GGCTAGCTACAACGA TCCCCAGG	5730
4718	GGGAGCUG A CACUUCUG	4445	CAGAAGTG GGCTAGCTACAACGA CAGCTCCC	5731
4720	GAGCUGAC A CUUCUGUA	4446	TACAGAAG GGCTAGCTACAACGA GTCAGCTC	5732
4726	ACACUUCU G UAAAACUA	4447	TAGTTTAA GGCTAGCTACAACGA AGAAGTGT	5733
4731	UCUGUAAA A CUAGAAGA	4448	TCTTCTAG GGCTAGCTACAACGA TTTACAGA	5734
4739	ACUAGAAG A UAAACCAG	4449	CTGGTTTA GGCTAGCTACAACGA CTTCTAGT	5735
4743	GAAGAUAA A CCAGGCRA	4450	TTGCCTGG GGCTAGCTACAACGA TTATCTTC	5736
4748	UAAACCAG G CAACGUAA	4451	TTAGCTTG GGCTAGCTACAACGA CTGGTTTA	5737
4751	ACCAGGCA A CGUAAGUG	4452	CACCTACG GGCTAGCTACAACGA TGCCTGGT	5738
4753	CAGGCAAC G UAAGUGUU	4453	AACACTTA GGCTAGCTACAACGA GTTGCCTG	5739
4757	CAACGUAA G UGUUCGAG	4454	CTCGAACA GGCTAGCTACAACGA TTACGTTG	5740
4759	ACGUAGU G UUCGAGGU	4455	ACCTCGAA GGCTAGCTACAACGA ACTTACGT	5741
4766	UGUUCGAG G UGUUGAAG	4456	CTTCAACA GGCTAGCTACAACGA CTCGAACA	5742
4768	UUCGAGGU G UUGAAGAU	4457	ATCTTCAA GGCTAGCTACAACGA ACCTCGAA	5743
4775	UGUUGAAG A UGGGAAGG	4458	CCTTCCCA GGCTAGCTACAACGA CTTCAACA	5744
4784	UGGGAAGG A UUUGCAGG	4459	CCTGCAAA GGCTAGCTACAACGA CCTTCCCA	5745
4788	AAGGAUUU G CAGGGCUG	4460	CAGCCCTG GGCTAGCTACAACGA AAATCCTT	5746



4793	UUUGCAGG G CUGAGUCU	4461	AGACTCAG GGCTAGCTACAACGA CCTGCAAA	5747
4798	AGGGCUGA G UCUAUCCA	4462	TGGATAGA GGCTAGCTACAACGA TCAGCCCT	5748
4802	CUGAGUCU A UCCAAGAG	4463	CTCTTGA GGCTAGCTACAACGA AGACTCAG	5749
4811	UCCAAGAG G CUUUGUUU	4464	AAACAAAG GGCTAGCTACAACGA CTCTTGA	5750
4816	GAGGCUUU G UUUAGGAC	4465	GTCCTAAA GGCTAGCTACAACGA AAAGCCTC	5751
4823	UGUUUAGG A CGUGGGUC	4466	GACCCACG GGCTAGCTACAACGA CCTAAACA	5752
4825	UUUAGGAC G UGGGUCCC	4467	GGGACCCA GGCTAGCTACAACGA GTCCTAAA	5753
4829	GGACGUGG G UCCCAAGC	4468	GCTTGGGA GGCTAGCTACAACGA CCACGTCC	5754
4836	GGUCCCAA G CCAAGCCU	4469	AGGCTTGG GGCTAGCTACAACGA TTGGGACC	5755
4841	CAAGCCAA G CCUUAAGU	4470	ACTTAAGG GGCTAGCTACAACGA TTGGCTTG	5756
4848	AGCCUUA A UGUGGAAU	4471	ATTCCACA GGCTAGCTACAACGA TTAAGGCT	5757
4850	CCUUAAGU G UGGAUUC	4472	GAATTCCA GGCTAGCTACAACGA ACTTAAGG	5758
4855	AGUGUGGA A UUCGGAUU	4473	AATCCGAA GGCTAGCTACAACGA TCCACACT	5759
4861	GAUUCGG A UUGAUAGA	4474	TCTATCAA GGCTAGCTACAACGA CCGAATTC	5760
4865	UCGGAUUG A UAGAAAGG	4475	CCTTTCTA GGCTAGCTACAACGA CAATCCGA	5761
4877	AAAGGAAG A CUAACGUU	4476	AACGTTAG GGCTAGCTACAACGA CTTCCTTT	5762
4881	GAAGACUA A CGUUAACU	4477	AGGTAACG GGCTAGCTACAACGA TAGTCTTC	5763
4883	AGACUAAC G UUACCUUG	4478	CAAGGTAA GGCTAGCTACAACGA GTTAGTCT	5764
4886	CUAACGUU A CCUUGCUU	4479	AAGCAAGG GGCTAGCTACAACGA AACGTTAG	5765
4891	GUUACCUU G CUUUGGAG	4480	CTCCAAG GGCTAGCTACAACGA AAGGTAAC	5766
4901	UUUGGAGA G UACUGGAG	4481	CTCCAGTA GGCTAGCTACAACGA TCTCCAAA	5767
4903	UGGAGAGU A CUGGAGCC	4482	GGCTCCAG GGCTAGCTACAACGA ACTCTCCA	5768
4909	GUACUGGA G CCUGCAA	4483	TTTGCAGG GGCTAGCTACAACGA TCCAGTAC	5769
4913	UGGAGCCU G CAAUUGCA	4484	TGCATTTG GGCTAGCTACAACGA AGGCTCCA	5770
4917	GCCUGCAA A UGCAUUGU	4485	ACAATGCA GGCTAGCTACAACGA TTGCAGGC	5771
4919	CUGCAAU G CAUUGUGU	4486	ACACAATG GGCTAGCTACAACGA ATTTGCAG	5772
4921	GCAAAUGC A UUGUGUUU	4487	AAACACAA GGCTAGCTACAACGA GCATTTGC	5773
4924	AAUGCAUU G UGUUUGCU	4488	AGCAACA GGCTAGCTACAACGA AATGCATT	5774
4926	UGCAUUGU G UUUGCUCU	4489	AGAGCAAA GGCTAGCTACAACGA ACAATGCA	5775
4930	UUUGUUUU G CUCUGGUG	4490	CACCAGAG GGCTAGCTACAACGA AAACACAA	5776
4936	UUGCUCUG G UGGAGGUG	4491	CACCTCCA GGCTAGCTACAACGA CAGAGCAA	5777
4942	UGGUGGAG G UGGGCAUG	4492	CATGCCCA GGCTAGCTACAACGA CTCCACCA	5778
4946	GGAGGUGG G CAUGGGGU	4493	ACCCCATG GGCTAGCTACAACGA CCACCTCC	5779
4948	AGGUGGGC A UGGGUCU	4494	AGACCCCA GGCTAGCTACAACGA GCCCACCT	5780
4953	GGCAUGGG G UCUGUUCU	4495	AGAACAGA GGCTAGCTACAACGA CCCATGCC	5781
4957	UGGGGUCU G UUCUGAAA	4496	TTTCAGAA GGCTAGCTACAACGA AGACCCCA	5782
4965	GUUCUGAA A UGUAAAGG	4497	CCTTTACA GGCTAGCTACAACGA TTCAGAAC	5783
4967	UCUGAAAU G UAAAGGGU	4498	ACCCTTTA GGCTAGCTACAACGA ATTTCAGA	5784
4974	UGUAAAGG G UUCAGACG	4499	CGTCTGAA GGCTAGCTACAACGA CCTTTACA	5785
4980	GGGUUCAG A CGGGUUU	4500	AAACCCCG GGCTAGCTACAACGA CTGAACCC	5786
4985	CAGACGGG G UUUCUGGU	4501	ACCAGAAA GGCTAGCTACAACGA CCGTCTG	5787
4992	GGUUUCUG G UUUUAGAA	4502	TTCTAAAA GGCTAGCTACAACGA CAGAAACC	5788
5002	UUUAGAAG G UUGCGUGU	4503	ACACGCAA GGCTAGCTACAACGA CTCTTAAA	5789
5005	AGAAGGUU G CGUGUUCU	4504	AGAACACG GGCTAGCTACAACGA AACCTTCT	5790
5007	AAGGUUGC G UGUUCUUC	4505	GAAGAACA GGCTAGCTACAACGA GCAACCTT	5791
5009	GGUUGCGU G UUCUUCGA	4506	TCGAAGAA GGCTAGCTACAACGA ACGCAACC	5792
5018	UUCUUCGA G UUGGGCUA	4507	TAGCCCAA GGCTAGCTACAACGA TCGAAGAA	5793
5023	CGAGUUGG G CUAAGUA	4508	TACTTTAG GGCTAGCTACAACGA CCAACTCG	5794
5029	GGGCUAAA G UAGAUUUC	4509	GAACCTTA GGCTAGCTACAACGA TTTAGCCC	5795
5034	AAAGUAGA G UUCGUUGU	4510	ACAACGAA GGCTAGCTACAACGA TCTACTTT	5796
5038	UAGAGUUC G UUGUGCUG	4511	CAGCACAA GGCTAGCTACAACGA GAACCTTA	5797
5041	AGUUCGUU G UGCUGUUU	4512	AAACAGCA GGCTAGCTACAACGA AACGAAC	5798
5043	UUCGUUGU G CUGUUUCU	4513	AGAAACAG GGCTAGCTACAACGA ACAACGAA	5799

5046	GUUGUGCU G UUCUGAC	4514	GTCAGAAA GGCTAGCTACAACGA AGCACAAC	5800
5053	UGUUUCUG A CUCCUAAU	4515	ATTAGGAG GGCTAGCTACAACGA CAGAAACA	5801
5060	GACUCCUA A UGAGAGUU	4516	AACTCTCA GGCTAGCTACAACGA TAGGAGTC	5802
5066	UAAUGAGA G UUCUUCC	4517	GGAAGGAA GGCTAGCTACAACGA TCTCATT	5803
5077	CCUCCAG A CCGUAGC	4518	GCTAACGG GGCTAGCTACAACGA CTGGAAGG	5804
5080	UCCAGACC G UAGCUGU	4519	ACAGCTAA GGCTAGCTACAACGA GGTCTGGA	5805
5084	GACCGUUA G CUGUCUC	4520	GGAGACAG GGCTAGCTACAACGA TAACGGTC	5806
5087	CGUAGCU G UCUCUUG	4521	CAAGGAGA GGCTAGCTACAACGA AGCTAACG	5807
5095	GUCUCCU G CCAAGCCC	4522	GGGCTTGG GGCTAGCTACAACGA AAGGAGAC	5808
5100	CUUGCCAA G CCCAGGA	4523	TCCTGGGG GGCTAGCTACAACGA TTGGCAAG	5809
5114	GGAAGAAA A UGAUGCAG	4524	CTGCATCA GGCTAGCTACAACGA TTTCTTCC	5810
5117	AGAAAUG A UGCAGCUC	4525	GAGCTGCA GGCTAGCTACAACGA CATTTTCT	5811
5119	AAAUGAU G CAGCUCUG	4526	CAGAGCTG GGCTAGCTACAACGA ATCATTTC	5812
5122	AUGAUGCA G CUCUGGCU	4527	AGCCAGAG GGCTAGCTACAACGA TGCATCAT	5813
5128	CAGCUCUG G CUCCUUGU	4528	ACAAGGAG GGCTAGCTACAACGA CAGAGCTG	5814
5135	GGCUCUU G UCUCACG	4529	CTGGGAGA GGCTAGCTACAACGA AAGGAGCC	5815
5144	UCUCCAG G CUGAUCCU	4530	AGGATCAG GGCTAGCTACAACGA CTGGGAGA	5816
5148	CCAGGCUG A UCCUUUAU	4531	ATAAAGGA GGCTAGCTACAACGA CAGCCTGG	5817
5155	GAUCCUUU A UUCAGAAU	4532	ATTCTGAA GGCTAGCTACAACGA AAAGGATC	5818
5162	UAUUCAGA A UACCACAA	4533	TTGTGGTA GGCTAGCTACAACGA TCTGAATA	5819
5164	UUCAGAAU A CCACAAAG	4534	CTTTGTGG GGCTAGCTACAACGA ATTCTGAA	5820
5167	AGAAUACC A CAAAGAAA	4535	TTTCTTTG GGCTAGCTACAACGA GGTATTCT	5821
5178	AAGAAAGG A CAUUCAGC	4536	GCTGAATG GGCTAGCTACAACGA CCTTTCTT	5822
5180	GAAAGGAC A UUCAGCUC	4537	GAGCTGAA GGCTAGCTACAACGA GTCCTTTC	5823
5185	GACAUUCA G CUCAAGGC	4538	GCCTTGAG GGCTAGCTACAACGA TGAATGTC	5824
5192	AGCUCAAG G CUCCUGC	4539	GCAGGGAG GGCTAGCTACAACGA CTTGAGCT	5825
5199	GGCUCUUU G CCGUGUUG	4540	CAACACGG GGCTAGCTACAACGA AGGGAGCC	5826
5202	UCCUGCC G UGUUGAAG	4541	CTCAACA GGCTAGCTACAACGA GGCAGGGA	5827
5204	CCUGCCG G UGAAGAG	4542	CTCTTCAA GGCTAGCTACAACGA ACGGCAGG	5828
5212	GUUGAAGA G UUCUGACU	4543	AGTCAGAA GGCTAGCTACAACGA TCTTCAAC	5829
5218	GAGUUCUG A CUGCACAA	4544	TTGTGCAG GGCTAGCTACAACGA CAGAACTC	5830
5221	UUCUGACU G CACAAACC	4545	GGTTTGTG GGCTAGCTACAACGA AGTCAGAA	5831
5223	CUGACUGC A CAAACCAG	4546	CTGGTTTG GGCTAGCTACAACGA GCAGTCAG	5832
5227	CUGCACAA A CCAGCUUC	4547	GAAGCTGG GGCTAGCTACAACGA TTGTGCAG	5833
5231	ACAAACCA G CUUCUGGU	4548	ACCAGAAG GGCTAGCTACAACGA TGGTTTGT	5834
5238	AGCUUCUG G UUUCUUCU	4549	AGAAGAAA GGCTAGCTACAACGA CAGAAGCT	5835
5250	CUUCUGGA A UGAUACC	4550	GGTATTCA GGCTAGCTACAACGA TCCAGAAG	5836
5254	UGGAUUGA A UACCCUCA	4551	TGAGGGTA GGCTAGCTACAACGA TCATTCCA	5837
5256	GAAUGAAU A CCCUCAUA	4552	TATGAGGG GGCTAGCTACAACGA ATTCATT	5838
5262	AUACCCUC A UAUCUGUC	4553	GACAGATA GGCTAGCTACAACGA GAGGGTAT	5839
5264	ACCCUCAU A UCUGUCCU	4554	AGGACAGA GGCTAGCTACAACGA ATGAGGGT	5840
5268	UCAUAUCU G UCCUGAUG	4555	CATCAGGA GGCTAGCTACAACGA AGATATGA	5841
5274	CUGUCCUG A UGUGAUAU	4556	ATATCACA GGCTAGCTACAACGA CAGGACAG	5842
5276	GUCCUGAU G UGAUAUGU	4557	ACATATCA GGCTAGCTACAACGA ATCAGGAC	5843
5279	CUGAUGUG A UAUGUCUG	4558	CAGACATA GGCTAGCTACAACGA CACATCAG	5844
5281	GAUGUGAU A UGUCUGAG	4559	CTCAGACA GGCTAGCTACAACGA ATCAGATC	5845
5283	UGUGAUAU G UCUGAGAC	4560	GTCTCAGA GGCTAGCTACAACGA ATATCACA	5846
5290	UGUCUGAG A CUGAAUGC	4561	GCATTGAG GGCTAGCTACAACGA CTCAGACA	5847
5295	GAGACUGA A UGCGGGAG	4562	CTCCCGCA GGCTAGCTACAACGA TCAGTCTC	5848
5297	GACUGAAU G CGGGAGGU	4563	ACCTCCCG GGCTAGCTACAACGA ATTCAGTC	5849
5304	UGCGGGAG G UUCAUUGU	4564	ACATTGAA GGCTAGCTACAACGA CTCCCGCA	5850
5309	GAGGUUCA A UGUGAAGC	4565	GCTTCACA GGCTAGCTACAACGA TGAACCTC	5851
5311	GGUCAAU G UGAAGCUG	4566	CAGCTTCA GGCTAGCTACAACGA ATTGAACC	5852

5316	AAUGUGAA G CUGUGUGU	4567	ACACACAG GGCTAGCTACAACGA TTCACATT	5853
5319	GUGAAGCU G UGUGUGGU	4568	ACCACACA GGCTAGCTACAACGA AGCTTCAC	5854
5321	GAAGCUGU G UGUGUGUGU	4569	ACACCACA GGCTAGCTACAACGA ACAGCTTC	5855
5323	AGCUGUGU G UGGUGUCA	4570	TGACACCA GGCTAGCTACAACGA ACACAGCT	5856
5326	UGUGUGUG G UGUCAAAG	4571	CTTTGACA GGCTAGCTACAACGA CACACACA	5857
5328	UGUGUGGU G UCAAAGUU	4572	AACTTTGA GGCTAGCTACAACGA ACCACACA	5858
5334	GUGUCAA G UUUCAGGA	4573	TCCTGAAA GGCTAGCTACAACGA TTTGACAC	5859
5346	CAGGAAGG A UUUUACCC	4574	GGGTAAAA GGCTAGCTACAACGA CCTTCCTG	5860
5351	AGGAUUUU A CCCUUUUG	4575	CAAAGGGG GGCTAGCTACAACGA AAAATCCT	5861
5359	ACCCUUUU G UUCUUCCC	4576	GGGAAGAA GGCTAGCTACAACGA AAAAGGGT	5862
5371	UUCCCCCU G UCCCCAAC	4577	GTTGGGGA GGCTAGCTACAACGA AGGGGGAA	5863
5378	UGUCCCCA A CCCACUCU	4578	AGAGTGGG GGCTAGCTACAACGA TGGGGACA	5864
5382	CCCAACCC A CUCUCACC	4579	GGTGAGAG GGCTAGCTACAACGA GGGTTGGG	5865
5388	CCACUCUC A CCCGCAA	4580	TTGCGGGG GGCTAGCTACAACGA GAGAGTGG	5866
5393	CUCACCCC G CAACCCAU	4581	ATGGGTTG GGCTAGCTACAACGA GGGGTGAG	5867
5396	ACCCCGCA A CCCAUCAG	4582	CTGATGGG GGCTAGCTACAACGA TGCGGGGT	5868
5400	CGCAACCC A UCAGUAUU	4583	AATACTGA GGCTAGCTACAACGA GGGTTGCG	5869
5404	ACCCAUCA G UAUUUUAG	4584	CTAAAATA GGCTAGCTACAACGA TGATGGGT	5870
5406	CCAUCAGU A UUUUAGUU	4585	AACTAAAA GGCTAGCTACAACGA ACTGATGG	5871
5412	GUUUUUUA G UUAUUUGG	4586	CCAAATAA GGCTAGCTACAACGA TAAAATAC	5872
5415	UUUUAGUU A UUUUGCCU	4587	AGGCCAAA GGCTAGCTACAACGA AACTAAAA	5873
5420	GUUUUUUG G CCUCUACU	4588	AGTAGAGG GGCTAGCTACAACGA CAAATAAC	5874
5426	UGGCCUCU A CUCCAGUA	4589	TACTGGAG GGCTAGCTACAACGA AGAGGCCA	5875
5432	CUACUCCA G UAAACCCG	4590	CAGGTTTA GGCTAGCTACAACGA TGGAGTAG	5876
5436	UCCAGUAA A CCUGAUUG	4591	CAATCAGG GGCTAGCTACAACGA TTACTGGA	5877
5441	UAAACCCG A UUGGGUUU	4592	AAACCCAA GGCTAGCTACAACGA CAGGTTTA	5878
5446	CUGAUUGG G UUGGUUCA	4593	TGAACAAA GGCTAGCTACAACGA CCAATCAG	5879
5450	UUGGGUUU G UUCACUCU	4594	AGAGTGAA GGCTAGCTACAACGA AAACCCAA	5880
5454	GUUUGUUC A CUCUCUGA	4595	TCAGAGAG GGCTAGCTACAACGA GAACAAAC	5881
5463	CUCUCUGA A UGAUUUAU	4596	AATAATCA GGCTAGCTACAACGA TCAGAGAG	5882
5466	UCUGAAUG A UUAUUAGC	4597	GCTAATAA GGCTAGCTACAACGA CATTTCAG	5883
5469	GAAUGAUU A UUAGCCAG	4598	CTGGCTAA GGCTAGCTACAACGA AATCATTC	5884
5473	GAUUUAUA G CCAGACUU	4599	AAGTCTGG GGCTAGCTACAACGA TAATAATC	5885
5478	UUAGCCAG A CUUCAAAA	4600	TTTTGAAG GGCTAGCTACAACGA CTGGCTAA	5886
5486	ACUUCAAA A UUAUUUUA	4601	TAAAATAA GGCTAGCTACAACGA TTTGAAGT	5887
5489	UCAAAUAU A UUUUAUAG	4602	CTATAAAA GGCTAGCTACAACGA AATTTTGA	5888
5494	AUUUUUUU A UAGCCCAA	4603	TTGGGCTA GGCTAGCTACAACGA AAAATAAT	5889
5497	AUUUUUAU G CCCAAAUU	4604	AATTTGGG GGCTAGCTACAACGA TATAAAAT	5890
5503	UAGCCCAA A UUAUAACA	4605	TGTATATA GGCTAGCTACAACGA TTGGGCTA	5891
5506	CCCAAAUU A UAACAUCU	4606	AGATGTTA GGCTAGCTACAACGA AATTTGGG	5892
5509	AAAUUAUA A CAUCUAUU	4607	AATAGATG GGCTAGCTACAACGA TATAATTT	5893
5511	AUUUAUAC A UCUAUUGU	4608	ACAATAGA GGCTAGCTACAACGA GTTATAAT	5894
5515	UAACAUCU A UUGUAUUA	4609	TAATACAA GGCTAGCTACAACGA AGATGTTA	5895
5518	CAUCUAUU G UAUUAUUU	4610	AAATAATA GGCTAGCTACAACGA AATAGATG	5896
5520	UCUAUUGU A UUAUUUAG	4611	CTAAATAA GGCTAGCTACAACGA ACAATAGA	5897
5523	AUUGUAUU A UUUAGACU	4612	AGTCTAAA GGCTAGCTACAACGA AATACAAT	5898
5529	UUUUUUAG A CUUUUAAC	4613	GTTAAAAG GGCTAGCTACAACGA CTAAATAA	5899
5536	GACUUUUA A CAUAUAGA	4614	TCTATATG GGCTAGCTACAACGA TAAAAGTC	5900
5538	CUUUUAAC A UAAGAGC	4615	GCTCTATA GGCTAGCTACAACGA GTTAAAAG	5901
5540	UUUAACAU A UAGAGCUA	4616	TAGCTCTA GGCTAGCTACAACGA ATGTTAAA	5902
5545	CAUAUAGA G CUUUUUCU	4617	AGAAATAG GGCTAGCTACAACGA TCTATATG	5903
5548	AUAGAGCU A UUUCUACU	4618	AGTAGAAA GGCTAGCTACAACGA AGCTCTAT	5904
5554	CUUUUUCU A CUGAUUUU	4619	AAAATCAG GGCTAGCTACAACGA AGAAATAG	5905

5558	UUCUACUG A UUUUUGCC	4620	GGCAAAAA GGCTAGCTACAACGA CAGTAGAA	5906
5564	UGAUUUUU G CCCUUGUU	4621	AACAAGGG GGCTAGCTACAACGA AAAAATCA	5907
5570	UUGCCCUU G UUCUGUCC	4622	GGACAGAA GGCTAGCTACAACGA AAGGGCAA	5908
5575	CUUGUUCU G UCCUUUUU	4623	AAAAAGGA GGCTAGCTACAACGA AGAACAA	5909
5597	AAAAGAAA A UGUGUUUU	4624	AAAACACA GGCTAGCTACAACGA TTTCTTTT	5910
5599	AAGAAAAU G UGUUUUUU	4625	AAAAAACA GGCTAGCTACAACGA ATTTTCTT	5911
5601	GAAAAUGU G UUUUUUGU	4626	ACAAAAAA GGCTAGCTACAACGA ACATTTTC	5912
5608	UGUUUUUU G UUUGGUAC	4627	GTACCAAA GGCTAGCTACAACGA AAAAAACA	5913
5613	UUUGUUUG G UACCAUAG	4628	CTATGGTA GGCTAGCTACAACGA CAAACAAA	5914
5615	UGUUUGGU A CCAUAGUG	4629	CATATGGG GGCTAGCTACAACGA ACCAAACA	5915
5618	UUGGUACC A UAGUGUGA	4630	TCACACTA GGCTAGCTACAACGA GGTACCAA	5916
5621	GUACCAUA G UGUGAAAU	4631	ATTTTACA GGCTAGCTACAACGA TATGGTAC	5917
5623	ACCAUAGU G UGAAAUUC	4632	GCATTTCA GGCTAGCTACAACGA ACTATGGT	5918
5628	AGUGUGAA A UGCUGGGA	4633	TCCCAGCA GGCTAGCTACAACGA TTCACACT	5919
5630	UGUGAAAU G CUGGGGAA	4634	GTTCCCAG GGCTAGCTACAACGA ATTTTACA	5920
5637	UGCUGGGA A CAAUGACU	4635	AGTCATTG GGCTAGCTACAACGA TCCCAGCA	5921
5640	UGGGAACA A UGACUUAU	4636	TATAGTCA GGCTAGCTACAACGA TGTTCCTA	5922
5643	GAACAAUG A CUUAAGA	4637	TCTTATAG GGCTAGCTACAACGA CATTGTTC	5923
5646	CAAGGACU A UAAGACAU	4638	ATGTCTTA GGCTAGCTACAACGA AGTCATTG	5924
5651	ACUAUAAG A CAUGCUAU	4639	ATAGCATG GGCTAGCTACAACGA CTTATAGT	5925
5653	UAUAAGAC A UGCUAUGG	4640	CCATAGCA GGCTAGCTACAACGA GTCTTATA	5926
5655	UAAGACAU G CUUUGGCA	4641	TGCCATAG GGCTAGCTACAACGA ATGTCTTA	5927
5658	GACAUGCU A UGGCACA	4642	ATGTGCCA GGCTAGCTACAACGA AGCATGTC	5928
5661	AUGCUAUG G CACAUUAU	4643	TATATGTG GGCTAGCTACAACGA CATAGCAT	5929
5663	GCUAUGGC A CAUAUAUU	4644	AATATATG GGCTAGCTACAACGA GCCATAGC	5930
5665	UAUGGCAC A UAUAUUA	4645	TAAATATA GGCTAGCTACAACGA GTGCCATA	5931
5667	UGGCACAU A UAUAUUA	4646	TATAAATA GGCTAGCTACAACGA ATGTGCCA	5932
5669	GCACAUUA A UUAUAUGU	4647	ACTATAAA GGCTAGCTACAACGA ATATGTGC	5933
5673	AUAUAUUU A UAGUCUGU	4648	ACAGACTA GGCTAGCTACAACGA AAATATAT	5934
5676	UAUAUAUA G UCUGUUUA	4649	TAAACAGA GGCTAGCTACAACGA TATAAATA	5935
5680	UAUAGUCU G UUAUGUA	4650	TACATAAA GGCTAGCTACAACGA AGACTATA	5936
5684	GUCUGUUU A UGUAGAAA	4651	TTTCTACA GGCTAGCTACAACGA AACAGAC	5937
5686	CUGUUUUU G UAGAAACA	4652	TGTTTCTA GGCTAGCTACAACGA ATAAACAG	5938
5692	AUGUAGAA A CAAUGUA	4653	TACATTGG GGCTAGCTACAACGA TTCTACAT	5939
5696	AGAAACAA A UGUUAUAU	4654	ATATTACA GGCTAGCTACAACGA TTGTTTCT	5940
5698	AAACAAAU G UAUAUAUA	4655	ATATATTA GGCTAGCTACAACGA ATTTGTTT	5941
5701	CAAAUGUA A UAUAUUA	4656	TTAATATA GGCTAGCTACAACGA TACATTGG	5942
5703	AAUGUAAU A UAUAUAAG	4657	CTTAATA GGCTAGCTACAACGA ATTACATT	5943
5705	UGUAUAUA A UUAAGGCC	4658	GGCTTTAA GGCTAGCTACAACGA ATATTACA	5944
5711	AUAUUAUA G CCUAUAUA	4659	ATATAAGG GGCTAGCTACAACGA TTTAATAT	5945
5716	AAAGCCUU A UAUAUAUA	4660	ATTATATA GGCTAGCTACAACGA AAGGCTTT	5946
5718	AGCCUUAU A UAUAUGA	4661	TCATTATA GGCTAGCTACAACGA ATAAGGCT	5947
5720	CCUUAUAU A UAAUGAAC	4662	GTTCAATA GGCTAGCTACAACGA ATATAAGG	5948
5723	UAUAUAUA A UGAACUUU	4663	AAAGTTCA GGCTAGCTACAACGA TATATATA	5949
5727	UAUAUAUA A CUUUGUAC	4664	GTACAAAG GGCTAGCTACAACGA TCATTATA	5950
5732	UGAACUUU G UACUAUUC	4665	GAATAGTA GGCTAGCTACAACGA AAAGTTCA	5951
5734	AACUUUGU A CUUAUCAC	4666	GTGAATAG GGCTAGCTACAACGA ACAAAGTT	5952
5737	UUUGUACU A UUCACAUU	4667	AATGTGAA GGCTAGCTACAACGA AGTACAAA	5953
5741	UACUAUUC A CAUUUUGU	4668	ACAAAATG GGCTAGCTACAACGA GAATAGTA	5954
5743	CUAUUCAC A UUUUGUAU	4669	ATACAAAA GGCTAGCTACAACGA GTGAATAG	5955
5748	CACAUUUU G UAUCAGUA	4670	TACTGATA GGCTAGCTACAACGA AAAATGTG	5956
5750	CAUUUUGU A UCAGUAUU	4671	AATACTGA GGCTAGCTACAACGA ACAAATG	5957
5754	UUGUAUCA G UAUAUUGU	4672	ACATAATA GGCTAGCTACAACGA TGATACAA	5958

151

5756	GUAUCAGU A UUAUGUAG	4673	CTACATAA GGCTAGCTACAACGA ACTGATAC	5959
5759	UCAGUAUU A UGUAGCAU	4674	ATGCTACA GGCTAGCTACAACGA AATACTGA	5960
5761	AGUAUUUU G UAGCAUAA	4675	TTATGCTA GGCTAGCTACAACGA ATAATACT	5961
5764	AUUAUGUA G CADAACAA	4676	TTGTTATG GGCTAGCTACAACGA TACATAAT	5962
5766	UAUGUAGC A UAACAAAG	4677	CTTTGTTA GGCTAGCTACAACGA GCTACATA	5963
5769	GUAGCAUA A CAAAGGUC	4678	GACCTTTG GGCTAGCTACAACGA TATGCTAC	5964
5775	UAACAAAG G UCAUAUUG	4679	CATTATGA GGCTAGCTACAACGA CTTTGTGA	5965
5778	CAAAGGUC A UAAUGCUU	4680	AAGCATTG GGCTAGCTACAACGA GACCTTTG	5966
5781	AGGUCAUA A UGCUUUA	4681	TGAAAGCA GGCTAGCTACAACGA TATGACCT	5967
5783	GUCAUAUU G CUUUCAGC	4682	GCTGAAAG GGCTAGCTACAACGA ATTATGAC	5968
5790	UGCUUUA G CAAUUGAU	4683	ATCAATTG GGCTAGCTACAACGA TGAAAGCA	5969
5793	UUUCAGCA A UUGAUGUC	4684	GACATCAA GGCTAGCTACAACGA TGCTGAAA	5970
5797	AGCAAUUG A UGUCAUUU	4685	AAATGACA GGCTAGCTACAACGA CAATTGCT	5971
5799	CAAUUGAU G UCAUUUUA	4686	TAAATGA GGCTAGCTACAACGA ATCAATTG	5972
5802	UUGAUGUC A UUUUADUA	4687	TAATAAAA GGCTAGCTACAACGA GACATCAA	5973
5807	GUCAUUUU A UUAAGAA	4688	TTCTTTAA GGCTAGCTACAACGA AAAATGAC	5974
5815	AUUAAAGA A CAUUGAAA	4689	TTTCAATG GGCTAGCTACAACGA TCTTTAAT	5975
5817	UAAAGAAC A UUGAAAAA	4690	TTTTTCAA GGCTAGCTACAACGA GTTCTTTA	5976

Input Sequence = AF035121. Cut Site = R/Y

Arm Length = 8. Core Sequence = GGCTAGCTACAACGA

AF035121 (Homo sapiens KDR/flk-1 protein mRNA, complete cds.; Acc# AF035121; 5830 bp)

## CLAIMS

1. A compound having Formula II: (SEQ ID NO: 5978)

5' -  $\text{u}_s\text{a}_c\text{a}_\text{au}$  ucU GAu Gag gcg aaa gcc Gaa Aag aca aB - 3'

5 wherein each a is 2'-O-methyl adenosine nucleotide, each g is a 2'-O-methyl guanosine nucleotide, each c is a 2'-O-methyl cytidine nucleotide, each u is a 2'-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2'-deoxy-2'-C-allyl uridine, and B is an inverted deoxybasic moiety.

10

2. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
3. A method of administering to a cell the compound of claim 1 comprising contacting said cell with the compound under conditions suitable for said administration.
- 15
4. The method of claim 3, wherein said cell is a mammalian cell.
5. The method of claim 3, wherein said cell is a human cell.
6. The method of claim 3, wherein said administration is in the presence of a delivery reagent.
- 20
7. The method of claim 6, wherein said delivery reagent is a lipid.
8. The method of claim 7, wherein said lipid is a cationic lipid.
9. The method of claim 7, wherein said lipid is a phospholipid.
10. The method of claim 6, wherein said delivery reagent is a liposome.
11. A method of administering to a cell the compound of claim 1 in conjunction with one or more other drug comprising contacting said cell
- 25

with the compound and the other drug(s) under conditions suitable for said administration.

12. A method of inhibiting ocular angiogenesis in a subject comprising the step of contacting said subject with the compound of claim 1 under conditions suitable for said inhibition.
13. The method of claim 12, wherein said angiogenesis is associated with diabetic retinopathy.
14. The method of claim 12, wherein said angiogenesis is associated with age related diabetic retinopathy.
15. A method of cleaving RNA comprising a sequence of KDR RNA comprising contacting the compound of claim 1 with said RNA under conditions suitable for the cleavage of said RNA.
16. The method of claim 15, wherein said cleavage is carried out in the presence of a divalent cation.
17. The method of claim 16, wherein said divalent cation is  $Mg^{2+}$ .
18. A method of administering to a mammal the compound of claim 1 comprising contacting said mammal with the compound under conditions suitable for said administration.
19. The method of claim 18, wherein said mammal is a human.
20. The method of claim 18 wherein said administration is in the presence of a delivery reagent.
21. The method of claim 18, wherein said delivery reagent is a lipid.
22. The method of claim 21, wherein said lipid is a cationic lipid.
23. The method of claim 21, wherein said lipid is a phospholipid.
24. The method of claim 20, wherein said delivery reagent is a liposome.

25. A method for treating a subject having endometriosis, comprising contacting said subject with a nucleic acid molecule that modulates the expression of VEGF, VEGFR1, and/or VEGFR2, under conditions suitable for said treatment.
- 5 26. The method of claim 25, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule.
27. The method of claim 25, wherein said nucleic acid molecule is an antisense nucleic acid molecule.
- 10 28. The method of claim 25, wherein said nucleic acid molecule is a dsRNA nucleic acid molecule.
29. The method of claim 25, wherein said nucleic acid molecule is a nucleic acid aptamer.
30. The method of claim 25, wherein said nucleic acid molecule comprises a sequence having SEQ ID NO: 5977.
- 15 31. The method of claim 26, wherein said enzymatic nucleic acid molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1 and/or VEGFR2 gene.
32. The method of claim 26, wherein said enzymatic nucleic acid molecule is in a hammerhead configuration.
- 20 33. The method of claim 26, wherein said enzymatic nucleic acid molecule is in an Inozyme configuration.
34. The method of claim 26, wherein said enzymatic nucleic acid molecule is in a Zinzyme configuration.
- 25 35. The method of claim 26, wherein said enzymatic nucleic acid molecule is in a DNAzyme configuration.
36. The method of claim 26, wherein said enzymatic nucleic acid molecule is in a G-cleaver configuration.
37. The method of claim 26, wherein said enzymatic nucleic acid molecule is in an Amberzyme configuration.



38. The method of claim 26, wherein said enzymatic nucleic acid molecule is an allozyme.
39. The method of claim 25, wherein said nucleic acid molecule is chemically synthesized.
- 5 40. The method of claim 25, wherein said nucleic acid molecule comprises at least one 2'-sugar modification.
41. The method of claim 25, wherein said nucleic acid molecule comprises at least one nucleic acid base modification.
42. The method of claim 25, wherein said nucleic acid molecule comprises at  
10 least one phosphate backbone modification.
43. The method of claim 25, wherein said subject is a human.
44. A method for treating a subject having endometriosis, comprising administering to the subject a nucleic acid molecule that modulates the expression of VEGF, VEGFR1, and/or VEGFR2, under conditions suitable  
15 for said treatment.
45. The method of claim 44 wherein said administration is in the presence of a delivery reagent.
46. The method of claim 45, wherein said delivery reagent is a lipid.
47. The method of claim 46, wherein said lipid is a cationic lipid.
- 20 48. The method of claim 46, wherein said lipid is a phospholipid.
49. The method of claim 45, wherein said delivery reagent is a liposome.
50. The method of claim 44, further comprising administering one or more other drug(s).
- 25 51. The method of claim 50, wherein said other drug(s) are chosen from GnRH (gonadotropin releasing hormone) agonists, Lupron Depot (Leuprolide Acetate), Synarel (naferalin acetate), Zolodex (goserelin acetate), Suprefact (buserelin acetate), Danazol, and oral contraceptives.
52. A compound having Formula I: (SEQ ID NO: 5977)



wherein each a is 2'-O-methyl adenosine nucleotide, each g is a 2'-O-methyl guanosine nucleotide, each c is a 2'-O-methyl cytidine nucleotide, each u is a 2'-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2'-deoxy-2'-C-allyl uridine, and B is an inverted deoxybasic moiety.

53. A composition comprising a compound of claim 52 in a pharmaceutically acceptable carrier or diluent.
- 10 54. A method of administering to a cell the compound of claim 52 comprising contacting said cell with the compound under conditions suitable for said administration.
55. The method of claim 54, wherein said cell is a mammalian cell.
56. The method of claim 54, wherein said cell is a human cell.
- 15 57. The method of claim 54, wherein said administration is in the presence of a delivery reagent.
58. The method of claim 57, wherein said delivery reagent is a lipid.
59. The method of claim 58, wherein said lipid is a cationic lipid.
60. The method of claim 58, wherein said lipid is a phospholipid.
- 20 61. The method of claim 57, wherein said delivery reagent is a liposome.
62. A method of administering to a cell the compound of claim 52 in conjunction with a chemotherapeutic agent comprising contacting said cell with the compound and the chemotherapeutic agent under conditions suitable for said administration.
- 25 63. The method of claim 62, wherein said chemotherapeutic agent is 5-fluoro uridine.


64. The method of claim 62, wherein said chemotherapeutic agent is Leucovorin.
65. The method of claim 62, wherein said chemotherapeutic agent is chosen from Irinotecan, CAMPTOSAR®, CPT-11, Camptothecin-11, or Campto.
- 5 66. The method of claim 62, wherein said chemotherapeutic agent is Paclitaxel.
67. The method of claim 62, wherein said chemotherapeutic agent is Carboplatin.
68. A mammalian cell comprising the compound of claim 52..
69. The mammalian cell of claim 68, wherein said mammalian cell is a human  
10 cell.
70. A method of inhibiting angiogenesis in a subject, comprising the step of contacting said subject with the compound of claim 52, under conditions suitable for said inhibition.
71. The method of claim 70, wherein said angiogenesis is tumor angiogenesis.
- 15 72. A method of treatment of a subject having a condition associated with an increased level of VEGF receptor comprising contacting cells of said subject with the compound of claim 52, under conditions suitable for said treatment.
73. The method of claim 72 further comprising the use of one or more drug  
20 therapies under conditions suitable for said treatment.
74. A method of cleaving RNA comprising a sequence of VEGFR1 (flt-1), comprising contacting the compound of claim 52 with said RNA under conditions suitable for the cleavage of said RNA.
75. The method of claim 74, wherein said cleavage is carried out in the  
25 presence of a divalent cation.
76. The method of claim 75, wherein said divalent cation is Mg<sup>2+</sup>.

77. The method of claim 72, wherein said condition is cancer.
78. The method of claim 77, wherein said cancer is breast cancer.
79. The method of claim 77, wherein said cancer is lung cancer.
80. The method of claim 77, wherein said cancer is colorectal cancer.
- 5 81. The method of claim 77, wherein said cancer is renal cancer.
82. The method of claim 77, wherein said cancer is melanoma.
83. The method of claim 77, wherein said cancer is pancreatic cancer.
84. The method of claim 79, wherein said lung cancer is non-small cell lung carcinoma.
- 10 85. The method of claim 81, wherein said renal cancer is renal cell carcinoma.
86. The method of claim 73, wherein said other therapy is 5-fluoro uridine.
87. The method of claim 73, wherein said other therapy is Leucovorin.
88. The method of claim 73, wherein said other therapy is Irinotecan, CAMPTOSAR®, CPT-11, Camptothecin-11, or Campto.
- 15 89. The method of claim 73, wherein said other therapy is Paclitaxel.
90. The method of claim 73, wherein said other therapy is Carboplatin.
91. A method of administering to a mammal the compound of claim 52 comprising contacting said mammal with the compound under conditions suitable for said administration.
- 20 92. The method of claim 91, wherein said mammal is a human.
93. The method of claim 91, wherein said administration is in the presence of a delivery reagent.
94. The method of claim 93, wherein said delivery reagent is a lipid.

95. The method of claim 94, wherein said lipid is a cationic lipid.
96. The method of claim 94, wherein said lipid is a phospholipid.
97. The method of claim 93, wherein said delivery reagent is a liposome.
98. A method of administering to a mammal the compound of claim 52 in  
5 conjunction with a chemotherapeutic agent comprising contacting said  
mammal with the compound and the chemotherapeutic agent under  
conditions suitable for said administration.
99. The method of claim 98, wherein said chemotherapeutic agent is 5-fluoro  
uridine.
- 10 100. The method of claim 98, wherein said chemotherapeutic agent is  
Leucovorin.
101. The method of claim 98, wherein said chemotherapeutic agent is Irinotecan,  
CAMPTOSAR®, CPT-11, Camptothecin-11, or Campto.
102. The method of claim 98, wherein said chemotherapeutic agent is Paclitaxel.
- 15 103. The method of claim 98, wherein said chemotherapeutic agent is  
Carboplatin.


1/11

**Figure 1: Anti-Flt-1 Ribozyme: *ANGIOZYME***



2/11


# ***Inhibition of LLC-HM Primary Tumor Growth Following Systemic ANGIOZYME***



**Figure 2**

3/11


# **ANGIOZYME Inhibition of Lung Metastases (LLC-HM Model)**

**Figure 3**



4/11

# ***Effect of ANGIOZYME on Liver Metastases in a Colorectal Cancer Model***




Note: > 100 metastases are indicated as 101.

**Figure 4**

5/11

**Figure 5: Plasma concentration profile of ANGIOZYME after a single subcutaneous dose of 10, 30, 100 or 300 mg/m<sup>2</sup>**



(SEQ ID NO. 5981)

5'-NNNNNNUH NNNNNNNN-3'

3'-nnnnnnnrA15.1 nnnnnnnn-5'

(SEQ ID NO. 5982)

a<sup>14</sup> U<sub>4</sub> rG<sub>5</sub> HH Rz

a<sup>13</sup> rG<sub>12</sub> rA<sub>6</sub>

a<sup>12</sup> c<sup>11</sup> g<sup>10</sup> a<sup>9</sup> rG<sup>8</sup> u<sup>7</sup>

a<sup>6</sup> n<sup>5</sup> n<sup>4</sup> n<sup>3</sup> n<sup>2</sup> a<sup>1</sup> g

Target

↓

(SEQ ID NO. 5983)

5'-NNNNNNCH NNNNNNNN-3'

3'-nnnnnnnrA15.1 nnnnnnnn-5'

(SEQ ID NO. 5984)

a<sup>14</sup> U<sub>4</sub> rG<sub>5</sub> NCH Rz

a<sup>13</sup> rG<sub>12</sub> rA<sub>6</sub>

a<sup>12</sup> c<sup>11</sup> g<sup>10</sup> a<sup>9</sup> rG<sup>8</sup> u<sup>7</sup>

a<sup>6</sup> n<sup>5</sup> n<sup>4</sup> n<sup>3</sup> n<sup>2</sup> a<sup>1</sup> g

(SEQ ID NO. 5985)

5'-NNNNNNYG NNNNNNNN-3'

3'-nnnnnnnng c<sup>9</sup> u<sup>8</sup> rG<sup>5</sup> rA<sup>6</sup>

(SEQ ID NO. 5986)

g<sup>9</sup> c<sup>8</sup> g<sup>7</sup> rG<sup>6</sup> rU<sup>5</sup>

u<sup>4</sup> a<sup>3</sup> c<sup>2</sup> a<sup>1</sup> rG

G-Cleaver Rz

Target

↓

(SEQ ID NO. 5987)

NNYNNN

Lower case = 2'-OMe

rN = ribonucleotide


S = phosphorothioate

U<sub>4</sub> = 2'-C-allyl


H = A, U, C

Y = U, C

7/11


**Figure 7: Stabilized Zinzyme Ribozyme Motif****Legend****Uppercase:** indicates natural ribo residues**C** : indicates 2'-deoxy-2'-amino Cytidine**Lowercase:** 2'-O-methyl**S:** phosphorothioate/phosphorodithioate linkage**B:** 3'-3' abasic moiety

**Figure 8: DNzyme Motif**




Legend  
Y = U or C  
R = A or G

9/11

*Figure 9: Soluble VEGFR1 Reduction*


*Figure 10: Mouse Model of Proliferative Retinopathy*



**Note:** Peak VEGF levels noted 12 hr after exposure to room air

11/11

**Figure 11: RPL.4731 Reduces Hypoxia-Induced Retinal Neovascularization in Neonatal Mice**



Results: ~40% decrease in retinal neovascularization following two intraocular injections of RPL.4731

SEQ ID NO: 5978



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**